Aaron, LA, 215P(ab)
Abdel-Dayem, HM, 212P(ab), 234P(ab), 271P(ab), 276P(ab)
Abdel-Nabi, H, 11P(ab), 86P(ab), 219P(ab)
Abdo, RV, 151P(ab)
Abdullah, N, 30P(ab)
Abe, H, 226P(ab)
Abe, K, 206P(ab)
Abe, M, 234P(ab)
Abe, S, 206P(ab)
Abernathy, MJ, 161P(ab)
Abi-Dargham, A, 228, 84P(ab)
Abós, MD, 1303
Abou-Khalil, BW, 30P(ab)
Abraham, S, 23P(ab)
Abrams, MJ, 29P(ab), 44P(ab), 45P(ab), 105P(ab)
Aburano, T, 172P(ab)
Acampa, W, 22P(ab), 96P(ab), 166P(ab)
Acevedo, M, 32P(ab), 119P(ab)
Achong, DM, 14P(ab)
Ackermann, B, 115P(ab)
Ackermann, R, 7P(ab)
Ackermann, RJ, 405, 1637
Adachi, I, 227P(ab)
Adair, J, 63P(ab)
Adam, MJ, 251P(ab)
Adelstein, SJ, 12P(ab), 79P(ab), 144P(ab), 162P(ab)
Adiseshan, P, 194P(ab)
Adkins, J, 252P(ab)
Adler, A, 213P(ab)
Adler, LJ, 198P(ab)
Affleck, DJ, 57P(ab), 248P(ab)
Afriyie, M, 15P(ab), 276P(ab)
Ahluwalia, R, 74
Ahn, CS, 164P(ab)
Ahn, S, 227P(ab)
Aho, K, 249P(ab)
Aicher, KP, 1342
Aitken, PW, 26P(ab)
Aizawa, Y, 1097
Akansel, G, 88P(ab), 232P(ab)
Akashi, N, 1279
Akashi, Y, 43P(ab), 227P(ab), 231P(ab)
Akella, SK, 94P(ab)
Akgün, E, 251P(ab)
Akiba, H, 217P(ab)
Akin, EA, 267P(ab), 273P(ab)
Akiyama, Y, 160P(ab)
Akizawa, H, 259P(ab)
Akkermans, L, 185(le)
Aksut, S, 126P(ab)
Aktolun, C, 1561(le), 2056(le), 172P(ab)
Alamos, F, 210P(ab)
Alanen, K, 1618, 117P(ab)
Alarcon, GS, 215P(ab)
Alavi, A, 164, 179, 1087, 1138, 1466, 1650, 13P(ab), 14P(ab), 24P(ab), 25P(ab), 53P(ab), 54P(ab), 74P(ab), 95P(ab), 102P(ab), 107P(ab), 120P(ab), 133P(ab), 171P(ab), 195P(ab), 206P(ab), 208P(ab), 209P(ab), 214P(ab), 215P(ab), 222P(ab), 226P(ab)
Alavi, JB, 222P(ab), 226P(ab)
Alazraki, NP, 1237, 27P(ab), 72P(ab), 126P(ab), 138P(ab)
Albert, R, 317
Albin, RL, 121P(ab)
Al-Darwich, MJ, 251P(ab)
Alderson, PO, 1351
Alexander, CW, 245P(ab)
Alexander, RW, 215P(ab)
Alexandrescu, C, 130P(ab)
Alexoff, D, 67P(ab), 85P(ab), 94P(ab), 129P(ab)
Ali, S, 229P(ab)
Alijani, M, 267P(ab)
Almeida, F, 1170
Almén, A, 158P(ab)
Almohanady, S, 133P(ab)
Aloisi, D, 1933
Alpert, NM, 496, 1308, 8P(ab), 23P(ab), 37P(ab), 75P(ab), 77P(ab), 107P(ab), 175P(ab), 254P(ab)
Altehoefer, C, 569, 108P(ab), 131P(ab), 230P(ab)
Al-Tikriti, MS, 128P(ab), 129P(ab), 201P(ab)
Altland, E, 556
Altmann, A, 1842
Alvarez, VL, 282
Alves, CM, 60P(ab)
Amano, J, 239P(ab)
Amino, S, 206P(ab)
Ammon, J, 111P(ab)
Amstutz, HP, 217P(ab)
Amyot, R, 15P(ab)
Amyotte, G, 235P(ab)
Anagnostou, E, 16P(ab)
Anand, D, 145P(ab)
Andersen, PH, 122P(ab)
Anderson, BA, 1586
Anderson, C, 162P(ab)
Anderson, CE, 74
Anderson, CJ, 1122, 12P(ab), 43P(ab), 106P(ab), 161P(ab)
Anderson, CM, 172P(ab), 175P(ab)
Anderson, HJ, 9P(ab)
Anderson, J, 222P(ab)
Anderson, JR, 1815
Anderson, TL, 349
André, L, 1328
Andreopoulos, D, 11P(ab)
Andrews, JC, 1637
Andrich, MP, 1471
Andries, H, 181P(ab)
Angelberger, P, 10P(ab), 44P(ab), 97P(ab)
Angelides, S, 195
Aninipot, R, 219P(ab)
Annane, D, 24P(ab)
Anner, H, 1802
Annicchiarico, C, 146P(ab)
Ansari, MS, 199P(ab)
Anscher, MS, 76P(ab)
Antar, MA, 37P(ab), 223P(ab)
Anthonio, RL, 3P(ab), 23P(ab), 157P(ab), 257P(ab)
Antich, PP, 216P(ab), 222P(ab)
Anton, J, 1028
Antoni, M, 95P(ab)
Antoniw, P, 63P(ab)
Aoki, M, 119P(ab)
Aoki, S, 214P(ab)
Aoyama, T, 1279
Appelbaum, J, 100P(ab)
Appelros, S, 224P(ab)
Arai, H, 206P(ab), 239P(ab)
Arano, Y, 326, 30P(ab), 259P(ab)
Aravind, S, 216P(ab)
Archer, GE, 1506
Arcomano, MA, 1145
Areeda, J, 356, 609, 103P(ab)
Argov, Z, 1802
Arias, JM, 100P(ab)
Arimizu, N, 238P(ab)
Arista, A, 144P(ab)
Arka, A, 172P(ab)
Armstrong, S, 153P(ab)
Arnstein, NB, 58P(ab), 125P(ab)
Arora, J, 159P(ab)
Arora, PK, 232P(ab)
Arosio, P, 218P(ab)
Arrigo, F, 601
Arthur, AL, 60P(ab)
Asenbaum, S, 10P(ab)
Asenjo, MJ, 1303
Asgarzadie, F, 8P(ab), 49P(ab)
Ash, JM, 449
Ashare, AB, 2048(e)
Ashburn, WL, 48P(ab), 170P(ab)
Ashburner, J, 185P(ab)
Ashby, C, 67P(ab)
Ashok, G, 15P(ab), 22P(ab), 229P(ab), 274P(ab)
Aso, H, 152P(ab)
Assi, NA, 154P(ab)
Assis, MLB, 264P(ab)
Assmann, S, 9P(ab)
Atkins, FB, 181P(ab)
Atkins, HL, 342, 37P(ab), 52P(ab), 145P(ab), 221P(ab)
Atochina, EN, 1358
Attie, NJ, 15P(ab)
Aubert, B, 159P(ab)
Augustine, SC, 144P(ab)
Auinger, C, 44P(ab)
Aull, S, 207P(ab)
Aurengo, A, 1631
Austin, MC, 31P(ab), 208P(ab)
Avraham, A, 257
Avril, N, 222P(ab), 231P(ab)
Azarian, R, 47P(ab)
Azuma, M, 169P(ab)

Baba, Y, 68P(ab)
Babchyck, B, 185P(ab)
Babich, JW, 1308, 1685, 19P(ab), 37P(ab), 44P(ab), 66P(ab), 105P(ab), 151P(ab), 174P(ab), 175P(ab), 254P(ab)
Bacharach, SL, 567, 90P(ab), 143P(ab), 183P(ab)
Bache, RJ, 1985
Badalament, R, 216P(ab)
Badger, CC, 300
Badrinath, Y, 218P(ab)
Badrudosa, M, 234P(ab)
Baer, L, 75P(ab)
Bag, R, 212P(ab), 271P(ab)
Bagni, B, 147P(ab)
Bagni, I, 147P(ab)
Baidoo, KE, 19P(ab)
Bailey, DL, 360, 50P(ab)
Bair, HJ, 86P(ab), 218P(ab)
Bair, J, 1436
Baker, JR, 107P(ab)
Bakker, WH, 162P(ab), 165P(ab), 226P(ab)
Baldini, MT, 1741
Baldwin, B, 123P(ab)
Baldwin, RM, 228, 399, 10P(ab), 11P(ab), 84P(ab), 128P(ab), 129P(ab), 130P(ab), 201P(ab)
Balfe, DM, 117P(ab)
Ball, W, 53P(ab)
Ballas, S, 36P(ab)
Ballinger, J, 44P(ab)
Ballinger, JR, 202P(ab)
Ban, R, 84
Bander, NH, 101P(ab)
Bandyopadhyay, D, 211P(ab)
Banish, M, 178P(ab)
Banks, WR, 252P(ab)
Banyai, S, 97P(ab)
Banzo, J, 1303
Baranczuk, RJ, 274P(ab)
Baranowska-Kortylewicz, J, 79P(ab), 144P(ab), 162P(ab)
Baratti, D, 1970
Barbarics, E, 19P(ab)
Barbet, J, 55P(ab)
Barclay, A, 23P(ab)
Bardet, S, 55P(ab), 69P(ab)
Barentsz, J, 165P(ab)
Bares, R, 108P(ab), 111P(ab), 131P(ab), 230P(ab), 256P(ab)
Barker, P, 1797
Barker, WC, 90P(ab)
Barker, WW, 7
Barloon, T, 229P(ab)
Barnes, DC, 245, 416
Barnett, GH, 223P(ab)
Barnett, PA, 1831
Barnhart, C, 16P(ab), 60P(ab)
Baron, E, 1155
Baron, JI, 26P(ab)
Barr, SA, 91P(ab)
Barrera, J, 212P(ab)
Barrett, HH, 28P(ab), 93P(ab)
Barrett, JA, 52P(ab), 241P(ab), 245P(ab)
Barrio, JR, 83P(ab)
Barron, BJ, 1167
Barros, NG, 206P(ab)
Barrow, SA, 44P(ab), 174P(ab)
Bar-Shalom, R, 465, 229P(ab)
Bartenstein, P, 9P(ab), 33P(ab)
Barth, A, 220P(ab)
Bartiromo, A, 22P(ab)
Bartlett, ML, 90P(ab)
Barzilai, D, 1155
Basheim, H, 1602
Basile, F, 1245
Basmadjian, GP, 200P(ab)
Bassevitch, R, 126P(ab)
Basten, A, 195
Bastidas, DA, 257P(ab)
Basu, S, 136P(ab)
Bateman, TM, 609, 625, 16P(ab), 60P(ab), 114P(ab)
Battista, JJ, 111P(ab)
Baudhuin, T, 77P(ab)
Bauer, B, 235P(ab)
Bauer, J, 1896
Baulac, M, 207P(ab)
Baulieu, F, 237P(ab)
Baulieu, J-L, 237P(ab)
Baumgartner, C, 207P(ab)
Bautovich, G, 195
Bavaria, G, 628
Bax, JJ, 136P(ab)
Baxter, KG, 274P(ab), 275P(ab)
Baxter, L, 186P(ab)
Bayouth, JE, 63, 37P(ab), 142P(ab), 143P(ab), 160P(ab)
Bayraktar, M, 204
Bazin, JP, 13P(ab)
Bazzicalupo, L, 22P(ab)
Beanlands, RSB, 1286, 3P(ab)
Beattie, B, 1407
Beauchamp, HT, 52P(ab), 246P(ab)
Beaumier, PL, 158P(ab)
Beblavy, M, 45P(ab)
Becherer, A, 85P(ab)
Beck, H, 1436
Becker, DV, 368
Becker, JA, 20P(ab), 116P(ab), 207P(ab), 210P(ab)
Becker, WS, 1436, 56P(ab), 86P(ab), 112P(ab), 218P(ab)
Beckers, C, 1951, 131P(ab)

Aaron, LA, 215P(ab)
Abdel-Dayem, HM, 212P(ab), 234P(ab), 271P(ab), 276P(ab)
Abdel-Nabi, H, 11P(ab), 86P(ab), 219P(ab)
Abdo, RV, 151P(ab)
Abdullah, N, 30P(ab)
Abe, H, 226P(ab)
Abe, K, 206P(ab)
Abe, M, 234P(ab)
Abe, S, 206P(ab)
Abernathy, MJ, 161P(ab)
Abi-Dargham, A, 228, 84P(ab)
Abós, MD, 1303
Abou-Khalil, BW, 30P(ab)
Abraham, S, 23P(ab)
Abrams, MJ, 29P(ab), 44P(ab), 45P(ab), 105P(ab)
Aburano, T, 172P(ab)
Acampa, W, 22P(ab), 96P(ab), 166P(ab)
Acevedo, M, 32P(ab), 119P(ab)
Achong, DM, 14P(ab)
Ackermann, B, 115P(ab)
Ackermann, R, 7P(ab)
Ackermann, RJ, 405, 1637
Adachi, I, 227P(ab)
Adair, J, 63P(ab)
Adam, MJ, 251P(ab)
Adelstein, SJ, 12P(ab), 79P(ab), 144P(ab), 162P(ab)
Adiseshan, P, 194P(ab)
Adkins, J, 252P(ab)
Adler, A, 213P(ab)
Adler, LJ, 198P(ab)
Affleck, DJ, 57P(ab), 248P(ab)
Afriyie, M, 15P(ab), 276P(ab)
Ahluwalia, R, 74
Ahn, CS, 164P(ab)
Ahn, S, 227P(ab)
Aho, K, 249P(ab)
Aicher, KP, 1342
Aitken, PW, 26P(ab)
Aizawa, Y, 1097
Akansel, G, 88P(ab), 232P(ab)
Akashi, N, 1279
Akashi, Y, 43P(ab), 227P(ab), 231P(ab)
Akella, SK, 94P(ab)
Akgün, E, 251P(ab)
Akiba, H, 217P(ab)
Akin, EA, 267P(ab), 273P(ab)
Akiyama, Y, 160P(ab)
Akizawa, H, 259P(ab)
Akkermans, L, 185(le)
Aksut, S, 126P(ab)
Aktolun, C, 1561(le), 2056(le), 172P(ab)
Alamos, F, 210P(ab)
Alanen, K, 1618, 117P(ab)
Alarcon, GS, 215P(ab)
Alavi, A, 164, 179, 1087, 1138, 1466, 1650, 13P(ab), 14P(ab), 24P(ab), 25P(ab), 53P(ab), 54P(ab), 74P(ab), 95P(ab), 102P(ab), 107P(ab), 120P(ab), 133P(ab), 171P(ab), 195P(ab), 206P(ab), 208P(ab), 209P(ab), 214P(ab), 215P(ab), 222P(ab), 226P(ab)
Alavi, JB, 222P(ab), 226P(ab)
Alazraki, NP, 1237, 27P(ab), 72P(ab), 126P(ab), 138P(ab)
Albert, R, 317
Albin, RL, 121P(ab)
Al-Darwich, MJ, 251P(ab)
Alderson, PO, 1351
Alexander, CW, 245P(ab)
Alexander, RW, 215P(ab)
Alexandrescu, C, 130P(ab)
Alexoff, D, 67P(ab), 85P(ab), 94P(ab), 129P(ab)
Ali, S, 229P(ab)
Alijani, M, 267P(ab)
Almeida, F, 1170
Almén, A, 158P(ab)
Almohanady, S, 133P(ab)
Aloisi, D, 1933
Alpert, NM, 496, 1308, 8P(ab), 23P(ab), 37P(ab), 75P(ab), 77P(ab), 107P(ab), 175P(ab), 254P(ab)
Altehoefer, C, 569, 108P(ab), 131P(ab), 230P(ab)
Al-Tikriti, MS, 128P(ab), 129P(ab), 201P(ab)
Altland, E, 556
Altmann, A, 1842
Alvarez, VL, 282
Alves, CM, 60P(ab)
Amano, J, 239P(ab)
Amino, S, 206P(ab)
Ammon, J, 111P(ab)
Amstutz, HP, 217P(ab)
Amyot, R, 15P(ab)
Amyotte, G, 235P(ab)
Anagnostou, E, 16P(ab)
Anand, D, 145P(ab)
Andersen, PH, 122P(ab)
Anderson, BA, 1586
Anderson, C, 162P(ab)
Anderson, CE, 74
Anderson, CJ, 1122, 12P(ab), 43P(ab), 106P(ab), 161P(ab)
Anderson, CM, 172P(ab), 175P(ab)
Anderson, HJ, 9P(ab)
Anderson, J, 222P(ab)
Anderson, JR, 1815
Anderson, TL, 349
André, L, 1328
Andreopoulos, D, 11P(ab)
Andrews, JC, 1637
Andrich, MP, 1471
Andries, H, 181P(ab)
Angelberger, P, 10P(ab), 44P(ab), 97P(ab)
Angelides, S, 195
Aninipot, R, 219P(ab)
Annane, D, 24P(ab)
Anner, H, 1802
Annicchiarico, C, 146P(ab)
Ansari, MS, 199P(ab)
Anscher, MS, 76P(ab)
Antar, MA, 37P(ab), 223P(ab)
Anthonio, RL, 3P(ab), 23P(ab), 157P(ab), 257P(ab)
Antich, PP, 216P(ab), 222P(ab)
Anton, J, 1028
Antoni, M, 95P(ab)
Antoniw, P, 63P(ab)
Aoki, M, 119P(ab)
Aoki, S, 214P(ab)
Aoyama, T, 1279
Appelbaum, J, 100P(ab)
Appelros, S, 224P(ab)
Arai, H, 206P(ab), 239P(ab)
Arano, Y, 326, 30P(ab), 259P(ab)
Aravind, S, 216P(ab)
Archer, GE, 1506
Arcomano, MA, 1145
Areeda, J, 356, 609, 103P(ab)
Argov, Z, 1802
Arias, JM, 100P(ab)
Arimizu, N, 238P(ab)
Arista, A, 144P(ab)
Arka, A, 172P(ab)
Armstrong, S, 153P(ab)
Arnstein, NB, 58P(ab), 125P(ab)
Arora, J, 159P(ab)
Arora, PK, 232P(ab)
Arosio, P, 218P(ab)
Arrigo, F, 601
Arthur, AL, 60P(ab)
Asenbaum, S, 10P(ab)
Asenjo, MJ, 1303
Asgarzadie, F, 8P(ab), 49P(ab)
Ash, JM, 449
Ashare, AB, 2048(e)
Ashburn, WL, 48P(ab), 170P(ab)
Ashburner, J, 185P(ab)
Ashby, C, 67P(ab)
Ashok, G, 15P(ab), 22P(ab), 229P(ab), 274P(ab)
Aso, H, 152P(ab)
Assi, NA, 154P(ab)
Assis, MLB, 264P(ab)
Assmann, S, 9P(ab)
Atkins, FB, 181P(ab)
Atkins, HL, 342, 37P(ab), 52P(ab), 145P(ab), 221P(ab)
Atochina, EN, 1358
Attie, NJ, 15P(ab)
Aubert, B, 159P(ab)
Augustine, SC, 144P(ab)
Auinger, C, 44P(ab)
Aull, S, 207P(ab)
Aurengo, A, 1631
Austin, MC, 31P(ab), 208P(ab)
Avraham, A, 257
Avril, N, 222P(ab), 231P(ab)
Azarian, R, 47P(ab)
Azuma, M, 169P(ab)

Baba, Y, 68P(ab)
Babchyck, B, 185P(ab)
Babich, JW, 1308, 1685, 19P(ab), 37P(ab), 44P(ab), 66P(ab), 105P(ab), 151P(ab), 174P(ab), 175P(ab), 254P(ab)
Bacharach, SL, 567, 90P(ab), 143P(ab), 183P(ab)
Bache, RJ, 1985
Badalament, R, 216P(ab)
Badger, CC, 300
Badrinath, Y, 218P(ab)
Badrudosa, M, 234P(ab)
Baer, L, 75P(ab)
Bag, R, 212P(ab), 271P(ab)
Bagni, B, 147P(ab)
Bagni, I, 147P(ab)
Baidoo, KE, 19P(ab)
Bailey, DL, 360, 50P(ab)
Bair, HJ, 86P(ab), 218P(ab)
Bair, J, 1436
Baker, JR, 107P(ab)
Bakker, WH, 162P(ab), 165P(ab), 226P(ab)
Baldini, MT, 1741
Baldwin, B, 123P(ab)
Baldwin, RM, 228, 399, 10P(ab), 11P(ab), 84P(ab), 128P(ab), 129P(ab), 130P(ab), 201P(ab)
Balfe, DM, 117P(ab)
Ball, W, 53P(ab)
Ballas, S, 36P(ab)
Ballinger, J, 44P(ab)
Ballinger, JR, 202P(ab)
Ban, R, 84
Bander, NH, 101P(ab)
Bandyopadhyay, D, 211P(ab)
Banish, M, 178P(ab)
Banks, WR, 252P(ab)
Banyai, S, 97P(ab)
Banzo, J, 1303
Baranczuk, RJ, 274P(ab)
Baranowska-Kortylewicz, J, 79P(ab), 144P(ab), 162P(ab)
Baratti, D, 1970
Barbarics, E, 19P(ab)
Barbet, J, 55P(ab)
Barclay, A, 23P(ab)
Bardet, S, 55P(ab), 69P(ab)
Barentsz, J, 165P(ab)
Bares, R, 108P(ab), 111P(ab), 131P(ab), 230P(ab), 256P(ab)
Barker, P, 1797
Barker, WC, 90P(ab)
Barker, WW, 7
Barloon, T, 229P(ab)
Barnes, DC, 245, 416
Barnett, GH, 223P(ab)
Barnett, PA, 1831
Barnhart, C, 16P(ab), 60P(ab)
Baron, E, 1155
Baron, JI, 26P(ab)
Barr, SA, 91P(ab)
Barrera, J, 212P(ab)
Barrett, HH, 28P(ab), 93P(ab)
Barrett, JA, 52P(ab), 241P(ab), 245P(ab)
Barrio, JR, 83P(ab)
Barron, BJ, 1167
Barros, NG, 206P(ab)
Barrow, SA, 44P(ab), 174P(ab)
Bar-Shalom, R, 465, 229P(ab)
Bartenstein, P, 9P(ab), 33P(ab)
Barth, A, 220P(ab)
Bartiromo, A, 22P(ab)
Bartlett, ML, 90P(ab)
Barzilai, D, 1155
Basheim, H, 1602
Basile, F, 1245
Basmadjian, GP, 200P(ab)
Bassevitch, R, 126P(ab)
Basten, A, 195
Bastidas, DA, 257P(ab)
Basu, S, 136P(ab)
Bateman, TM, 609, 625, 16P(ab), 60P(ab), 114P(ab)
Battista, JJ, 111P(ab)
Baudhuin, T, 77P(ab)
Bauer, B, 235P(ab)
Bauer, J, 1896
Baulac, M, 207P(ab)
Baulieu, F, 237P(ab)
Baulieu, J-L, 237P(ab)
Baumgartner, C, 207P(ab)
Bautovich, G, 195
Bavaria, G, 628
Bax, JJ, 136P(ab)
Baxter, KG, 274P(ab), 275P(ab)
Baxter, L, 186P(ab)
Bayouth, JE, 63, 37P(ab), 142P(ab), 143P(ab), 160P(ab)
Bayraktar, M, 204
Bazin, JP, 13P(ab)
Bazzicalupo, L, 22P(ab)
Beanlands, RSB, 1286, 3P(ab)
Beattie, B, 1407
Beauchamp, HT, 52P(ab), 246P(ab)
Beaumier, PL, 158P(ab)
Beblavy, M, 45P(ab)
Becherer, A, 85P(ab)
Beck, H, 1436
Becker, DV, 368
Becker, JA, 20P(ab), 116P(ab), 207P(ab), 210P(ab)
Becker, WS, 1436, 56P(ab), 86P(ab), 112P(ab), 218P(ab)
Beckers, C, 1951, 131P(ab)

Bedigian, MP, 58P(ab), 125P(ab)
Beekman, FJ, 28P(ab)
Beeley, NRA, 63P(ab)
Beer, G, 1802
Beger, HG, 117P(ab), 224P(ab)
Behr, TM, 56P(ab), 86P(ab), 218P(ab), 1436
Behrendt, DB, 104P(ab)
Beilin, I, 569
Bekdik, CF, 204, 150P(ab)
Bekhechi, D, 1782, 114P(ab), 155P(ab)
Belakhlef, A, 211P(ab)
Belezzuoli, EV, 48P(ab), 170P(ab)
Belin, CA, 1444
Bell, WR, 80P(ab)
Bellande, E, 334, 261P(ab)
Bellemann, ME, 1842, 1569(le), 228P(ab)
Beller, GA, 674, 16P(ab), 47P(ab)
Belles, B, 266P(ab)
Bellina, CR, 144P(ab)
Beltran, M, 209P(ab)
Benali, H, 13P(ab)
Benari, B, 103P(ab)
Ben-Arie, Y, 465
Bender, H, 87P(ab), 214P(ab), 233P(ab)
Bendriem, B, 24P(ab), 50P(ab), 66P(ab), 67P(ab), 137P(ab), 187P(ab), 255P(ab)
Benedetto, AR, 1023, 172P(ab)
Ben-Haim, S, 1129, 229P(ab)
Benjamin, C, 1245
Benvenuti, C, 80P(ab), 110P(ab)
Beppu, Y, 226P(ab)
Bergh, G, 176P(ab)
Bergman, J, 989, 249P(ab), 252P(ab)
Bergmann, H, 272P(ab)
Bergmann, SR, 15S, 558, 1122, 23P(ab), 39P(ab)
Bergqvist, L, 158P(ab)
Berkovic, SF, 31P(ab), 208P(ab)
Berlad, G, 143P(ab)
Berlatzky, Y, 1802
Berlin, JA, 171P(ab)
Berman, DS, 356, 542, 609, 683, 1193, 59P(ab), 81P(ab), 103P(ab), 116P(ab)
Berman, HL, 1351
Berman, KF, 53P(ab)
Berná, L, 236P(ab)
Bernal, JM, 174P(ab)
Bernard, AM, 55P(ab)
Bernard, HF, 165P(ab)
Bernard, EJ, 1928
Bernardo, M, 935
Bernardo-Filho, M, 264P(ab)
Bernardy, JD, 80P(ab), 97P(ab)
Berridge, MS, 1665, 192(le), 6P(ab), 77P(ab), 248P(ab)
Berringer, J, 235P(ab)
Berry, CR, 157P(ab), 255P(ab)
Bertrand, A, 114P(ab)
Besnard, JC, 247P(ab), 257P(ab)
Best, SE, 130P(ab)
Betocchi, S, 1766
Better, N, 1805
Bettinardi, V, 107P(ab)
Bettman, L, 1129, 1155
Beyer, J, 96P(ab)
Bhadkamkar, VA, 37P(ab), 101P(ab)
Bhargava, S, 451
Bhattathiry, M, 8P(ab), 230P(ab), 273P(ab)
Bianchi, R, 146P(ab)
Bice, AN, 141
Biedermann, M, 569
Biedler, JL, 1179, 232P(ab)
Biegel, J, 199P(ab)
Biersack, HJ, 461, 1485, 1896, 151P(ab), 169P(ab), 208P(ab), 234P(ab), 247P(ab), 87P(ab), 214P(ab)
Bihl, H, 217P(ab)
Bijnens, B, 40P(ab)
Bilko, S, 22N
Billotey, C, 1631
Biniakiewicz, DS, 580, 1698, 244P(ab), 263P(ab)
Binns, RM, 276
Bischoff, H, 75P(ab)
Bishop, H, 41P(ab), 184P(ab)
Bisi, G, 1254, 1274, 49P(ab)
Bisson, G, 1245
Black, L, 30P(ab)
Black, SE, 1547
Bladin, PF, 31P(ab), 208P(ab)
Blahd, WH, 230P(ab), 273P(ab)
Blanchet, F, 125P(ab)
Blanksma, PK, 3P(ab), 23P(ab), 157P(ab)
Blasberg, RG, 1407
Blatter, J, 1842, 228P(ab)
Blaufox, MD, 254, 99P(ab), 100P(ab), 265P(ab)
Blecic, S, 1162
Blend, MJ, 180P(ab)
Blijham, GH, 1423
Block, P, 1758, 50P(ab)
Blohm, K, 50P(ab)
Blok, LM, 202P(ab)
Bloom, M, 95P(ab)
Blumenfeld, J, 99P(ab)
Blumenkopf, B, 30P(ab)
Blumenthal, RD, 55P(ab), 102P(ab), 219P(ab)
Blumer, ME, 242P(ab)
Bocher, M, 1802
Böck, F, 44P(ab)
Bockisch, A, 96P(ab), 162P(ab)
Boecking, A, 230P(ab)
Bogdanov, AA Jr., 1880
Boggi, U, 146P(ab)
Bohdiewicx, PJ, 274P(ab)
Bohuslavizki, KH, 186P(ab)
Boja, JW, 199P(ab)
Bok, BD, 113, 79P(ab)
Bol, A, 39P(ab), 77P(ab), 157P(ab)
Boles Ponto, LL, 104P(ab), 158P(ab), 182P(ab), 188P(ab)
Bolser, B, 109P(ab)
Bom, HS, 109P(ab)
Bomanji, JB, 251
Bonasera, TA, 6P(ab), 53P(ab), 141P(ab)
Bond, H, 239P(ab)
Bongiovanni, JA, 99P(ab), 265P(ab)
Bonino, C, 1571
Bonnin, F, 69P(ab), 134P(ab)
Boonvisut, S, 1792
Bootsma, A, 21P(ab)
Borer, JS, 169, 60P(ab), 77P(ab), 80P(ab)
Borgers, M, 38P(ab)
Borght, TV, 974
Bormans, G, 35P(ab), 83P(ab)
Borsato, N, 126P(ab)
Boscaino, A, 263
Bossuyt, A, 942, 1758, 50P(ab), 181P(ab)
Bossuyt, PMM, 151P(ab)
Böttcher, M, 39P(ab)
Botti, LE, 138P(ab)
Bottlaender, M, 66P(ab), 207P(ab), 261P(ab)
Botvinick, EH, 57P(ab), 135P(ab)
Bouchard, G, 2055(le)
Boudreau, RJ, 243P(ab)
Bounameaux, H, 189(le)
Bourachot, ML, 110P(ab), 78P(ab)
Bourgoignie, J, 266P(ab)
Bourguet, P, 55P(ab), 175P(ab)
Bourguignon, M, 47P(ab), 122P(ab), 176P(ab), 187P(ab), 261P(ab)
Bourque, J, 241P(ab), 245P(ab)
Bourquet, P, 1782
Bouvard, M, 75P(ab)
Bowen, WD, 246P(ab), 248P(ab)
Bowers, TR, 1985
Bowsher, JE, 17P(ab)
Boyce, BA, 63P(ab)
Boyer, AL, 123P(ab), 160P(ab)
Braat, SH, 587, 1581
Brackney, M, 142P(ab)
Bradfield, HA, 1134
Bradley, LA, 215P(ab)
Brady, LW, 87P(ab), 233P(ab)
Brady, TJ, 1880
Brakeman, P, 197P(ab)
Brambilla, M, 601
Brambs, H-J, 1342
Brandau, W, 9P(ab), 139P(ab)
Brass, L, 64P(ab)
Braun, DK, 173P(ab)
Braun, U, 233P(ab)
Braunstein, G, 15P(ab)
Brechbiel, MW, 1851, 29P(ab), 62P(ab), 63P(ab)
Brecht-Krauß, D, 113P(ab)
Bree, RL, 1145
Breeman, WAP, 162P(ab), 226P(ab)
Breen, SL, 111P(ab)
Breese, G, 130P(ab)
Breiter, HC, 75P(ab)
Breitz, HB, 191(le), 100P(ab), 158P(ab)
Bremner, JD, 228
Brennan, KM, 73P(ab)
Brenner, L, 84P(ab)
Brenner, NJ, 52P(ab), 246P(ab)
Brenner, W, 186P(ab)
Brenot, F, 47P(ab)
Bresnick, MN, 260P(ab)
Bressi, S, 95P(ab)
Bretagne, J-F, 1781, 175P(ab)
Bridge, P, 118P(ab)
Bridger, GJ, 29P(ab)
Briganti, V, 1254
Briggs, DE, 1612
Brihaye, C, 1116
Brill, AB, 368, 2058(br)
Brill, D, 1887(br)
Brinninger, G, 231P(ab)
Britton, KE, 251
Brizel, DM, 38P(ab)
Brodack, JW, 160P(ab)
Brodie, JD, 1457, 85P(ab)
Broekhuizen, AH, 151P(ab)
Broos, P, 35P(ab)
Broussard, EL, 102P(ab), 232P(ab)
Brown, CK, 182P(ab)
Brown, CV, 230P(ab), 273P(ab)
Brown, EA, 251
Brown, J, 130P(ab)
Brown, JK, 195P(ab)
Brown, KA, 169, 556, 703
Brown, RS, 141P(ab)
Brown, SJ, 471, 14P(ab), 227P(ab), 272P(ab)
Brown, T, 139P(ab)
Brown, WD, 185P(ab)
Brownell, A-L, 140P(ab), 198P(ab)
Brucato, V, 334, 261P(ab)
Brücke, T, 10P(ab), 207P(ab)
Brugger, RM, 242P(ab)
Bruland, ØS, 1506
Bruner, TA, 91P(ab), 172P(ab), 175P(ab), 178P(ab)
Brunetti, A, 263, 9P(ab), 21P(ab)
Brunetti, JC, 216P(ab)
Brunken, R, 707, 49P(ab), 110P(ab), 135P(ab), 155P(ab), 167P(ab)
Brunot, B, 1321
Brunotte, F, 114P(ab)
Bruns, C, 317
Bryan, RN, 9P(ab), 32P(ab)
Buachum, V, 1792
Bucciero, A, 9P(ab)
Buchbinder, BR, 107P(ab)
Buchbinder, SF, 1714
Buchegger, F, 101P(ab)
Buchpiguel, C, 95P(ab), 206P(ab)
Buchpiguel, CA, 1650, 53P(ab), 206P(ab), 215P(ab), 222P(ab), 226P(ab)
Buchsbaum, DJ, 258P(ab)
Buchsbaum, M, 24
Buchtel, HA, 138P(ab)
Buck, A, 18P(ab), 184P(ab)
Buckley, KR, 41P(ab)
Budd, RS, 1338
Budinger, TF, 183P(ab)
Buell, U, 569, 108P(ab), 111P(ab), 131P(ab), 230P(ab), 256P(ab)
Bueschen, AJ, 1017
Bugaj, JE, 139P(ab)
Buijs, W, 163P(ab)
Bujenovic, LS, 91P(ab), 115P(ab)
Büller, HR, 189(le)
Bump, K, 1217
Bundsen, P, 195
Buonocore, E, 220P(ab)
Buraggi, GL, 1741, 86P(ab)
Buralli, S, 144P(ab)
Burger, C, 18P(ab), 184P(ab)
Burgers, J, 216P(ab)
Burgess, J, 101P(ab)
Burke, G, 99P(ab)
Burke, JF, 177P(ab)
Burney, RJ, 141P(ab)
Burnham, D, 185(le)
Burns, HD, 6P(ab), 52P(ab), 124P(ab), 137P(ab), 246P(ab)
Burrows, L, 266P(ab)
Burt, RW, 49P(ab), 64P(ab), 111P(ab)
Burton, CA, 29P(ab)
Burton, F, 169P(ab)
Buscombe, JR, 240P(ab)
Buse, P, 117P(ab)
Bushnell, DL, 229P(ab), 194P(ab)
Busin, M, 151P(ab)
Butchko, G, 101P(ab)
Butler, SP, 1928
Butler, TT, 189(le)
Button, T, 342
Buttram, S, 257P(ab)
Buxton, R, 496
Byars, L, 41P(ab)

Cabahug, CJ, 37P(ab), 145P(ab), 201P(ab)
Cabana, MD, 171P(ab)
Cabico, JA, 59P(ab)
Cadiot, G, 96P(ab)
Cadorette, JE, 1390
Caglar, M, 150P(ab)
Cahill, C, 185P(ab)
Caillat-Vigneron, N, 1444, 231P(ab)
Caldeira-de-Araújo, A, 264P(ab)
Caldwell, CB, 1547
Callahan, RJ, 1880
Calne, DB, 18
Calvitto, M, 112P(ab), 218P(ab)
Camargo, EE, 211P(ab)
Camblin, JG, 89P(ab)
Camera, L, 1851, 63P(ab), 89P(ab)
Cameron, JA, 1880
Cameron, K, 195
Cameron, O, 141P(ab)
Camilleri, M, 159P(ab)
Caminis, J, 120P(ab)
Campbell, A, 1797

Campbell, MG, 223P(ab)
Campbell, S, 162P(ab), 209P(ab)
Campori, F, 144P(ab)
Campos, R, 211P(ab)
Camus, M, 217P(ab)
Canal, N, 95P(ab)
Candell, J, 469
Candini, GC, 147P(ab)
Caner, B, 204
Cann, CE, 195P(ab)
Cannizzaro, G, 601
Cannon, EP, 139P(ab)
Cannon, L, 102P(ab)
Cano, M, 1333
Cao, Z-J, 191P(ab)
Caracò, C, 1429
Caraher, J, 98P(ab)
Caravaglios, G, 146P(ab)
Carey, D, 638
Carey, JE, 405
Caride, VJ, 99P(ab)
Carlson, KJ, 78P(ab)
Carmant, L, 134P(ab), 207P(ab)
Carnaille, B, 57
Carney, BI, 168P(ab)
Carnochan, P, 42P(ab)
Carpenter, S, 99P(ab)
Carpinelli, A, 1571, 255P(ab)
Carr, C, 20P(ab)
Carrasquillo, JA, 1851, 29P(ab), 63P(ab), 89P(ab), 100P(ab)
Carretta, RF, 24N, 114P(ab)
Carril, JM, 174P(ab)
Carrió, I, 236P(ab)
Carroll, RG, 89P(ab)
Carroll, T, 21P(ab), 52P(ab), 138P(ab), 241P(ab), 245P(ab)
Carson, RE, 567, 183P(ab)
Carter, E, 175P(ab)
Casale, F, 1429
Casassus, P, 231P(ab)
Casati, R, 1571, 255P(ab)
Cascinelli, N, 1741
Casey, KL, 33P(ab)
Casillas, J, 99P(ab)
Cassel, D, 50P(ab), 136P(ab)
Cassidy, EH, 77P(ab), 248P(ab)
Castaigne, A, 80P(ab), 81P(ab), 110P(ab)
Castell, J, 469
Castellani, MR, 1741
Castelli, L, 1110, 9P(ab), 21P(ab), 114P(ab), 115P(ab)
Catafau, AM, 935, 1041
Cauvin, JC, 43P(ab)
Cavalli, A, 1933
Cavallini, AR, 147P(ab)
Cavanaugh, D, 221P(ab)
Cave, V, 50P(ab), 136P(ab)
Cawley, B, 184(le)
Cearlock, JR, 163P(ab)
Ceccarelli, C, 1418
Centoni, R, 1418
Cerqueira, MD, 169, 1731, 90P(ab), 254P(ab)
Cesani, F, 215P(ab), 229P(ab)
Cesaro, P, 1444
Chae, SC, 535
Chaiwatanarat, T, 1792
Chakraborty, DP, 2048(e)
Chakraborty, PK, 7P(ab), 98P(ab)
Chalon, S, 247P(ab), 257P(ab)
Chaly, T, 955, 10P(ab)
Chambers, JW, 1985
Champlin, R, 37P(ab)
Chan, B, 9P(ab), 74P(ab), 130P(ab), 196P(ab), 197P(ab)
Chan, KH, 17P(ab), 61P(ab), 170P(ab)
Chan, M, 70, 1313
Chan, YW, 152P(ab), 18P(ab)
Chandarlapaty, SKC, 68P(ab)
Chandler, ST, 188(le)
Chandramouli, B, 164, 76P(ab)
Chang, CP, 113P(ab), 205P(ab), 209P(ab)
Chang, CW, 142P(ab)
Chang, F, 200P(ab)
Chang, HK, 29P(ab)
Chang, IC, 176P(ab)
Chang, L, 43P(ab)
Chang, RS, 246P(ab)
Chang, SL, 204P(ab), 209P(ab), 219P(ab)
Chang, V, 64P(ab)
Chang, W, 5P(ab), 27P(ab), 92P(ab), 124P(ab), 190P(ab), 192P(ab)
Chapman, PT, 276, 45P(ab)
Charalambous, A, 256P(ab)
Charkes, ND, 65P(ab), 88P(ab), 170P(ab)
Charles, HC, 38P(ab)
Charlier, AA, 479
Charney, DS, 228, 399, 10P(ab), 11P(ab), 84P(ab), 128P(ab), 129P(ab), 130P(ab), 201P(ab)
Charron, M, 451
Chatal, JF, 12P(ab), 55P(ab)
Chatterjee, A, 21P(ab)
Chatterton, B, 88P(ab)
Chaudhuri, TK, 218P(ab)
Chaudhuri, TR, 218P(ab)
Chen, CC, 1471
Chen, C-T, 33P(ab)
Chen, DCP, 58P(ab), 125P(ab)
Chen, EQ, 68P(ab), 275P(ab)
Chen, FW, 98P(ab)
Chen, G, 1976
Chen, GTY, 1781
Chen, J-C, 28P(ab), 93P(ab)
Chen, JQ, 258P(ab)
Chen, KY, 142P(ab), 2031
Chen, M, 39P(ab)
Chen, MN, 241P(ab)
Chen, R, 94P(ab)
Chen, WL, 164P(ab), 242P(ab), 263P(ab)
Cheng, KT, 102P(ab)
Cheng, KY, 242P(ab)
Cheng, R, 100P(ab)
Cherry, SR, 110P(ab), 187P(ab)
Chetanneau, A, 55P(ab)
Chevres, A, 227P(ab)
Chiao, P, 1265, 108P(ab), 109P(ab), 115P(ab), 124P(ab), 185P(ab)
Chiariello, M, 1766
Chiba, H, 237P(ab)
Chiccoli, L, 147P(ab)
Chierichetti, F, 126P(ab)
Chiesa, R, 112P(ab)
Chin, CT, 14P(ab)
Chin, LM, 1217
Chinol, M, 15P(ab), 266P(ab)
Chiotellis, E, 263P(ab)
Chisin, R, 1802
Chiu, ML, 510
Chlouverakis, G, 60P(ab)
Cho, K, 68P(ab), 119P(ab)
Choe, YS, 53P(ab)
Choi, CW, 120P(ab)
Choi, J, 1007
Choi, NC, 1308, 8P(ab), 37P(ab)
Choi, Y, 50P(ab), 71P(ab), 141P(ab), 184P(ab)
Chossat, F, 114P(ab), 155P(ab)
Chou, KL, 113P(ab), 205P(ab), 209P(ab)
Christian, BT, 78P(ab)
Christian, PE, 74, 484, 5P(ab), 91P(ab), 172P(ab), 175P(ab), 178P(ab)
Christian, TF, 26P(ab), 114P(ab)
Chu, LS, 113P(ab), 205P(ab), 209P(ab)
Chu, TH, 638, 23P(ab)
Chua, T, 356, 116P(ab)
Chugani, HT, 104P(ab)
Chumpradit, S, 128P(ab), 246P(ab)
Chun, J, 99P(ab)
Chung, D-G, 217
Chung, EK, 1989
Chung, J-K, 1499, 113P(ab), 120P(ab), 240P(ab)
Chung, KY, 1125
Chung, W. 175P(ab)
Chung, Y, 100P(ab)
Churchwell, KB, 23P(ab)
Ciarmiello, A, 1766
Cideciyan, AV, 34P(ab)
Cikret, DF, 64P(ab)
Cinotti, L, 75P(ab)
Cintract, L, 159P(ab)
Cipolla, MS, 221P(ab)
Citron, B, 103P(ab)
Cittanti, C, 155P(ab)
Civelek, AC, 48P(ab), 80P(ab)
Clack, R, 5P(ab)
Claessens, RAMJ, 45P(ab), 89P(ab)
Clanton, JA, 199P(ab)
Clark, AJM, 416
Clark, J, 188P(ab)
Clark, R, 178P(ab)
Clarke, LP, 143P(ab), 161P(ab)
Clarke, SEM, 187(le)
Clarkston, W, 169P(ab)
Class, R, 233P(ab)
Clausen, M, 186P(ab)
Cleeland, R, 175P(ab)
Clifford, K, 186P(ab)
Cloninger, K, 609
Clorius, JH, 228P(ab)
Cloutier, DJ, 26P(ab)
Clunie, G, 37P(ab)
Coakley, D, 1450
Coates, GG, 149P(ab)
Cochoff, S, 1292
Coderre, JA, 342
Cody, R, 142P(ab)
Coenen, HH, 51, 32P(ab)
Coffey, J, 1450
Cohen, D, 133P(ab)
Cohen, I, 59P(ab)
Cohen, WA, 1476
Colacurcio, C, 48P(ab)
Colamussi, P, 155P(ab)
Colao, A, 165P(ab), 166P(ab)
Colas-Linhart, N, 79P(ab)
Coleman, RE, 135, 1398, 1707, 1771, 17P(ab), 25P(ab), 27P(ab), 33P(ab), 38P(ab), 44P(ab), 48P(ab), 76P(ab), 157P(ab), 179P(ab), 180P(ab), 190P(ab), 195P(ab), 196P(ab), 225P(ab), 228P(ab), 234P(ab), 255P(ab)
Collier, BD, 88P(ab), 127P(ab), 232P(ab)
Collignon, MA, 47P(ab)
Collins, J, 146P(ab)
Collins, P, 88P(ab)
Colombo, F, 1571, 255P(ab)
Colouris, GC, 273P(ab)
Colp, C, 476
Colvin, RB, 99P(ab)
Comar, D, 391, 1116, 1996, 82P(ab), 251P(ab)
Comazzi, V, 334, 261P(ab)
Combs, MJ, 159P(ab), 170P(ab)
Comet, M, 334, 114P(ab)
Comi, GC, 95P(ab)
Compagnone, G, 1933
Conley, RC, 74P(ab), 197P(ab)
Conlin, C, 120P(ab)
Connett, JM, 12P(ab), 161P(ab)
Connor, S, 72P(ab)
Constantine, JJ, 14P(ab)
Constantinesco, A, 1321
Constantinescu, A, 216P(ab), 222P(ab)
Conte, P, 1028
Conti, J, 102P(ab)
Conti, PS, 9P(ab), 134P(ab)
Conway, JJ, 26N, 432, 59P(ab)
Conzo, G, 166P(ab)
Cook, SA, 39P(ab)
Cooke, CD, 609, 1185, 126P(ab), 190P(ab)
Cooke, I, 139P(ab)
Cooper, AJL, 77P(ab)
Cooper, JA, 58P(ab), 154P(ab), 181P(ab), 238P(ab), 272P(ab)
Cooper, M, 139P(ab)
Cooper, S, 18
Coppola, R, 199P(ab), 247P(ab)
Corbett, JR, 32S, 4P(ab), 91P(ab), 109P(ab), 114P(ab), 155P(ab), 194P(ab)
Corcoran, D, 154P(ab)
Cordes, M, 1921
Corlija, M, 241P(ab), 260P(ab)
Cornel, JH, 136P(ab)
Cornelius, E, 275P(ab)
Coronado, L, 964
Correia, JA, 175P(ab), 177P(ab), 254P(ab)
Corstens, F, 163P(ab), 165P(ab)
Corstens, FHM, 1488, 45P(ab), 89P(ab), 240P(ab)
Cortadellas, J, 469
Cosgrove, GR, 107P(ab)
Cosimi, AB, 99P(ab)
Costa, A, 146P(ab)
Cotton, LA, 7P(ab), 1637, 115P(ab)
Cottraux, J, 75P(ab)
Coupland, DB, 1662
Cowan, KH, 89P(ab), 100P(ab)
Cox, MA, 217P(ab)
Coyle, JJ Jr., 273P(ab)
Cradduck, TD, 30N, 127P(ab), 180P(ab), 272P(ab)
Craik, FIM, 201P(ab)
Crane, A, 176P(ab)
Crane, PD, 225P(ab)
Crane, PL, 21P(ab)
Crawford, D, 215P(ab)
Crawford, S, 101P(ab)
Crayton, JW, 54P(ab), 204P(ab)
Crebs, CK, 172P(ab), 175P(ab)
Crebs, K, 74
Cremer, S, 194P(ab)
Cremerius, U, 131P(ab), 230P(ab)
Croft, BY, 159P(ab), 170P(ab)
Cromeens, DM, 66P(ab), 256P(ab)
Cronin, V, 86P(ab)
Crouzel, C, 78P(ab)
Cruz, N, 176P(ab)
Cullom, SJ, 1185, 189P(ab), 190P(ab)
Cumming, P, 10P(ab), 212P(ab)
Cunniff, D, 1028
Cuocolo, A, 621, 1110, 114P(ab), 115P(ab), 153P(ab), 165P(ab)
Curley, T, 36P(ab)
Curt, G, 100P(ab)
Cutler, PD, 51P(ab), 158P(ab)
Cutrone, J, 22P(ab)
Cyr, JE, 18P(ab), 138P(ab)
Czerniak, P, 225P(ab)
Czernin, J, 2031, 24P(ab), 39P(ab), 49P(ab), 110P(ab), 135P(ab), 155P(ab), 265P(ab)
Czichosz, R, 1116

DaCosta, M, 74P(ab)
Dadparvar, S, 471, 14P(ab), 227P(ab)

Dae, MW, 57P(ab), 135P(ab)
Daghighian, F, 1407, 36P(ab), 102P(ab)
Dahl, JR, 11P(ab)
Dahl, R, 955
Dahlberg, ST, 47P(ab), 82P(ab), 92P(ab), 125P(ab), 152P(ab)
Dahlbom, M, 51P(ab), 141P(ab), 187P(ab)
Dal, T, 150P(ab)
D'Alessandro, AM, T12P(ab)
D'Alessandro, T, 37P(ab)
Daley, JR, 26P(ab)
Dalipaj, M, 3P(ab)
Dalrymple, GV, 190(le), 117P(ab), 144P(ab)
Daltrozzo, E, 139P(ab)
Daly, JL, 273P(ab)
Damasio, H, 182P(ab)
Damhaut, P, 1996
Damphousse, D, 52P(ab)
Damphousse, P, 241P(ab), 262P(ab)
Danaceau, MA, 53P(ab)
Danilov, SM, 1358
Danna, SJ, 143P(ab)
Dannals, RF, 6P(ab), 9P(ab), 31P(ab), 52P(ab), 67P(ab), 73P(ab), 74P(ab), 85P(ab), 118P(ab), 124P(ab), 130P(ab), 137P(ab), 196P(ab), 250P(ab), 253P(ab)
Danos, P, 214P(ab)
Dansereau, RN, 242P(ab), 243P(ab)
Daou, D, 87P(ab)
Darcourt, J, 43P(ab)
D'Arcy, BJ, 115P(ab)
Darji, JT, 106P(ab), 210P(ab)
Dartevelle, P, 47P(ab)
Das, S, 70P(ab)
DaSilva, JN, 252P(ab)
Datseris, IE, 251
Datz, FL, 74, 484, 91P(ab), 100P(ab), 172P(ab), 175P(ab), 178P(ab), 240P(ab)
Daube-Witherspoon, ME, 40P(ab), 143P(ab)
Davis, R, 134P(ab)
Davis, RT, 134P(ab)
Day, DE, 242P(ab)
Dayanikli, F, 1265, 4P(ab), 115P(ab)
Dean, GW, 273P(ab)
Dean, RT, 80P(ab), 257P(ab)
de Bruln, K, 174P(ab)
Decety, J, 107P(ab)
Decker, E, 151P(ab)
deCosta, BR, 247P(ab)
De Deyn, P, 212P(ab)
De Fabritiis, A, 1933
Defer, G, 1444
Defrise, M, 5P(ab)
De Geest, H, 40P(ab)
De Geeter, F, 1758, 181P(ab)
Değirmenci, B, 1569(le)
DeGrado, TR, 51, 1398, 57P(ab), 157P(ab), 255P(ab)
De Groof, M, 2031
de Groot, TJ, 257P(ab)
Degueldre, C, 391, 1116
Dehdashti, F, 12P(ab), 117P(ab), 141P(ab), 230P(ab)
de Herder, WW, 163P(ab)
De Jager, R, 100P(ab), 86P(ab)
DeJesus, OT, 185P(ab)
de Jong, BM, 456
de Jong, M, 165P(ab)
de Jong, RM, 3P(ab)
de Kerviler, E, 96P(ab)
de Klerk, JMH, 1423, 163P(ab), 236P(ab)
Delaage, M, 55P(ab)
de Labriolle-Vaylet, C, 113
Delaloye, AB, 101P(ab)
Delaloye, B, 101P(ab)
Delatour, F, 87P(ab)
Delbeke, D, 30P(ab), 223P(ab)
de Leeuw, A, 163P(ab)
DelFiore, G, 82P(ab)
Delforge, J, 66P(ab), 67P(ab), 137P(ab), 255P(ab)
DelMonte, M, 124P(ab)
DeLong, DM, 1771, 225P(ab), 228P(ab), 25P(ab)
Delpassand, ES, 66P(ab), 256P(ab)
del Rosario, RB, 7P(ab), 109P(ab)
Del Sole, A, 210
De Maeght, S, 974
De Meyere, P, 236P(ab)
Demidecki, AJ, 1562(le)
Demoor, D, 1758, 50P(ab)
Demus, DD, 60P(ab)
De Nardi, P, 1970
DeNardo, DA, 1381, 158P(ab)
DeNardo, GL, 1381, 122P(ab), 158P(ab), 177P(ab), 244P(ab), 259P(ab)
DeNardo, SJ, 1381, 122P(ab), 158P(ab), 177P(ab), 244P(ab), 259P(ab)
Dence, CS, 249P(ab), 250P(ab)
Dendale, P, 1758
de Paulis, T, 199P(ab)
De Pauw, M, 77P(ab)
DePuey, EG, 169, 17N, 609, 699, 1237, 1292, 1593, 27P(ab), 70P(ab), 103P(ab), 154P(ab)
Derian, CK, 45P(ab)
De Roo, M, 35P(ab), 38P(ab), 40P(ab), 88P(ab), 211P(ab)
De Rosch, MA, 139P(ab)
Dertinger, S, 239P(ab)
De Sadeleer, C, 50P(ab), 265P(ab)
Desai, R, 1407
Descarries, L, 1822, 67P(ab)
Desgrez, A, 1328
DeSimone, PA, 146P(ab)
Desmond, TJ, 121P(ab)
Dethy, S, 1162
Deugnier, YM, 1782
Deutsch, E, 580, 1571, 1698, 139P(ab)
Deutsch, G, 21P(ab), 108P(ab)
Deutsch, K, 1571
Deutsch, KF, 139P(ab), 160P(ab)
De Vathaire, F, 159P(ab)
Deveaux, M, 57
de Ville de Goyet, J, 59P(ab)
Devillers, A, 175P(ab)
Devous, MD Sr., 16, 1094, 31P(ab), 54P(ab), 189P(ab), 191P(ab), 212P(ab)
DeVries, DJ, 189P(ab), 192P(ab)
de Vries, EGE, 83P(ab)
Dewan, N, 76P(ab)
Dewanjee, MK, 1054, 42P(ab), 65P(ab), 145P(ab), 153P(ab), 173P(ab), 263P(ab)
Dewey, SL, 67P(ab), 85P(ab), 94P(ab), 128P(ab), 129P(ab), 130P(ab), 140P(ab)
Dewhirst, MW, 38P(ab)
Dewhurst, TA, 1731, 254P(ab)
Dey, HM, 399, 64P(ab), 159P(ab)
Dhawan, V, 955, 10P(ab), 11P(ab), 211P(ab)
Dhingra, K, 101P(ab)
Diamond, GA, 59P(ab)
Díaz, C, 237P(ab)
Diaz, M, 11P(ab)
Díaz, R, 237P(ab)
Di Carli, M, 707, 135P(ab), 167P(ab), 49P(ab), 60P(ab)
Di Carlo, V, 1970
Dickinson, CZ, 206P(ab)
Diego, I, 11P(ab)
Diehl, DJ, 32P(ab)
Dienel, G, 176P(ab)
Dierckx, R, 212P(ab)
Dietrich, WD, 153P(ab)
Diggles, L, 22P(ab), 62P(ab)
DiGiovanni, L, 14P(ab)
Diksic, M, 10P(ab), 212P(ab)
Di Leo, C, 55P(ab), 112P(ab), 218P(ab)
Dilley, J, 98P(ab)
Dilsizian, V, 90P(ab), 183P(ab)
Di Luca, L, 144P(ab)
Dimitrakopoulou-Strauss, A, 38P(ab), 231P(ab), 236P(ab)
Ding, XS, 206P(ab)
Ding, Y-S, 7P(ab), 67P(ab), 85P(ab), 94P(ab), 129P(ab)
Di Paola, R, 13P(ab)
Diril, H, 219P(ab), 258P(ab)
Di Rocco, RJ, 1514
Di Sacco, S, 144P(ab)
Di Stefano, R, 144P(ab)
Ditlow, C, 98P(ab)
di Tullio, MT, 1429
Divgi, CR, 1748, 1976, 101P(ab), 102P(ab), 232P(ab), 235P(ab)
Dobbeleir, A, 212P(ab)
Dobbin, S, 252P(ab)
Doerr, RJ, 11P(ab), 219P(ab)
Dogan, AS, 432, 1558(le), 104P(ab)
Dognon, AM, 247P(ab)
Dohmen, BM, 108P(ab), 111P(ab)
Doll, J, 75P(ab), 220P(ab)
Dominquez, V, 24P(ab)
Donahoe, K, 368
Dondi, M, 601, 1933
Dong, VM, 16P(ab), 60P(ab)
Donohoe, KJ, 171P(ab)
Donohoe, M, 260P(ab), 262P(ab)
Donohue, TJ, 23P(ab)
Dooneief, G, 118P(ab)
Dop, F-J, 96P(ab)
Dorffner, G, 2041
Dörr, U, 217P(ab)
Dose, J, 222P(ab), 231P(ab)
Douville, C, 64P(ab)
Dowell, J, 145P(ab)
Downing, PD, 70P(ab)
Doyley, M, 42P(ab)
Drane, WE, 1051
Dresel, S, 11P(ab)
Druck, MN, 2055(le)
Drum, DE, 47P(ab)
Drury, I, 141P(ab)
Duara, R, 7
Duatti, A, 334, 155P(ab), 261P(ab)
Duboc, D, 24P(ab)
Dubois-Randé, JL, 81P(ab)
Duckett, JW, 1602, 237P(ab)
duCret, RP, 1985
Dufault, R, 262P(ab)
Duit-Schedlmayer, J, 2041
Duncan, D, 1466, 209P(ab)
Duncan, DB, 202P(ab)
Duncan, G, 44P(ab)
Duncan, JR, 1560(le)
Dunigan, K, 142P(ab)
Dunn, EK, 2054(le)
Dunn, TJ, 139P(ab)
Dunn, WL, 159P(ab)
Dupont, P, 187P(ab)
Durack, LD, 180P(ab)
Durak, H, 1569(le)
Duryea, RA, 98P(ab), 198P(ab)
Dutschka, K, 33P(ab)
Duvauferrier, R, 1782
Dworkin, HJ, 274P(ab)

Eades, CG, 1777, 104P(ab)
Early, T, 215P(ab)
Eary, JF, 192(le), 180P(ab)
Eaves, C, 23P(ab)
Eber, B, 2057(le)
Eber, O, 2057(le)
Ebert, A, 51
Eckard, DA, 275P(ab)
Eckelman, WC, 53P(ab), 83P(ab), 200P(ab), 249P(ab)
Eckerman, KF, 1377, 112P(ab)
Edelbroek, M, 185(le)
Edlund, B, 983
Edwards, DS, 241P(ab), 243P(ab), 245P(ab)
Edwards, GK, 1992
Edwards, JCW, 37P(ab)
Edwards, S, 52P(ab)
Edwards, WB, 106P(ab)
Efange, SMN, 94P(ab), 243P(ab)
Effert, P, 230P(ab)
Efird, JT, 37P(ab)
Egan, T, 151P(ab)
Ehrhardt, GJ, 241P(ab), 242P(ab), 244P(ab)
Ehrlich, LE, 1547
Eichling, JO, 158P(ab)
Eidelberg, D, 955, 10P(ab), 11P(ab), 211P(ab)
Einhorn, LH, 117P(ab)
Eisenberg, B, 149?(ab)
Eisner, RL, 638, 23P(ab)
Elbert, T, 33P(ab)
Elder, RC, 580, 1698
Elgarresta, L, 235P(ab)
Elgazzar, AH, 580, 1753, 166P(ab), 239P(ab), 271P(ab), 276P(ab), 277P(ab)
Elger, CE, 1896, 208P(ab)
Eli, PJ, 425, 1110, 37P(ab), 240P(ab)
Ellert, E, 77P(ab)
Ellidokuz, E, 1569(le)
Elliott, AT, 186(le)
Elmaleh, DR, 496, 1685, 121P(ab), 140P(ab), 151P(ab), 198P(ab), 254P(ab)
Elsinga, PH, 83P(ab), 257P(ab)
Elsworth, JD, 140P(ab)
Emlein, GE, 125P(ab)
Emrich, D, 36P(ab), 132P(ab)
Emrich, JG, 87P(ab), 233P(ab)
Enas, JD, 73P(ab)
Encabo, G, 469
Enderle, G, 1342
Endo, K, 296, 504, 1174, 1482, 1677, 197P(ab)
Engeler, CE, 1985
English, RJ, 61P(ab), 116P(ab)
Ensminger WD, 1637
Epelbaum, R, 465
Erb, D, 86P(ab)
Eriksson, P, 983
Erlandsson, K, 342, 221P(ab)
Ernstoff, R, 206P(ab)
Eshima, D, 349, 1198, 262P(ab), 264P(ab)
Eskridge, JM, 64P(ab)
Espinosa, A, 237P(ab)
Espinosa, RE, 26P(ab)
Esposito, G, 53P(ab)
Espy, C, 57P(ab)
Esselstyn, CB, 68?(ab)
Esser, PD, 61P(ab), 65P(ab)
Essiambre, R, 15P(ab)
Esteban, JE, 234P(ab)
Estes, J, 101P(ab)
Estorch, M, 236P(ab)
Ethier, S, 141P(ab)
Eulitz, C, 33P(ab)
Evans, N, 86P(ab)
Even-Sapir, E, 245, 416, 1129, 229P(ab)
Ewels, BA, 260P(ab)
Excalera, T, 1303
Ezquerra, NF, 116P(ab)

Ezuddin, S, 42P(ab), 65P(ab), 263P(ab)

Faber, TL, 1185, 72P(ab), 138P(ab), 155P(ab), 189P(ab), 190P(ab)
Fabian, C, 274P(ab)
Fagret, D, 334, 114P(ab), 155P(ab)
Fahey, FH, 1777, 104P(ab)
Fain, R, 117P(ab)
Faivre-Chauvet, A, 12P(ab)
Falcone, A, 144P(ab)
Falke, THM, 1152
Fallani, F, 1933
Fang, QW, 29P(ab)
Fanti, S, 1933
Faraggi, M, 96P(ab), 98P(ab), 125P(ab)
Farahati, J, 238P(ab)
Farahi, JB, 273P(ab)
Farde, L, 84P(ab), 122P(ab), 253P(ab)
Farnsworth, A, 63P(ab)
Farragi, M, 113
Farrell, E, 86P(ab)
Fass, J, 108P(ab)
Faught, E, 30P(ab)
Fawwaz, R, 95P(ab)
Fawwaz, RA, 216P(ab), 258P(ab)
Fayad, P, 64P(ab)
Fazio, F, 210, 1571, 1970, 55P(ab), 95P(ab), 107P(ab), 112P(ab), 218P(ab), 255P(ab)
Fazio, S, 165P(ab)
Fazzini, PF, 1254, 1274, 49P(ab)
Fedders, G, 256P(ab)
Fein, G, 214P(ab)
Feine, U, 1342
Feinendegen, LE, 51, 1644, 8P(ab)
Feinmesser, R, 257
Feistel, H, 239P(ab)
Feldstein, ML, 47P(ab)
Felix, R, 1921
Feng, D, 105P(ab)
Feng, YX, 90P(ab)
Fennell, R, 1051
Ferdeghini, M, 146P(ab)
Ferguson, D, 275P(ab)
Ferlin, G, 126P(ab)
Fernandez, OA, 167P(ab)
Fernandez-Pol, JA, 273P(ab)
Fernandez-Ulloa, M, 166P(ab)
Ferone, D, 166P(ab)
Ferrant, A, 131P(ab)
Ferrazzini, S, 147P(ab)
Ferrieri, RA, 42P(ab)
Fessler, JA, 405, 652, 68P(ab), 82P(ab)
Feuerestein, I, 100P(ab)
Fialka, V, 150P(ab)
Ficaro, EP, 652, 1265, 7P(ab), 91P(ab), 92P(ab), 115P(ab), 191P(ab)
Ficker, JH, 239P(ab)
Fields, CG, 106P(ab)
Fields, GB, 106P(ab)
Fig, LM, 1013, 1333, 109P(ab), 217P(ab)
Figueroa, N, 228P(ab)
Filipow. L, 272P(ab)
Finat-Duclos, F, 219P(ab)
Fine, E, 99P(ab)
Finestone, H, 476
Fink, GR, 2011, 119P(ab), 202P(ab)
Fink, LM, 190(le)
Fink-Bennett, D, 609, 206P(ab), 274P(ab)
Finley, P, 19P(ab)
Finn, RD, 1407, 232P(ab)
Fioravanti, C, 52P(ab), 246P(ab)
Fioretti, PM, 136P(ab)
Firestone, LL, 198P(ab)
Firouzbakht, ML, 253P(ab)
Fischer, DR, 300
Fischman, AJ, 269, 496, 1308, 1685, 1880, 8P(ab), 19P(ab), 20P(ab), 23P(ab), 35P(ab), 37P(ab), 44P(ab), 45P(ab), 66P(ab), 75P(ab), 77P(ab), 89P(ab), 105P(ab), 107P(ab), 121P(ab), 140P(ab), 151P(ab), 174P(ab), 175P(ab), 177P(ab), 198P(ab), 254P(ab)
Fisher, AB, 1358
Fisher, RS, 88P(ab)
Fisher, S, 141P(ab)
Fishman, DL, 1989
Flameng, W, 38P(ab)
Flamm, SD, 60P(ab), 135P(ab)
Flanagan, RJ, 628
Fleischmann, W, 113P(ab)
Fleming, RG, 1808
Flesher, J, 128P(ab)
Fletcher, JW, 2003, 120P(ab), 154P(ab), 273P(ab)
Flood, M, 47P(ab)
Flores, C, 165P(ab)
Floyd, CE Jr., 17P(ab), 48P(ab)
Fogarasi, M, 127, 105P(ab), 242P(ab)
Foged, C, 122P(ab), 253P(ab)
Fojaja, MRG, 166P(ab)
Folke, M, 266
Folks, R, 609, 1198, 190P(ab), 262P(ab)
Foragrasi, M, 1568(le)
Ford, PV, 178P(ab)
Fordyce, W, 100P(ab)
Forrester, JW, 199P(ab)
Forstrom, LA, 26P(ab), 159P(ab), 275P(ab)
Foss, JN, 68P(ab), 99P(ab)
Fossella, FV, 63
Foster, NL, 20P(ab)
Fouchier, JHCM, 163P(ab)
Foulon, C, 94P(ab)
Foult, JM, 125P(ab)
Fowler, JS, 7P(ab), 42P(ab), 67P(ab), 85P(ab), 94P(ab), 129P(ab), 130P(ab), 140P(ab), 213P(ab)
Frackowiak, RSJ, 181P(ab), 185P(ab), 186P(ab)
Fraile, M, 469
Franano, FN, 1560(le)
Franceschi, D, 342, 37P(ab), 221P(ab)
Franceschi, G, 144P(ab)
Franceschi, M, 210, 342, 221P(ab)
Francis, IR, 1145, 1714, 101P(ab)
Franck, G, 391
Franco, JA, 189(le)
François, D, 59P(ab)
Franculli, F, 1766
Frangin, Y, 247P(ab)
Frank, RJ, 182P(ab)
Frankel, A, 445
Franken, PR, 1758, 50P(ab), 181P(ab)
Franks, W, 217
Franssen, EJF, 456, 1560(le), 83P(ab), 210P(ab)
Frederic, P, 108P(ab)
Frederick, D, 93P(ab), 128P(ab), 246P(ab)
Freedman, NMT, 90P(ab)
Freeman, E, 215P(ab)
Freitas, JE, 24P(ab)
Frenkel, A, 1129, 1155
Fretzayas, AM, 1048
Frey, EC, 17P(ab), 91P(ab), 115P(ab), 195P(ab)
Frey, KA, 405, 949, 1528, 20P(ab), 33P(ab), 68P(ab), 93P(ab), 119P(ab), 121P(ab), 140P(ab), 141P(ab)
Freyne, P, 1450
Fridrich, R, 317
Friedlander, G, 125P(ab)
Friedman, HS, 38P(ab), 44P(ab)
Friedman, JD, 542, 609, 683, 59P(ab), 81P(ab), 103P(ab)
Friedman, M, 1292
Frist, WH, 223P(ab)
Frith, CD, 181P(ab), 185P(ab)
Froment, JC, 75P(ab)
Front, A, 411
Front, D, 445, 465, 1129, 1155, 229P(ab)
Frost, JJ, 31P(ab), 67P(ab), 182P(ab), 197P(ab)
Frouin, F, 13P(ab)
Frouin, V, 50P(ab)
Fry, J, 216P(ab)
Fugazzola, L, 1418
Fujibayashi, Y, 1910, 156P(ab), 201P(ab), 246P(ab)
Fujii, R, 121P(ab)
Fujimori, K, 233P(ab)
Fujita, F, 197P(ab)
Fujita, H, 1097, 201P(ab)
Fujita, M, 1366, 131P(ab), 203P(ab)
Fujita, T, 27, 109P(ab), 179P(ab), 194P(ab), 196P(ab), 200P(ab), 208P(ab)
Fukuchi, K, 1371, 46P(ab), 64P(ab), 194P(ab)
Fukuchi, M, 153P(ab)
Fukui, H, 13P(ab)
Fukui, M, 43P(ab)
Fukuma, H, 226P(ab)
Fukumoto, M, 224P(ab)
Fukumura, T, 43P(ab), 210P(ab), 227P(ab), 231P(ab)
Fukunaga, M, 149P(ab)
Fukuyama, H, 1
Fulmer, H, 70P(ab)
Furudate, M, 233P(ab)
Furukata, K, 250P(ab)
Furukawa, T, 237P(ab)
Furukawa, Y, 149P(ab)
Fusamoto, H, 13P(ab)
Fuseau, C, 57P(ab), 78P(ab)
Fusselman, MJ, 141P(ab)
Futami, S, 44

Gabel, M, 1698
Gabor, FV, 74
Gaehle, GG, 249P(ab)
Gage, HD, 1777, 104P(ab)
Gaitini, D, 465
Galetta, S, 209P(ab)
Galgon, R, 198P(ab)
Galinier, E, 247P(ab)
Gallagher, R, 476
Galt, JR, 20N, 72P(ab), 138P(ab)
Galve, E, 469
Galy, G, 75P(ab)
Gandelman, MS, 201P(ab)
Gandler, WR, 40P(ab), 61P(ab)
Ganju-Krishan, A, 42P(ab), 145P(ab)
Gansow, OA, 1851, 29P(ab), 62P(ab), 63P(ab)
Ganz, W, 42P(ab), 65P(ab), 133P(ab), 263P(ab)
Garada, B, 1902, 210P(ab)
Garber, CE, 26P(ab)
Garber, EW, 60P(ab)
Garcia, A, 469
Garcia, EV, 609, 1005, 1185, 1237, 72P(ab), 126P(ab), 138P(ab), 189P(ab), 190P(ab)
Garcia, JR, 35P(ab), 76P(ab), 131P(ab), 220P(ab)
García, L, 228P(ab)
Garcia, MJ, 26P(ab)
Garcia-Miralles, M, 1303
Gardin, I, 113, 79P(ab)
Gardner, KA, 51P(ab)
Garg, PK, 1506, 157P(ab), 255P(ab)
Garg, S, 1506, 157P(ab), 255P(ab)
Gargan, PE, 80P(ab)
Garmestani, K, 1851, 29P(ab), 63P(ab)
Garoufi, AI, 1048
Garreau, L, 247P(ab)
Garrison, DA, 156P(ab)
Gärtner, H-V, 1342
Gascoyne, RD, 1662
Gaskin, G, 132P(ab)
Gasparini, M, 1741, 86P(ab)
Gasperi, M, 1418
Gass, MA, 149P(ab)
Gasson, HJ, 8P(ab)
Gaston, R, 1303
Gatley, SJ, 67P(ab), 85P(ab), 94P(ab), 129P(ab), 130P(ab), 140P(ab)
Gaul, FE, 29P(ab)
Gavriljuk, V, 1358
Geissbuhler, A, 41P(ab)
Gelardi, G, 95P(ab)
Gelbard, AS, 77P(ab)
Gelfand, MJ, 1753
Geltman, EM, 39P(ab)
Gentile, R, 144P(ab)
Georgiou, M, 34P(ab), 68P(ab), 99P(ab), 266P(ab)
Gérard, D, 75P(ab)
Gerard, SK, 154P(ab), 214P(ab)
Gerbaudo, VH, 135P(ab), 167P(ab)
Gerber, BL, 39P(ab), 157P(ab)
Germain, P, 1321
Germano, G, 356, 542, 609, 683, 1193, 81P(ab), 103P(ab), 116P(ab)
Gerrits, CJH, 132P(ab)
Gerson, MC, 580, 1698
Gervino, EV, 740
Gestin, JF, 12P(ab)
Gewirtz, H, 23P(ab), 77P(ab)
Geworski, L, 32P(ab), 33P(ab)
Ghaemi, M, 107P(ab)
Ghafouripour, AK, 1054, 42P(ab), 65P(ab), 145P(ab), 173P(ab), 263P(ab)
Ghali, SK, 1959
Ghesani, M, 70P(ab), 154P(ab)
Ghods, M, 16P(ab), 27P(ab), 136P(ab)
Giap, HB, 123P(ab), 142P(ab), 143P(ab), 160P(ab), 196P(ab)
Gibbons, RJ, 26P(ab), 114P(ab)
Gibson, RE, 52P(ab), 124P(ab), 137P(ab), 246P(ab)
Giganti, M, 114P(ab), 155P(ab)
Gilardi, MC, 210
Gildersleeve, DL, 405, 109P(ab), 98P(ab)
Gilewski,T, 235P(ab)
Gilland, DR, 135, 1707, 17P(ab), 180P(ab), 196P(ab)
Gillet, M, 101P(ab)
Gilmore, MP, 47P(ab)
Gilson, S, 118P(ab)
Ginos, JZ, 1407
Gioia, G, 27P(ab)
Gips, S, 411, 1155
Giulianotti, PC, 146P(ab)
Gjedde, A, 10P(ab), 185P(ab), 196P(ab), 212P(ab)
Gladding, R, 53P(ab)
Glajch, JL, 243P(ab), 260P(ab)
Glaser, R, 142P(ab)
Glaspy, JA, 8P(ab), 141P(ab), 221P(ab)
Glass, DM, 132P(ab), 172P(ab)
Glass, EC, 8P(ab), 230P(ab), 273P(ab)
Glatting, G, 156P(ab)
Glazer, GM, 1145
Glenn, S, 101P(ab)
Glenville, B, 136P(ab)

Glick, SJ, 188P(ab), 192P(ab), 193P(ab)
Glover, DK, 47P(ab)
Glowacka, D, 241P(ab), 245P(ab)
Glynn, TP Jr., 1808
Gmeiner, B, 63P(ab)
Go, KG, 213P(ab), 227P(ab)
Go, RT, 26P(ab), 39P(ab), 68P(ab), 133P(ab)
Gobar, LS, 221P(ab)
Goddu, SM, 303, 521, 1861, 123P(ab)
Godoy, N, 220P(ab)
Goeckeler, W, 100P(ab)
Gohchi, K, 1811
Goins, B, 1491, 42P(ab)
Goldberg, B, 86P(ab)
Goldenberg, DM, 1028, 1436, 55P(ab), 56P(ab), 62P(ab), 102P(ab), 112P(ab), 219P(ab), 236P(ab), 258P(ab), 259P(ab)
Goldfine, SM, 77P(ab)
Goldhaber, SZ, 47P(ab)
Goldman, S, 1162
Goldschmidt, H, 231P(ab)
Goldsmith, SJ, 9N, 168, 368, 1748, 1976, 7P(ab), 97P(ab)
Goldstein, DS, 964
Goldstein, SR, 40P(ab)
Golsch, GJ, 1753
Golub, RJ, 26P(ab)
Gomez, CA, 235P(ab)
Gómez-Barquín, R, 174P(ab)
Gong, W, 54P(ab), 189P(ab), 191P(ab)
Gonzales, E, 23P(ab)
Gonzalez, CE, 1333
Gonzalez, JA, 59P(ab)
González, R, 165P(ab)
González, RG, 20P(ab)
Gonzalez-Mangers, E, 189(le)
Gonzalez-Monclús, E, 935
Goodbody, A, 44P(ab)
Goodman, P, 228P(ab)
Gooneratne, N, 1292
Gordon, E, 235P(ab)
Gordon, I, 438
Gordon, L, 125P(ab)
Gorenberg, M, 445
Gorey, JG, 199P(ab), 247P(ab)
Görges, R, 162P(ab)
Goris, ML, 161P(ab)
Gortel, ZW, 5P(ab)
Gosfield, E, 1138
Gosselin, M, 1782
Goto, I, 210P(ab)
Gotoff, RA, 88P(ab)
Gotoh, E, 226P(ab)
Gotsman, MS, 1802
Gottschalk, A, 1931(e)
Gould, HR, 220P(ab), 239P(ab)
Gould, JS, 88P(ab)
Govindan, SV, 62P(ab), 258P(ab), 259P(ab)
Grabowski, TJ, 182P(ab)
Grady, C, 7
Graeff, H, 222P(ab), 231P(ab)
Graf, R, 197P(ab)
Grafström, G, 158P(ab)
Grafton, ST, 134P(ab)
Graham, DL, 349
Graham, MC, 1407, 1976, 7P(ab), 36P(ab), 101P(ab), 112P(ab), 123P(ab)
Graham, MM, 34P(ab), 273P(ab)
Graham, W, 44P(ab), 174P(ab)
Gramatzki, M, 1436
Graney, WF, 95P(ab)
Grant, EJ, 101P(ab), 111P(ab), 142P(ab), 143P(ab)
Grassi, F, 210, 95P(ab)
Gravelle, DR, 1959
Graves, M, 133P(ab)
Gray, BG, 217
Gray, L, 209P(ab)
Grebenau, R, 258P(ab), 259P(ab)
Green, G, 87P(ab)
Green, JM, 243P(ab), 260P(ab), 262P(ab)
Green, MV, 1538, 40P(ab), 61P(ab), 143P(ab)
Greenough, R, 195
Greenspan, 368
Greer, KL, 135, 1707, 179P(ab), 180P(ab), 196P(ab)
Gregel, C, 162P(ab)
Gregoriou, GK, 4P(ab)
Greiff, L, 176P(ab)
Greiling, H, 256P(ab)
Greiner, DP, 259P(ab)
Greiner, JW, 101P(ab)
Grenman, S, 1618, 117P(ab)
Gretzer, MB, 66P(ab), 256P(ab)
Greve, JC, 174P(ab)
Griffeth, LK, 117P(ab), 141P(ab), 230P(ab)
Griffin, BP, 26P(ab)
Griffiths, C, 188(le)
Griffiths, GL, 62P(ab), 219P(ab), 258P(ab), 259P(ab)
Grimmel, S, 223P(ab), 224P(ab)
Grimon, G, 1328, 47P(ab)
Grizzle, WE, 1017
Groch, MW, 178P(ab)
Grootoonk, S, 50P(ab), 181P(ab)
Gropler, RJ, 999, 39P(ab), 156P(ab)
Groshar, D, 445
Gross, K, 149P(ab), 271P(ab)
Gross, MD, 1013, 1145, 1333, 108P(ab), 109P(ab), 124P(ab), 256P(ab)
Grossi, D, 21P(ab)
Grossman, M, 206P(ab), 209P(ab)
Grossman, S, 9P(ab)
Growdon, J, 20P(ab)
Gruaz-Guyon, A, 55P(ab)
Grummon, GD, 139P(ab)
Grünwald, F, 461, 1485, 1896, 151P(ab), 169P(ab), 208P(ab), 214P(ab)
Gu, ZQ, 247P(ab)
Guan, D, 87P(ab)
Guan, S-I, 134P(ab)
Guelar, A, 1041
Guerchaft, M, 213P(ab)
Guererro, JL, 1076
Guerin, F, 24P(ab)
Guerra, J, 266P(ab)
Guerreau, D, 261P(ab)
Guerreiro, CA, 211P(ab)
Guerreiro, MM, 211P(ab)
Guerrero, TM, 187P(ab)
Guhlke, S, 73P(ab), 247P(ab)
Guillaud, C, 261P(ab)
Guillaume, M, 1116
Guillevin, L, 231P(ab)
Guilloteau, D, 247P(ab), 257P(ab)
Guimaraes, A, 20P(ab)
Gulfo, J, 102P(ab)
Gullberg, GT, 484, 4P(ab), 5P(ab), 18P(ab), 81P(ab), 91P(ab)
Gunasekera, R, 172P(ab)
Gunter, DL, 33P(ab)
Günther, I, 18P(ab)
Guo, LW, 161P(ab)
Guo, WY, 204P(ab), 209P(ab)
Gupta, NC, 164, 1566(le), 76P(ab)
Gur, RC, 54P(ab), 74P(ab), 214P(ab)
Gur, RE, 54P(ab), 74P(ab), 214P(ab)
Guttman, FM, 168P(ab)
Guyader, D, 1782
Gyulai, L, 53P(ab)

Haaparanta, M, 989, 252P(ab)
Haasler, GB, 232P(ab)
Haaxma, R, 456
Habbab, N, 212P(ab), 271P(ab)
Haberkorn, U, 1842, 220P(ab), 228P(ab)
Hacein-Bey, L, 65P(ab)
Hachamovitch, R, 59P(ab)
Hada, Y, 154P(ab)
Hademenos, GJ, 143
Hagemeister, FB, 35P(ab), 131P(ab)
Hahn, EG, 239P(ab)
Hahn, EW, 216P(ab)
Hahn, K, 74P(ab), 87P(ab), 96P(ab), 162P(ab)
Haidet, GC, 1985
Haines, A, 63P(ab)
Haire, WD, 190(le)
Haist, JL, 1808
Hakman, ME, 163P(ab)
Halama, JR, 271P(ab)
Halasz, NA, 170P(ab)
Halber, M, 71P(ab)
Haldemann, AR, 145P(ab), 217P(ab), 220P(ab)
Halkar, RK, 234P(ab)
Hall, H, 84P(ab)
Halldin, C, 84P(ab), 122P(ab), 253P(ab)
Haller, D, 102P(ab)
Halldin, C, 250P(ab)
Hällsten, U, 249P(ab)
Halmos, G, 259P(ab)
Ham, HR, 168P(ab)
Hamacher, K, 73P(ab)
Hamada, S, 81P(ab)
Hamamoto, K, 1134, 171P(ab), 189P(ab), 203P(ab)
Hamberg, LM, 1308, 8P(ab), 37P(ab)
Hamet, P, 628
Hamill, JJ, 92P(ab)
Hamill, TG, 6P(ab), 52P(ab), 124P(ab), 137P(ab)
Hamilton, D, 1450
Hamlet, S, 1007
Hammes, RJ, T12P(ab)
Hamzei, A, 156P(ab)
Han, BK, 150P(ab)
Han, SH, 1423
Hancock, L, 275P(ab)
Handa, N, 32, 1226, 203P(ab)
Handler, CE, 16P(ab)
Handt, S, 131P(ab), 230P(ab)
Hanna, M, 263P(ab)
Hanna, MG Jr., 86P(ab)
Hanrahan, SM, 73P(ab)
Hanrath, P, 569
Hansen, CL, 38S, 49P(ab)
Hansen, HJ, 1028, 62P(ab), 236P(ab), 258P(ab), 259P(ab)
Hansen, HW, 2031
Hansen, L, 1198, 262P(ab), 264P(ab)
Hanson, J, 185P(ab)
Hanson, M, 228P(ab)
Hanson, RN, 121P(ab)
Hanyu, H, 206P(ab)
Har-El, G, 2054
Harada, K, 19P(ab)
Haradahira, T, 248P(ab), 255P(ab)
Haraga, LT, 236P(ab)
Harasko-van der Meer, C, 10P(ab)
Harding, LK, 186(le)
Harding, P, 88P(ab)
Hardoff, R, 411, 1155
Har-El, G, 2053(le)
Harkness, BA, 1777, 104P(ab)
Harkönen, R, 989
Haronian, H, 91P(ab)
Harper Mozley, LM, 214P(ab)
Harris, J, 195, 130P(ab)
Harris, L, 44P(ab), 228P(ab)
Harris, PJ, 118P(ab)
Harris, TD, 52P(ab), 241P(ab), 245P(ab), 262P(ab)
Harris, TS, 212P(ab)
Harrison, AA, 276
Harrison, KA, 190(le), 117P(ab), 144P(ab), 221P(ab)
Harrison, RD, 260P(ab)
Harrison, RL, 34P(ab), 105P(ab)
Hartiala, J, 989
Hartikainen, P, 118P(ab)
Hartman, JJ, 558, 23P(ab)
Hartman, N, 3P(ab)
Hartman, NG, 1570(le)
Hartmann, O, 134P(ab)
Hartung, T, 117P(ab)
Harvey, RH, 179
Harwood, SJ, 89P(ab), 217P(ab)
Hasegawa, A, 84
Hasegawa, BH, 195P(ab)
Hasegawa, H, 193P(ab), 194P(ab)
Haseman, MK, 76P(ab)
Hashikawa, K, 32, 1226, 203P(ab)
Hashimoto, K, 1371, 46P(ab)
Hashimoto, N, 205P(ab)
Hashimoto, T, 110P(ab)
Hashizume, S, 289, 217P(ab)
Haskard, DO, 276, 45P(ab)
Hatazawa, J, 1097, 2019, 63P(ab), 201P(ab)
Hattner, RS, 429, 2056(le)
Hattori, N, 146P(ab)
Haug, CE, 99P(ab)
Hautmann, R, 223P(ab)
Hawk, TC, 76P(ab)
Hawkins, RA, 8P(ab), 71P(ab), 137P(ab), 141P(ab)
Hawman, EG, 92P(ab), 191P(ab)
Hay, RV, 256P(ab)
Hayase, N, 197P(ab)
Hayashi, I, 84
Hayashi, N, 13P(ab), 169P(ab)
Hayashida, K, 64P(ab), 81P(ab), 156P(ab), 205P(ab), 211P(ab)
Hayes, DL, 26P(ab)
Haynie, TP, 35P(ab), 76P(ab), 131P(ab)
Haynor, D, 105P(ab)
Haynor, DR, 34P(ab)
He, XS, 247P(ab)
He, ZX, 266P(ab)
Heanue, JA, 195P(ab)
Hebert, ME, 76P(ab)
Hegge, J, 211P(ab)
Heggie, JCP, 191(le)
Heinz, AE, 124P(ab)
Heironimus, JD, 2056(le)
Heiss, W-D, 2011, 119P(ab), 202P(ab), 71P(ab), 107P(ab), 197P(ab), 235P(ab)
Helkala, E-L, 118P(ab)
Heller, GV, 26P(ab), 60P(ab)
Heller, LI, 152P(ab)
Heller, S, 99P(ab)
Hellman, RS, 127P(ab), 232P(ab)
Hellsström, KE, 1831
Hellström, I, 1831
Hellyer, P, 157P(ab), 255P(ab)
Helvie, M, 142P(ab)
Heminway, S, 21P(ab), 52P(ab)
Hendel, RC, 23S
Hendricks, K, 269
Hendrix, GH, 125P(ab)
Heneghan, W, 124P(ab)
Henkin, RE, 20N, 54P(ab), 69P(ab), 133P(ab), 204P(ab), 213P(ab), 271P(ab)
Henneman, RA, 115P(ab)
Hennemann, G, 163P(ab)
Henrich, MM, 51, 156P(ab)

Henry, TR, 138P(ab)
Henson, GW, 29P(ab)
Henson, P, 1797
Henze, E, 186P(ab)
Henzlova, MJ, 575
Heo, J, 4S, 535, 549, 16P(ab), 27P(ab), 49P(ab), 50P(ab), 126P(ab), 136P(ab)
Herbst, CP, 179P(ab), 193P(ab)
Heresbach, D, 175P(ab)
Herholz, K, 2011, 71P(ab), 107P(ab), 119P(ab), 235P(ab)
Herman, LW, 19P(ab)
Herman, PG, 276P(ab)
Herman, SD, 26P(ab)
Hermann, M, 63P(ab)
Hermus, A, 163P(ab), 165P(ab)
Herregodts, MC, 40P(ab)
Herrero, P, 558
Herrold, EM, 60P(ab), 77P(ab), 80P(ab)
Hertz, M, 222P(ab), 231P(ab)
Herzog, H, 51, 8P(ab), 233P(ab), 253P(ab)
Hesse, B, 266
Heuser, G, 210P(ab)
Hew, JM, 456, 210P(ab), 213P(ab)
Heyman, S, 436, 1602, 1656, 120P(ab), 237P(ab)
Heyndrickx, GR, 77P(ab)
Hichwa, R, 1396
Hichwa, RD, 104P(ab), 158P(ab), 182P(ab), 188P(ab)
Hicks, K, 1206, 184P(ab)
Hicks, RJ, 1338
Hidaka, A, 146P(ab)
Hiddemann, W, 132P(ab)
Hierholzer, J, 1921
Higashi, K, 66P(ab), 170P(ab)
Higashi, Y, 108P(ab)
Higazi, E, 133P(ab), 234P(ab)
Higginbotham, C, 260P(ab)
Higgins, JD, 44P(ab), 105P(ab)
Higuchi, T, 209P(ab)
Hijioka, T, 13P(ab)
Hildebrand, J, 1162
Hill, TC, 1455, 199P(ab), 202P(ab)
Hill, TL, 216P(ab)
Hilson, AJW, 1318
Hilton, J, 9P(ab)
Hilton, S, 1976
Hilton, TC, 70P(ab)
Hinkle, GH, 216P(ab)
Hirai, J, 1279
Hirano, T, 197P(ab), 214P(ab)
Hirata, M, 254P(ab)
Hiroe, M, 239P(ab)
Hironaka, FH, 206P(ab)
Hirose, Y, 64P(ab), 81P(ab), 156P(ab)
Hirsch, JI, 264P(ab)
Hirschowitz, J, 74P(ab)
Hirshhorn, M, 218P(ab)
Hiruma, K, 193P(ab)
Hisada, K, 1279, 1937, 29P(ab), 172P(ab), 225P(ab)
Hittmaier, K, 207P(ab)
Hitzemann, RJ, 1457
Hnatowich, DJ, 127, 1568(le), 105P(ab), 242P(ab), 260P(ab)
Ho, CL, 117P(ab)
Ho, KC, 1313
Ho, M, 153P(ab)
Ho, SKW, 70, 1313
Ho, VB, 120P(ab)
Hodgson, HJF, 132P(ab)
Hoekstra, A, 28P(ab)
Hoekstra, HJ, 90
Hoekstra, OS, 224P(ab)
Hoey, K, 45P(ab)
Hoffer, PB, 228, 399, 10P(ab), 11P(ab), 84P(ab), 116P(ab), 129P(ab), 130P(ab), 140P(ab)
Hoffman, EJ, 187P(ab)
Hoffman, HT, 113P(ab)
Hoffman, JM, 1398, 1771, 44P(ab), 225P(ab), 228P(ab)
Hoffman, TJ, 260P(ab)
Hoffschir, D, 334, 261P(ab)
Höflich, G, 214P(ab)
Hogan, K, 628
Högberg, T, 84P(ab)
Hoh, CK, 8P(ab), 51P(ab), 71P(ab), 137P(ab), 141P(ab), 167P(ab), 221P(ab), 230P(ab), 265P(ab)
Hoitsma, AJ, 1488
Holburn, G, 199P(ab)
Holdeman, KP, 190(le), 117P(ab), 144P(ab), 221P(ab),
Holden, JE, 18
Holland, FW, 153P(ab)
Holliday, J, 1007
Holman, BL, 1444, 1455, 1902, 20P(ab), 116P(ab), 207P(ab), 210P(ab)
Holmes, G, 134P(ab)
Holmes, RA, 139P(ab), 241P(ab), 260P(ab)
Holschbach, M, 94P(ab)
Holzer, H, 173P(ab)
Homs, C, 124P(ab)
Honeycutt, W, 1038
Hood, JT Jr., 53P(ab)
Hoogland, D, 48P(ab)
Hooper, HR, 5P(ab)
Hopkins, DM, 76P(ab)
Horii, H, 121P(ab)
Horimoto, M, 13P(ab)
Hornykiewicz, S, 10P(ab)
Horowitz, M, 185(le), 88P(ab), 168P(ab), 169P(ab)
Horowitz, SF, 638
Hoshi, H, 44
Hosogami, T, 250P(ab)
Hosoi, H, 153P(ab)
Hosono, M, 296, 504, 1174, 1482, 1677, 56P(ab)
Hosono, MN, 296, 504, 56P(ab)
Hotze, AL, 461, 1485, 169P(ab), 151P(ab), 214P(ab)
Houle, S, 182P(ab), 197P(ab), 201P(ab), 252P(ab)
Houston, AS, 239
Howell, RW, 303, 521, 531, 1861, 1564(le), 123P(ab), 179P(ab)
Hoy, A, 111P(ab)
Hruban, RH, 9P(ab)
Hsieh, JF, 265P(ab)
Hsu, CY, 163P(ab), 164P(ab), 171P(ab), 232P(ab)
Hsu, E, 156P(ab)
Hsu, L-C, 153P(ab), 173P(ab)
Hu, HH, 205P(ab)
Hua, W, 90P(ab)
Huang, CL, 176P(ab)
Huang, G, 5P(ab), 27P(ab), 92P(ab), 190P(ab), 192P(ab)
Huang, S, 186P(ab)
Huang, Sc, 137P(ab), 183P(ab), 71P(ab), 83P(ab), 155P(ab), 187P(ab)
Huang, WS, 164P(ab)
Huang, WT, 245P(ab)
Huber, R, 139P(ab)
Huber, W, 32P(ab)
Huberty, JP, 57P(ab)
Hubner, KF, 220P(ab)
Huesman, RH, 18P(ab), 183P(ab)
Huſnagel, A, 1896, 208P(ab)
Hughes, E, 206P(ab)
Hughes, JA, 166P(ab), 239P(ab)
Hughes, JMB, 132P(ab)
Hughes, KS, 217P(ab)
Hughes, L, 11P(ab), 217P(ab)
Hughey, BJ, 249P(ab)
Huglo, D, 57
Humes, HD, 124P(ab)
Humm, JL, 1217
Hundeshagen, H, 1557(le)
Hunteman, RK, 1805
Hunter, GJ, 1308, 8P(ab), 37P(ab)
Hunter, K, 220P(ab)
Hurwitz, GA, 1959, 127P(ab), 180P(ab)
Husni, M, 1959
Hussey, D, 182P(ab), 197P(ab)
Hutchins, GD, 1286, 117P(ab)
Hutchinson, HG, 1989
Hutchinson, RJ, 135P(ab)
Hutson, K, 239P(ab)
Hüttinger, M, 63P(ab)
Hutton, BF, 360
Huysmans, D, 163P(ab), 165P(ab)
Hwang, D-R, 252P(ab)
Hyde, TM, 228

Iaconetta, G, 9P(ab)
Ichihara, T, 193P(ab)
Ichikawa, A, 172P(ab)
Ichise, M, 217, 202P(ab)
Ichiya, Y, 43P(ab), 210P(ab), 227P(ab), 231P(ab)
Ichiyanagi, K, 1279
Ide, S, 250P(ab)
Ido, T, 97, 104, 1067, 45P(ab)
Iftikhar, I, 16P(ab)
Igarashi, M, 153P(ab)
Ii, Y, 214P(ab)
Iida, H, 2019, 63P(ab), 137P(ab), 183P(ab), 191P(ab)
Iida, Y, 146P(ab), 247P(ab)
Iimori, T, 250P(ab)
Iio, S, 13P(ab)
Ikeda, A, 207P(ab)
Ikeda, M, 118P(ab)
Ikegami, S, 250P(ab)
Ikegami, T, 203P(ab)
Ikekubo, K, 59P(ab)
Iles, SE, 416
Ilgin, N, 48P(ab)
Imada, K, 56P(ab)
Imahori, Y, 121P(ab)
Imam, K, 116P(ab)
Imamura, M, 222P(ab)
Imbriaco, M, 1110, 114P(ab), 115P(ab), 153P(ab), 165P(ab)
Inampudi, C, 210P(ab)
Indolfi, P, 1429
Ingels, M, 942
Inglese, E, 601
Innis, RB, 228, 399, 10P(ab), 11P(ab), 84P(ab), 128P(ab), 129P(ab), 130P(ab), 140P(ab), 159P(ab), 201P(ab)
Inokuma, T, 1965, 222P(ab), 225P(ab)
Inoue, H, 68P(ab)
Inoue, K, 136P(ab)
Inoue, M, 56P(ab)
Inoue, O, 248P(ab), 255P(ab)
Inoue, T, 326, 197P(ab), 203P(ab)
Inoue, Y, 108P(ab), 127P(ab), 178P(ab)
Intenzo, C, 36P(ab), 271P(ab)
Inugami, A, 1097
Iorio, L, 151P(ab)
Iorio, R, 151P(ab)
Iosilevsky, G, 1129, 1155
Irvin, G III, 68P(ab)
Isacson, O, 140P(ab)
Isensee, C, 32P(ab)
Ishibashi, K, 169P(ab)
Ishida, Y, 64P(ab), 81P(ab), 156P(ab), 205P(ab), 211P(ab)
Ishigaki, T, 118P(ab)
Ishiguro, S, 153P(ab)
Ishihara, M, 119P(ab), 141P(ab)
Ishii, K, 110P(ab)
Ishii, S, 248P(ab), 249P(ab), 250P(ab)
Ishii, Y, 169P(ab)
Ishikawa, M, 1104, 43P(ab)
Ishikawa, T, 10P(ab), 11P(ab), 211P(ab)
Ishiwata, K, 110P(ab), 248P(ab), 249P(ab), 256P(ab)
Ishiwata, S, 110P(ab)
Ishizu, K, 1104, 1910, 43P(ab), 95P(ab), 194P(ab), 196P(ab), 201P(ab), 204P(ab), 207P(ab)
Isitman, AT, 88P(ab), 232P(ab)
Iskandrian, AS, 1S, 4S, 535, 549, 734, 16P(ab), 27P(ab), 49P(ab), 50P(ab), 126P(ab), 136P(ab)
Israel, O, 465, 1129, 1155, 229P(ab)
Istfan, D, 215P(ab)
Ito, K, 118P(ab)
Ito, T, 13P(ab)
Itoh, A, 160P(ab)
Itoh, H, 2019, 63P(ab), 191P(ab)
Itoh, K, 93
Itoh, M, 1870
Itti, L, 43P(ab)
Itti, R, 587, 1581
Ivançević, V, 132P(ab), 36P(ab)
Ivanovic, M, 342, 61P(ab), 221P(ab)
Iwama, T, 205P(ab)
Iwamoto, K, 1691
Iwanaga, S, 57P(ab)
Iwasaki, Y, 27
Iwata, R, 256P(ab)

Jackels, SC, 243P(ab)
Jacobs, A, 942, 2011, 119P(ab)
Jacobs, M, 142P(ab)
Jacobs, S, 95P(ab)
Jacobson, AF, 48P(ab), 225P(ab)
Jacobson, D, 144P(ab)
Jadali, F, 170P(ab)
Jaggi, J, 206P(ab)
Jahan, MS, 234P(ab)
Jain, D, 664
Jain, RK, 37P(ab)
Jain, VK, 161P(ab)
Jakse, G, 230P(ab), 256P(ab)
Jamar, F, 1951, 45P(ab), 131P(ab)
Jan, J, 259P(ab)
Jang, J-J, 1499
Jang, S, 179P(ab)
Janicek, MJ, 230P(ab)
Jänicke, F, 222P(ab), 231P(ab)
Jansen, DE, 1586
Jansen, HML, 456, 210P(ab), 213P(ab)
Jarry, M, 15P(ab)
Jaszczak, RJ, 135, 1707, 17P(ab), 27P(ab), 33P(ab), 179P(ab), 180P(ab), 190P(ab), 195P(ab), 196P(ab)
Jatlow, A, 1138
Jayatilak, PG, 18P(ab), 152P(ab)
Jaywook, S, 1685
Jeannerod, M, 107P(ab)
Jeekel, J, 21P(ab)
Jenike, MA, 75P(ab)
Jenkins, D, 67P(ab)
Jeon, K, 175P(ab)
Jeong, JM, 1851

Jerusalmi, J, 445
Jester, D, 45P(ab)
Jewett, D, 140P(ab)
Jiang, HJ, 107P(ab)
Jiménez, J, 174P(ab)
Jin, Y, 190P(ab)
Jinnouchi, S, 44
Jivan, S, 251P(ab)
Jobalia, K, 239P(ab)
Jobst, KA, 20P(ab)
Jochelson, M, 22P(ab), 223P(ab)
Joensuu, H, 1618, 117P(ab)
John, CS, 246P(ab), 248P(ab)
John, EK, 86P(ab), 259P(ab)
Johnson, D, 99P(ab)
Johnson, DK, 234P(ab)
Johnson, E, 178P(ab)
Johnson, EL, 180P(ab)
Johnson, G III, 46P(ab)
Johnson, JE, 88P(ab)
Johnson, KA, 1902, 20P(ab), 116P(ab), 207P(ab), 210P(ab)
Johnson, LL, 689
Johnson, PJ, 70, 1313
Johnson, RW, 45P(ab)
Johnson, VE, 17P(ab)
Johnston, RE, 91P(ab), 115P(ab)
Jolly, D, 212P(ab)
Jonckheer, MH, 1559(le)
Jones, AG, 79P(ab)
Jones, DN, 1347, 38P(ab)
Jones, DW, 199P(ab)
Jones, KL, 88P(ab), 168P(ab)
Jones, M, 126P(ab)
Jones, PL, 12P(ab)
Jones, T, 181P(ab), 185P(ab), 186P(ab)
Jones-Wilson, TM, 243P(ab)
Jönsson, P-E, 224P(ab)
Joshi, V, 30P(ab), 259P(ab)
Jujiwara, T, 1870
Jung, Y-W, 7P(ab), 93P(ab)
Juni, JE, 1891, 2048(e), 24P(ab), 206P(ab), 274P(ab)
Jureidini, IM, 112P(ab)
Jurisson, SS, 41P(ab), 241P(ab)
Jyawook, SL, 269, 254(ab)

Kabalka, G, 162P(ab)
Kadrmas, DJ, 33P(ab)
Kageyama, M, 1659
Kahn, B, 1842
Kahn, D, 194P(ab)
Kairemo, K, 179P(ab)
Kaiser, HJ, 108P(ab)
Kakishita, M, 1659
Kalaigian, H, 1976, 7P(ab), 123P(ab)
Kalhori, N, 169P(ab)
Kallergi, M, 143P(ab), 161P(ab)
Kamada, T, 32, 1226, 13P(ab), 203P(ab)
Kämäräinen, E-L, 252P(ab)
Kamei, T, 1659
Kamen, B, 222P(ab)
Kaminaga, T, 205P(ab), 211P(ab)
Kaminski, MS, 1714, 38P(ab), 101P(ab), 233P(ab)
Kamp, O, 136P(ab)
Kamphuis, C, 28P(ab)
Kanagawa, K, 93
Kanamaru, R, 97
Kanaya, K, 289, 14P(ab), 217P(ab)
Kanaya, S, 14P(ab), 217P(ab)
Kanbe, N, 160P(ab)
Kanno, I, 1097, 63P(ab), 201P(ab)
Kantoff, PW, 1624
Kao, CH, 163P(ab), 164P(ab), 171P(ab), 232P(ab), 240P(ab), 241P(ab), 245P(ab)
Kao, PC, 146P(ab)
Kao, PF, 85P(ab), 137P(ab)
Kao, T, 186P(ab)
Kapadvanjwala, M, 1054, 42P(ab), 65P(ab), 145P(ab), 153P(ab), 173P(ab), 263P(ab)
Kaplan, MS, 34P(ab)
Kaplan, WD, 1624, 230P(ab)
Kappeler, C, 32P(ab)
Kappes, RS, 2054(le)
Kapur, S, 182P(ab), 197P(ab), 201P(ab)
Karambatsakidou, A, 176P(ab)
Karasawa, K, 249P(ab)
Karatela, RA, 126P(ab)
Karbe, H, 107P(ab)
Karesh, SM, 69P(ab)
Karlsson, P, 84P(ab), 122P(ab)
Karp, JS, 41P(ab), 127P(ab), 188P(ab), 195P(ab)
Karp, K, 983
Karpathios, TE, 1048
Karube, Y, 1691
Kasagi, K, 474, 2057(le), 146P(ab), 155P(ab)
Kase, K, 368
Kashiwagi, T, 13P(ab), 169P(ab)
Kasi, LP, 63, 11P(ab), 37P(ab), 101P(ab)
Kasina, S, 254P(ab)
Kasliwal, R, 98P(ab), 198P(ab)
Kasper, S, 214P(ab)
Kassiou, M, 250P(ab)
Kassis, AI, 12P(ab), 79P(ab), 144P(ab), 162P(ab)
Katholi, CR, 108P(ab)
Katial, R, 1038
Kato, C, 93
Kato, H, 59P(ab)
Kato, M, 289, 210P(ab), 211P(ab), 217P(ab)
Kato, T, 118P(ab)
Katti, KV, 139P(ab)
Katz, J, 2055(le)
Katz, RD, 22P(ab), 274P(ab)
Katz, RL, 101P(ab)
Katzenellenbogen, JA, 53P(ab), 141P(ab), 250P(ab)
Katznelson, D, 58P(ab)
Kauffman, G, 16P(ab)
Kavanagh, PB, 1193, 116P(ab)
Kawada, T, 145P(ab)
Kawakami, K, 226P(ab), 240P(ab), 267P(ab)
Kawamoto, M, 594, 59P(ab), 110P(ab), 135P(ab), 155P(ab), 156P(ab), 203P(ab)
Kawanaka, M, 153P(ab)
Kawano, S, 13P(ab)
Kawasugi, K, 1811
Kazmers, A, 90P(ab), 271P(ab)
Kebbou, M, 98P(ab)
Keelan, ETM, 276
Kegel, J, 549
Kehtarnavaz, ND, 177P(ab)
Keiler, A, 231P(ab)
Kemeny, N, 102P(ab)
Kemp, BJ, 92P(ab)
Kemp, PM, 239
Kempf, J, 212P(ab), 271P(ab), 276P(ab)
Kempner, KM, 1538
Kern, MJ, 23P(ab)
Kertzman, C, 1538
Keske, U, 1921
Kessler, J, 107P(ab), 119P(ab)
Kessler, ML, 1714
Kessler, RM, 30P(ab), 199P(ab)
Ketchum, L, 11N(12)
Ketring, AR, 41P(ab), 139P(ab), 241P(ab)
Keuppens, F, 265P(ab)
Keyes, JW Jr., 1777, 104P(ab)
Keyeux, A, 479
Khalkhali, I, 22P(ab), 240P(ab)
Khan, AS, 471, 14P(ab), 227P(ab)
Khan, S, 15P(ab), 22P(ab), 223P(ab), 229P(ab)
Khandekar, S, 133P(ab)
Khann, S, 14P(ab), 227P(ab)
Khanna, S, 60P(ab)
Khare, AB, 94P(ab)
Khaw, B-A, 1076, 4P(ab), 98P(ab), 145P(ab)
Khaw, S, 145P(ab)
Khawaja, IT, 1044
Khazaeli, MB, 1017, 258P(ab)
Khedkar, N, 274P(ab)
Khonsary, SA, 230P(ab), 273P(ab)
Kiat, H, 356, 542, 609, 683, 1193, 59P(ab), 81P(ab), 103P(ab), 116P(ab)
Kidd, CR, 78P(ab)
Kieswetter, DO, 200P(ab)
Kihikoinen, PK, 1916
Kijewski, MF, 4P(ab), 17P(ab), 60P(ab), 61P(ab), 116P(ab), 210P(ab)
Kikuchi, H, 1104, 43P(ab), 204P(ab)
Kilbourn, MR, 20P(ab), 72P(ab), 83P(ab), 84P(ab), 121P(ab), 140P(ab), 256P(ab)
Kilcoin, TT, 241P(ab), 261P(ab)
Kim, A, 24P(ab)
Kim, BK, 113P(ab)
Kim, CK, 164, 1138, 1566(le), 14P(ab), 171P(ab)
Kim, EE, 11P(ab), 35P(ab), 76P(ab), 131P(ab), 220P(ab), 228P(ab), 256P(ab)
Kim, HJ, 195P(ab), 93P(ab), 129P(ab), 157P(ab), 160P(ab)
Kim, JH, 240P(ab)
Kim, JY, 109P(ab)
Kim, NK, 120P(ab)
Kim, S, 271P(ab)
Kim, SC, 258P(ab)
Kim, SE, 32P(ab), 52P(ab), 74P(ab), 85P(ab), 124P(ab), 137P(ab), 196P(ab), 197P(ab), 199P(ab)
Kim, SK, 1125
Kim, YT, 150P(ab)
Kim, YW, 240P(ab)
Kimes, AS, 118P(ab)
Kimmel, M, 124P(ab)
Kimura, J, 1
Kimura, Y, 171P(ab)
King, DJ, 63P(ab)
King, MA, 143, 82P(ab), 92P(ab), 188P(ab), 189P(ab), 192P(ab), 193P(ab)
King, P, 67P(ab), 130P(ab)
King, S, 27P(ab)
King, SB, 1237
Kinoshita, T, 1811
Kinter, CM, 31P(ab), 67P(ab), 245P(ab)
Kinuya, S, 1851, 29P(ab), 63P(ab), 172P(ab), 225P(ab)
Kinzl, L, 113P(ab)
Kippenhan, JS, 7
Kirby, RA, 262P(ab)
Kirchner, PT, 1558(le), 104P(ab), 229P(ab)
Kirgan, D, 8P(ab), 230P(ab)
Kirsch, C-M, 11P(ab), 74P(ab), 87P(ab)
Kish, SJ, 252P(ab)
Kishida, Y, 169P(ab)
Kitahara, T, 119P(ab)
Kitano, T, 154P(ab)
Kiwit, JCW, 8P(ab)
Klain, M, 263, 166P(ab)
Klein, GJ, 183P(ab)
Klein, J, 100P(ab)
Klein, MW, 86P(ab), 218P(ab)
Klein, WP, 28P(ab), 93P(ab)
Klemm, E, 208P(ab), 214P(ab)
Klesewetter, DO, 53P(ab), 83P(ab)
Kletter, K, 85P(ab), 124P(ab), 167P(ab), 264P(ab)
Klever, P, 108P(ab)
Klingensmith, WC, 1612
Klinkowstein, RE, 249P(ab)
Klipper, R, 1491, 42P(ab)
Kloppenborg, P, 163P(ab), 165P(ab)
Klopper, JF, 37P(ab)
Knable, MB, 199P(ab)
Knapp, FF Jr., 93P(ab), 201P(ab), 245P(ab)
Knight, LC, 282, 257P(ab)
Knight, RQ, 149P(ab)
Knight, SB, 30P(ab), 223P(ab)
Knopp, MV, 75P(ab)
Knust, EJ, 32P(ab)
Knuuti, J, 183P(ab)
Knuuti, MJ, 989
Kobayashi, H, 296, 1174, 1482, 1677, 14P(ab), 56P(ab), 146P(ab), 217P(ab)
Koch, G, 207P(ab)
Kocher, F, 156P(ab), 223P(ab)
Kock, R, 256P(ab)
Kodama, T, 44
Koenders, EB, 45P(ab)
Koeppe, RA, 405, 949, 1528, 20P(ab), 33P(ab), 68P(ab), 82P(ab), 121P(ab), 138P(ab), 140P(ab)
Koeppel, JA, 104P(ab), 188P(ab)
Koga, S, 202P(ab)
Kögler, A, 36P(ab)
Koh, C-S, 1499, 113P(ab), 120P(ab), 240P(ab)
Kohler, TR, 1731
Kohse, LM, 68P(ab)
Koizumi, M, 119P(ab)
Kojima, A, 19P(ab)
Kolbert, K, 179P(ab), 123P(ab)
Kolobrodov, VV, 625
Kolodny, GM, 28N, 1129, 1155, 171P(ab)
Kolsky, KL, 259P(ab)
Költringer, P, 2057(le)
Komaki, R, 76P(ab)
Komori, T, 227P(ab)
Kondo, A, 56P(ab)
Konishi, J, 1, 27, 296, 326, 474, 594, 1104, 1174, 1366, 1482, 1677, 1910, 1965, 2057(le), 30P(ab), 43P(ab), 56P(ab), 59P(ab), 95P(ab), 110P(ab), 135P(ab), 146P(ab), 155P(ab), 156P(ab), 179P(ab), 194P(ab), 196P(ab), 200P(ab), 201P(ab), 204P(ab), 207P(ab), 208P(ab), 222P(ab), 225P(ab), 234P(ab), 246P(ab), 247P(ab), 254P(ab)
Konopka, LM, 54P(ab), 204P(ab), 213P(ab)
Kontestabile, E, 158P(ab)
Kooij, PPM, 162P(ab), 226P(ab)
Koops, HS, 90
Kopin, IJ, 964
Koplan, BA, 47P(ab)
Koppel, PL, 82P(ab)
Koppeschaar, HPF, 163P(ab)
Koral, KF, 1013, 1714, 82P(ab)
Korf, J, 456, 210P(ab), 213P(ab)

Korkmaz, M, 11P(ab)
Kornhuber, J, 10P(ab)
Kortylewicz, ZP, 79P(ab)
Kostakoglu, L, 232P(ab), 235P(ab)
Kosten, T, 130P(ab)
Kosternik, JGW, 456
Kosugi, Y, 177P(ab)
Kothari, K, 261P(ab)
Kothari, P, 1407
Kotoura, Y, 1174
Kotzerke, J, 1557(le)
Kousaka, T, 146P(ab)
Koutelou, M, 16P(ab)
Kozak, RW, 62P(ab)
Kozlov, B, 203P(ab)
Kozuka, T, 169P(ab)
Kramer, EL, 1034, 217P(ab)
Krappel, C, 214P(ab)
Krasnow, AZ, 232P(ab)
Krauss, G, 31P(ab)
Krausz, Y, 1802
Kraut, MA, 32P(ab)
Krawczynska, EG, 1237, 27P(ab), 126P(ab)
Krebs, D, 234P(ab)
Kremens, B, 238P(ab)
Krenning, EP, 21P(ab), 132P(ab), 162P(ab), 163P(ab), 165P(ab), 226P(ab)
Krisanachinda, A, 1792
Krishna, L, 471, 14P(ab), 227P(ab)
Krishnan, R, 135P(ab)
Kriss, VM, 1753
Krivanek, K, 167P(ab)
Krivokapich, J, 39P(ab), 135P(ab)
Krivonogov, N, 203P(ab)
Kroboth, P, 184P(ab)
Kroiss, A, 44P(ab)
Kronauge, JF, 510, 19P(ab), 230P(ab)
Kroon, D, 45P(ab)
Krummeich, C, 94P(ab)
Kuang, L-R, 256P(ab)
Kubori, S, 136P(ab)
Kubota, K, 104, 1067, 45P(ab), 152P(ab), 256P(ab)
Kubota, M, 194P(ab)
Kubota, R, 104, 1067, 45P(ab), 152P(ab), 256P(ab)
Kudela, S, 30P(ab)
Kuhar, MJ, 199P(ab)
Kuhl, C, 208P(ab)
Kuhl, DE, 405, 949, 1528, 20P(ab), 33P(ab), 68P(ab), 82P(ab), 119P(ab), 121P(ab), 140P(ab), 141P(ab)
Kuhle, W, 110P(ab)
Kuhlmeier, V, 50P(ab)
Kuikka, JT, 118P(ab)
Kukis, DL, 244P(ab), 259P(ab)
Kulbertus, HE, 1116
Kulkarni, PV, 216P(ab), 222P(ab)
Kumar, A, 53P(ab)
Kumar, D, 229P(ab)
Kumar, K, 54P(ab)
Kume, N, 1520, 109P(ab)
Kumpuris, T, 1007
Kundrat, S, 2041
Kung, HF, 93P(ab), 128P(ab), 129P(ab), 160P(ab), 243P(ab), 246P(ab), 252P(ab)
Kung, M-P, 93P(ab), 128P(ab), 246P(ab), 252P(ab)
Kuniyasu, Y, 1811
Kunkel, SL, 256P(ab)
Kuntz, CD, 1476
Kuo, SW, 164P(ab)
Kupfer, DJ, 32P(ab)
Kupfer, S, 266P(ab)
Kurami, M, 97P(ab)
Kurbacher, CM, 1485
Kurman, M, 235P(ab)
Kurtaran, A, 264P(ab)
Kusakabe, K, 289, 14P(ab), 217P(ab)
Kusuoka, H, 1226, 1371, 46P(ab), 97P(ab), 131P(ab), 136P(ab), 237P(ab)
Kuwabara, H, 10P(ab), 185P(ab), 212P(ab)
Kuwabara, Y, 43P(ab), 210P(ab), 227P(ab), 231P(ab)
Kuwert, T, 8P(ab)
Kuyama, J, 238P(ab)
Kuzniecky, R, 30P(ab)
Kuzuhara, S, 214P(ab)
Kwekkeboom, DJ, 162P(ab), 163P(ab), 226P(ab)
Kwiatkowski, M, 1571

Labar, D, 974
Lafaille, F, 1822, 67P(ab)
Lahiri, A, 587, 1581, 16P(ab), 136P(ab)
Laihinen, AO, 1916
Laks, H, 49P(ab)
Lal, R, 261P(ab)
Lalonde, D, 1245
Lalush, DS, 28P(ab), 82P(ab), 91P(ab), 115P(ab), 195P(ab)
LaManna, M, 169
Lamberg, R, 15P(ab)
Lambert, CR, 93P(ab)
Lambert, R, 628, 1245, 168P(ab)
Lamberts, SWJ, 21P(ab), 132P(ab), 162P(ab), 163P(ab), 226P(ab)
Lambotte, L, 974
Lambrecht, RM, 195, 250P(ab)
Lamki, L, 1167
Lammertsma, AA, 1878
Landy, BR, 999
Lang, L, 83P(ab), 249P(ab)
Lang, RM, 26P(ab)
Langen, K-J, 8P(ab)
Langhammer, HR, 222P(ab)
Langlois, Y, 628
Langman, CB, 59P(ab)
Langmore, S, 109P(ab)
Langsteger, W, 2057(le)
Laorpatanaskul, C, 1792
Lapela, M, 1618, 117P(ab)
Laplane, D, 207P(ab)
Larsen, SK, 29P(ab), 105P(ab)
Larson, SM, 1179, 1407, 1653, 1748, 1976, 7P(ab), 36P(ab), 101P(ab), 102P(ab), 112P(ab), 123P(ab), 179P(ab), 232P(ab), 235P(ab)
Larsson, I, 158P(ab), 224P(ab)
Laruelle, M, 228, 84P(ab), 129P(ab), 201P(ab)
Lastoria, S, 263, 1429, 22P(ab), 80P(ab), 96P(ab), 97P(ab), 166P(ab)
Laterre, C, 974
Latino, FA, 349
Lau, W-Y, 70, 1313
Lau, YH, 37P(ab), 213P(ab)
Lau, Y-K, 39P(ab)
Laux, G, 214P(ab)
Laven, DL, 89P(ab)
Lavenne, F, 75P(ab)
Lawrence, SK, 30P(ab)
Lawson, RS, 187(le)
Layer, G, 1485
Lazewatsky, J, 21P(ab)
Lazzari, S, 144P(ab)
LDamphousse, P, 245P(ab)
Le, N, 29P(ab)
Leahy, R, 34P(ab), 72P(ab)
Lear, JL, 28P(ab), 98P(ab), 198P(ab)
Leavitt, JI, 1805
Leb, G, 173P(ab)
Le Bars, D, 75P(ab)
LeBherz, D, 101P(ab)
LeBrun, GP, 245
Lebtahi, R, 87P(ab), 96P(ab), 125P(ab)
Leclercq, B, 587, 1581
Lecloirec, J, 175P(ab)
Lecomte, R, 1390
Le Doussal, JM, 55P(ab)
Lee, BH, 1125
Lee, CH, 219P(ab)
Lee, D-S, 1499, 39P(ab), 120P(ab)
Lee, F-T, 195
Lee, H, 74P(ab), 257P(ab)
Lee, HB, 100P(ab), 265P(ab)
Lee, J, 535, 175P(ab)
Lee, JD, 1125, 35P(ab)
Lee, JT, 29P(ab), 53P(ab), 83P(ab), 200P(ab)
Lee, K, 535
Lee, KH, 167P(ab), 240P(ab)
Lee, KII, 120P(ab)
Lee, KS, 39P(ab), 199P(ab), 247P(ab)
Lee, LC, 84P(ab)
Lee, M-C, 1499, 113P(ab), 120P(ab), 240P(ab)
Lee, RF, 149P(ab)
Lee, S, 167P(ab)
Lee, SJ, 8P(ab), 221P(ab)
Lee, TW, 242P(ab), 263P(ab)
Leeds, NE, 220P(ab)
Leenders, K, 18P(ab)
Lees, A, 80P(ab)
Lees, R, 80P(ab)
Legemate, D, 202P(ab)
Leger, G, 10P(ab)
Le Guludec, D, 87P(ab), 96P(ab), 98P(ab), 114P(ab), 125P(ab)
Lehikoinen, P, 1618, 117P(ab)
Lehnert, H, 96P(ab)
Lehtovirta, M, 118P(ab)
Leibowitz, B, 221P(ab)
Leibundgut, K, 217P(ab)
Leichner, PK, 1721, 79P(ab), 144P(ab)
Leisure, GP, 1665
Leitha, T, 63P(ab), 150P(ab), 167P(ab)
Lemaire, C, 391, 1996, 82P(ab), 251P(ab)
Lemmens, JAM, 89P(ab)
Lemoine, P, 1822, 67P(ab)
Leners, N, 1951, 131P(ab)
Leonard, MH Jr., 229P(ab)
Leoncini, M, 1254
Leong, C, 1662
Leonhardt, CL, 1547
Leppo, JA, 730, 3P(ab), 16P(ab), 47P(ab), 125P(ab), 152P(ab), 180P(ab)
Leroy, RF, 31P(ab)
Leskinen-Kallio, S, 1618, 1564(le), 117P(ab)
Lesser, R, 31P(ab)
Leung, NWY, 70, 1313
Leung, SO, 62P(ab), 236P(ab)
Leung, WT, 70, 1313
Levchenko, A, 232P(ab)
Léveillé, J, 15P(ab)
Lever, JR, 31P(ab), 67P(ab), 128P(ab), 245P(ab)
Lever, SZ, 19P(ab)
Levin, CS, 187P(ab)
Levin, J, 210P(ab)
Levin, JM, 1902
Levin, VA, 220P(ab), 228P(ab)
Levine, GM, 1028
Levine, ML, 276P(ab)
Levis-Dusseau, S, 68P(ab)
Levivier, M, 1162
Levy, R, 257
Lewellen, TK, 34P(ab), 105P(ab), 180P(ab), 188P(ab)
Lewington, G, 186P(ab)
Lewis, DH, 1476, 64P(ab)
Lewis, PJ, 929, 1647
Li, AKC, 70, 1313
Li, H-D, 161P(ab)
Li, J, 135, 27P(ab), 81P(ab), 86P(ab), 179P(ab), 190P(ab), 259P(ab)
Li, M, 122P(ab)
Li, S, 170P(ab)
Li, ST, 90P(ab)
Li, X, 105P(ab)
Li, Y, 100P(ab)
Liang, Z, 190P(ab)
Liao, SQ, 163P(ab), 232P(ab)
Libertino, JA, 218P(ab)
Licata, AA, 68P(ab)
Lich, LL, 53P(ab)
Licho, R, 188P(ab), 193P(ab)
Lie, KI, 3P(ab), 23P(ab)
Lieberman, L, 9P(ab), 58P(ab)
Ligon, R, 16P(ab)
Lill, DW, 210P(ab)
Lim, AD, 644, 1170
Lim, J-L, 6P(ab)
Lim, R, 212P(ab)
Lim, S, 175P(ab)
Limburg, M, 202P(ab)
Lin, HD, 219P(ab)
Lin, HM, 244P(ab)
Lin, J, 70, 1313
Lin, K, 186P(ab)
Lin, KP, 105P(ab)
Lin, S, 263P(ab)
Lin, WY, 163P(ab), 232P(ab)
Lindblom, P, 249P(ab)
Linder, KE, 18P(ab), 138P(ab), 260P(ab)
Lindinger, G, 207P(ab)
Line, BR, 143P(ab), 242P(ab), 243P(ab)
Ling, CC, 161P(ab)
Linke, MJ, 1028
Linke, R, 87P(ab)
Links, JM, 16, 182P(ab), 197P(ab)
Liou, WL, 242P(ab)
Liow, J-S, 51P(ab)
Lipiecki, J, 103P(ab)
Lipp, RW, 173P(ab)
Lippi, F, 1418
Lipszyc, H, 74P(ab), 257P(ab)
Lisbona, R, 273P(ab)
Lister-James, J, 80P(ab), 257P(ab)
Littlefield, J, 169P(ab)
Littlefield, JL, 120P(ab)
Liu, A, 1561(le)
Liu, GB, 36P(ab)
Liu, HG, 106P(ab), 210P(ab)
Liu, J, 92P(ab), 190P(ab)
Liu, RS, 113P(ab), 142P(ab), 186P(ab), 204P(ab), 205P(ab), 209P(ab), 244P(ab), 265P(ab)
Liu, S, 52P(ab), 241P(ab), 245P(ab)
Liu, T, 1017
Liu, X, 118P(ab)
Liu, XJ, 90P(ab), 266P(ab)
Liu, Y, 88P(ab), 232P(ab)
Liu, YY, 175P(ab)
Liu, YZ, 266P(ab)
Livne, PM, 445
Livni, E, 496, 175P(ab), 254P(ab)
Ljungberg, M, 78P(ab), 82P(ab), 123P(ab), 189P(ab)
Ljungberg, MH, 143
Ljunggren, K, 342, 179P(ab)
Llorens, AS, 218P(ab)
Lloyd-Still, JD, 432
Lo, JM, 245P(ab)
LoBuglio, AF, 1017
Loc'h, C, 57P(ab), 110P(ab), 122P(ab), 253P(ab), 255P(ab)
Lodi, M, 147P(ab)
Loessner, A, 1650, 53P(ab)
Logan, J, 85P(ab), 129P(ab), 130P(ab), 140P(ab)
Loisance, D, 80P(ab), 110P(ab)
Lombardi, G, 166P(ab)
Lomeña, FJ, 935, 1041
Loncaric, S, 5P(ab), 27P(ab), 92P(ab), 192P(ab)
London, ED, 118P(ab)

Longley, CB, 29P(ab)
Looby, R, 52P(ab), 241P(ab), 245P(ab)
Lopez, DM, 1054, 65P(ab)
Lopez, FG, 1303
Lopez, IA, 99P(ab)
Lora, M, 100P(ab)
Lorberbovm, M, 9P(ab)
Lorenz, WJ, 38P(ab), 75P(ab), 231P(ab)
Loring, NA, 8P(ab)
Lortholary, P, 231P(ab)
Losman, MJ, 62P(ab)
Lötter, MG, 179P(ab), 193P(ab)
Lottgen, J, 202P(ab), 71P(ab), 197P(ab)
Low, D, 63P(ab)
Lowe, VJ, 1771, 44P(ab), 76P(ab), 225P(ab), 228P(ab)
Löwenberg, B, 132P(ab)
Lu, J, 251P(ab)
Lu, P, 80P(ab)
Lu, X-M, 269
Lubin, A, 168P(ab)
Lubin, E, 257, 126P(ab)
Lubushitzky, R, 1155
Lucignani, G, 210, 255P(ab)
Luck, D, 212P(ab)
Luger, S, 207P(ab)
Lui, D, 37P(ab)
Lui, MT, 113P(ab)
Luk, WK, 51P(ab)
Lukban, A, 273P(ab)
Lukes, J, 580
Lull, RJ, 644, 1170
Lumbroso, J, 69P(ab), 134P(ab)
Lunghi, F, 1571
Luo, D-S, 92P(ab)
Luo, J-Q, 1714, 82P(ab)
Lupoli, G, 263
Lüscher, D, 220P(ab)
Lusiak, P, 139P(ab)
Lusins, J, 422
Lutrin, CL, 76P(ab)
Luxen, A, 1162, 82P(ab), 251P(ab)
Lyle, LR, 256P(ab)
Lynch, T, 275P(ab), 276P(ab)

Ma, C, 73P(ab)
Ma, D, 241P(ab)
Macapinlac, HA, 1407, 1748, 1976, 7P(ab), 123P(ab)
Macey, DJ, 63, 37P(ab), 101P(ab), 111P(ab), 123P(ab), 142P(ab), 143P(ab), 160P(ab), 196P(ab)
Macfarlane, D, 7P(ab)
MacGillivray, J, 235P(ab)
MacGregor, RR, 67P(ab), 130P(ab), 140P(ab)
Mach, JP, 101P(ab)
Mach, RH, 94P(ab)
Machac, J, 41, 575, 74P(ab), 266P(ab)
Machecourt, J, 114P(ab)
Machida, M, 119P(ab)
Machii, K, 214P(ab)
MacIntyre, DL, 150P(ab)
MacIntyre, WJ, 39P(ab), 68P(ab)
Mack, E, 164P(ab)
MacKay, S, 214P(ab)
Mäcke, HR, 317
MacKinnon, CD, 197P(ab)
Macklis, RM, 1217
Macleod, MA, 239
Madajewicz, S, 37P(ab), 145P(ab)
Madar, I, 31P(ab), 67P(ab)
Maddahi, J, 542, 609, 672, 683, 707, 8P(ab), 49P(ab), 60P(ab), 141P(ab), 167P(ab), 221P(ab), 230P(ab)
Maddox, A, 88P(ab)
Madras, BK, 121P(ab), 140P(ab), 198P(ab)
Madsen, MT, 113P(ab), 194P(ab)
Maecke, HR, 101P(ab)
Maeda, H, 202P(ab)
Maeda, S, 97
Maegdenbergh, V, 88P(ab)
Maeno, M, 81P(ab), 156P(ab)
Maes, A, 38P(ab), 40P(ab)
Maffioli, L, 1741, 86P(ab)
Magata, Y, 27, 1104, 1910, 1965, 43P(ab), 95P(ab), 110P(ab), 135P(ab), 155P(ab), 156P(ab), 196P(ab), 201P(ab), 222P(ab), 225P(ab), 234P(ab), 247P(ab), 254P(ab)
Magid, NM, 77P(ab)
Magil, HL, 43S
Magnani, P, 1970, 55P(ab), 112P(ab), 218P(ab)
Magoun, S, 146P(ab), 149P(ab), 271P(ab)
Maguire, C, 272P(ab)
Maguire, P, 184P(ab)
Maguire, WM, 15P(ab), 173P(ab), 266P(ab)
Mah, E, 272P(ab)
Mahmarian, JJ, 16P(ab)
Mahmood, A, 79P(ab)
Mahmood, K, 251P(ab)
Mainenti, PP, 21P(ab)
Mainolfi, C, 22P(ab), 97P(ab)
Maislin, G, 1602
Makhoul, E, 168P(ab)
Mäki, M, 989, 14P(ab), 217P(ab)
Mako, F, 61P(ab)
Makrigiorgos, GM, 79P(ab), 162P(ab)
Malesci, A, 218P(ab)
Malison, RT, 11P(ab), 128P(ab), 129P(ab), 130P(ab)
Mallavarapu, C, 126P(ab)
Mallek, R, 124P(ab)
Mallin, W, 42P(ab), 65P(ab), 133P(ab), 235P(ab), 263P(ab)
Malmberg, M, 224P(ab)
Malmud, LS, 65P(ab), 88P(ab)
Malveaux, EJ, 1198, 262P(ab)
Mandel, F, 955
Mandelkern, MA, 273P(ab)
Mangili, FM, 1970
Mangner, TJ, 104P(ab), 256P(ab)
Maniam, S, 158P(ab)
Maniawski, PJ, 193P(ab)
Manil, L, 13P(ab)
Mankoff, DA, 34P(ab)
Mann, LS, 243P(ab)
Manning, RG, 199P(ab)
Mantil, J, 142P(ab), 252P(ab)
Manzo, PA, 75P(ab)
Manzone, T, 65P(ab)
Maor, D, 143P(ab)
Maquet, P, 391
Marcel, R, 3P(ab), 152P(ab), 180P(ab)
Marchandise, X, 57
Marciano, D, 167P(ab)
Marder, K, 118P(ab)
Mardon, K, 56P(ab), 57P(ab)
Marek, K, 10P(ab)
Marenco, S, 32P(ab), 85P(ab), 130P(ab), 196P(ab), 197P(ab)
Marengo, M, 1933
Margouleff, C, 11P(ab)
Margouleff, D, 112P(ab), 185P(ab)
Mariani, G, 144P(ab), 146P(ab)
Marie, PY, 114P(ab)
Markham, J, 156P(ab)
Marmion, ME, 139P(ab), 1571
Marquis, CE, 175P(ab)
Marriot, CJ, 1390
Martell, AE, 43P(ab), 243P(ab)
Martiat P, 131P(ab)
Martin, C, 1880
Martin, D, 199P(ab)
Martin, I, 228P(ab)
Martin, J, 215P(ab)
Martin, RH, 245, 416
Martin, SE, 638
Martin, T, 67P(ab)
Martinez, B, 214P(ab)
Martinez, C, 274P(ab)
Martino, E, 1418
Marumo, F, 239P(ab)
Maruno, H, 110P(ab)
Marwick, TH, 39P(ab)
Marzilli, LG, 1198, 262P(ab)
Mascheroni, L, 1741
Masdeu, J, 212P(ab)
Masika, M, 3P(ab)
Mason, NS, 199P(ab)
Mason, RP, 216P(ab)
Massengill, S, 1051
Masters, PR, 1753
Mastin, S, 1051
Mastro, AA, 166P(ab)
Mastrostamatis, S, 263P(ab)
Masuda, K, 43P(ab), 210P(ab), 227P(ab), 231P(ab)
Matalka, KZ, 12P(ab)
Matamoros, A, 117P(ab)
Matecka, D, 247P(ab)
Mathews, D, 1557(le)
Mathews, WB, 6P(ab), 31P(ab), 52P(ab), 73P(ab), 85P(ab), 124P(ab), 130P(ab), 137P(ab), 250P(ab), 253P(ab)
Mathias, SC, 206P(ab)
Mathis, CA, 184P(ab), 251P(ab)
Matoba, M, 1279
Matoba, N, 27
Matsubara, N, 136P(ab)
Matsuda, J, 1811
Matsui, R, 227P(ab)
Matsui, Y, 474, 2057(le)
Matsumori, A, 110P(ab), 135P(ab)
Matsumoto, M, 32, 1226, 203P(ab)
Matsumura, K, 152P(ab), 154P(ab), 202P(ab), 214P(ab)
Matsunari, I, 1279
Mattar, AG, 1959
Mattay, VS, 53P(ab)
Mattes, J, 65P(ab)
Mattes, MJ, 55P(ab)
Matteucci, F, 144P(ab)
Matthew, E, 199P(ab), 202P(ab)
Matzen, K, 65P(ab)
Matzer, L, 609
Maublant, J, 46P(ab), 103P(ab), 219P(ab)
Mauclaire, L, 261P(ab)
Mauguiere, F, 75P(ab)
Maurea, S, 263, 621, 1429, 22P(ab), 114P(ab), 115P(ab), 153P(ab), 165P(ab), 166P(ab)
Maurer, AH, 282, 170P(ab)
Maurer, G, 39P(ab)
Mausner, LF, 30P(ab), 37P(ab), 52P(ab), 244P(ab), 259P(ab)
Maxon, HR, 244P(ab), 263P(ab), 276P(ab), 277P(ab)
Mayberg, HS, 929
Mayeur, S, 88P(ab)
Mayeux, R, 118P(ab)
Maynard, C, 90P(ab)
Mayo, K, 259P(ab)
Mazaika, T, 21P(ab)
Mazière, B, 56P(ab), 57P(ab), 110P(ab), 122P(ab), 253P(ab), 255P(ab), 257P(ab), 261P(ab)
Mazière, M, 122P(ab), 207P(ab), 261P(ab)
Mazzanti, M, 81P(ab)
Mazziotta, J, 107P(ab)
Mazzotta, D, 146P(ab)
McAfee, JG, 281, 89P(ab), 246P(ab), 248P(ab)
McBride, WJ, 257P(ab)
McCallum, RW, 170P(ab)
McCandless, BK, 58P(ab), 154P(ab), 181P(ab), 238P(ab), 272P(ab)
McCarthy, TJ, 73P(ab)
McCartney, WH, 91P(ab), 115P(ab)
McClellan, JR, 26P(ab)
McCormick, CI, 1831
McCormick, JW, 33P(ab)
McCowage, G, 38P(ab)
McDonald, GA, 218P(ab)
McElgin, W, 93P(ab), 128P(ab), 129P(ab), 157P(ab), 160P(ab), 246P(ab)
McEwan, A, 235P(ab)
McEwan, J, 14P(ab)
McEwan, JR, 227P(ab)
McEwan AJB, 272P(ab)
McGhie, AI, 155P(ab)
McGill, JB, 156P(ab)
McGoron, AJ, 1698
McGowan, D, 235P(ab)
McGuire, AH, 141P(ab), 230P(ab)
McIntosh, DG, 117P(ab)
McIntyre, WJ, 223P(ab)
McKay, WJ, 31P(ab), 208P(ab)
McKenzie, AF, 1338
McKenzie, DC, 150P(ab)
McKenzie, MR, 1662
McKusick, KA, 927(br)
McLaughlin, M, 230P(ab)
McLeod, MK, 1145
McLorie, GA, 449
McLoud, TC, 37P(ab)
McMackin, D, 273P(ab)
McMahan, CA, 88P(ab)
McMahon, M, 91P(ab)
McMurry, TJ, 63P(ab)
McPherson, DW, 93P(ab), 201P(ab)
McRee, RC, 93P(ab)
Means, J, 102P(ab)
Meares, CF, 12P(ab), 122P(ab), 259P(ab)
Mease, RC, 12P(ab), 30P(ab)
Meatherall, J, 240P(ab)
Mechanick, JI, 167P(ab)
Mechem, CM, 23P(ab)
Mechlis-Frish, S, 257
Meeder, JG, 3P(ab), 23P(ab)
Meehan, D, 222P(ab), 226P(ab)
Meek, A, 37P(ab), 213P(ab)
Meghdadi, S, 264P(ab)
Megnigbeto, A, 69P(ab)
Mehta, BM, 1179, 232P(ab)
Mehta, VD, 216P(ab)
Meihoffer, M, 471
Meijer, S, 224P(ab)
Meikle, SR, 360
Meinken, GE, 12P(ab), 30P(ab), 37P(ab), 52P(ab), 259P(ab)
Meins, S, 1557(le)
Mejia, MA, 1870
Mekhmandarov, S, 58P(ab)
Melancon, S, 1593, 70P(ab), 103P(ab)
Melin, JA, 39P(ab), 77P(ab), 157P(ab)
Melissano, G, 112P(ab)
Melon, PG, 1116
Meltzer, CC, 32P(ab), 182P(ab), 197P(ab)
Meltzer, P, 121P(ab)
Memsic, L, 22P(ab), 223P(ab), 229P(ab)
Mena, F, 62P(ab)
Mena, I, 22P(ab), 43P(ab), 62P(ab), 210P(ab)
Mendelson, J, 210P(ab)
Mendelson, JH, 1903
Meng, XJ, 254P(ab)
Mentes, T, 204
Menzel, C, 461, 1485, 1896,

151P(ab), 208P(ab), 214P(ab)
Mercado, Z, 237P(ab)
Meredith, RF, 1017
Merhige, ME, 115P(ab)
Merkl, M, 239P(ab)
Merlet, P, 24P(ab), 56P(ab), 78P(ab), 80P(ab), 81P(ab), 110P(ab)
Merola, B, 166P(ab)
Merouche, M, 87P(ab)
Merrill, WH, 223P(ab)
Merton, D, 86P(ab)
Mertz, L, 159P(ab)
Messa, C, 210
Messinger, DE, 26P(ab)
Mestas, D, 103P(ab)
Metcalfe, DD, 1471
Metelev, V, 151P(ab)
Metreweli, C, 70, 1313
Metz, CE, 135
Meulemans, A, 98P(ab), 125P(ab)
Meyer, G, 162P(ab)
Meyer, JH, 168P(ab)
Meyer, M, 94P(ab), 162P(ab), 209P(ab)
Meyers, R, 186P(ab)
Mican, JM, 1471
Michel, C, 39P(ab), 157P(ab)
Mickanin, J, 206P(ab)
Middlekauff, HR, 265P(ab)
Middleton, GW, 619
Middleton, ML, 265P(ab)
Mielke, R, 2011, 119P(ab)
Miers, LA, 122P(ab)
Mies, G, 176P(ab)
Mignon, M, 96P(ab)
Miguel, EC, 75P(ab)
Miki, T, 68P(ab)
Milenic, D, 100P(ab)
Milik, AW, 101P(ab)
Milius, RA, 128P(ab)
Millar, K, 63P(ab)
Millard, RW, 1698
Miller, B, 43P(ab)
Miller, D, 53P(ab)
Miller, DD, 23P(ab), 154P(ab)
Miller, J, 99P(ab)
Miller, L, 7N, 9N, 12N, 13N, 15N, 17N, 18N, 19N, 21N, 22N, 26N
Miller, RF, 240P(ab)
Miller, TR, 429, 999, 82P(ab)
Millet, P, 67P(ab)
Millican, TA, 63P(ab)
Mills, SL, 200P(ab)
Milo, T, 54P(ab)
Milshtein, D, 1129
Minami, H, 254P(ab)
Minderhoud, JM, 210P(ab), 213P(ab)
Minn, H, 1564(le), 7P(ab), 75P(ab)
Minoshima, S, 405, 949, 1528, 33P(ab), 68P(ab), 119P(ab), 138P(ab), 140P(ab), 141P(ab), 238P(ab)
Mintun, MA, 32P(ab), 41P(ab), 50P(ab), 184P(ab), 198P(ab)
Miraldi, F, 1665, 77P(ab), 248P(ab)
Mirick, GR, 259P(ab)
Miró, JM, 1041
Mirzadeh, S, 245P(ab)
Misaaki, T, 5136(le)
Misaki, T, 474, 2057(le), 146P(ab), 155P(ab)
Mitchell, MJ, 416
Mittermayer, C, 131P(ab), 230P(ab)
Miura, S, 63P(ab), 201P(ab)
Miyake, Y, 156P(ab)
Miyamoto, C, 87P(ab)
Miyamoto, S, 474, 2057(le), 146P(ab)
Miyaoka, RS, 34P(ab)
Miyasaka, M, 239P(ab)
Miyatake, K, 81P(ab)
Miyatake, S, 1104, 43P(ab)
Miyauchi, T, 29P(ab), 172P(ab), 225P(ab)
Miyazono, N, 68P(ab)
Mizuiri, S, 84
Mochizuki, K, 289
Mochizuki, T, 1134, 189P(ab)
Mock, BH, 117P(ab), 251P(ab)
Modell, JG, 215P(ab)
Mody, F, 49P(ab)
Moeller, JR, 10P(ab), 211P(ab)
Moerlein, SM, 122P(ab)
Mohsin, J, 1138, 13P(ab), 171P(ab)
Moisakis, S, 218P(ab)
Moisan, A, 175P(ab)
Molgaard, CP, 1044
Molina, IL, 89P(ab)
Möller, C, 239P(ab)
Möller, H-J, 214P(ab)
Momose, T, 127P(ab), 177P(ab), 178P(ab), 205P(ab)
Monetti, N, 1933
Mongoij, V, 1741
Mönks, T, 151P(ab)
Moody, TW, 248P(ab)
Mooe, T, 983
Moon, DH, 35P(ab), 150P(ab)
Moore, M, 209P(ab)
Moore, RH, 99P(ab)
Moore, RY, 32P(ab)
Moore, SC, 4P(ab), 17P(ab), 60P(ab), 61P(ab)
Moore, WH, 169, 177P(ab), 178P(ab)
Morabito, MD, 87P(ab)
More, N, 216P(ab)
Moresco, RM, 255P(ab)
Moretti, C, 75P(ab)
Moretti, J-L, 113, 1444, 1631, 231P(ab)
Morgan, GF, 31P(ab)
Morgan, HT, 91P(ab), 92P(ab), 193P(ab), 195P(ab)
Mori, T, 155P(ab)
Mori, Y, 1351, 226P(ab), 240P(ab), 267P(ab)
Morioka, T, 43P(ab)
Morisco, C, 1110, 114P(ab), 115P(ab), 153P(ab)
Morishita, K, 97P(ab)
Morishita, S, 97P(ab)
Morishita, T, 153P(ab)
Morita, K, 233P(ab)
Morita, R, 207P(ab)
Moriwaki, H, 32, 1226, 203P(ab)
Moriya, E, 226P(ab), 240P(ab), 267P(ab)
Morley, J, 169P(ab)
Morozumi, T, 194P(ab)
Morr, I, 1842, 228P(ab)
Morris, JC, 167P(ab)
Morris, JS, 218P(ab)
Morrison, P, 23P(ab)
Morrison, S, 18
Morrissey, MA, 89P(ab)
Morrow, TJ, 33P(ab)
Mortelmans, L, 35P(ab), 38P(ab), 40P(ab), 187P(ab)
Mortensen, SA, 266
Mortimer, JE, 141P(ab)
Morton, D, 8P(ab), 230P(ab)
Morton, KA, 74, 100P(ab), 172P(ab), 175P(ab)
Mosca, F, 144P(ab), 146P(ab)
Moscatelli, G, 144P(ab)
Moskovitz, B, 445
Moskowitz, GW, 15P(ab), 275P(ab), 276P(ab), 277P(ab)
Mostbeck, G, 124P(ab)
Motekaitis, RJ, 43P(ab)
Motomura, N, 193P(ab)
Motonari, H, 259P(ab)
Motzer, RJ, 101P(ab)
Moulin, ML, 13P(ab)
Mountain, A, 63P(ab)
Mountz, JD, 106P(ab), 215P(ab)
Mountz, JM, 21P(ab), 30P(ab), 106P(ab), 108P(ab), 210P(ab), 215P(ab)
Mourad, M, 1951
Moutsouris, CX, 1048
Moyer, BR, 257P(ab)
Moyse, D, 80P(ab)
Mozley, D, 246P(ab)
Mozley, LH, 54P(ab), 74P(ab)
Mozley, PD, 1138, 1602, 54P(ab), 74P(ab), 93P(ab), 107P(ab), 120P(ab), 129P(ab), 157P(ab), 160P(ab), 214P(ab), 237P(ab)
Mrhac, L, 238P(ab)
Mrini, A, 1822, 67P(ab)
Muehllehner, G, 41P(ab)
Mueller, SP, 4P(ab)
Mukai, T, 326, 194P(ab), 196P(ab), 259P(ab)
Mukherjee, J, 139P(ab), 252P(ab)
Mukhopadhyay, S, 93P(ab), 140P(ab)
Mulder, RU, 170P(ab)
Mulholland, GK, 20P(ab), 72P(ab), 251P(ab)
Mullan, BP, 132P(ab), 149P(ab)
Mullani, NA, 1586
Müller, L, 253P(ab)
Müller, SP, 32P(ab), 33P(ab), 60P(ab), 238P(ab)
Müller-Gärtner, HW, 233P(ab), 253P(ab), 8P(ab)
Mullick, R, 116P(ab)
Mulligan, T, 100P(ab)
Mulnix, TL, 127P(ab), 178P(ab)
Muls, V, 168P(ab)
Mumcuoglu, EU, 34P(ab), 72P(ab)
Munda, R, 166P(ab)
Munz, DL, 36P(ab), 132P(ab)
Münzing, W, 87P(ab)
Murakami, H, 289
Murakami, M, 63P(ab)
Murakami, T, 169P(ab)
Murase, K, 1134, 10P(ab), 171P(ab), 185P(ab), 189P(ab), 203P(ab)
Murashima, S, 154P(ab)
Murata, H, 110P(ab)
Murata, K, 154P(ab)
Murata, R, 234P(ab)
Murphy, J, 1450
Murphy, PH, 177P(ab), 178P(ab)
Murray, GL, 43S
Murray, JL, 101P(ab), 111P(ab)
Murray, P, 195
Murthy, K, 61P(ab)
Murthy, S, 167P(ab)
Musachio, JL, 31P(ab), 73P(ab), 124P(ab), 128P(ab), 130P(ab), 137P(ab), 250P(ab), 253P(ab)
Muto, P, 22P(ab), 80P(ab), 97P(ab)
Muzik, O, 104P(ab), 185P(ab)
Muzinic, M, 74P(ab)
Muzykantov, VR, 1358
Myers, RA, 76P(ab)
Myott, TC, 260P(ab)

Nabeshima, M, 19P(ab)
Nadler, L, 230P(ab)
Nagamachi, S, 44
Nagaraj, N, 15P(ab), 22P(ab), 166P(ab), 223P(ab), 229P(ab), 274P(ab)
Nagata, T, 169P(ab), 207P(ab)
Nagata, Y, 234P(ab)
Nagel, J, 7
Nagel, JH, 34P(ab)
Nagle, CC, 24P(ab), 274P(ab)
Någren, K, 1618, 1916, 117P(ab), 250P(ab)
Nair, CN, 218P(ab), 232P(ab)
Nair, N, 218P(ab), 232P(ab)
Naito, Y, 95P(ab)
Najean, Y, 1631
Nakabeppu, Y, 68P(ab)
Nakagawa, T, 152P(ab), 154P(ab), 202P(ab), 214P(ab)
Nakajima, K, 1937, 172P(ab)
Nakajo, M, 68P(ab)
Nakamsura, E, 177P(ab)
Nakamura, T, 1870
Nakanishi, T, 1520, 109P(ab)
Nakano, M, 206P(ab)
Nakashima, H, 202P(ab)
Nakashima, Y, 205P(ab)
Nakata, Y, 227P(ab)
Nakatani, N, 168P(ab)
Nakayama, J, 19P(ab)
Nakayama, M, 19P(ab)
Nakazawa, M, 2019, 191P(ab)
Nallamothu, N, 16P(ab)
Namba, R, 227P(ab)
Nanjappan, P, 18P(ab), 260P(ab), 261P(ab), 262P(ab)
Nanto, S, 136P(ab)
Napel, SA, 161P(ab)
Napolitano, EN, 250P(ab)
Nappi, A, 1110, 115P(ab), 153P(ab), 165P(ab)
Narabayashi, I, 227P(ab)
Narayana, S, 158P(ab)
Narkar, AA, 218P(ab)
Narra, RK, 14514, 18P(ab)
Naruki, Y, 168P(ab)
Narula, J, 1076, 4P(ab), 98P(ab), 145P(ab)
Natale, D, 91P(ab)
Natanzon, A, 143P(ab)
Nathan, MA, 229P(ab)
Nauck, C, 132P(ab)
Naude, H, 179P(ab)
Naylor, EM, 6P(ab), 246P(ab)
Neary, J, 99P(ab)
Negrón, J, 237P(ab)
Nelson, AD, 1665, 77P(ab)
Nelson, CA, 225P(ab)
Neptune, M, 74
Neumaier, B, 233P(ab)
Neumaier, M, 234P(ab)
Neumann, DR, 26P(ab), 68P(ab), 133P(ab)
Neumann, PH, 143P(ab)
Neumann, RD, 1851, 29P(ab), 89P(ab)
Neumayr, A, 44P(ab)
Neumeyer, JL, 128P(ab), 129P(ab), 201P(ab)
Neuwelt, EA, 1831
Newell, DW, 64P(ab)
Newell, JB, 1076
Newman, GE, 25P(ab)
Newman, OC, 256P(ab)
Newman, S, 103P(ab)
Newton, MR, 31P(ab), 208P(ab)
Ng, CK, 46P(ab)
Nguyen, KN, 46P(ab)
Nguyen, T, 222P(ab)
Ni, B, 5P(ab), 27P(ab), 92P(ab), 190P(ab), 192P(ab)
Nichols, K, 1292, 1593, 70P(ab), 103P(ab), 154P(ab)
Nichols, TE, 32P(ab)
Nickerson, J, 142P(ab)
Nickles, RJ, 6P(ab), 78P(ab), 127P(ab), 178P(ab), 185P(ab)
Nicol, PD, 1076, 145P(ab)
Nicolai, E, 621, 1110, 114P(ab), 153P(ab), 165P(ab)

Niederle, B, 167P(ab)
Nielsen, KK, 161P(ab)
Niewig, OE, 90
Nigam, SK, 260P(ab)
Nijran, KS, 251
Nishigauchi, K, 1520, 109P(ab)
Nishigori, H, 263P(ab)
Nishikawa, J, 127P(ab), 177P(ab), 178P(ab), 205P(ab)
Nishimura, H, 2019, 191P(ab)
Nishimura, K, 136P(ab)
Nishimura, T, 32, 1226, 1371, 46P(ab), 64P(ab), 81P(ab), 97P(ab), 131P(ab), 136P(ab), 156P(ab), 194P(ab), 203P(ab), 205P(ab), 211P(ab), 237P(ab)
Nishino, M, 118P(ab)
Nishiyama, HN, 277P(ab)
Nishizawa, S, 27, 1104, 1910, 43P(ab), 95P(ab), 179P(ab), 194P(ab), 196P(ab), 200P(ab), 201P(ab), 204P(ab), 207P(ab), 208P(ab)
Nitrini, R, 206P(ab)
Nitzsche, EU, 265P(ab)
Nocaudie-Calzada, M, 57
Noelpp, U, 145P(ab)
Nohara, R, 594, 1366, 59P(ab), 110P(ab), 135P(ab), 156P(ab)
Noiseaux, S, 218P(ab)
Nojima, S, 249P(ab)
Nomoto, K, 289
Nomura, E, 119P(ab)
Nonogi, H, 156P(ab)
Nordman, E, 117P(ab)
Norrgren, K, 258P(ab)
Nossiff, ND, 1076
Nour, R, 1928, 65P(ab)
Novak, S, 153P(ab), 173P(ab)
Novak-Hofer, I, 217P(ab)
Novell, JR, 1318
Novgorodov, AF, 253P(ab)
Nowotnik, DP, 18P(ab), 138P(ab), 260P(ab), 261P(ab), 262P(ab)
Nozaki, T, 248P(ab), 249P(ab), 250P(ab)
Nunn, AD, 1514, 18P(ab), 260P(ab)
Nusynowitz, ML, 1023, 172P(ab)
Nutt, R, 41P(ab)
Nuutila, P, 989
Nuyts, J, 35P(ab), 38P(ab), 40P(ab), 187P(ab)
Nyberg, S, 84P(ab)

Oakes, TR, 185P(ab)
Oates, E, 14P(ab)
Oberdorfer, F, 1842, 38P(ab), 75P(ab), 220P(ab), 228P(ab)
Obuchowski, N, 68P(ab)
Ochrymowicz-Bemelmans, DA, 479
O'Connell, JW, 57P(ab)
O'Connell, R, 212P(ab)
Oda, K, 249P(ab), 263P(ab)
Odano, I, 192P(ab), 205P(ab), 209P(ab)
Odom-Maryon, T, 234P(ab)
O'Donnell, S, 1076
Oei, HY, 21P(ab), 132P(ab), 163P(ab)
Offord, S, 84P(ab)
Ogata, E, 119P(ab)
Ogawa, K, 160P(ab), 193P(ab), 249P(ab)
Ogawa, M, 1
Ogawa, T, 1097
Ogawa, Y, 224P(ab)
Ogilvy, CS, 107P(ab)
Ohara, T, 84, 136P(ab)
O'Hare, N, 1450
Ohe, T, 81P(ab)
Ohguchi, M, 170P(ab)
Ohishi, Y, 267P(ab)
Ohkubo, M, 192P(ab), 205P(ab), 209P(ab)
Ohlin, P, 224P(ab)
Ohmomo, Y, 30P(ab), 254P(ab)
Ohmori, Y, 121P(ab)
Ohnishi, T, 44
Ohshio, G, 222P(ab)
Ohta, S, 203P(ab)
Ohta, T, 118P(ab)
Ohta, Y, 14P(ab), 239P(ab)
Ohtake, T, 127P(ab), 178P(ab)
Oikawa, H, 97
Oikonen, VJ, 1916
Okada, RD, 46P(ab)
Okada, S, 119P(ab)
Okazaki, Y, 32, 1226
Okazawa, H, 1104, 1910, 43P(ab), 95P(ab), 156P(ab), 194P(ab), 201P(ab), 204P(ab), 207P(ab)
O'Keefe, JH, 114P(ab)
O'Keefe, JH Jr., 625, 16P(ab), 60P(ab)
Okimura, T, 170P(ab)
Oku, N, 32, 1226, 203P(ab)
Oku, S, 127P(ab), 178P(ab)
Okuda, K, 594, 1366
Okudera, T, 1097
Okuma, M, 56P(ab)
Olbrich, A, 207P(ab)
Old, LJ, 101P(ab)
Oldhoff, J, 90
Oliner, C, 49P(ab)
Ollinger, JM, 51P(ab)
Olsen, J, 216P(ab)
Olson, C, 399
Olsson, CA, 216P(ab)
Olsson, O, 176P(ab)
Omagari, J, 231P(ab)
O'Mahony, D, 1450
Omar, AM, 133P(ab)
Omar, YT, 234P(ab)
Ombetta, JE, 247P(ab)
O'Neil, JP, 53P(ab), 73P(ab)
Önerci, M, 150P(ab)
Ong, GL, 55P(ab)
Onishi, Y, 2019, 191P(ab), 194P(ab)
Ono, Y, 137P(ab)
Onoyama, Y, 504
Onthank, D, 21P(ab)
Ooe, T, 197P(ab)
Oohira, T, 214P(ab)
Oosterwijk, E, 101P(ab)
Oppenheim, BE, 49P(ab), 111P(ab)
Orduña, E, 165P(ab), 228P(ab), 237P(ab)
Orenstein, SR, 451
O'Shaughnessy, J, 89P(ab), 100P(ab)
Osieka, R, 131P(ab)
Oster, ZH, 202, 106P(ab), 201P(ab)
Ostertag, HJ, 1569(le)
Ostrem, JL, 53P(ab)
O'Sullivan, F, 105P(ab), 188P(ab)
Oswald, SG, 1038
Otsuka, M, 210P(ab)
Otsuka, N, 149P(ab)
Otsuka, S, 168P(ab)
Ott, RJ, 42P(ab)
Otte, JB, 59P(ab)
Otto, AC, 179P(ab)
O'Tuama, LA, 43P(ab), 134P(ab), 207P(ab)
Ou, HE, 41P(ab)
Overbeck, B, 169P(ab), 208P(ab)
Owunwanne, A, 133P(ab), 234P(ab)
Oya, N, 234P(ab)
Oyamada, H, 119P(ab)
Oyen, WJG, 45P(ab), 89P(ab), 240P(ab)
Ozeki, K, 19P(ab)
Ozker, K, 88P(ab)

Paans, AMJ, 90, 456, 32P(ab), 157P(ab), 210P(ab), 213P(ab), 227P(ab)
Pace, L, 1110, 1766, 153P(ab)
Pacini, F, 1418
Packard, AB, 134P(ab)
Padhy, AK, 251
Padmanabhan, S, 29P(ab)
Paganelli, G, 1571, 1970, 55P(ab), 112P(ab), 218P(ab)
Page, RL, 1506
Pai, LH, 63P(ab)
Paik, CH, 1851, 29P(ab), 53P(ab), 63P(ab), 83P(ab), 100P(ab), 200P(ab)
Pajeau, TS, 6P(ab), 43P(ab), 106P(ab)
Pajevic, S, 183P(ab)
Pak, KY, 4P(ab)
Palacios de Caretta, N, 99P(ab)
Palatianos, GN, 153P(ab), 173P(ab)
Palekar, D, 145P(ab)
Palestro, CJ, 15P(ab), 112(ab), 150P(ab), 173P(ab), 174P(ab), 266P(ab), 276P(ab), 277P(ab)
Palevsky, H, 25P(ab), 133P(ab)
Palmer, DW, 127P(ab)
Palmer, EI, 927P(br)
Palmer, EL, 89P(ab)
Palmer, RH, 185(le)
Palmer, S, 190(le)
Palmer, WE, 35P(ab)
Palmieri, G, 96P(ab)
Palser, A, 3P(ab)
Pameijer, FA, 163P(ab)
Pan, D, 94P(ab)
Pan, HC, 204P(ab), 209P(ab)
Pan, T-S, 82P(ab), 188P(ab), 189P(ab), 193P(ab)
Pancholy, S, 136P(ab)
Pang, I, 28P(ab), 93P(ab)
Pantano, M, 169P(ab)
Papadopoulos, M, 263P(ab)
Papatheofanis, FJ, 54P(ab), 133P(ab), 204P(ab), 213P(ab)
Pappas, AA, 190(le)
Pappas, N, 67P(ab), 130P(ab)
Pappata, S, 67P(ab)
Parellada, E, 935
Parisi, MT, 429
Park, CH, 1989, 36P(ab), 271P(ab)
Park, CY, 1125
Park, S, 113P(ab)
Park, SG, 29P(ab), 53P(ab), 83P(ab), 200P(ab)
Park, TL, 37P(ab), 213P(ab)
Parker, JA, 740, 47P(ab), 171P(ab), 272P(ab)
Parkey, RW, 222P(ab)
Parkman, H, 88P(ab)
Parmentier, C, 69P(ab), 134P(ab)
Parmett, S, 465
Parrott, SJ, 138P(ab)
Parsons, SM, 94P(ab)
Pasqualini, R, 334, 114P(ab), 155P(ab), 261P(ab)
Pastan, I, 63P(ab)
Pate, J, 239P(ab)
Patel, BA, 180P(ab)
Patel, BC, 18P(ab)
Patel, BP, 152P(ab)
Patel, JU, 89P(ab)
Patel, NH, 48P(ab)
Patel, RB, 232P(ab)
Patterson, M, 103P(ab)
Patterson, RE, 638, 23P(ab), 27P(ab)
Patton, DD, 28P(ab), 93P(ab)
Patz, EF Jr., 1771, 225P(ab), 228P(ab)
Paul, R, 252P(ab)
Pauwels, S, 974, 59P(ab), 131P(ab)
Pavel, DG, 180P(ab)
Pavía, J, 935
Pavics, L, 1896, 169P(ab), 208P(ab), 214P(ab)
Pawitan, Y, 105P(ab),
Patz, EF Jr., 1771 188P(ab)
Pawlik, G, 202P(ab)
Payer, F, 107P(ab), 206P(ab)
Payne, JK, 54P(ab), 212P(ab)
Payne, SE, 349
Peels, JOJ, 23P(ab)
Pek, S, 4P(ab)
Peker, MC, 87P(ab), 98P(ab)
Pelizzari, C, 1781, 1976
Peller, PJ, 120P(ab), 274P(ab)
Pellevoisin, C, 257P(ab)
Peltier, P, 55P(ab)
Penagini, R, 168P(ab)
Pennell, DJ, 425
Penney, BC, 92P(ab), 192P(ab), 193P(ab)
Pentlow, K, 1976
Perani, D, 210, 95P(ab), 107P(ab)
Perentesis, P, 100P(ab)
Perez, JE, 39P(ab)
Perez, VL, 48P(ab)
Perkins, OW, 49P(ab)
Perlman, SB, 78P(ab)
Perlmutter, JS, 122P(ab)
Perneczky, G, 44P(ab)
Pernegger, C, 231P(ab)
Pert, C, 118P(ab)
Pescatore, F, 271P(ab)
Peschke, P, 216P(ab)
Pesl, H, 231P(ab)
Peters, AM, 276, 438, 45P(ab), 132P(ab), 172P(ab)
Peters, TL, 243P(ab)
Peterson, C, 142P(ab)
Petiet, A, 98P(ab)
Petras, S, 1321
Petric, A, 83P(ab)
Petrov, A, 4P(ab), 98P(ab)
Petry, N, 101P(ab)
Petrylak, DP, 216P(ab)
Petta, P, 2041
Pettigrew, RI, 1185, 1237, 27P(ab), 190P(ab)
Phelps, ME, 2031, 8P(ab), 24P(ab), 49P(ab), 60P(ab), 71P(ab), 135P(ab), 137P(ab), 141P(ab), 167P(ab), 183P(ab), 186P(ab), 221P(ab)
Phillips, DJ, 115P(ab)
Phillips, E, 22P(ab), 223P(ab), 229P(ab), 274P(ab)
Phillips, R, 277P(ab)
Phillips, RL, 118P(ab)
Phillips, WT, 1491, 42P(ab), 87P(ab), 88P(ab)
Philpott, GW, 12P(ab), 158P(ab), 161P(ab)
Piccolo, S, 22P(ab)
Picher, WC, 23P(ab)
Pickett, RD, 46P(ab)
Piepsz, A, 265P(ab)
Pieri, P, 1076
Pieslak, I, 98P(ab)
Pietrzyk, U, 2011, 107P(ab), 119P(ab), 207P(ab), 235P(ab)
Piffanelli, A, 114P(ab), 155P(ab)
Pike, M, 44P(ab), 45P(ab)
Pile-Spellman, J, 65P(ab)
Pillai, MRA, 261P(ab)
Pilon, C, 15P(ab)
Pinchera, A, 1418
Pinsky, CM, 217P(ab)
Pirker, W, 10P(ab)
Pirmettis, I, 263P(ab)
Pirro, J, 260P(ab)
Pirro, JP, 1514
Pisani, DE, 100P(ab)
Piscione, F, 1766
Pitaktong, U, 48P(ab)
Pitt, S, 115P(ab)
Piwnica-Worms, D, 510, 1064, 19P(ab), 230P(ab)
Plag, C, 233P(ab)

Platsch, G, 239P(ab)
Platts, EA, 46P(ab)
Plenevaux, A, 1996, 82P(ab), 251P(ab)
Plott, WE, 1017
Podoloff, DA, 11P(ab), 35P(ab), 37P(ab), 66P(ab), 76P(ab), 101P(ab), 111P(ab), 123P(ab), 131P(ab), 143P(ab), 220P(ab), 228P(ab), 256P(ab)
Podreka, I, 10P(ab), 207P(ab)
Poewe, W, 1921
Poirier, M, 241P(ab), 245P(ab)
Polisson, RP, 35P(ab)
Polk, DH, 164P(ab)
Pollack, W, 106P(ab)
Pollak, A, 44P(ab), 262P(ab)
Pollard, KR, 34P(ab), 180P(ab)
Poncioni, L, 101P(ab)
Ponsonnaille, J, 103P(ab)
Ponto, JA, 158P(ab)
Popenoe, E, 221P(ab)
Porenta, G, 2041, 110P(ab)
Port, SC, 721, 1301, 70P(ab)
Poshyachinda, M, 1792
Postema, PTE, 163P(ab)
Posthumus, H, 157P(ab)
Postiglione, A, 9P(ab), 21P(ab)
Poston, JW, 189(le)
Potter, N, 94P(ab)
Pottier, J-M, 237P(ab)
Pouillart, F, 80P(ab), 81P(ab)
Pounds, TR, 76P(ab)
Powars, D, 134P(ab)
Powell, M, 1051
Pozderac, RV, 163P(ab)
Poznanski, AK, 59P(ab)
Pozniakof, T, 95P(ab)
Pozzera, A, 10P(ab)
Prato, FS, 92P(ab)
Prats, E, 1303
Pratt, JP, 28P(ab), 98P(ab)
Prescott, DM, 38P(ab)
Presti, D, 214P(ab)
Preston, DF, 274P(ab), 275P(ab)
Pretorius, PH, 179P(ab), 193P(ab)
Prevost, P, 273P(ab)
Price, JC, 67P(ab)
Price, JE, 256P(ab)
Prieto, I, 1245
Primus, FJ, 234P(ab)
Prince, MR, 89P(ab)
Prior, J, 222P(ab)
Prohovnik, I, 1566(le), 118P(ab)
Prontera, C, 146P(ab)
Prosser, BL, 175P(ab)
Proye, C, 57
Pruckmayer, M, 167P(ab)
Pruim, J, 90, 456, 3P(ab), 23P(ab), 32P(ab), 210P(ab), 213P(ab), 227P(ab)
Pugin, J, 120
Pulmano, C, 149P(ab), 271P(ab)
Purcell-Tornai, S, 155P(ab)
Purnell, GL, 190(le)
Pusey, CD, 132P(ab)
Puskas, C, 95
Put, E, 942
Pyatt, B, 30P(ab), 37P(ab), 52P(ab)

Qaim, SM, 233P(ab), 253P(ab)
Qian, W, 143P(ab)
Quesenberry, J, 229P(ab)
Quigley, MR, 223P(ab)
Quinn, RJ, 1928
Quinones, N, 273P(ab)
Quint, LE, 75P(ab)
Quint, RH, 139P(ab)
Quirce, R, 174P(ab)
Quirijnen, JMSP, 236P(ab)

Rabasa, JM, 174P(ab)
Rabito, CA, 99P(ab)
Rackson, M, 476
Radcliffe, R, 282
Raderer, M, 85P(ab), 97P(ab)
Radford, DM, 141P(ab)
Raichlen, JS, 1989
Raffel, D, 57P(ab)
Raffestin, B, 1328
Raftery, EB, 16P(ab), 136P(ab)
Raghab, A, 234P(ab)
Rahmy, AIA, 1788
Rai, T, 177P(ab)
Rain, J-D, 1631
Raja, S, 133P(ab), 220P(ab)
Rajashekharrao, B, 1944
Rajeevan, N, 193P(ab)
Rajopadhye, M, 52P(ab), 241P(ab), 245P(ab)
Raju, N, 18P(ab), 260P(ab), 261P(ab)
Rails, PW, 125P(ab)
Rama, PR, 60P(ab)
Ramalingam, K, 18P(ab), 260P(ab), 261P(ab), 262P(ab)
Ramamoorthy, N, 261P(ab)
Ramanna, L, 15P(ab)
Ramos, CD, 211P(ab)
Ramsey, FL, 1831
Rao, DV, 303, 521, 1861, 1564(le), 123P(ab), 179P(ab)
Rao, V, 19P(ab)
Rao, VV, 510
Raoul, J-L, 1781
Rapaport, E, 151P(ab)
Raphael, M, 231P(ab)
Rappersberger, H, 264P(ab)
Raptopoulou, CP, 263P(ab)
Rask, P, 983
Ratliff, B, 100P(ab)
Rattner, Z, 228
Raubitschek, AA, 1562(le), 234P(ab)
Rauch, SL, 75P(ab)
Rauh, D, 240P(ab)
Rauh, DA, 74, 1858
Raval, U, 16P(ab), 136P(ab)
Ravert, HT, 6P(ab), 9P(ab), 31P(ab), 52P(ab), 73P(ab), 74P(ab), 85P(ab), 124P(ab), 130P(ab), 137P(ab), 196P(ab), 250P(ab), 253P(ab)
Ray, JS, 193P(ab)
Ray, S, 218P(ab)
Raylman, RR, 157, 1286, 104P(ab)
Reba, RC, 24N, 26P(ab), 93P(ab), 200P(ab)
Reddy, EP, 65P(ab)
Redmond, DE Jr., 140P(ab)
Reeb, S, 76P(ab)
Reed, L, 31P(ab)
Reed, M, 275P(ab)
Reese, L, 92P(ab)
Regan, D, 233P(ab)
Regenold, W, 929
Rehder, K, 7P(ab)
Rehm, K, 1815
Rehm, P, 267P(ab), 273P(ab)
Rehmann, CJ, 174P(ab), 202P(ab)
Reich, H, 13P(ab), 171P(ab)
Reichmann, K, 1896
Reid, WD, 150P(ab)
Reiger, PT, 101P(ab)
Reijs, AEM, 226P(ab)
Reiling, R, 142P(ab)
Reilley, J, 195P(ab)
Reiman, RE, 234P(ab)
Reiners, C, 32P(ab), 238P(ab)
Reinhardt, CP, 3P(ab), 152P(ab), 180P(ab)
Reinhold, U, 461
Reist, HW, 317
Reivich, M, 206P(ab)
Ren, JF, 27P(ab)
Reno, J, 158P(ab), 254P(ab)
Renshaw, P, 20P(ab), 207P(ab)
Repp, R, 1436
Resch, C, 182P(ab)
Reske, SN, 113P(ab), 117P(ab), 156P(ab), 223P(ab), 224P(ab)
Restelli, C, 167P(ab)
Retos, C, 21P(ab)
Reubi, J-C, 132P(ab), 21P(ab), 220P(ab)
Reuland, E, 200P(ab)
Reuland, P, 1342
Reutens, D, 185P(ab), 212P(ab)
Reyes, J, 258P(ab), 259P(ab)
Rezai, K, 1558(le), 113P(ab)
Rhind, SK, 63P(ab)
Rhodes, BA, 106P(ab)
Riauka, TA, 5P(ab)
Ribe, JY, 273P(ab)
Ricard, M, 159P(ab)
Ricci, S, 144P(ab)
Rice, KC, 247P(ab)
Rice, TW, 133P(ab)
Rich, D, 64P(ab)
Richards, D, 28P(ab), 93P(ab)
Richmond, JC, 104P(ab), 188P(ab)
Richter, W, 1921
Riddell, C, 187P(ab)
Rieker, O, 461, 1485, 151P(ab)
Riekkinen, P Sr., 118P(ab)
Rifat, S, 259P(ab)
Riggin, SL, 222P(ab), 226P(ab)
Rigo, P, 391, 587, 1116, 1581
Rijntjes, M, 32P(ab), 33P(ab)
Rimac, A, 75P(ab)
Rinne, JO, 1916
Rinne, UK, 1916
Riva, N, 144P(ab)
Riva, P, 144P(ab)
Riviello, J, 134P(ab)
Rizzo, G, 210
Roach, P, 134P(ab), 207P(ab)
Roamniello, G, 160P(ab)
Robert, A, 39P(ab)
Roberts, AD, 6P(ab), 185P(ab)
Roberts, K, 239P(ab)
Robeson, W, 955, 11P(ab), 112P(ab), 185P(ab)
Robinson, L, 1167
Robinson, M, 79P(ab)
Robinson, PS, 1797
Robinson, RA, 229P(ab)
Robinson, RG, 274P(ab)
Rocco, TP, 1805
Rodgers, RA, 190P(ab)
Rodney, RA, 114P(ab)
Rodwell, JD, 282
Roemer, J, 139P(ab)
Rogers, WL, 652, 1265, 115P(ab), 185P(ab)
Rogulski, MM, 28P(ab)
Rohde, D, 256P(ab)
Rojas, J, 10N(12)
Rokosh, E, 3P(ab)
Rokshar, S, 49P(ab)
Roland, J, 236P(ab)
Rolleman, E, 165P(ab)
Roman, R, 471
Romaniello, G, 128P(ab), 129P(ab)
Romano, M, 9P(ab), 21P(ab)
Romero, VR, 18P(ab)
Roolker, W, 151P(ab), 174P(ab)
Ropchan, JR, 273P(ab)
Ros, D, 935
Rosa, E, 1179, 165P(ab)
Rösch, F, 233P(ab), 253P(ab)
Rose, M, 275P(ab), 276P(ab)
Rose, R, 201P(ab)
Rosebrough, SF, 1738
Rosen, B, 20P(ab)
Rosenberg, C, 178P(ab)
Rosenblat, W, 84P(ab)
Rosenblum, MG, 101P(ab)
Rosenthall, DI, 35P(ab)
Rosenthall, L, 120P(ab)
Rosik, LO, 139P(ab)
Rösler, H, 145P(ab), 217P(ab), 220P(ab)
Rosner, G, 197P(ab)
Ross, C, 101P(ab)
Rossetti, C, 1571
Rossi, V, 49P(ab)
Roth, CA, 260P(ab)
Roth, D, 99P(ab)
Roth, RH, 140P(ab)
Rothkirch, T, 36P(ab)
Rottenberg, DA, 1815
Rousseau, J, 1390
Rouveix, B, 87P(ab)
Rowe, B, 164P(ab)
Rowe, CC, 31P(ab)
Rowe, FA, 159P(ab)
Rowen, M, 556
Royal, H, 368
Royal, HD, 2003
Rozanski, A, 70P(ab), 103P(ab), 154P(ab)
Rubbert-Slawek, KA, 266P(ab)
Rubello, D, 126P(ab)
Rubin, PJ, 39P(ab), 156P(ab)
Rubin, RH, 44P(ab), 89P(ab), 99P(ab), 175P(ab)
Rubinow, DR, 53P(ab)
Rubinstein, M, 213P(ab)
Ruddy, TD, 3P(ab)
Rudolph, AS, 1491
Ruff, M, 118P(ab)
Ruiz, C, 228P(ab)
Ruiz, M, 47P(ab)
Rumsey, WL, 18P(ab), 152P(ab), 260P(ab)
Ruotsalainen, U, 989, 1618, 1916, 117P(ab), 183P(ab)
Ruottinen, HM, 1916
Ruppel, S, 100P(ab)
Rusckowski, M, 127, 1568(le), 105P(ab), 242P(ab), 260P(ab)
Rush, AJ, 54P(ab)
Russell, CD, 1017
Russell, J, 126P(ab), 16P(ab)
Russell, JM, 215P(ab)
Ruth, TJ, 18, 41P(ab)
Rux, A, 259P(ab)
Ryan, J, 166P(ab), 239P(ab), 276P(ab)
Ryman JC, 1377
Ryo, UY, 149P(ab)
Ryu, JS, 35P(ab), 150P(ab)

Sabharwal, CL, 999
Sabry, S, 56P(ab)
Saccavini, JC, 257P(ab)
Sacktor, N, 118P(ab)
Sadato, N, 27, 1104, 43P(ab), 95P(ab), 200P(ab), 204P(ab)
Sadzot, B, 391
Safavy, A, 258P(ab)
Saga, T, 1279, 1851
Saha, GB, 133P(ab)
Sahu, SK, 79P(ab), 162P(ab)
Sain, J, 28P(ab), 93P(ab)
Saito, R, 197P(ab)
Saitta, B, 126P(ab)
Saji, H, 247P(ab), 254P(ab)
Sakahara, H, 296, 326, 1174, 1482, 1677, 30P(ab), 56P(ab), 146P(ab)
Sakai, K, 192P(ab)
Sakai, T, 169P(ab)
Sakaki, S, 203P(ab)
Sakowski, R, 1896
Salako, Q, 122P(ab), 158P(ab), 244P(ab), 259P(ab)
Salama, A, 1647
Salata, C, 85P(ab)
Salensky, H, 1292, 1593, 70P(ab), 103P(ab), 154P(ab)
Sallan, SE, 43P(ab)
Salmon, E, 391
Saltzberg, MT, 664
Salvadori, PA, 144P(ab)
Salvatore, M, 263, 621, 1110, 1429, 1766, 9P(ab), 21P(ab), 22P(ab), 80P(ab), 96P(ab), 97P(ab), 114P(ab),

115P(ab), 153P(ab), 165P(ab), 166P(ab)
Samnick, S, 9P(ab)
Samson, Y, 66P(ab), 207P(ab)
Samuel, A, 55P(ab), 112P(ab), 218P(ab)
Samuel, AM, 1944
Sancho, A, 145P(ab)
Sandler, ED, 429, 2056(le)
Sandler, MP, 1152, 223P(ab)
Sandrock, D, 36P(ab), 132P(ab)
Sanfield, JA, 1145
San Pedro, E, 14P(ab)
Sanpitak, P, 190P(ab)
Santoro, GM, 1254, 1274, 49P(ab)
Santoro, J, 1992
Santulli, R, 45P(ab)
Sapp, S, 39P(ab)
Sara, R, 601
Sarda, L, 96P(ab)
Sarfati, E, 1631
Sargent, B, 223P(ab)
Sarkar, SD, 2054(le)
Sarosi, MG, 24P(ab)
Sarti, G, 144P(ab)
Sartor, J, 247P(ab)
Sasaki, M, 43P(ab), 210P(ab), 227P(ab), 231P(ab)
Sasaki, T, 249P(ab), 250P(ab), 263P(ab)
Sasaki, Y, 84, 108P(ab), 127P(ab), 177P(ab), 178P(ab), 205P(ab)
Sasayama, S, 594, 1366, 59P(ab), 110P(ab), 135P(ab), 156P(ab)
Sase, M, 177P(ab)
Sashin, D, 50P(ab), 184P(ab)
Sastrodjojo, B, 200P(ab)
Satlin, A, 20P(ab), 116P(ab), 207P(ab)
Sato, S, 289, 217P(ab)
Satoh, N, 249P(ab)
Satter, M, 142P(ab), 252P(ab)
Satyamurthy, N, 83P(ab)
Saunders, RC, 199P(ab), 247P(ab)
Savage, CR, 75P(ab)
Sawano, S, 119P(ab)
Scalliet, P, 236P(ab)
Scanley, BE, 201P(ab)
Scasnar, V, 1390
Schad, NC, 43S
Schally, AV, 259P(ab)
Schaper, K, 1815
Schauwecker, DS, 49P(ab), 111P(ab), 117P(ab)
Schechter, D, 1802
Schecter, L, 275P(ab)
Scheele, JR, 86P(ab), 218P(ab)
Scheffel, U, 19P(ab), 52P(ab), 73P(ab), 85P(ab), 128P(ab), 199P(ab), 245P(ab), 250P(ab)
Scheidler, V, 9P(ab)
Scheinberg, DA, 112P(ab)
Scheithauer, W, 85P(ab), 97P(ab)
Schelbert, HR, 1S, 8S, 707, 2031, 24P(ab), 39P(ab), 49P(ab), 60P(ab), 71P(ab), 110P(ab), 135P(ab), 155P(ab), 167P(ab), 265P(ab)
Schelosky, L, 1921
Scher, H, 36P(ab)
Scherer, J, 74P(ab)
Schiefelbein, ML, 274P(ab)
Schiepers, C, 35P(ab), 38P(ab), 187P(ab), 211P(ab)
Schlebusch, H, 234P(ab)
Schleicher, UM, 111P(ab)
Schlemper, EO, 41P(ab), 241P(ab), 261P(ab)
Schlom, J, 1017, 1976, 100P(ab), 101P(ab), 102P(ab), 235P(ab)
Schlumberger, M, 69P(ab)
Schlyer, DJ, 128P(ab), 130P(ab), 140P(ab), 253P(ab)
Schmarkey, S, 638, 23P(ab)
Schmeling, GT, 88P(ab)
Schmidt, K, 176P(ab)
Schmidt, MA, 139P(ab)
Schmidt, P, 195
Schmidt, PJ, 53P(ab)
Schmitz, F, 82P(ab)
Schneider, F, 54P(ab)
Schneider, JA, 1748
Schneider, PM, 178P(ab)
Schneiderman, MH, 144P(ab)
Schnorr, L, 181P(ab), 185P(ab), 186P(ab)
Schober, O, 9P(ab), 33P(ab), 139P(ab)
Schoenberg, OI, 35P(ab)
Schomburg, A, 151P(ab), 169P(ab), 214P(ab)
Schönberger, JA, 117P(ab)
Schramm, M, 186P(ab)
Schroth, G, 145P(ab)
Schteingart, DE, 1145
Schubiger, PA, 18P(ab), 101P(ab)
Schulte, M, 113P(ab)
Schultes, B, 234P(ab)
Schulthess, GK, 18P(ab), 184P(ab)
Schulzer, M, 18
Schumpelick, V, 108P(ab)
Schussler, GC, 2054(le)
Schwaiger, M, 652, 693, 1265, 1286, 43P(ab), 65P(ab), 91P(ab), 92P(ab), 104P(ab), 109P(ab), 115P(ab), 191P(ab), 222P(ab), 231P(ab)
Schwartz, DA, 29P(ab)
Schwartz, J, 87P(ab), 88P(ab)
Schwarz, J, 74P(ab)
Schwarz, SW, 12P(ab), 158P(ab), 161P(ab)
Sciagrà, R, 1254, 1274
Sciuk, J, 95, 9P(ab)
Scott, AM, 1407, 1748, 1976, 7P(ab), 101P(ab), 102P(ab), 123P(ab), 232P(ab)
Scott, AS, 112P(ab)
Scott, DV, 272P(ab)
Scott, GC, 274P(ab)
Scott, JA, 89P(ab)
Seabold, JE, 1738, 113P(ab), 229P(ab)
Seale, T, 200P(ab)
Secchi, V, 237P(ab)
Segal, K, 257
Seibyl, IB, 159P(ab)
Seibyl, JP, 228, 399, 10P(ab), 11P(ab), 84P(ab), 116P(ab), 129P(ab)
Seidel, J, 1538, 40P(ab), 61P(ab), 143P(ab)
Seidman, AD, 1748
Seike, Y, 32
Seiler, C, 100P(ab)
Seiler, R, 220P(ab)
Seki, T, 93
Sekine, H, 119P(ab)
Seldin, DW, 1044, 82P(ab), 114P(ab), 151P(ab), 217P(ab), 218P(ab)
Selland, DL, 14P(ab)
Selliti, Dr., 213P(ab)
Selman, H, 237P(ab)
Semah, F, 66P(ab), 207P(ab)
Semlitsch, G, 2057(le)
Semmler, W, 1921
Senda, M, 110P(ab), 248P(ab), 249P(ab), 250P(ab), 263P(ab)
Senekowitsch, R, 65P(ab)
Senior, R, 16P(ab), 136P(ab)
Senneff, MJ, 558
Seo, IS, 124P(ab)
Serafini, AN, 1054, 42P(ab), 65P(ab), 133P(ab), 145P(ab), 153P(ab), 173P(ab), 235P(ab), 263P(ab)
Seregni, E, 1741
Serrano, J, 174P(ab)
Servais, J, 236P(ab)
Setaka, M, 249P(ab)
Seto, H, 1659
Setoain, J, 935, 1041
Seward, J, 181P(ab)
Sfakianakis, GN, 1054, 34P(ab), 42P(ab), 65P(ab), 68P(ab), 99P(ab), 145P(ab), 153P(ab), 173P(ab), 263P(ab), 266P(ab)
Sgouros, G, 1976, 7P(ab), 112P(ab), 123P(ab), 161P(ab), 179P(ab)
Shams, J, 476
Shanahan, M, 13N(12)
Shand, DC, 193P(ab)
Shapiro, B, 1013, 1145, 1333, 1338, 1637, 1559(le), 109P(ab), 256P(ab)
Sharif, D, 133P(ab)
Sharkey, RM, 1028, 102P(ab), 219P(ab), 236P(ab)
Shattuc, S, 90P(ab)
Shattuck, L, 264P(ab)
Shattuck, LA, 349
Shea, C, 67P(ab), 140P(ab)
Shea, F, 65P(ab), 88P(ab)
Sheehan, F, 569
Shefer, RE, 249P(ab)
Shemesh, E, 58P(ab)
Shen, LH, 242P(ab), 263P(ab)
Shen, MYH, 91P(ab)
Shen, S, 1381, 158P(ab), 177P(ab), 244P(ab)
Shen, YH, 70P(ab)
Shen, YY, 176P(ab)
Sherman, PS, 7P(ab), 72P(ab), 83P(ab), 84P(ab), 93P(ab), 98P(ab), 256P(ab)
Shevitz, J, 236P(ab), 258P(ab)
Shi, Q, 664
Shi, RF, 90P(ab)
Shibasaki, H, 194P(ab), 196P(ab), 207P(ab)
Shibazaki, T, 197P(ab)
Shields, AF, 34P(ab)
Shields, RA, 186(le), 187(le)
Shigeno, C, 1482
Shih, LB, 236P(ab)
Shih, WJ, 146P(ab), 149P(ab), 271P(ab)
Shima, T, 154P(ab)
Shimada, T, 226P(ab), 240P(ab)
Shimizu, K, 1520
Shimizu, M, 1659, 1937
Shimizu, T, 227P(ab)
Shimonagata, T, 136P(ab)
Shimoni, A, 257
Shimosegawa, E, 63P(ab)
Shimosegawa, Eku, 1097
Shin, DH, 1125
Shin, MJ, 35P(ab), 150P(ab)
Shinners, P, 164P(ab)
Shinoda, M, 248P(ab)
Shiono, H, 30P(ab)
Shipulin, V, 203P(ab)
Shirai, T, 267P(ab)
Shirakami, Y, 97P(ab)
Shirakawa, S, 179P(ab)
Shirakawa, T, 226P(ab)
Shirato, M, 296
Shirazi, P, 54P(ab), 133P(ab), 204P(ab), 213P(ab)
Shiue, C-Y, 252P(ab)
Shiue, GG, 252P(ab)
Shivalkar, B, 38P(ab)
Shively, JE, 234P(ab)
Shochat, D, 63P(ab)
Shore, RM, 59P(ab)
Shore, S, 65P(ab)
Shoup, TM, 1685, 121P(ab), 140P(ab), 198P(ab)
Shrem, Y, 143P(ab)
Shreve, P, 108P(ab), 124P(ab)
Shuke, N, 29P(ab), 172P(ab), 225P(ab)
Shukla, R, 236P(ab)
Shulkin, BL, 135P(ab)
Shvera, I, 203P(ab)
Sicagrà, R, 49P(ab)
Siccardi, AG, 1970, 55P(ab)
Siegel, BA, 12P(ab), 117P(ab), 141P(ab), 230P(ab)
Siegel, JA, 152, 1213
Siegel, ME, 58P(ab), 125P(ab), 167P(ab)
Siegfied, W, 239P(ab)
Silagan, G, 542, 609
Silberman, A, 22P(ab)
Silberstein, EB, 368, 1994(e), 36P(ab), 90P(ab), 166P(ab)
Silbersweig, DA, 181P(ab), 185P(ab), 186P(ab)
Silva, F, 165P(ab), 228P(ab), 237P(ab)
Silva, FCP, 264P(ab)
Silver, DL, 180P(ab)
Silverman, IE, 95P(ab)
Silverman, J, 223P(ab)
Simkowitz, P, 85P(ab)
Simonneau, G, 47P(ab)
Simons, M, 740
Simpson, N, 184P(ab), 251P(ab)
Singer, H, 130P(ab)
Singh, PR, 139P(ab)
Sinnige, LGF, 210P(ab)
Sinusas, AJ, 664, 46P(ab), 91P(ab)
Siraj, QH, 251
Sireci, SN, 216P(ab)
Sirisriro, R, 143P(ab)
Sisson, JC, 135P(ab)
Sixt, R, 438
Sjögren, H-O, 258P(ab)
Skinner, RS, 256P(ab)
Skolnick, P, 247P(ab)
Slade, SA, 248P(ab)
Slansky, I, 2011
Slizofski, WJ, 471, 14P(ab), 227P(ab)
Slomka, P, 127P(ab), 272P(ab)
Slonim, SM, 1044
Slooff, TJJH, 89P(ab)
Slosman, DO, 120
Smart, SC, 49S
Smith, A, 101P(ab)
Smith, AM, 484, 18P(ab)
Smith, EO, 399, 10P(ab), 116P(ab), 140P(ab)
Smith, GS, 85P(ab)
Smith, GT, 220P(ab), 239P(ab)
Smith, JS, 67P(ab)
Smith, KF, 124P(ab)
Smith, MF, 17P(ab)
Smith, ML, 117P(ab)
Smith, R, 1466
Smith, RJ, 54P(ab), 188P(ab), 222P(ab), 226P(ab)
Smith, WE, 28P(ab), 93P(ab)
Smith, WH, 47P(ab)
Smith, WI, 1612
Smith-Jones, PM, 317
Smulian, AG, 1028
Snow, BJ, 18
Snyder, H, 1602, 237P(ab)
Snyder, SE, 72P(ab)
Sobhani, I, 96P(ab)
Sochor, H, 2041, 176P(ab)
Soher, BJ, 32P(ab)
Soininen, H, 118P(ab)
Sokole, EB, 176P(ab)
Sokoloff, L, 176P(ab)
Sola, M, 1041
Solin, O, 249P(ab), 252P(ab)
Solomon, HF, 45P(ab), 105P(ab)
Solymosi, L, 208P(ab)
Som, P, 202, 106P(ab), 201P(ab)
Song, HC, 109P(ab)
Songalede, JA, 46P(ab), 219P(ab)
Songini, C, 55P(ab), 112P(ab), 218P(ab)

Sonnenschein, W, 238P(ab)
Sood, V, 93P(ab)
Soricelli, A, 1110, 9P(ab), 21P(ab), 114P(ab), 115P(ab)
Sossi, V, 41P(ab)
Sostman, HD, 25P(ab), 38P(ab), 48P(ab)
Sostre, S, 48P(ab), 119P(ab)
Soucy, J-P, 1822, 67P(ab)
Soufer, R, 46P(ab), 64P(ab)
South, MS, 101P(ab)
Southern, JF, 1076
Sparks, RB, 159P(ab)
Spaziante, R, 97P(ab)
Spelle, L, 66P(ab)
Spencer, A, 132P(ab)
Spencer, SS, 116P(ab)
Sperling, RA, 20P(ab)
Spetsieris, P, 955
Spicer, JA, 274P(ab)
Spicer, KM, 102P(ab)
Spinelli, A, 144P(ab)
Spradling, J, 182P(ab)
Springer, S, 1902
Squame, F, 114P(ab), 115P(ab)
Squifflet, J-P, 1951
Sridhara, B, 1581
Sridhara, BS, 16P(ab), 136P(ab)
Srinivasan, A, 139P(ab)
Srivastava, SC, 12P(ab), 30P(ab), 37P(ab), 52P(ab), 244P(ab), 259P(ab)
Stabin, MG, 152, 516, 1377, 191(le), 192(le), 78P(ab), 112P(ab), 160P(ab)
Stachler, R, 1007
Stafford, K, 115P(ab)
Stanberry, C, 4S
Stapleton, SJ, 1547
Starling, J, 164P(ab)
Stathis, M, 73P(ab), 128P(ab), 245P(ab)
Stauch, C, 186P(ab)
Staudenherz, A, 63P(ab), 150P(ab), 167P(ab)
Stazyk, MW, 41P(ab)
Stearns, CW, 1398
Stecker, MM, 1087, 53P(ab), 208P(ab)
Stein, L, 49P(ab)
Stein, SD, 1538
Stein, V, 186P(ab)
Steiner, E, 167P(ab)
Steinert, H, 96P(ab)
Steinmetz, A, 58P(ab)
Stella, M, 1970
Stepan, V, 173P(ab)
Stephens, A, 117P(ab)
Steplewski, Z, 30P(ab)
Stern, C, 20P(ab), 107P(ab)
Stern, E, 181P(ab), 185P(ab), 186P(ab)
Stern, Y, 118P(ab)
Stevens, M, 4P(ab)
Steventon, R, 109P(ab)
Stewart, JR, 223P(ab)
Stewart, KE, 215P(ab)
Stiegler, C, 173P(ab)
Stiekema, J, 100P(ab)
Stipp, V, 149P(ab), 271P(ab)
Stöcklin, G, 8P(ab), 73P(ab), 94P(ab), 233P(ab), 253P(ab)
Stöcklin, GL, 51
Stoffel, M, 1951, 131P(ab)
Stokkel, MPM, 1423
Stollfuss, J, 117P(ab), 224P(ab)
Stolz, B, 317
Stone, CK, 78P(ab), 178P(ab)
Stout, M, 112P(ab), 185P(ab)
Stowasser, G, 231P(ab)
Stowe, LA, 32P(ab), 200P(ab)
Stowers, SA, 70P(ab)
Strand, S-E, 143, 342, 78P(ab), 123P(ab), 157P(ab), 176P(ab), 179P(ab), 189P(ab), 221P(ab), 224P(ab), 258P(ab)
Strandh, M, 78P(ab)
Strashun, AM, 2054(le)
Stratton, JR, 1731, 254P(ab)
Straub, B, 231P(ab)
Strauss, HW, 496, 1076, 1685, 89P(ab)
Strauss, LG, 38P(ab), 220P(ab), 231P(ab), 236P(ab)
Streckenback, H, 1436
Streeter, J, 23P(ab)
Strijckmans, V, 253P(ab)
Stritzke, PH, 266P(ab)
Stroobandt, G, 974
Strother, SC, 1815, 51P(ab)
Stubbs, JB, 399, 78P(ab), 129P(ab), 157P(ab), 158P(ab), 159P(ab), 160P(ab)
Stumbris, RS, 271P(ab)
Stumpf, MJ, 31P(ab), 182P(ab), 197P(ab)
Sturiale, C, 144P(ab)
Sturm, V, 235P(ab)
Su, FM, 242P(ab)
Subramanian, M, 263P(ab)
Subramanian, P, 239P(ab)
Sudati, F, 55P(ab), 112P(ab), 218P(ab)
Suehiro, M, 85P(ab), 253P(ab)
Sueyoshi, K, 227P(ab)
Suga, K, 1520, 109P(ab)
Sugano, A, 109P(ab)
Sugano, Y, 129P(ab)
Sugawara, Y, 171P(ab), 203P(ab)
Sugii, A, 19P(ab)
Sugimoto, K, 169P(ab)
Suhara, T, 84P(ab)
Sullo, P, 1766
Sulzer, M, 220P(ab)
Sumiya, H, 225P(ab)
Sumner-Smith, M, 44P(ab)
Sun, B-F, 29P(ab)
Sun, K, 39P(ab), 135P(ab)
Sun, KT, 2031
Sun, WM, 168P(ab)
Sun, Y, 43P(ab)
Sun, YH, 243P(ab)
Sunderland, J, 117P(ab), 221P(ab)
Supino, P, 60P(ab)
Surveyor, I, 1797, 184(le)
Susskind, H, 207, 342, 221P(ab)
Suvanapha, R, 1792
Suzuki, A, 239P(ab)
Suzuki, K, 248P(ab), 255P(ab)
Suzuki, N, 97P(ab)
Suzuki, T, 206P(ab)
Swahn, C-G, 84P(ab), 122P(ab)
Swayne, LC, 1028
Sweet, M, 259P(ab)
Sy, WM, 124P(ab)
Sylvester, JM, 22N, 26N, 38N
Syrota, A, 24P(ab), 50P(ab), 56P(ab), 57P(ab), 66P(ab), 67P(ab), 78P(ab), 80P(ab), 81P(ab), 110P(ab), 122P(ab), 137P(ab), 187P(ab), 255P(ab)
Szabo, Z, 48P(ab), 52P(ab), 85P(ab), 124P(ab), 137P(ab), 182P(ab)
Szasz, IJ, 150P(ab)

Tada, M, 104, 1067, 152P(ab), 256P(ab)
Tadamura, E, 594, 59P(ab), 110P(ab), 135P(ab), 155P(ab), 156P(ab), 179P(ab)
Tadary, B, 107P(ab)
Tadokoro, M, 118P(ab)
Tagami, T, 152P(ab)
Tagesson, M, 78P(ab), 123P(ab)
Tai, Y-C, 187P(ab)
Taillefer, R, 1245, 15P(ab), 2058(br)
Taillon, LA, 26P(ab), 69P(ab)
Tait, J, 254P(ab)
Tajima, N, 246P(ab)
Takagi, T, 234P(ab)
Takahashi, A, 137P(ab)
Takahashi, H, 97
Takahashi, M, 19P(ab), 276P(ab)
Takahashi, N, 594, 59P(ab), 81P(ab), 156P(ab), 169P(ab), 179P(ab), 192P(ab), 205P(ab), 209P(ab)
Takahashi, T, 97, 152P(ab), 256P(ab)
Takano, M, 84
Takano, YM, 168P(ab)
Takara, T, 168P(ab)
Takasaki, M, 206P(ab)
Takata, J, 1691
Takechi, T, 1134, 171P(ab), 189P(ab)
Takeda, K, 152P(ab), 154P(ab), 214P(ab)
Takeuchi, A, 202P(ab)
Takeuchi, R, 474, 2057(le), 146P(ab)
Taki, J, 1279, 1937, 225P(ab)
Taki, W, 204P(ab)
Takikawa, S, 955
Tamahashi, N, 104, 1067, 256P(ab)
Tamaki, J, 169P(ab)
Tamaki, M, 179P(ab)
Tamaki, N, 27, 594, 1104, 1366, 1910, 1965, 43P(ab), 59P(ab), 95P(ab), 110P(ab), 135P(ab), 155P(ab), 156P(ab), 194P(ab), 196P(ab), 200P(ab), 201P(ab), 204P(ab), 222P(ab), 225P(ab), 234P(ab)
Tamamura, H, 170P(ab)
Tamgac, F, 1444
Tamir, A, 411
Tamminga, CA, 74P(ab), 197P(ab)
Tamura, Y, 137P(ab)
Tan, ES, 23P(ab)
Tan, P, 67P(ab)
Tan, WD, 1788
Tanada, S, 1134, 171P(ab), 189P(ab), 203P(ab)
Tanahashi, K, 247P(ab)
Tanaka, A, 1965, 225P(ab)
Tanaka, C, 254P(ab)
Tanaka, F, 1910, 43P(ab), 194P(ab), 201P(ab), 204P(ab), 207P(ab), 208P(ab)
Tanaka, H, 149P(ab), 239P(ab)
Tanaka, Y, 169P(ab)
Tanda, K, 93
Tankurt, E, 1569(le)
Tarolo, GL, 601
Tartaglia, D, 628
Tatsch, K, 74P(ab), 87P(ab)
Tatsu, Y, 227P(ab)
Tatton, WG, 197P(ab)
Tatum, WO, 1087
Tauxe, WN, 1134, 58P(ab), 189P(ab)
Taylor, A, 2055(le)
Taylor, AJ Jr, 349, 1198, 1237, 1992, 2054(le), 2054(le), 27P(ab), 262P(ab), 264P(ab)
Taylor, MD, 185P(ab)
Taylor, SE, 73P(ab)
Tazawa, S, 56P(ab)
Teates, CD, 159P(ab), 170P(ab)
Tedder, TE, 1538
Tedeschi, E, 9P(ab), 21P(ab)
Telatar, F, 204
Telfeyan, D, 167P(ab)
Tenenbaum, F, 134P(ab)
ten Kroode, HFJ, 236P(ab)
Tennenhouse, A, 120P(ab)
Teoh, SK, 1902
Ter, S, 179
Teräs, M, 989, 1618, 117P(ab)
Terashima, M, 224P(ab)
Terauchi, T, 226P(ab)
Terpenning, M, 109P(ab)
Terui, S, 226P(ab)
Terzis, A, 263P(ab)
Teule, GJJ, 136P(ab), 224P(ab)
Tezuka, F, 97
Thakur, ML, 1567(le), 86P(ab), 259P(ab)
Theodoulou, M, 235P(ab)
Thisted, R, 31P(ab)
Thom, E, 175P(ab)
Thomas, C, 210P(ab)
Thomas, GE, 234P(ab)
Thomas, J, 52P(ab)
Thomas, JD, 26P(ab), 39P(ab)
Thomas, PJ, 26P(ab)
Thompson, BH, 113P(ab)
Thompson, CJ, 61P(ab)
Thompson, NW, 1145
Thompson, RC, 70P(ab)
Thomson, WH, 188(le)
Thornton, BG, 193P(ab)
Thorpe, SR, 55P(ab)
Ticheler, CHJM, 1488
Tiel-van Buul, MMC, 151P(ab), 174P(ab), 202P(ab)
Tighe, DA, 1989
Tikofsky, RS, 227, 947
Timpe, GM, 1556(le)
Tjuvajev, JG, 1407
Tluczek, L, 109P(ab)
Todde, S, 255P(ab)
Todd-Pokropek, A, 143P(ab), 272P(ab)
Tolkoff-Rubin, NE, 99P(ab)
Tomas, MB, 15P(ab), 173P(ab), 266P(ab)
Tomiyoshi, K, 197P(ab)
Tompkins, RG, 269, 175P(ab), 254P(ab)
Toms, MB, 277P(ab)
Tonami, N, 1937, 29P(ab), 172P(ab), 225P(ab)
Tondini, C, 86P(ab)
Tonino, AJ, 1788
Topchik, S, 266P(ab)
Torizuka, T, 594, 1965, 59P(ab), 110P(ab), 135P(ab), 155P(ab), 156P(ab), 179P(ab), 222P(ab), 225P(ab)
Torres, G, 236P(ab)
Toubert, M-E, 1631
Tourassi, GD, 48P(ab)
Tow, DE, 1805
Townsend, DW, 41P(ab), 50P(ab), 184P(ab)
Toyama, H, 110P(ab), 202P(ab), 249P(ab), 263P(ab)
Toyama, S, 1677
Train, KV, 1193, 103P(ab)
Tran, HD, 1167
Tran, L, 44P(ab)
Travin, MI, 26P(ab), 60P(ab)
Trebossen, R, 50P(ab)
Treffert, JD, 178P(ab)
Tremblay, J, 628
Treuer, H, 235P(ab)
Treves, ST, 1608, 43P(ab), 134P(ab), 207P(ab)
Triana, M, 215P(ab)
Trigo, P, 237P(ab)
Trimarco, B, 153P(ab)
Trivedi, MH, 54P(ab), 212P(ab)
Truckenbrodt, R, 65P(ab)
Tsaboyama, T, 1174
Tsai, ZT, 241P(ab), 242P(ab), 263P(ab)
Tse, K, 14P(ab)
Tse, KKM, 120P(ab), 226P(ab)
Tse, N, 141P(ab)
Tsuchida, T, 27, 1104, 1910,

43P(ab), 200P(ab), 201P(ab)
Tsuchimochi, S, 135P(ab), 208P(ab)
Tsuda, T, 171P(ab), 189P(ab)
Tsui, BMW, 4P(ab), 17P(ab), 28P(ab), 81P(ab), 82P(ab), 91P(ab), 115P(ab), 191P(ab), 195P(ab)
Tsuji, A, 19P(ab)
Tsuruo, T, 232P(ab)
Tuchida, T, 169P(ab)
Tulchinsky, M, 227P(ab)
Tung, CH, 91P(ab)
Turek, P, 1602
Turkington, T, 179P(ab)
Turkington, TG, 135, 1398, 1707, 180P(ab)
Turner, A, 63P(ab)
Turpin, S, 15P(ab)

Uccelli, L, 155P(ab)
Uchida, I, 160P(ab)
Uchida, Y, 238P(ab)
Uchisako, H, 1520, 109P(ab)
Uchiyama, M, 1624
Uchiyama, T, 56P(ab)
Udelson, JE, 740
Udem, S, 1028
Uebis, R, 569
Ueda, R, 296, 504
Ueda, S, 121P(ab)
Ueda, T, 44
Uehara, T, 32, 1226, 136P(ab), 156P(ab), 194P(ab), 203P(ab)
Uemura, K, 1097, 2019, 63P(ab), 191P(ab)
Ueno, K, 204P(ab)
Uerlich, M, 461
Uezono, T, 259P(ab)
Ugur, O, 204
Ulanski, J, 134P(ab)
Ultee, ME, 29P(ab)
Ulutuncel, N, 204, 150P(ab)
Umeda, IO, 263P(ab)
Uno, K, 238P(ab)
Urbain, D, 168P(ab)
Urbain, JL, 65P(ab), 88P(ab), 170P(ab)
Uri, N, 411
Uribe, J, 40P(ab)
Urso, K, 184P(ab)
Ussov, W, 203P(ab)
Ussov, WY, 132P(ab), 172P(ab)
Uygur, GA, 232P(ab)
Uzum, F, 88P(ab)

v.d. Vliet, AM, 456, 210P(ab)
Vaalburg, W, 90, 3P(ab), 23P(ab), 32P(ab), 83P(ab), 157P(ab), 200P(ab), 210P(ab), 213P(ab), 227P(ab), 257P(ab)
Vagg, R, 1028
Vaidyanathan, G, 57P(ab), 180P(ab), 248P(ab)
Vaillant, L, 237P(ab)
Valdivia, S, 100P(ab), 172P(ab), 175P(ab)
Valent, P, 97P(ab)
Valette, H, 57P(ab), 78P(ab), 110P(ab)
Valk, PE, 76P(ab)
Vallabhajosula, S, 24, 41, 74P(ab), 257P(ab)
Valsa, JO, 264P(ab)
van Aswegen, A, 179P(ab), 193P(ab)
van Beek, EJR, 189(le), 151P(ab)
van Beek, WA, 28P(ab)
VanBrocklin, HF, 73P(ab)
Van Decker, W, 49P(ab)
van den Anker-Lugtenburg, PJ, 132P(ab)
van den Broek, W, 163P(ab)
Vander Borght, TM, 121P(ab)
van der Graaf, WTA, 83P(ab)
van der Hem, LG, 1488
Vanderheyden, J-L, 139P(ab)
van der Linden, CJ, 1488
Vandermeiren, R, 212P(ab)
Vande Streek, P, 114P(ab)
van de Ven, M, 163P(ab)
Van de Werf, F, 40P(ab)
van Dijk, A, 1423
van Dijk, RB, 23P(ab)
Van Dort, ME, 98P(ab)
van Dyck, CH, 11P(ab), 84P(ab)
van Eijck, CHJ, 21P(ab)
Vanhagen, PM, 132P(ab)
van Heerden, BB, 70P(ab)
van Heerden, PDR, 70P(ab)
Van Heertum, RL, 61P(ab), 65P(ab), 95P(ab), 118P(ab), 216P(ab), 258P(ab)
van het Schip, AD, 1423
Van Horn, JD, 53P(ab)
van Horn, JR, 89P(ab)
van Isselt, JW, 163P(ab)
van Kaick, G, 1842, 38P(ab), 75P(ab), 220P(ab), 228P(ab), 231P(ab), 236P(ab)
van Lier, JE, 1390
van Lingen, A, 136P(ab), 224P(ab)
Van Nerom, C, 1951
Vanoli, G, 1571
Vanoverschelde, J-L, 39P(ab), 77P(ab), 157P(ab)
van Pel, R, 21P(ab)
van Rijk, PP, 1423, 28P(ab), 163P(ab), 236P(ab)
van Royen, EA, 174P(ab), 202P(ab)
Vansant, J, 27P(ab)
Vansant, JP, 1005, 1237
Van Train, KF, 542, 609, 683, 103P(ab)
van Waarde, A, 157P(ab), 227P(ab), 257P(ab)
Vargas, H, 22P(ab)
Vargas-Cuba, R, 235P(ab)
Varma, VM, 248P(ab)
Varnum, J, 259P(ab)
Varpula, M, 1618, 117P(ab)
Varrella, P, 22P(ab), 80P(ab), 96P(ab), 97P(ab), 166P(ab)
Vasello, M, 7P(ab)
Vasin, AP, 625
Vavrek, MT, 72P(ab), 251P(ab)
Veglia, F, 1970
Vekemans, MC, 65P(ab), 88P(ab)
Vemulakonda, U, 165P(ab)
Venegas, R, 22P(ab)
Venkatesh, M, 41P(ab), 241P(ab)
Venz, S, 1921
Verani, MS, 716, 737, 16P(ab)
Verbruggen, A, 1951, 35P(ab), 38P(ab)
Vergara, E, 22P(ab), 80P(ab), 96P(ab), 97P(ab), 166P(ab)
Verrelle, P, 219P(ab)
Verrier, MC, 197P(ab)
Vessotski, J, 128P(ab), 246P(ab)
Veyre, A, 46P(ab), 103P(ab), 219P(ab)
Vidne, B, 126P(ab)
Vienneau, D, 44P(ab)
Viergever, MA, 28P(ab)
Villamil-Perez, L, 21P(ab)
Villanueva-Meyer, J, 215P(ab), 229P(ab)
Villegas, BJ, 16P(ab), 125P(ab), 152P(ab)
Villemagne, VL, 118P(ab)
Vilner, BJ, 246P(ab), 248P(ab)
Vinciguerra, V, 185P(ab)
Vinee, P, 1321
Vingerhoets, FJG, 18
Virgolini, I, 85P(ab), 97P(ab)
Virzi, F, 127, 1568(le), 105P(ab), 242P(ab), 260P(ab)
Visser, CA, 136P(ab)
Visser, FC, 136P(ab)
Visser, GM, 83P(ab), 157P(ab), 227P(ab), 257P(ab)
Visser, TJ, 157P(ab), 162P(ab), 165P(ab), 226P(ab)
Vitkun, S, 85P(ab)
Vitols, P, 664
Voges, J, 235P(ab)
Voipio-Pulkki, L-M, 989, 183P(ab)
Volkert, WA, 41P(ab), 139P(ab), 241P(ab), 260P(ab)
Volkow, ND, 1457, 85P(ab), 94P(ab), 129P(ab), 130P(ab), 140P(ab), 213P(ab)
Volterrani, D, 144P(ab)
vom Dahl, J, 569
Von Feldt, JM, 95P(ab)
Vonlanthen, T, 145P(ab)
von Smekal, A, 461
Vos, MG, 257P(ab)
Votaw, JR, 71P(ab), 72P(ab), 138P(ab)

Wackers, FJT, 169, 664, 726, 91P(ab)
Wada, K, 246P(ab)
Wagner, HN, 13N, 22N
Wagner, HN Jr., 21N, 929, 19P(ab), 73P(ab), 85P(ab), 118P(ab), 124P(ab), 128P(ab), 137P(ab), 253P(ab)
Wagner, HP, 217P(ab)
Wagner, RH, 213P(ab), 271P(ab)
Wagner, U, 234P(ab)
Wagner, W, 9P(ab)
Wahl, RL, 157, 1714, 7P(ab), 38P(ab), 66P(ab), 75P(ab), 101P(ab), 141P(ab), 142P(ab), 173P(ab), 233P(ab)
Wahner, HW, 1159
Wakasugi, S, 56P(ab)
Wakasugi, T, 1279
Wakisaka, K, 326, 30P(ab)
Wakisaka, S, 44
Wakita, K, 121P(ab)
Wakui, A, 97
Walgenbach, S, 162P(ab)
Walker, SC, 1637
Wallace, E, 11P(ab), 129P(ab), 130P(ab)
Wallace, S, 256P(ab)
Wallis, JW, 999, 82P(ab)
Walsh, B, 1450
Walsh, RA, 580, 1698
Walzer, PD, 1028
Wang, DY, 90P(ab)
Wang, FP, 59P(ab), 103P(ab)
Wang, FZ, 90P(ab)
Wang, G-J, 1457, 85P(ab), 106P(ab), 201P(ab), 213P(ab)
Wang, H, 27P(ab), 190P(ab), 195P(ab)
Wang, JK, 186P(ab)
Wang, P, 217
Wang, S, 128P(ab)
Wang, SJ, 163P(ab), 164P(ab), 171P(ab), 232P(ab), 240P(ab), 241P(ab), 245P(ab)
Wang, TST, 216P(ab), 258P(ab)
Wang, YL, 245P(ab)
Warren, MF, 127P(ab)
Warshawski, R, 272P(ab)
Wartski, M, 47P(ab)
Waser, B, 220P(ab)
Washburn, LC, 580, 1698, 244P(ab), 263P(ab)
Wasserman, HJ, 70P(ab)
Wassmann, H, 9P(ab)
Watabe, H, 1870
Watanabe, K, 44, 197P(ab)
Watanabe, T, 97, 127P(ab), 177P(ab), 178P(ab), 205P(ab), 206P(ab)
Watanabe, Y, 214P(ab)
Watkins, GL, 158P(ab), 182P(ab), 188P(ab)
Watson, C, 235P(ab)
Watson, DD, 47P(ab)
Watson, MW, 264P(ab)
Watzlowik, P, 231P(ab)
Waugh, R, 195
Waxman, A, 15P(ab), 22P(ab), 223P(ab), 229P(ab), 274P(ab)
Weber, DA, 342, 37P(ab), 61P(ab), 221P(ab)
Weber, P, 1342
Weber, PC, 113P(ab)
Weber, WJ, 157P(ab)
Webner, P, 167P(ab)
Webster, EW, 368
Webster, WB, 89P(ab)
Wedeking, P, 18P(ab)
Weemaes, AMA, 157P(ab), 257P(ab)
Wegelius, U, 989, 117P(ab), 183P(ab)
Weiden, P, 100P(ab)
Weil, JA, 8P(ab)
Weiller, C, 32P(ab), 33P(ab)
Weinberg, IN, 61P(ab)
Weinberger, DR, 53P(ab), 199P(ab), 247P(ab)
Weinmann, P, 1444
Weinstein, GS, 179
Weinstein, H, 3P(ab), 180P(ab), 192P(ab)
Weintraub, SW, 27P(ab), 126P(ab)
Weiss, M, 231P(ab)
Weiss, S, 254P(ab)
Weissleder, R, 1880
Weissman, AS, 173P(ab)
Weitman, S, 222P(ab)
Welch, A, 81P(ab), 91P(ab)
Welch, MJ, 1560(le), 6P(ab), 12P(ab), 43P(ab), 53P(ab), 73P(ab), 106P(ab), 122P(ab), 141P(ab), 158P(ab), 161P(ab), 243P(ab), 249P(ab), 250P(ab)
Weller, R, 156P(ab)
Wellman, HN, 49P(ab)
Welsh, PC, 248P(ab)
Welt, S, 101P(ab)
Wen, M-L, 152P(ab)
Wen, WT, 154P(ab)
Wendt, RE III, 177P(ab), 178P(ab)
Wenger, S, 10P(ab)
Wesner, B, 86P(ab)
West, B, 275P(ab)
Wester, HJ, 73P(ab)
Westera, G, 18P(ab), 184P(ab)
Wheatley, G, 30P(ab)
Wheeler, RH, 1017
White, T, 28P(ab)
White, TA, 93P(ab)
Whiting, JH, 74, 100P(ab), 172P(ab), 175P(ab)
Wieland, DM, 405, 7P(ab), 68P(ab), 93P(ab), 98P(ab), 109P(ab)
Wienhard, K, 107P(ab), 197P(ab)
Wijers, AA, 32P(ab), 200P(ab)
Wijns, W, 39P(ab), 77P(ab), 157P(ab)
Wiklund, U, 983
Wilder, S, 86P(ab), 259P(ab)
Wilkinson, RA, 1880, 254P(ab)
Willem, L, 145P(ab)
Willemsen, ATM, 3P(ab), 32P(ab), 200P(ab), 210P(ab), 213P(ab), 227P(ab)
Willenbrock, R, 628
Williams, BR, 1586
Williams, C, 36P(ab), 103P(ab)

Williams, JH, 619
Williams, JJ, 1398
Williams, KA, 26P(ab), 69P(ab)
Williams, LE, 1377, 1562(le), 234P(ab)
Williams, NE, 243P(ab), 260P(ab)
Williams, PA, 37P(ab)
Williams, SV, 171P(ab)
Willich, N, 9P(ab)
Willins, JD, 123P(ab), 161P(ab)
Wilner, F, 274P(ab)
Wilson, AA, 252P(ab)
Wilson, D, 182P(ab)
Wilson, JM, 252P(ab)
Wilson, M, 12P(ab), 164P(ab)
Wimberger, D, 207P(ab)
Wingardh, K, 224P(ab)
Winn, HR, 1476, 64P(ab)
Winnard, P Jr., 127, 1568(le) 105P(ab), 242P(ab), 260P(ab)
Winship, J, 112P(ab), 172P(ab)
Winter, PM, 198P(ab)
Wirnsberger, GH, 173P(ab)
Wirth, M, 202P(ab)
Wiseman, GA, 132P(ab), 149P(ab)
Wishart, J, 185(le), 88P(ab)
Wisniewski, G, 116P(ab)
Witt, RM, 49P(ab), 64P(ab)
Wittry, MD, 120P(ab), 154P(ab)
Wittstock, D, 230P(ab)
Witzig, TE, 132P(ab)
Wolf, AP, 1457, 7P(ab), 42P(ab), 67P(ab), 85P(ab), 94P(ab), 129P(ab), 130P(ab), 140P(ab), 213P(ab), 253P(ab)
Wolf, FG, 1436, 56P(ab), 86P(ab), 112P(ab), 218P(ab), 239P(ab)
Wolf, G, 2057(le)
Wolf, H, 186P(ab)
Wolf, I, 231P(ab)
Wolf, JE, 114P(ab)
Wolf, W, 145P(ab)
Wolfrum, I, 36P(ab)
Wollenweber, SD, 158P(ab)
Wollmer, P, 176P(ab)
Wolmer, I, 549
Wong, C, 213P(ab)
Wong, CYO, 119P(ab)
Wong, DF, 9P(ab), 32P(ab), 73P(ab), 74P(ab), 85P(ab), 118P(ab), 130P(ab), 196P(ab), 197P(ab), 198P(ab)
Wong, FCL, 35P(ab), 76P(ab), 131P(ab), 220P(ab), 228P(ab)
Wong, FP, 542
Wong, JYC, 1562(le), 234P(ab)
Wong, W-H, 1206, 35P(ab), 40P(ab), 76P(ab), 131P(ab), 184P(ab), 220P(ab)
Wong, WYO, 9P(ab)
Woo, K, 175P(ab)
Woolf, SH, 2003
Wörmann, B, 132P(ab)
Worsley, CF, 25P(ab)
Worsley, DF, 24P(ab), 25P(ab)
Worthy, MA, 638
Wortzman, G, 217
Woulfe, SR, 1571
Wu, C, 29P(ab), 33P(ab), 62P(ab), 63P(ab)
Wu, HM, 71P(ab), 137P(ab)
Wu, LC, 113P(ab), 142P(ab), 176P(ab), 186P(ab), 205P(ab), 209P(ab)
Wu, QW, 90P(ab)
Wu, SY, 164P(ab)
Wu, Y, 1659
Wunderbaldinger, P, 150P(ab)
Würker, M, 2011, 107P(ab), 235P(ab)

Xu, M, 51P(ab)

Yadegar, J, 22P(ab), 223P(ab), 229P(ab), 274P(ab)
Yaffe, MJ, 1547
Yaghmai, V, 275P(ab), 276P(ab)
Yagi, D, 171P(ab)
Yagoda, A, 216P(ab)
Yahav, Y, 58P(ab)
Yamada, K, 119P(ab)
Yamada, N, 1520
Yamada, S, 104, 1067, 45P(ab), 136P(ab), 152P(ab), 256P(ab)
Yamada, T, 118P(ab)
Yamada, Y, 160P(ab)
Yamaga, LI, 206P(ab)
Yamagami, H, 194P(ab)
Yamaguchi, S, 1
Yamakado, K, 152P(ab)
Yamamichi, Y, 97P(ab)
Yamamoto, F, 226P(ab)
Yamamoto, I, 170P(ab), 207P(ab)
Yamamoto, K, 1965, 169P(ab), 225P(ab)
Yamamoto, M, 119P(ab)
Yamamuro, T, 1174
Yamaoka, Y, 1965, 225P(ab)
Yamashita, T, 119P(ab)
Yamauchi, D, 234P(ab)
Yamauchi, H, 1
Yamazaki, J, 153P(ab)
Yan, M, 188P(ab)
Yan, MXH, 127P(ab)
Yang, C, 1338
Yang, DH, 109P(ab)
Yang, DJ, 35P(ab), 66P(ab), 76P(ab), 131P(ab), 142P(ab), 256P(ab)
Yang, HI, 113P(ab)
Yang, J, 47P(ab)
Yang, Y, 1217
Yang, Z-Y, 139P(ab), 252P(ab)
Yano, S, 179P(ab)
Yao, WJ, 8P(ab), 221P(ab)
Yao, Z, 56P(ab), 146P(ab)
Yao, Z-S, 1482, 1677
Yarmush, ML, 269
Yarranton, GT, 63P(ab)
Yaster, M, 198P(ab)
Yasuhara, Y, 171P(ab), 185P(ab), 203P(ab)
Yasumoto, K, 289
Ye, J, 189P(ab), 190P(ab)
Yeh, SDJ, 36P(ab)
Yeh, SH, 113P(ab), 142P(ab), 163P(ab), 171P(ab), 176P(ab), 186P(ab), 204P(ab), 205P(ab), 209P(ab), 219P(ab), 232P(ab), 240P(ab), 244P(ab), 265P(ab)
Yen, C-K, 644, 1170
Yen, SH, 142P(ab)
Yen, TC, 219P(ab)
Yeo, JS, 113P(ab)
Yeomans, ME, 24P(ab)
Yeon, KM, 240P(ab)
Yeung, DWC, 48P(ab), 170P(ab)
Yi, J, 2031
Yki-Järvinen, H, 989
Yokoi, F, 130P(ab), 196P(ab), 197P(ab), 198P(ab)
Yokoyama, A, 326, 30P(ab), 246P(ab), 247P(ab), 254P(ab), 259P(ab)
Yokoyama, K, 29P(ab), 172P(ab), 225P(ab)
Yokoyama, R, 226P(ab)
Yonekura, Y, 1, 27, 594, 1104, 1910, 1965, 43P(ab), 59P(ab), 95P(ab), 110P(ab), 135P(ab), 155P(ab), 156P(ab), 179P(ab), 194P(ab), 196P(ab), 200P(ab), 201P(ab), 204P(ab), 207P(ab), 208P(ab), 222P(ab), 225P(ab), 247P(ab), 254P(ab)
Yoon, CM, 109P(ab)
Yoon, YS, 240P(ab)
Yorke, ED, 161P(ab)
Yoshida, M, 112P(ab)
Yoshida, S, 224P(ab)
Yoshida, T, 43P(ab), 210P(ab), 227P(ab), 231P(ab)
Yoshimura, N, 224P(ab)
Yoshioka, T, 97
Yost, R, 169P(ab)
Younès, A, 46P(ab), 219P(ab)
Young, C, 102P(ab)
Young, DC, 229P(ab)
Young, PR, 1797, 184(le)
Young, WL, 65P(ab)
Yousef, K, 106P(ab), 201P(ab)
Yu, DC, 83P(ab), 183P(ab)
Yu, JN, 1777, 104P(ab)
Yu, K, 241P(ab), 245P(ab)
Yu, MD, 242P(ab), 263P(ab)
Yu, SM, 204P(ab), 209P(ab)
Yu, TW, 142P(ab), 244P(ab)
Yuan, A, 1381, 158P(ab)
Yue, N, 9P(ab)
Yung, B, 9P(ab), 130P(ab)
Yung, WKA, 220P(ab), 228P(ab)

Zachoval, R, 11P(ab)
Zafrir, N, 126P(ab)
Zager, L, 164P(ab)
Zakheim, DS, 150P(ab), 174P(ab), 276P(ab), 277P(ab)
Zakko, S, 238P(ab)
Zaknun, J, 151P(ab)
Zalutsky, MR, 1506, 57P(ab), 157P(ab), 179P(ab), 180P(ab), 248P(ab), 255P(ab)
Zambuto, G, 21P(ab)
Zamecnik, PC, 151P(ab)
Zamora, PO, 106P(ab), 247P(ab)
Zampiero, A, 126P(ab)
Zanco, P, 126P(ab)
Zangara, LM, 89P(ab)
Zanzi, I, 955, 112P(ab), 185P(ab)
Zanzonico, P, 77P(ab), 80P(ab)
Zaret, BL, 664, 46P(ab)
Zasadny, KR, 1714, 1564(le), 38P(ab), 75P(ab), 101P(ab), 142P(ab), 233P(ab)
Zatz, S, 257
Zea-Ponce, Y, 228, 399, 11P(ab), 84P(ab), 128P(ab), 129P(ab), 130P(ab), 201P(ab)
Zeeberg, BR, 93P(ab), 200P(ab)
Zeffiro, TA, 1538
Zeit, RM, 95P(ab)
Zelissen, PMJ, 163P(ab)
Zeng, GL, 5P(ab), 18P(ab)
Zeng, L, 91P(ab)
Zeng, W, 260P(ab), 262P(ab)
Zenorini, A, 210
Zerauschek, F, 1274
Zhang, HZ, 101P(ab)
Zhang, JJ, 1407, 1976, 7P(ab), 123P(ab), 232P(ab)
Zhang, WH, 266P(ab)
Zhang, Z, 266P(ab)
Zhao, XD, 115P(ab), 195P(ab)
Zheng, B, 143P(ab)
Zheng, L, 1665, 73P(ab)
Zhong, G-R, 122P(ab)
Zhou, H, 77P(ab)
Zhou, YG, 106P(ab)
Zhou, Z, 72P(ab)
Zhuang, ZP, 252P(ab), 93P(ab)
Ziegler, S, 222P(ab), 231P(ab)
Ziegler, SI, 220P(ab)
Ziemons, K, 8P(ab)
Ziessman, HA, 165P(ab), 181P(ab), 267P(ab), 273P(ab)
Ziffer, J, 609, 1237, 27P(ab)
Zimmer, W, 179
Zimmerman, RE, 17P(ab), 61P(ab), 116P(ab)
Zinn, KR, 12P(ab), 106P(ab), 161P(ab), 218P(ab)
Zito, F, 210, 1571, 1970
Zoghbi, SS, 228, 399, 10P(ab), 11P(ab), 84P(ab), 128P(ab), 129P(ab), 130P(ab), 140P(ab), 201P(ab)
Zonnenberg, BA, 1423, 236P(ab)
Zubal, IG, 399, 64P(ab), 99P(ab), 116P(ab)
Zubieta, JK, 20P(ab), 67P(ab), 182P(ab), 197P(ab)
Zukerberg, BW, 133P(ab), 208P(ab)
Zwaag, RV, 43S

A

Abdominal aortic aneurysm, mural thrombus of, photon deficiency, radionuclide study, 271P(ab)
Abscess, staphylococcal, imaging comparisons, 175P(ab)
Absorbed fractions
cellular dosimetry, 303
multicellular dosimetry, micrometastases, 521
Absorptiometry
dual energy X-ray, children with bone mineral disorders, 59P(ab)
^{153}Gd dual photon, osteoporosis, 90P(ab)
Acetazolamide
HMPAO SPECT enhanced with
cerebral arteriovenous malformations, 65P(ab)
evaluation of carotid endarterectomy, 64P(ab)
1-Acetyl-7-deacetylforskolin, non-specific analog of ^{11}C forskolin, 250P(ab)
Achalasia, pneumatic dilatation in treatment of, radionuclide assessment, 276P(ab)
Acipimox, enhancement of glucose metabolism, myocardial, 989
Acquired immunodeficiency syndrome, *See also* Human immunodeficiency virus
^{67}Ga abdominal imaging in, 174P(ab)
lung infection and, ^{111}In IgG multicenter clinical trial, 240P(ab)
Pneumocystis carinii pneumonia, immunoscintigraphy of, 1028, 1034
thoracic diseases in, radionuclide imaging, 277P(ab)
Acromegaly, left ventricular diastolic filling, impairment of, 165P(ab)
Activity quantitation, ^{123}I SPECT, 1707
Adenocarcinoma
intestinal, vasoactive intestinal peptide receptor imaging, 97P(ab)
metastatic ^{177}Lu labeled CC49, pharmacokinetics and biodistribution of, 100P(ab)
refractory, EDTA and 90-Y, 102P(ab)
targeting of, ^{111}In, after interferon gamma, 85P(ab)
Adenosine
myocardial perfusion imaging, coronary artery disease, 734, 1110
^{201}Tl biokinetics with, 535
Adrenal gland, masses, clinically silent, scintigraphic evaluation, 1145, 1152
Adrenal medullary disease, screening, patients with medullary thyroid carcinoma, 69P(ab)
Aebersold award, 20N(5)
Affective disorder, primary, paralimbic hypoperfusion in, 929
Aging
changes related to, cerebral distribution of ^{99m}Tc HMPAO, 107P(ab)
gastric emptying, elderly patients and younger subjects, 169P(ab)
relative activity of dopa decarboxylase and, 10P(ab)
Agreement states, NRC's mismanagement of medical misadministration, 17N(2)
AIDS, *see* Acquired immunodeficiency syndrome; Human immunodeficiency virus
AIDS dementia complex, cerebral glucose metabolism in, PET-FDG study of, 118P(ab)
Alcohol, absorption, erythromycin effects, 184(le)
Aldosteronoma, deactivation by absolute ethanol, scintigraphic assessment of, 68P(ab)
***N*-Alkyl pyridoxal,** cationic ^{99m}Tc complexes of, renal function agents, 1691
Allergic reactions, ^{99m}Tc mebrofenin, 1569(le)
Alpha particles, cellular dosimetry, 303
Alveolar-capillary membrane, permeability, ^{99m}Tc DTPA aerosol for measurement of, 207
Alzheimer's disease
altered cerebral energy metabolism, PET, 1
blindness procedures in, 1566(le)
brain PET, anatomic standardization of, 1528
cerebral perfusion in, atrophy-corrected SPECT and, 20P(ab)
characterization of, muscarinic agonists, 83P(ab)
diagnostic criteria, ^{18}F FDG cerebral metabolic deficits, 119P(ab)
differential diagnosis, PET, 391
early and late onset, cerebral hemodynamics, SPECT, 206P(ab)
fluoroalkyl QNB, graphical analysis of, 200P(ab)
HMPAO brain SPECT images, significance of abnormalities in, 239
mapping of cholinergic neurons in, SPECT and ^{123}I IBVM, 68P(ab)
muscarinic receptor binding in, ^{11}C NMPB and PET, 20P(ab)
neural network classification of subjects, PET, 7
parietal SPECT, magnetic resonance spectroscopy comparison, 207P(ab)
probable, PET and SPECT comparison, 210
quantitative SPECT, scatter correction, 116P(ab)
semiquantitative SPECT data, discriminant value of, 1450, 1455
stereotactic PET atlas, human brain, 949
subgroups of, regional cerebral blood flow in, 118P(ab)
subserving semantic judgments in, neural network, 206P(ab)
^{99m}Tc HMPAO SPECT and temporal lobe CT diagnosis of, 20P(ab)
American Board of Nuclear Medicine
components of professional competence, 1234
health care reform and graduate medical education, 32N(5)
Amino acids, radioiodinated, synthesis and biodistribution, 94P(ab)
D-Amphetamine
dopamine release induced by, binding potential of ^{123}I IBF, 84P(ab)
effects, dopamine D2 receptor radiotracers, 139P(ab)
Anger, Hal O., inventor of gamma camera, 13N(5)
Anger camera, planar images, ^{131}I imaging, breast, 142P(ab)
Angina, unstable, ^{99m}Tc PYP uptake as indicator of, 1366
Angiocardiography
biplane first pass radionuclide, scintillation camera use in, 70P(ab)
first-pass radionuclide
dipyridamole infusion with, evaluation of coronary artery disease, 1254
scintillation camera and perpendicular detectors, 1593
Angiodysplasia, hemobilia complicating, scintigraphy, 870
Angiography
coronary
stress SPECT scintigraphy, 16P(ab)
^{201}Tl, tetrofosmin imaging versus, 587
first-pass, detection of regional wall motion, perfusion defects, 70P(ab)
magnetic resonance, scrotal scintigraphy combination, varicocele, 267P(ab)
radionuclide
evaluation of left ventricular asynchrony, 1766
^{99m}Tc HMPAO
estimation cerebral collateral circulation, 204P(ab)
estimation of brain perfusion, 203P(ab)
Angiotensin-converting enzyme, accumulation, pulmonary endothelium, 1358
Angiotensin
II antagonists, ^{11}C labeling of, 6P(ab)
Angiotensin II receptors
characterization of, 52P(ab)
imaging agent, compartmental modeling, 137P(ab)
labelling with ^{11}C-L-159,884, 52P(ab)
PET imaging of, 124P(ab)
radioiodinated nonpeptide, 246P(ab)
Anhydrides, comparison of four, anti-melanoma 225-MAb, 258P(ab)
Animals, small, pharmaceutical biodistribution in, high-resolution PET with photodiode detectors, 1390, 1396
Annexin V, ^{99m}Tc, left atrial and coronary thrombi, 254P(ab)
Anti-B-cell antibody, lymphoma, chimeric and humanized, preclinical evaluation, 236P(ab)
Antibodies, *See also* specific antibody
immunoscintigraphy of *Pneumocystis carinii,* AIDS patients, 1028, 1034
radiolabeled, CC49, treatment of metastatic prostate cancer, 1017
Antibody conjugates, fate of, 899
Anti-idiotypic antibodies, cellular immune response and, after MAB OC125, 234P(ab)
Antimyosin antibody, radiolabeled, dual-tracer imaging with, myocardial infarct size, 1076
Antipsychotic drug therapy
calculations, ^{123}I IBZM infusion effects, 84P(ab)
dopamine receptors in schizophrenics, ^{123}I IBZM SPECT studies of, 74P(ab)
Antisense probe
noninvasive imaging, c-*myc* oncogenes, mammary tumor model, 1054, 1064
scintigraphic imaging of, 65P(ab)
^{99m}Tc labeled, P388 leukemic cells, 263P(ab)
Antithrombin III, congenital deficiency, detection of multiple thromboembolism in, ^{111}In-platelet scintigraphy, 1811
Antithyroglobulin antibody, bone marrow uptake, abnormal cells, thyroid cancer, 218P(ab)
Antithyroid medication, ^{131}I-Na therapy and, Graves' disease, 14P(ab)
Aortic dissection, ventilation-perfusion lung scan in, 1044
Aortic stenosis, dipyridamole ^{201}Tl SPECT, computer evaluation of, 983
Arteriovenous fistula
malfunction, hemodialysis patients, evaluation by radionuclide fistulogram, 124P(ab)
reversible ^{201}Tl perfusion defect and, 1808

Arteriovenous malformation
blood flow dynamics before and after embolization, PET, 205P(ab)
cerebral, acetazolamide enhanced HMPAO SPECT, 65P(ab)
regional cerebral blood flow and glucose metabolism, ^{18}FDG PET, 209P(ab)
small, radiosurgery, cerebral hemodynamic changes after, SPECT, 204P(ab)
Arteriovenous shunt, platelet GPIIb/IIIa antagonists, potential thrombus imaging agents, 52P(ab)
Arthritis
inflammatory
E-selection as marker of endothelial activation, 45P(ab)
wrist, FDG metabolism during treatment, 35P(ab)
rheumatoid, radionuclide-synoviorthesis versus cortico-steroid-injection in, 36P(ab)
septic, ^{111}In IgG scintigraphy, 89P(ab)
Arthrography, radionuclide, hip prosthesis lossening, 851
Artificial intelligence
comparisons, diagnosis of coronary artery disease, 180P(ab)
expert systems, ventilation-perfusion scans, pulmonary embolism, 797
Ascorbate
direct labeling of antibodies, ^{99m}Tc with, 127
role in labeling proteins with ^{99m}Tc, 1566(le)
Asialoglycoprotein, receptor-mediated uptake, liver targeting by, 269
Asialoglycoprotein receptor, estimation of amount in liver, ^{99m}Tc DTPA use in, 172P(ab)
Aspiration, quantifying of, scintigraphic deglutition testing, 1007, 1013
Astatine-211, radiotherapeutic agents, quantitative imaging in small volumes, 180P(ab)
Asymmetric-fan-beam, reconstruction, algorithms for, 5P(ab)
Atherosclerotic lesions, visualization, 98P(ab)
theroscleroticplaques, synthetic peptide fragments for imaging of, ^{99m}Tc, 80P(ab)
ATL cells, proliferation sites, detection, SCID mice, 56P(ab)
Atrial natriuretic peptide, receptor imaging with, 628
Attenuation correction
extended acquisition, SPECT cardiac perfusion imaging, 625
fast iterative reconstruction algorithms, cardiac SPECT, 195P(ab)
perfusion and ventilation quantification, SPECT and CT data, 784
quantitative Bremsstrahlung SPECT imaging, 1213
semi-automated boundary detection, SPECT, 196P(ab)
^{201}Tl SPECT, ^{241}Am and ^{99m}Tc as transmission sources for, 652
Autoradiography
comparison of two SPECT ligands, dopamine transporter, 129P(ab)
^{18}F FDG, uptake mechanisms, cancer cells, 1067
intratumoral distribution of FDG, breast carcinoma, 141P(ab)
measurement of oxidative metabolism, cardiac, 98P(ab)
quantitative, measurement of carcinoembryonic antigen distribution, 1499
radiolabeled acetate use, clearance of cerebral oxidative metabolites, 198P(ab)
regional blood flow determination, 180P(ab)
tissue section, radionuclide distribution analysis, 1217
whole-body, biodistribution of ^{99m}Tc sestamibi, 159P(ab)
Avidin
imaging, prosthetic vascular graft injection, 112P(ab)
improved clearance of radiolabeled biotinylated monoclonal antibody, 1677
localization in tumor xenografts, pretreatment with biotinylated monoclonal antibody, 12P(ab)
Avidin-biotin system
pre-targeted immunoscintigraphy with, 55P(ab)
pretargeting, radioimmunotherapy, 219P(ab)
radioimmunoguided surgery using, 1970

B

Balloon occlusion test, cerebral blood flow changes induced by, during hypotension, 204P(ab)
Basal ganglia, blood flow, ^{99m}Tc HMPAO SPECT assessment of, 54P(ab)
Benzamide, radiolabeled, scintigraphic detection of melanoma metastasis, 1741
Benzodiazepine receptors
brain, SPECT measurement of, 228
^{11}C flumazenil interaction, PET, 67P(ab)
^{11}C iomazenil, tracer kinetic modeling, 184P(ab)
diazepam-insensitive, SPECT imaging of, 247P(ab)
occupancy by unlabeled drugs, PET, 141P(ab)
quantification with ^{123}I iomazenil, SPECT, 194P(ab)
SPECT radioligand, biodistribution and dosimetry of, 399
Beta-adrenoceptors, binding of carazolol, PET measurement of, 1665
Beta-blocking therapy, failing heart, improved adrenergic nerve function in, 81P(ab)
Betamethylheptadecanoic acid, myocardial extraction of, 496
Beta-methyliodophenylpentadecanoic acid, uptake, myocardial infarction after coronary thrombolysis, 1758
Beta particles
absorbed fractions for, spheres of various sizes, 152
dosimetry, unified approach, 1721
radionuclide therapy, magnetically enhanced, 157
BGO, PET camera, inexpensive circular phototubes, 40P(ab)
Bifunctional chelates
formulation of, Rh-105 and, 41P(ab)
hydroxamic acid derivatives used as, 258P(ab)
^{105}Rh and ^{131}I, 241P(ab)
Bile, leak, cholescintigraphy for evaluation of, 13P(ab)
Bile duct, obstruction, hepatobiliary scintigraphy in, 13P(ab)
Bile leak, hepatobiliary patterns, predictive value, 171P(ab)
Biodistribution, pharmaceutical, small animal, high-resolution PET imaging with avalanche photodiode detectors, 1390, 1396
Biotin
^{18}F labeled with, infection localization with, 1685
^{111}In-labeled imaging, prosthetic vascular graft injection, 112P(ab)
radiolabeled, experimental myocardial infarction, 98P(ab)
Bladder, cancer
FDG PET, preoperative lymphodestaging, 223P(ab)
^{123}I IUdR and ^{125}I IUDR in management of, 144P(ab)
Blood-brain barrier
disruption, carcinoma xenografts, lung, 1831
permeability, RMP-7 effects, 95P(ab)
transendothelial permeability, compared with single-pass brain extraction, 1514
Blood flow
cerebellar, deficits, brain SPECT images, 1547
cerebrovascular, cocaine abuse effects, gender differences, SPECT study of women, 1902
myocardial, *See* Myocardial blood flow
renal, deconvolution analysis, postrenal transplant complications, 1792
Blood flow, cerebral
after acute closed head trauma, ^{99m}Tc HMPAO SPECT in, 213P(ab)
balloon occlusion test effects, during hypotension, 204P(ab)
brain activation paradigms, PET, 182P(ab)
carotid artery stenosis, PET evaluation of, 64P(ab)
change with pharmacological intervention, split dose ^{123}I IMP SPECT, 1226
collateral, ^{99m}Tc HMPAO radionuclide angiography in, 204P(ab)
^{62}Cu PTSM as a perfusion tracer, PET, 1910
diurnal variation, PET demonstration of, 32P(ab)
enhanced detectability, ^{15}O water PET studies, 138P(ab)
glucose metabolism and, arteriovenous malformations, ^{18}FDG PET, 209P(ab)
gonadal steroid effects, PET, 53P(ab)
hyperfixation, ^{99m}Tc HMPAO SPECT diagnosis of, 204P(ab)
^{123}I IMP SPECT, measurement, one point arterial monitoring, 209P(ab)
^{123}I IMP split dose method of measurement, 208P(ab)
moyamoya disease, IMP SPECT evaluation of, 44
neurotoxic chemical effects, 210P(ab)
^{15}O water determination of, distributed model for, 273P(ab)
paralimbic hypoperfusion, ^{99m}Tc HMPAO SPECT in unipolar depression, 929
periventricular hyperintensity and, ^{15}O PET evaluation, 211P(ab)
PET, anatomic standardization of, 1528
prediction of infarction, ^{99m}Tc HMPAO SPECT, 1097
prefrontal and temporal, schizophrenia, ^{99m}Tc HMPAO SPECT, 935
quantitative mapping with ^{123}I IMP and SPECT, 2019
regional
abnormalities, obsessive-compulsive disorder, PET scan study, 75P(ab)
dynamic ^{133}Xe SPECT, 189P(ab)
^{123}I IMP quantification of, 192P(ab)
language processing, PET ^{15}O water study, 200P(ab)
mapping of, ^{123}I IMP validation of, 191P(ab)
mood induction effects, ^{15}O PET study, 54P(ab)
noninvasive method, ^{15}O-water PET, 1870, 1878
PET, brain perfusion SPECT compared with, 200P(ab)
subgroups of Alzheimer's disease, 118P(ab)

^{99m}Tc ECD, cortical activation studies with, 199P(ab)
^{99m}Tc HMPAO and ^{133}Xe SPECT relative to, 212P(ab)
^{99m}Tc HMPAO SPECT measurement of, 108P(ab)
Sneddon syndrome, ^{99m}Tc HMPAO SPECT studies, 461
SPECT localization, validation study, 755
temporal lobe seizures, ^{99m}Tc HMPAO SPECT, 208P(ab)
Blood-pool imaging
count-based radionuclide method, ventricular volume, 644
radionuclide, synthetic copolymer kit for, 1880
Blood sampling, automated, errors introduced with, 128P(ab)
Blood time activity curve, extraction of, PET FDG studies, 71P(ab)
Blood-to-tissue transfer constants, graphic analysis method for estimation, 34P(ab)
Body fat, FDG corrected uptake values, 164
Body mass index, glucose and insulin levels, gastric emptying comparisons, 88P(ab)
Bone
cortical and trabecular measurement, children, absorptiometry in, 59P(ab)
heterotopic formation, scintigraphy, 276P(ab)
metabolism, ^{99m}Tc MDP, women with osteoporosis, 1155, 1159
metastases
breast cancer, ^{89}Sr palliation of, 236P(ab)
hepatic carcinoma, ^{99m}Tc HIDA, 1342
pain, ^{89}Sr for palliation of, 2054(le)
prostate cancer
prostate specific antigen levels and, 225P(ab)
^{186}Re HEDP palliation of, 236P(ab)
^{186}Re/^{188}Re (Sn)HEDP treatment of, 244P(ab)
^{153}Sm EDTMP as palliative agent, 235P(ab)
thrombocytopenia in, ^{186}Re HEDP dosage recommendations and, 1423
pain, palliation with Sn-117m(4+)DTPA, 37P(ab), 52P(ab)
tumors, ^{99m}Tc DMSA and ^{99m}Tc MDP comparison, 232P(ab)
one marrow
dose conversion factors, by skeletal regions, 112P(ab)
dosimetry, region-specific S-values for, 112P(ab)
double labeling of granulocytes, prosthetic hip infection, 172P(ab)
hematopoietic, radiation effects, immunoscintigraphy evaluation of, 111P(ab)
immunoscintigraphy
clinical significance in tumor patients, 120P(ab)
^{99m}Tc antigranulocyte antibody, hematologic disease, 113P(ab)
mastocytosis, bone scan abnormalities in, 1471
metastasis, from breast cancer, radioimmune bone marrow scintigraphy, 1485
red, radioimmunotherapy patients challenged with interferon, 111P(ab)
scintigraphy, reconstruction of irradiation fields, 236P(ab)
skeletal metastases, ^{153}Sm-EDTMP for pain, 63
uptake, ^{18}F FDG, after chemotherapy, 221P(ab)
Bone scan
abnormalities, mastocytosis, 1471
clinical utility of, pleural effusion, 2056(le)
cone-beam SPECT, distal extremities, 914
evaluation for systemic mast cell diseases, 149P(ab)
index, ^{186}Re HEDP dosage recommendations, thrombocytopenia and, 1423
metastasis, from breast cancer, radioimmune bone marrow scintigraphy, 1485
pinhole scintigraphic sign, chondromalacia patellae, 855
radionuclide, multifocal osteonecrosis, small-cell bronchogenic carcinoma patient, 1347
Book reviews
Atlas of Radiologic Anatomy, 5th edition, 1887
Frontiers in Cardiovascular Imaging, 927
Monoclonal Antibodies in Cardiovascular Disease, 2058
NCRP Report No. 116, Limitation of Exposure to Ionizing Radiation, 2058
Nuclear Medicine Annual 1993, 927
Physics of Radiology, 927
Radiation Protection of Patients, 1887
Bowel laxation, improving gallium scintigraphy diagnosis, 174P(ab)
Brachytherapy, glass seeds for, neutron-activatable, 242P(ab)
Brain
activation, dual isotope imaging for, 194P(ab)
benzodiazepine receptors, SPECT measurement of, 228
^{11}C raclopride distribution volume, continuous infusion technique, 140P(ab)
degenerative disease, neuronal damage, ^{55}Co PET studies, 210P(ab)
FDG PET scans, automatic anatomical mapping of, 71P(ab)
four-dimensional imaging, FASTSPECT, 93P(ab)
functional imaging, validation of SPECT localization, 755
glucose metabolism, intersubject variability, young normal males, 1457, 1466
head holder, PET studies, 186P(ab)
hematoma, ^{11}C and ^{18}F FDG PET study of, 1162
HMPAO SPECT images, significance of abnormalities in, 239
^{123}I IPT cocaine analogue uptake, 129P(ab)
intracranial tumors, ^{18}F tetrafluoroborate evaluation in, historical article, 424
ischemic damage, ^{55}Co PET visualization of, 456
kinetics, ^{18}F FES, 255P(ab)
ligand liphophilicity, correlation, 255P(ab)
during memory task, ^{15}O water PET study, 201P(ab)
oxidative metabolites, clearance of, radiolabeled acetate in evaluation, 198P(ab)
perfusion studies
abnormalities, substance abusers, ^{99m}Tc HMPAO SPECT, 214P(ab)
cocaine abuse effects, SPECT study of women, 1902
^{99m}Tc pertechnetate as whole blood marker for, 479
rest and cognitive activation, dementia, 21P(ab)
PET imaging
anatomic standardization of, 1528
head motion during, 40P(ab)
head movement in, with and without head restraint, 1538
potentials, temporal and spatial origins of, PET, 197P(ab)
quantitative mapping of monoamine oxidase activity, clorgyline derivative, 254P(ab)
radiation necrosis, brain, FDG and ^{201}Tl comparison, 222P(ab)
recurrent tumor, ^{201}Tl and FDG PET comparison, 223P(ab)
scanning, ^{99m}Tc pertechnetate for, historical article, 478
signal transduction images, PET, 121P(ab)
SPECT imaging
automated co-registration and statistical analyses, 191P(ab)
comparison of four scatter correction methods, 143
ictal and interictal, epilepsy, 1896
nonuniform attenuation in, 188P(ab)
stereotactic PET atlas, 949
stroke model, ^{131}I Anti-ICAM-1 in, 106P(ab)
^{99m}Tc HMPAO kinetics, linear alkylation effects, 260P(ab)
three-dimensional surface MRI, real-time reconstruction, 127P(ab)
transient, randomly occurring neuropsychological events, PET imaging of, 185P(ab)
traumatic injury
^{99m}Tc HMPAO, CT and MRI in evaluation of, 217, 227
prospective evaluation of ^{99m}Tc HMPAO SPECT in, 942, 947
tumor
after therapy, comparison of ^{201}Tl SPECT and CT scans, 9P(ab)
childhood
FDG-PET evaluation of, 44P(ab)
^{201}Tl SPECT evaluation of, 43P(ab)
^{11}C MET and ^{123}I IMT comparison, 8P(ab)
^{11}C thymidine imaging, 974
^{11}C tyrosine visualization of, 227P(ab)
^{55}Co and ^{11}C tyrosine PET in, 213P(ab)
FDG PET evaluation of, 228P(ab)
hyperglycemia effects on FDG uptake, 1104
proliferative activity, ^{131}I iododeoxyuridine imaging of, 1407
regional glucose metabolism in, radiotherapy effects, 213P(ab)
transfer from PET to SPECT, ^{123}I IMT assessment, 9P(ab)
uptake, ^{99m}Tc HMPAO, normalization of, 212P(ab)
verbal tasks, left prefrontal cortex in, PET, 201P(ab)
Brain death, clinical diagnosis, radionuclide scintigraphy in, 275P(ab)
Breast
cancer
augmented breasts, PET imaging, 872
bone marrow metastasis from, radioimmune bone marrow scintigraphy, 1485
bone metastases from, ^{89}Sr palliation of, 236P(ab)
^{11}C labeled estrogens as imaging agents for, 250P(ab)
estrogen-receptor sites and, iodotamoxifen for imaging, 256P(ab)
FDG PET, quantitative methods in, 142P(ab)
^{18}F FDG in cell cultures of, 186P(ab)
^{131}I, radioimmunotherapy trial with, 235P(ab)
^{123}I E2 SPECT in detection of, 274P(ab)
intratumoral distribution of FDG, autoradiography, 141P(ab)
lymphoscintigraphy, prediction of lymph edema development, 224P(ab)
metastatic, flare on bone scintigraphy after chemotherapy, 1748
PET with FDG and FES, 141P(ab)
prognostic value of ^{201}Tl scan in, 228P(ab)
radioimmunodetection of, 217P(ab)
scintimammography in, 22P(ab)

sigma receptors for imaging tumors, 246P(ab)
somatostatin receptor scintigraphy in, 21P(ab)
suspected, ^{99m}Tc sestamibi and ^{201}Tl comparison, 231P(ab)
suspicious lesions, ^{99m}Tc MIBI SPECT in, 933
^{99m}Tc MDP scintigraphy in, 22P(ab)
^{99m}Tc MIBI in evaluation of, 22P(ab)
^{99m}Tc sestamibi detection of, 274P(ab)
^{99m}Tc sestamibi imaging in, 2055(le)
^{99m}Tc sestamibi scintigraphy in, 22P(ab)
^{99m}Tc sestamibi SPECT in, 229P(ab)
^{99m}Tc sestamibi use in, 229P(ab)
^{201}Tl and ^{99m}Tc imaging comparison, 222P(ab)
Yttrium-90 DOTA peptide chimeric L6 toxicity and therapeutic potential in, 122P(ab)
dense, imaging of, ^{99m}Tc sestamibi compared with MRI in, 223P(ab)
FDG accumulation, aging effects, 142P(ab)
low dose positron emission mammography, feasibility study, 61P(ab)
metastatic cancer
bone scintigraphy, bisphosphonate effects, 119P(ab)
changes in skeletal images, 89P(ab)
^{131}I CC49 plus alpha interferon in, 101P(ab)
tumor
c-neu OncoMouse, ^{99m}Tc sestamibi retention in, 21P(ab)
^{111}In imaging of c-erbB2 oncogene mRNA in, 65P(ab)
scintigraphy guided stereotaxic localization of, 62P(ab)
suspicion of, FDG PET in assessment of, 222P(ab)

Breast milk, ^{131}I in, after therapy for thyroid carcinoma, 1797

Breath test, gastric emptying, liquids and solids, 824

Bremsstrahlung
quantitative SPECT imaging, attenuation-correction, 1213
radiation dose
yttrium-90, planar gamma camera imaging, 1381
yttrium-90 therapy applications, 1377

Bromine-76 β-CIT, imaging of dopamine uptake sites, 253P(ab)

Bronchogenic carcinoma
increased ^{201}Tl uptake, collapsed lung, 1125
radiation treatment of, chest wall FDG accumulation, 76P(ab)
therapeutic response in, ^{18}F FDG PET in, 231P(ab)

Bronchopleural fistulae
detection of, ^{133}Xe ventilation imaging, 133P(ab)
localization of, ventilation scintigraphy, 867

C

Camera systems, cardiovascular nuclear medicine, 20N(4)

Cancer cells, intratumoral, FDG uptake in, 104

Captopril, renal scintigraphy, hypertension and renal failure, 251, 254

Carazolol, beta-adrenoceptor binding of, PET measurement of, 1665

Carbohydrate-addition-site, site-specific conjugations, grafting of, 243, 244

Carbon-11
daunorubicin labeled with, multidrug resistance, 83P(ab)
$GABA_A$-gated chloride ion channel blockers, 72P(ab)
labeling, nonpeptide angiotensin II antagonists, 6P(ab)
production for PET, 248P(ab)

Carbon-11 A-69024, non-benzazepine ligand, studies of dopamine D1 receptors, 250P(ab)

Carbon-11 acetate
assessment of myocardial oxidative metabolism, hyperthyroidism, 155P(ab)
dynamic-gated PET, myocardial oxygen and energy conversion, 110P(ab)
FDG-PET
myocardial metabolism, 110P(ab)
oxidative and glucose metabolism, cardiomyopathy, 110P(ab)
kinetics, simultaneous fitting of coupled multiple ROIs, 1286
PET
pancreas and related diseases, 108P(ab)
renal disease, 124P(ab)

Carbon-11 BnNM, studies of sigma receptors, 73P(ab)

Carbon-11 CFT, PET imaging of, MPTP-treated monkeys, 140P(ab)

Carbon-11 CGP 12177
assessment of β-adrenergic receptor concentration, 921(le)
metabolism, cardiac and pulmonary β-receptors, 157P(ab)

Carbon-11 cocaine, binding, tracer and pharmacological doses, baboon brain, 130P(ab)

Carbon-11 FLB 457, PET examination, extrastriatal dopamine D2 receptors, 84P(ab)

Carbon-11 flumazenil
benzodiazepine interaction model, PET, 67P(ab)
compartment modeling analysis, brain, 184P(ab)
PET, hippocampal neuronal loss, 207P(ab)

Carbon-11 forskolin, imaging of adenylate cyclase-related second messenger system, 250P(ab)

Carbon-11 HED, stereoisomers of, 98P(ab)

Carbon-11 iodomethane, PET, dopamine transporter, 252P(ab)

Carbon-11 iomazenil
PET-SPECT comparison, 18P(ab)
tracer kinetic modeling of, 184P(ab)

Carbon-11 L-159,884, imaging angiotensin II receptors, compartmental modeling, 137P(ab)

Carbon-11 L-365,260, synthesis, PET studies of brain cholecystokinin receptors, 248P(ab)

Carbon-11 labeled estrogens, imaging agents, breast tumors, 250P(ab)

Carbon-11 McN5652
imaging serotonin transporter sites, brain, 85P(ab)
synthesis, thioester precursors, 253P(ab)

Carbon-11 MeNTI, tracer kinetic analysis, brain, PET study, 67P(ab)

Carbon-11 MET
comparison with ^{123}I IMT, brain tumor patients, 8P(ab)
normal organ uptake, PET scans in oncologic patients, 220P(ab)
PET, differentiation of thoracic tumors from post-treatment changes, 76P(ab)

Carbon-11 methionine
^{18}F FDG PET comparison, lung and mediastinal disorders, 227P(ab)
PET
brain hematoma, 1162
uterine carcinoma, 1618
PET and, uterine carcinoma, 117P(ab)

Carbon-11 methoxy rotenone, marker, mitochondrial complex I activity, 256P(ab)

Carbon-11 MP
PET, pharmacokinetics and distribution in the brain, 85P(ab)
presynaptic dopaminergic neuron, 129P(ab)

Carbon-11 NMPB, muscarinic receptor binding, Alzheimer's disease, 20P(ab)

Carbon-11 NMSP, PET, clozapine measured by, schizophrenic patients, 74P(ab)

Carbon-11 NNC 112, PET examination, extrastriatal dopamine D1 receptors, 122P(ab)

Carbon-11 NNC 756, PET, dopamine D1 receptors, brain, 1916

Carbon-11 PAF, imaging of PAF receptors, tumor and spleen, 249P(ab)

Carbon-11 PHEN, mapping of neuronal enzyme function, heart, 109P(ab)

Carbon-11 phenylephrine, marker, neuronal heart monoamine oxidase, 7P(ab)

Carbon-11 raclopride
distribution volume, brain, continuous infusion technique, 140P(ab)
serotonin-dopamine interactions measured with, 85P(ab)

Carbon-11 radioligands, improved synthesis, PET, 250P(ab)

Carbon-11 SCH 39166, PET, dopamine D1 receptors, brain, 1916

Carbon-11 substance P, synthesis, PET studies, 254P(ab)

Carbon-11 TBZ, alkylated derivatives, structure-activity study, 84P(ab)

Carbon-11 thymidine, PET, DNA synthesis rate, brain glioblastoma, 9P(ab)

Carbon-11 tyrosine, visualization of brain tumors, protein synthesis and, 227P(ab)

Carbon-11 WIN
binding potential of, dopamine reuptake, normal human brain, 196P(ab)
dopamine reuptake sites measured by
Lesch-Nyhan disease, 130P(ab)
Tourette syndrome, 130P(ab)

Carbon-13, breath tests, laser spectroscopy for, 108P(ab)

Carbon-13 glycine, breath test, monitoring of gastric emptying of liquids and solids, 824

Carbon-14 colchicine, uptake, identification of tumor multidrug resistance, 1179

Carbon-14 FDG, uptake, tumor cell spheroids, 65P(ab)

Carbon-14 octanoic acid, breath test, monitoring of gastric emptying of liquids and solids, 824

Carbon-64 monoclonal antibody, PET, colorectal cancer, 12P(ab)

Carbon dioxide
cerebral circulation response to, technetium-99m-HMPAO SPECT, 32
superficial fluids, radiotracer synthesis and purification, 42P(ab)

Carbon dioxide-11, reversible solid-phase traps for, 251P(ab)

Carcinoembryonic antigen, concentration and distribution, measured by quantitative autoradiography, 1499

Carcinoma, hepatocellular, measuring lung shunting in, ^{99m}Tc-MAA use in, 70

Cardiac motion analysis, normal directional flow constraint, 176P(ab)

Cardiolite
chemistry of, 138P(ab)
clinical quality control procedure, 262P(ab)
Cardiomyopathy
diabetic, ^{123}I MIBG myocardial uptake, 154P(ab)
dilated, myocardial blood flow in, 23P(ab)
HIV, children, early detection, 237P(ab)
hypertrophic
^{123}I BMIPP and thallium uptake, myocardial, 135P(ab)
impaired oxidative and glucose metabolism, PET, 110P(ab)
myocardial metabolism in, FDG-PET, 110P(ab)
idiopathic dilated, ^{123}I MIBG myocardial images, 81P(ab)
myocardial clearance of ^{125}I MIBG, deteriorated transport to neuronal vesicles, 152P(ab)
nonobstructive hypertrophic, left ventricular functional reserve in, 1937
Cardiopulmonary bypass
cerebral emboli during, 173P(ab)
neutrophil activation during, pig model, 153P(ab)
Cardiovascular nuclear medicine
new instrumentation for, 20N(4)
training guidelines, 169
Cardiovascular surgery, decreased hippocampal blood flow after, SPECT, 64P(ab)
Carotid artery disease, hemodynamic and metabolic data in, 202P(ab)
Carotid artery occlusion, internal, ocular symptoms in, SPECT evaluation, 203P(ab)
Carotid artery stenosis
cerebral perfusion reserve in, surgical and rheological therapy, 203P(ab)
^{99m}Tc HMPAO diamox SPECT in, 202P(ab)
Cassen Prize, first, Hal O. Anger, inventor of gamma camera, 13N(5)
Cavity-to-myocardial count ratio, with ^{99m}Tc sestamibi, left ventricular function, 70P(ab)
CC49, radiolabeled antibody, treatment of metastatic prostate cancer, 1017
Central nervous system, tumors, pretherapeutic radioembolization of, 145P(ab)
Cerebellum, metabolism and perfusion, discordance between, SPECT vs PET, 209P(ab)
Cerebral artery, ischemia, multicenter sequential PET of, 197P(ab)
Cerebral cortex, intraoperative functional mapping, ^{15}O PET and, 107P(ab)
Cerebral emboli, platelet, hollow-fiber devices, cardiopulmonary bypass, 173P(ab)
Cerebral infarction, visualization of, ligand for dopamine transporter, 131P(ab)
Cerebral perfusion imaging
CNS toxoplasmosis, early HMPAO SPECT appearance, 1041
neural network classifier for, 771
Cerebral perfusion reserve
carbon dioxide reactivity, ^{99m}Tc HMPAO SPECT, 32
carotid artery stenosis, 203P(ab)
crossed cerebellar diaschisis and, cerebrovascular disease, 203P(ab)
Cerebral vascular disease, perfusion imaging, high-dose aspirin, 206P(ab)
Cerebral vasospasm, papaverine for, brain SPECT and transcranial Doppler evaluations, 64P(ab)
Cerebrovascular diseases
cerebral versus myocardial stress perfusion imaging, editorial, 41
^{99m}Tc ethyl cysteinate dimer in, SPECT images, 27
Cerium-134/lanthanum-134 system, source of radiopharmaceuticals, PET, 42P(ab)
Chase, avidin as, improved clearance of radiolabeled biotinylated monoclonal antibody, 1677
Chemotactic peptides
hydrazino nicotinamide derivatized, co-ligand effects, 19P(ab)
radiolabeled
chelators linked to, 44P(ab)
infection imaging, 44P(ab)
scintigraphy, acute inflammatory lesions, 256P(ab)
^{99m}Tc diaminedithiolate derivatives, imaging of inflammation, 19P(ab)
Chemotherapy
lymphoma masses after, FDG-PET for metabolism classification of, 131P(ab)
multifocal osteonecrosis and, small-cell bronchogenic carcinoma patient, 1347
response, advanced neuroblastoma, ^{131}I MIBG imaging to monitor, 1429
response monitoring, FDG PET utility in, 75P(ab)
Taxol, metastatic breast cancer, flare on bone scintigraphy after, 1748
Chimera, ^{111}In anti-CEA, pretherapy imaging trial, CEA-producing malignancies, 234P(ab)
Chloride ion channel blockers, $GABA_A$-gated, ^{11}C and ^{18}F labeling of, 72P(ab)
Cholecystitis
acute, RIM sign in, 14P(ab)
hepatobiliary imaging, morphine-augmented versus conventional, 171P(ab)
Cholecystokinin, brain, PET studies, ^{11}C L-365,260, 248P(ab)
Cholescintigraphy
diagnosis of rotor syndrome, 1048
evaluation of bile leaks, 13P(ab)
gallbladder emptying, reproducibility in scintigraphy, 835
radionuclide, evaluation of gallbladder, 171P(ab)
Cholinergic neuron, mapping, ^{123}I IBVM SPECT, 405
Chondromalacia patellae, pinhole scintigraphic sign in, older subjects, 855
Chromatography
quality control for Cardiolite, 262P(ab)
third-layer, quality control of ^{99m}Tc sestamibi, 264P(ab)
Chromium-51 EDTA, glomerular filtration rate, normalization of, children, 438
Chronic fatigue syndrome, brain stem SPECT and MRI in, 215P(ab)
Chylous ascites, intraperitoneal leakage of ^{99m}Tc DTPA, after renal transplantation, 93
Cigarette smoke, effects on permeability of alveolar epithelial membrane, ^{99m}Tc HMPAO aerosol use in, 133P
Cineangiography, radionuclide, three vessel coronary artery disease, 60P(ab)
Cirrhosis
alcoholic
inferior mesenteric shunt in, 168P(ab)
^{201}Tl per rectum scintigraphy in, 832
intestinal protein loss, ^{111}I transferrin study, 168P(ab)
Cisplatin, Pt-195m, tumor pharmacokinetics, 145P(ab)
Clinical trials, ^{123}I IPPA, myocardial viability, 32S
Clozapine, measured by ^{11}C NMSP PET, schizophrenic patients, 74P(ab)
c-*myc* oncogene, noninvasive imaging, antisense probes, 1054, 1064
c-myc probe, membrane-transport and intracellular hybridization of, radionuclide effects, leukemic cells, 42(ab)
Cobalt-55, PET
brain tumors, 213P(ab)
degenerative brain disease, neuronal damage in, 210P(ab)
visualization of ischemic damage to brain tissue, 456
Cobalt-57-bleomycin, SPECT quantitation of, lung cancer, 1129
Cocaine
^{11}C, binding at tracer and pharmacological doses, baboon brain, 130P(ab)
dependence, quantitative brain perfusion SPECT in, 210P(ab)
effect on cerebrovascular perfusion, gender differences, SPECT study of women, 1902
^{123}I IPT analogue of
brain and cardiac uptake, 129P(ab)
euphorogenic doses of, 130P(ab)
muscarinic agonist isomers, microimaging studies of, 201P(ab)
receptor probe, SPECT, 200P(ab)
Colchicine, uptake, identification of multidrug resistance and, 1179
Collimator
cast and foil, multiinstitutional study, 180P
cone beam
distal extremities, 914
fanbean, parallel-beam, lesion detectability with, 135
medium energy, characterization and performance testing, 195P(ab)
off-center fan beam, simultaneous transmission tomography with, 191P(ab)
optimal choice, combined ^{99m}Tc and ^{123}I studies, 181P(ab)
parallel-plus, SPECT, 33P(ab)
Colon carcinoma
biokinetic studies, ^{67}Cu anti-cea MAB, 101P(ab)
metastatic, radioimmunotherapy with ^{131}I CC49 and deoxyspergualine, 102P(ab)
Colorectal carcinoma
detection
FDG-PET and CEA-immunoscintigraphy, 108P(ab)
^{111}In CYT-372, 219P(ab)
^{99}Tc 88BV59 monoclonal antibody, 86P(ab)
with liver metastases, ^{123}I IUdR infusion into hepatic artery for, 144P(ab)
liver metastases of, tumor targeting, 56P(ab)
localization, In-111 CYT-103 and In-111 CYT-372 monoclonal antibodies in, 11P(ab)
radiolabeled monoclonal antibody studies in, SPECT and CT/MRI image registration, 1976
recurrence, ^{111}In DTPA imaging of, 55P(ab)
Commercial supplier, radioisotopes from, 19N(10)
Competitiveness, international PET conference, 14N(1)
Compton free imaging, new scatter correction method, 143P(ab)
Compton scattering, transmission-dependent method, SPECT, 360
Computed tomography (CT)
asymmetric fan transmission
attenuation correction, 92P(ab)
transverse slat collimation for, 27P(ab)

brain studies, image registration, 2011
cone beam, renal cortical defects, infants, 58P(ab)
co-registration of SPECT and, radiation-induced lung disease, 276P(ab)
emission-transmission system, 195P(ab)
fan beam transmission, extrapolation of truncated projections, 33P(ab)
^{67}Ga, extragonadal and gonadal seminomas, 1624

Computers
CAMAC-modular gamma camera, research imaging, 178P(ab)
genetic algorithm, synthetic discriminant function filters, analytical entropy, spinal tumor, 178(ab)
MedTRAC, data entry clinical database, 181P(ab)
simulation, gastric emptying, 170P(ab)

Cone-beam data
SPECT, shift-variant filtered-backprojection, 5P(ab)
sufficiency, reconstruction variance and, evaluation, 5P(ab)

Conjugate imaging, count-based radionuclide method, ventricular volume, 644

Consensus development, producing diagnostic procedure guidelines, SPECT brain perfusion imaging with exametazime, 2003

Copper-62 PTSM
generator-produced, brain perfusion tracer for PET, 1910, 201P(ab)
myocardial kinetics, comparison with potassium-38, 1116, 1122
myocardial perfusion tracer, PET, 78P(ab), 156P(ab)

Copper-64
PET images of, whole-body dosimetry from, 158P(ab)
radiation measurement, nuclear medicine radioisotope dose calibrator, 244P(ab)
radioimmunotherapy, tumor-bearing hamsters, 161P(ab)

Copper-64 TETA-D-Phe octreotide, receptor binding of, PET imaging of somatostatin receptors, 106P(ab)

Copper-67
production and evaluation, tumor radioimmunotherapy, 259P(ab)
radiation measurement, nuclear medicine radioisotope dose calibrator, 244P(ab)
radiocontaminant in, dosimetry evaluation of radioimmunotherapy for, 158P(ab)

Copper-67 Anti-Cea, biokinetic studies, colon carcinoma, 101P(ab)

Copper-67 2IT-BAT-Lym-1, immunoreactivity, substitution effects, 259P(ab)

Coralline hydroxyapatite, implants, vascularization of, 151P(ab)

Coronary artery disease
abnormal exercise scintigraphy, pectus excavatum, 1985
artificial neural net, inductive decision tree learning comparison, 180P(ab)
chronic, resting ^{99m}Tc MIBI redistribution in, 114P(ab)
defect severity in MIBI SPECT, 569
detection using ^{82}Ru, community hospital-based PET center, 1586
dipyridamole ^{201}Tl SPECT in, 983
exercise myocardial perfusion imaging, 726
exercise SPECT thallium images, women, 27P(ab)
^{123}I IPPA use in, 38S
MIBI SPECT in, 126P(ab)
multicenter trial for quantitative analysis of ^{99m}Tc sestamibi myocardial tomography, 609
myocardial glucose utilization, Patlak graphical analysis, 156P(ab)
myocardial perfusion imaging with PET, 689
myocardial viability, 4S
metabolic imaging of, 8S
nicotinic acid derivative enhancement of glucose uptake, 989
PET rubidium-82 myocardial perfusion imaging, accuracy of, 23P(ab)
prognostic value of ^{99m}Tc sestamibi cardiac imaging, 554
radionuclide ventriculography in prognosis of, 721
reversible ^{201}Tl perfusion defect, 1808
simultaneous stress dobutamine sestamibi SPECT detection of, 16P(ab)
stress/rest thallium studies, ^{99m}Tc teboroxime compared with, 114P(ab)
^{99m}Tc Q3 and ^{201}Tl comparison, 581
^{99m}Tc sestamibi evaluation, dipyridamole infusion and, 1254
^{99m}Tc tetrofosmin myocardial tomography, 594
teboroxime washout imaging, dipyridamole with, 115P(ab)
thallium SPECT, lung uptake, 126P(ab)
three vessel, radionuclide cineangiography, 60P(ab)
^{201}Tl and PET imaging in evaluation of myocardial viability, 707
^{201}Tl dipyridamole, high dose or standard dose, 1245
^{201}Tl exercise SPECT studies, reproducibility of, 1237
^{201}Tl myocardial perfusion imaging in, 703
^{201}Tl reinjection for detection of viable myocardium, 621

Coronary bypass surgery
grafting, extent of function-perfusion mismatch, 126P(ab)
left ventricular function changes after, 136P(ab)

Coronary flow reserve
fast dynamic SPECT, compartmental analysis of ^{99m}Tc teboroxime and, 115P(ab)
reduced, diabetes, nitrogen-13-ammonia PET, 4P(ab)

Coronary revascularization, prediction of recovery ^{123}I IPPA and, 49P(ab)
^{99m}Tc sestamibi nitrate imaging, 49P(ab)

Corticosteroids, multifocal osteonecrosis and, small-cell bronchogenic carcinoma patient, 1347

Cost effectiveness
international PET conference, 14N(1)
nuclear medicine practitioners evaluate, 13N(2)

Cramer-Rao bound
estimation tasks, multiple energy window data, 4P(ab)
model of multiparameter quantitation, 60P(ab)

Crohn's disease, with fistulization, ^{111}In WBC imaging in, 245

Crossed cerebellar diaschisis, cerebral perfusion reserve and, cerebrovascular disease, 203P(ab)

Cushing's adenomas, preclinical, adrenal scintigraphy in detection of, 69P(ab)

Cyanoimipramine
experimental validation of, marker for serotonin innervation density, rat brain, 67P(ab)
serotonin marker, innervation density, brain, 1822

Cyclodextrins, ^{99m}Tc TcN with, interaction, 261P(ab)

Cyclotron, PET, stable isotope content in biological samples, 177P(ab)

Cysteine, antibodies to, tumor from, ^{99m}Tc transchelation in, 105P(ab)

Cystic fibrosis, liver disease and, children, hepatobiliary scintigraphy in, 432, 436, 58P(ab)

Cytokeratin 19, serum, measurement in gastrointestinal and gynecological malignancies, 146P(ab)

Cytokines
DTPA-stimulated release, neutrophils, 133P(ab)
intervention, radioantibody-induced myelotoxicity, 102P(ab)
radiolabeled, scintigraphy of acute inflammatory lesions, 256P(ab)

Cytomegalovirus, infection, lung, gallium scintigraphic patterns, 133P(ab)

D

Data base, European nuclear cardiology, 176P(ab)

Daunorubicin, ^{11}C-labeled, multidrug resistance, 83P(ab)

Deconvolution study
renal blood flow, posttransplant complications, 1792
^{99m}Tc DTPA, transplanted kidney, 84

***N*-Deglycosylation,** lung tumor xenografts by, antibody uptake, 289

Delta opioid receptors, cerebral, radioiodinated 7'iodonaltrindole use in, 245P(ab)

Dementia
Alzheimer's disease, PET differential diagnosis, 391
Alzheimer's type, brain perfusion in, 21P(ab)
differential diagnosis, regional SPECT analysis in, 206P(ab)
functional MRI, PET and, 20P(ab)
perfusion imaging, high-dose aspirin, 206P(ab)
primary degenerative and vascular, ^{99m}Tc HMPAO SPECT and FDG PET in, 119P(ab)
white matter lesions in, ^{99m}Tc HMPAO SPECT identification of, 21P(ab)

Dendrimers, poly-metal chelates based on, preparation and characterization of, 62P(ab)

Deoxyspergualine, ^{131}I CC49 and, metastatic colon cancer, 102P(ab)

Department of energy, grant, NBTF, isotope supply, 12N(1)

Depression, unipolar, paralimbic hypoperfusion in, 929

Desmoid tumor, extra-abdominal, ^{99m}Tc pertechnetate scintigraphy in, 226P(ab)

D3FES, compared to fluoroestradiol, 6P(ab)

Diabetes
gastric emptying, postprandial glucose and insulin levels in, 87P(ab)
noninsulin-dependent
gastric emptying in, 164P(ab)
^{133}Xe washout method in lower limbs, 163P(ab)
solid and liquid gastric emptying, determinants of, 88P(ab)

Diabetes mellitus
cardiac sympathetic nervous dysfunction with, ^{123}I MIBG, 153P(ab)
impaired lung epithelial permeability in, ^{99m}Tc DTPA aerosol scintigraphy detection, 204, 207

otitis externa in, differentiation, SPECT bone scintigraphy, 411
Diagnostic procedures, nuclear medicine practitioners, 17N(11)
Diamox, ^{99m}Tc HMPAO SPECT, carotid artery stenosis, 202P(ab)
Dihydropyridine, myocardial binding sites, PET study, 78P(ab)
Diprenorphine, analogues of, ligands for cerebral opioid receptors, 128P(ab)
Dipyridamole
intravenous, combined symptom-related stress testing, 2055(le)
kinetics of heptadecanoic acid after, heart, 51
^{99m}Tc sestamibi, evaluation of coronary artery disease, 1254
myocardial perfusion imaging, coronary artery disease, 730
pharmacological stress myocardial perfusion imaging, pediatric patients, 135P(ab)
planar cardiac ^{201}Tl stress-redistribution scintigrams, automated interpretation, 2041, 2047
stress test, transient neurological events during, 1802
^{99m}Tc teboroxime washout imaging, coronary artery disease, 115P(ab)
thallium scintigraphy, vascular patients, left ventricular size, 125P(ab)
^{201}Tl, high dose or standard dose, coronary artery disease, 1245
^{201}Tl biokinetics with, 535
^{201}Tl SPECT, computer evaluation of, aortic stenosis, 983
Discriminant function analysis, SPECT, mild Alzheimer's disease, 1450, 1455
Disseminated intravascular coagulation, metastatic prostate cancer, ^{89}Sr therapy, 1662
DNA
antisense delivery, in vivo, liver, 269
cobalt-57-bleomycin bound to, SPECT, lung cancer, 1129
fluorescent molecule conjugated by, molecular dosimetry using, 79P(ab)
strand breaks, after positional decay of ^{125}I, 79P(ab)
synthesis rate, brain glioblastoma, C-11 thymidine PET imaging in, 9P(ab)
Dobutamine
low dose, wall motion and flow response, myocardium, 39P(ab)
myocardial perfusion imaging, coronary artery disease, 737
stress agent, myocardial perfusion imaging, 125P(ab)
thallium imaging, false-positive reversible perfusion defect during, left bundle branch block, 1989
^{201}Tl biokinetics with, 535
Dopa decarboxylase, relative activity of, aging effects, 10P(ab)
Dopamine
^{123}-β-CIT content and, MPTP-treated monkeys, 140P(ab)
metabolism, ^{18}F FDOPA used in imaging of, 248P(ab)
reuptake sites, selective SPECT agent for, 121P(ab)
reuptake tracer, radiofluorinated, 83P(ab)
transporters, age-related decline, ^{123}I β-CIT SPECT, 11P(ab)
uptake sites
^{76}Br β-CIT PET for, 253P(ab)
radioligands for exploration of, SPECT, 247P(ab)
reserpine effects, 199P(ab)
Dopamine receptors
^{11}C FLB 457 examination of, 84P(ab)
^{18}F NMB binding to, reversibility and non-internalization of, 122P(ab)
imaging agent, FIDA2, 128P(ab)
^{123}I OH-PIPAT, SPECT imaging, 246P(ab)
occupancy, assessment with PET, 197P(ab)
Dopamine D1 receptors
brain, PET studies, 1916
extrastriatal, ^{11}C NNC 112 for examination of, 122P(ab)
non-benzazepine ligand for study of, ^{11}C A-69024, 250P(ab)
Dopamine D2 receptors
D-amphetamine effects, 139P(ab)
baboon and human, ^{123}I NCQ-298 use in, 122P(ab)
comparison of three, animal models of quantitative receptor alterations, 257P(ab)
FIDA-2, biodistribution and dosimetry of, 160P(ab)
^{123}I IBC binding to, compartmental modeling, 743
^{123}I IBZM SPECT, idiopathic rotational torticollis, 1921
low and high affinity, PET studies with, 140P(ab)
potent SPECT radioligand for, 199P(ab)
quantitation, equilibrium analysis, ^{125}I IBZM use in, 202P(ab)
selective imaging, ^{11}C PET, 198P(ab)
SPECT studies, radioiodinated YM-09151-2 derivative, 247P(ab)
Dopamine transporter
^{123}I β-CIT binding to, 129P(ab)
imaging agents for, Methylphenidate, 94P(ab)
^{123}I SPECT probes for, non-human primate brain, 201P(ab)
ligand for, visualization of cerebral infarction with, 131P(ab)
PET imaging of, ^{11}C iodomethane in, 252P(ab)
SPECT imaging, ^{123}I analogues, 128P(ab)
two SPECT ligands for, comparison, 129P(ab)
Dopaminergic nerve cells, loss, Parkinson's disease, ^{123}I β-CIT SPECT imaging, 10P(ab)
Doppler blood flow measurements, comparison with myocardial perfusion imaging, endothelial functions, 23P(ab)
Dose point kernel convolution technique, ^{131}I internal dosimetry, 160P(ab)
Dose-rate effects, linear-quadratic model, radioimmunotherapy, 1861
Dose uptake ratio, index of glucose metabolism, 1308
Dosimeters, mini-TL, in vivo measurements, 78P(ab)
Dosimetry
biodistribution and, dopamine D2 receptor antagonist, 160P(ab)
bone marrow, region-specific S-values for, 112P(ab)
cellular, diagnostic and therapeutic nuclear medicine, 303
electron paramagnetic resonance, unsealed source radiotherapy, 111P(ab)
^{18}F 6F-DA, 964
^{123}I β-CIT biodistribution, brain SPECT imaging, 764
^{123}I iomazenil, SPECT, 399
^{111}In decay effects, pBR322 DNA, 162P(ab)
internal
Bremstrahlung radiation dose in yttrium-90 applications, 1377
^{131}I, dose point kernel convolution technique for, 160P(ab)
interactive dosimetric evaluation program in, 159P(ab)
prostate in, 516
^{131}I therapy, large, multinodular goiters, 163P(ab)
lungs, cellular level, after ^{99m}Tc labeled microspheres, 79P(ab)
microdosimetry, tumor size and radiation dose distribution, 233P(ab)
molecular, ^{99m}Tc- and ^{125}I-induced OH radicals, 79P(ab)
^{99m}Tc teboroxine, 923(le)
multicellular, micrometastases, 521
^{15}O water, physiologic approach, 158P(ab)
photon and beta particle, 1721
photon and beta-particle, unified approach to, 79P(ab)
projected whole body dose, radioimmunotherapy based on, 233P(ab)
quantitative evaluation, remnant thyroid ablation after surgery, 1944
radiation
electron absorbed fractions in spheres, 152
^{111}In GRAN, 159P(ab)
intrasynovial administration of ^{153}Sm particulates, 160P(ab)
for radioimmunotherapy of ^{64}Cu radiocontaminant, 158P(ab)
yttrium-90 Bremsstrahlung, 1381
radioimmunotherapy, SPECT-based 3-D methodology for, 123P(ab)
for radioiodine therapy, thyroid cancer, 112P(ab)
^{186}Re NR-LU-10, compartmental modeling and radiation dose, 158P(ab)
three-dimensional, microchannel plate detector in, 179P(ab)
three-dimensional internal, dose-volume histogram representation of, 123P(ab)
tissue distribution data, electronic mouse model, 161P(ab)
whole-body, PET images with ^{64}Cu, 158P(ab)
Drinking water, radon risk, EPA, 9N(1)
Drug approval, ^{131}I MIBG, 13N(6)
Dual isotope acquisition, ^{201}Tl and ^{123}I BMIPP myocardial SPECT, triple energy window method, 194P
Dubin-Johnson syndrome, rotor syndrome and, cholescintigraphy in diagnosis, 1048
Dysprosium-166, separation from ^{166}Ho, development of method for, 241P(ab)

E

Echocardiography
detection of coronary disease and ischemia, arbutamine infusions and, 16P(ab)
utility in assessment of myocardial viability, 49S
Editorials
are animal scanners really necessary for PET?, 1396
artificial neural networks: better than the real thing?, 2047
assessment of mechanical function as an adjunct to myocardial perfusion/metabolism emission tomography studies, 1005
cancer or inflammation? a holy grail for nuclear medicine, 1653
can DMSA detect early renal injury in children with vesicoureteral reflux?, 449

cardiovascular nuclear medicine: state-of-the-art, 672
cerebral versus myocardial stress perfusion imaging, 41
classification of silent adrenal masses: time to get practical, 1152
clinical cone-beam SPECT, 141
detection and comparison of patterns in images, 16
discriminant function analysis: toward a more rigorous approach to SPECT interpretation, 1455
estimating the risk of osteoporosis, 1159
evaluating traumatic brain injury: correlating perfusion patterns and function, 227
first-pass ventricular function study: why now?, 1301
image correlation: applications in nuclear medicine and beyond, 1781
imaging vascular endothelial activation, 281
iodine-131-lipiodol for hepatocellular carcinoma: the benefits of targeting, 1318
is there a role for FDG PET imaging in the management of patients with sarcoidosis, 1650, 1653
making sense out of antisense: challenges of imaging gene translation with radiolabeled oligonucleotides, 1064
microdosimetric considerations of hepatic radioembolization, 1644
noninvasive estimation of cerebral blood flow, 1878
ongoing challenge of diagnosis and treatment of urinary tract infection, vesicoureteral reflux and renal damage in children, 1608
PCP, AIDS and nuclear medicine, 1034
PET studies in psychiatry, 24
predicting outcome in traumatic brain injury: what role for rCBF/SPECT?, 947
progress and promise, 1858
quantification of aspiration: methodological and clinical perspectives, 1013
role of SPECT brain imaging in epilepsy, 1094
in search of perfect PET flow tracer, 1122
should the role of captopril renography extend to the evaluation of chronic renal disease?, 254
something borrowed, something blue, 168
SPECT evaluation of lumbar spinal fusion: will it make the medal round?, 422
^{99m}Tc DTPA aerosol to measure alveolar-capillary membrane permeability, 207
thrombus-specific imaging: approaching the elusive goal, 202
V/Q imaging and the diagnosis of PE: can we shift the gray to black and white?, 1931
what are the sources of error in measuring and calculating cerebral metabolic rates with ^{18}F FDG and PET, 1466
whither water?, 567
will a radiolabeled antibody replace ^{111}In platelets to detect active thrombosis, 1738

EDTA, 90-Y and, refractory adenocarcinoma, 102P(ab)

Effective dose equivalent, application to nuclear medicine patients, 185(le), 186(le), 187(le), 188(le)

Ejection fraction
calculation of, gated PET, 104P(ab)
left ventricular
equilibrium radionuclide angiography, historical article, 566, 720
gated tomography sestamibi, 154P(ab)
nonobstructive hypertrophic cardiomyopathy, 1937
prediction of perioperative events, vascular surgery, 90P(ab)
regional, wall motion comparison, rest and exercise, historical article, 593
right ventricular, determination of, 177P(ab)
ventricular, single-crystal nuclear camera, 1292, 1301

Elastic mapping, three-dimensional intersubject medical image registration, 186P(ab)

Electroconvulsive therapy, sites of action, SPECT-HMPAO brain imaging, 53P(ab)

Electroencephalography, correlation of HMPAO brain SPECT results, partial status epilepticus, 1087, 1094

Electrons, cellular dosimetry, 303

Emergency room, chest pain patients, ^{99m}Tc sestamibi imaging, myocardium, 275

Encephalomyelitis, myaligic, brain stem SPECT and MRI in, 215P(ab)

Encephalopathy
neurotoxicity due to manganese toxicity, ^{99m}Tc HMPAO brain SPECT evaluation of, 863
reversible, ^{99m}Tc HMPAO SPECT in, 210P(ab)

Endocrine tumor
intestinal, vasoactive intestinal peptide receptor imaging, 97P(ab)
pancreatic, ^{123}-I-Tyr-3, somatostatin scan of, 57

Endometrium, imaging, radiolabeled estrogen receptor ligands, 66P(ab)

Endoscopy, aspiration risks, neurologic patients, 109P(ab)

Endothelial cells, adhesion, radiolabeled monoclonal antibodies against, 276, 281

Energy spectrum fitting, general-purpose scatter correction based on, 34P(ab)

Energy window, Cramer-Rao bound for estimation tasks, 4P(ab)

Environmental radiation, radon update, 368

EPA, radon risk, drinking water, 9N(1)

Epilepsy
extra-temporal lobe, ^{99m}Tc HMPAO SPECT use in, 112, 117
ictal and interictal brain SPECT, using ^{99m}Tc ECD, 1896
inter-ictal brain perfusion SPECT, FDG PET compared with, 207P(ab)
PET metabolic and receptor images, right-left asymmetry profiles for, 31P(ab)
refractory, interictal brain SPECT in children, 134P(ab)
SPECT brain imaging in, meta analysis, 31P(ab)
^{99m}Tc HMPAO SPECT
ictal and interictal, 116P(ab)
MR comparison, 208P(ab)
temporal lobe
^{11}C flumazenil PET, 207P(ab)
delta opioid receptors in, PET, 31P(ab)

Erythromycin, alcohol absorption and, 184(le)

Erythromycin ethylsuccinate, formulations, gastric emptying and, 87P(ab)

E-selectin, marker of endothelial activation, inflammatory arthritis, 45P(ab)

Esophagus, motility disorders, esophageal transit scintigraphy in, 169P(ab)

Estrogen receptor, radiolabeled ligands, imaging endometrium, 66P(ab)

Ethics, resolutions on, 29N(8)

Ethylenediamines, ^{111}I-labeled, biological evaluation of, 43P(ab)

Ethylene-dicysteine, D,D- and D,L-, ^{99m}Tc L,L,EC comparison, 262P(ab)

Euglycemic hyperinsulinemic glucose clamp, FDG imaging, identification of viable myocardium, 39P(ab)

Exercise
dipyridamole stress test, transient neurological events during, 1802
radionuclide ventriculography, new motion-correction algorithm for, 179P(ab)
^{201}Tl biokinetics with, 535
testing, dipyridamole injection, heptadecanoic acid kinetics after, heart, 51

Expectation maximization algorithm, MAP-EM reconstruction using, 193P(ab)

Expert systems, ventilation-perfusion scans, pulmonary embolism, 797

Extracellular fluid, volume, normalization of glomerular filtration rate, children, 438

F

Fab fragments
immunoscintigraphy, 218P(ab)
^{111}In antimyosin, pulmonary uptake, after cardiac transplantation, 266
MH1, detection of thrombi, 80P(ab)
multivalent, pharmacokinetics of Yttrium-90 delivery with, 63P(ab)
^{99m}Tc, comparison to labeled leukocytes for detection of infection, 172P(ab)
^{99m}Tc-antigranulocyte, imaging of infectious disease, 112P(ab)
^{99m}Tc labeling of
hydrazinopyridine linkers for, 29P(ab)
radioimmunodetection, 259P(ab)

Facet joints, lumbar spinal fusion, painful late effect, SPECT assessment, 416, 422

Fan-beam collimation, off-center focus, emission/transmission SPECT, 92P(ab)

Fatty acids
betamethylheptadecanoic acid, myocardial extraction of, 496
free, metabolism, hibernating myocardium, 136P(ab)
^{123}I BMIPP, myocardial kinetics, 97P(ab)
imaging kinetics, rest, exercise, and dipyridamole injection, heart, 51

FDG imaging, *See also* Fluorine-18 FDG; Fluorodeoxyglucose
during euglycemic hyperinsulinemic glucose clamp, viable myocardium, 39P(ab)
increased uptake, pancreatic carcinoma, GLUT-1 in, 117P(ab)

FES, *See* Fluoroestradiol

Fetus, thyroid function, assessment in maternal serum, 164P(ab)

Fibroblast growth factor, activity, ^{201}T SPECT evaluation, childhood brain tumors, 43P(ab)

Fibromyalgia, caudate nuclei rCBF in, ^{99m}Tc HMPAO brain SPECT in, 215P(ab)

FIDA2, dopamine receptor imaging agent, 128P(ab)

Filtered backprojection, negativity artifacts in, suppression, 105P(ab)

Filters, neural, gamma camera Brensstrahlung image restoration, 143P(ab)

Fluoride, aqueous, high power targets for production of, 6P

Fluorine-18
androgen receptor ligands labeled with, prostate imaging, baboon, 53P(ab)
biotin labeled with, infection localization with, 1685

dopamine reuptake tracer, 83P(ab)
enantioselective synthesis, 251P(ab)
$GABA_A$-gated chloride ion channel blockers, 72P(ab)
labeling of proteins, potential applications, PET, 73P(ab)
nucleophilic substitution reactions
methylsulfone in, 251P(ab)
quarternary piperazine n-oxide, 252P(ab)
PET, high-risk femoral head, osteonecrosis, 35P(ab)
protein labeling, one-step synthesis, 249P(ab)
Fluorine-18 FBnNM, studies of sigma receptors, 73P(ab)
Fluorine-18 6F-DA, pharmacokinetics and dosimetry, 964
Fluorine-18 FDG
accumulation, human cancers heterotransplanted in nude mice, 97
cerebral metabolic deficits, Alzheimer's disease, diagnostic criteria, 119P(ab)
^{11}C methionine comparison, lung and mediastinal disorders, 227P(ab)
corrected uptake values, body surface area and body weight correction, 164
FDG-PET, myocardial metabolism, 110P(ab)
glucose ingestion and, effects on normal liver, 818
glucose metabolism studies, microdialysis in, 252P(ab)
hepatocellular carcinoma, monitoring after interventional therapy, 1965
^{111}In OS comparison, colorectal and ovarian cancer, 274P(ab)
insulin-dependent accumulation of, cell cultures in breast cancer, 186P(ab)
metabolic pathways, prostate cancer, 256P(ab)
myocardial uptake
enhancement by a nicotinic acid derivative, 989
hyperglycemia, 152P(ab)
normal organ uptake, PET scans in oncologic patients, 220P(ab)
PET
bone lymphoma, 35P(ab)
brain hematoma, 1162
chemotherapy evaluation with, 90
comparison with MIBI SPECT, myocardial viability assessment, 569
detection of early Parkinson's disease, 10P(ab)
differentiation of thoracic tumors from post-treatment changes, 76P(ab)
direct gene testing for Huntington's disease, 94P(ab)
pallidotomy for Parkinson's disease, 11P(ab)
recurrent rectal cancer, 118P(ab)
semiquantitative and visual analysis, pulmonary abnormalities, 1771
standard uptake values measured with, 185P(ab)
therapeutic response on bronchogenic carcinoma, 231P(ab)
production system, frozen ^{18}O-enriched carbon dioxide, 253P(ab)
radiation detection, positron-sensitive surgical probe, 909
SPECT, prediction of wall motion abnormalities, 136P(ab)
thrombolytic therapy by, glucose metabolism in ischemic myocardium, 156P(ab)
uptake
bone marrow, after chemotherapy, 221P(ab)
glycolysis-associated gene and, PET, 220P(ab)
intratumoral dynamics, 104
malignant cells, 228P(ab)
sarcoidosis, 1647, 1650
uptake and phosphorylation, thermal injury effects, 175P(ab)
uptake mechanisms, cancer cells, 1067
Fluorine-18 FDHR, synthesis and evaluation, mitochondrial electron transport chain, PET, 73P(ab)
Fluorine-18 FDOPA
clearance of, protein-rich diet effects, 212P(ab)
PET, imaging dopamine metabolism, 248P(ab)
quantitation, Parkinsonism, 955
stereoselective synthesis, via fluorodestannylation, 251P(ab)
Fluorine-18 FDTal, regional brain distribution, PET tracer for galactokinase activity, 255P(ab)
Fluorine-18 FES, systemic and cerebral kinetics, 255P(ab)
Fluorine-18 fluoride, no-carrier-added, synthesis of fluorodopa from, 1996
Fluorine-18 fluorocarazolol, PET, imaging of pulmonary β-adrenoceptors, 257P(ab)
Fluorine-18 FMISO
detection of odontogenic infections, 113P(ab)
hypoxia detection, nasopharyngeal carcinoma, 142P(ab)
PET, ischemic penumbra in acute stroke, 205P(ab)
synthesis, PET, 73P(ab)
Fluorine-18 LDOPA, PET studies, validation of venous input function in, 185P(ab)
Fluorine-18 L-FDG, biodistribution, PET studies, rats and monkeys, 254P(ab)
Fluorine-18 MIBG, synthesis and preliminary evaluation, 248P(ab)
Fluorine-18 NMB, reversibility and non-internalization, binding to dopamine receptors, PET, 122P(ab)
Fluorine-18 PFBG
kinetics, coronary artery occlusion model, 157P(ab)
uptake, myocardial and adrenal uptake of, 255P(ab)
Fluorine-18 Phe, amino acid transport, cerebral infarction, 63P(ab)
Fluorine-18 tetrafluoroborate, intracranial tumors, preliminary evaluation, historical article, 424
Fluorine-18 uracil, PET, liver metastases with intraarterial chemotherapy, 38P(ab)
Fluorodeoxyglucose (FDG)
dose uptake ratio for blood radioactivity, glucose metabolic rate and, 8P(ab)
^{131}I iododeoxyuridine comparison, brain tumor proliferative activity, 1407
neural network classification, Alzheimer's disease subjects, 7
standardized uptake values, 1564(lc)
uptake
cell stress and, 120
hyperglycemia effects, brain and glioma, 1104
in vitro, 1842
whole-body, sarcoidosis, 1647, 1650, 1653
Fluorodestannylation, stereoselective synthesis of ^{18}F FDOPA via, 251P(ab)
Fluorodopa
PET, reproducibility of, 18
synthesis, from no-carrier-added fluorine-18-fluoride, 1996
Fluoroestradiol, synthesis and metabolic studies, compared to D3FES, 6P(ab)
Fluoroetanidazole
production, high power targets for, 6P(ab)
synthesis, hypoxia imaging evaluation, 6P(ab)
Fluoro-iodobenzylguanidine, PET, synthesis and preliminary evaluation, 248P(ab)
Fluoroscopy, aspiration risks, neurologic patients, 109P(ab)
Fluoxetine, treatment for major depression, changes in rCBF abnormalities after, 54P(ab)
Folate receptors, ^{125}I imaging of, scintillating optical fibers in, 222P(ab)
Fractionation, temporal image, motion artifacts in myocardial SPECT, 1193
Fracture
scaphoid, suspected, bone scintigraphy in, 151P(ab)
stress, bone scintigraphy in young athletes, 120P(ab)
Free radicals, detection, PET, 83P(ab)
Functional endoscopic sinus surgery, chronic sinusitis after, evaluation with ^{99m}Tc DTPA, 150P(ab)
Functional mean transit time, transplanted kidneys, ^{99m}Tc DTPA study, 84
Furosemide, good response to, normal separate clearance and, children, 265P(ab)

G

Gallbladder
motility, reproducibility in scintigraphic studies, 835
sludge or stones, evaluation with radionuclide cholescintigraphy, 171P(ab)
Gallium
bone scan and, value in malignant fibrous histiocytoma, 232P(ab)
focal uptake, PCP, HIV patients, 1038
imaging, vertebral osteomyelitis, 173P(ab)
scintigraphic patterns, lung cytomegalovirus infection, 133P(ab)
scintigraphy, routine bowel laxation for, 174P(ab)
Gallium-67
abdominal imaging, AIDS, 174P(ab)
imaging, lymphoma, immunophenotypic studies, 231P(ab)
PET imaging, somatostatin receptor-positive tumors, 317
radiochemical design for antibodies, 326
scintigraphy, liver lymphoma, 229P(ab)
sequential imaging, non-Hodgkin's lymphoma, 230P(ab)
triazacyclononane ligands for use with, 243P(ab)
uptake, benign transformation of Hodgkin's disease, 465
Gallium-67 citrate
detection, phenytoin-induced pneumonitis, 471
differentiation, bone lymphoma, post-treatment changes, 131P(ab)
extragonadal and gonadal seminomas, radiologic findings and, 1624
MRI comparison, schwannoma of the extremities, 1174
Gallium-67 DMS, preparation and evaluation, potential tumor-seeking agent, 242P(ab)
Gallium-67 monoclonal antibodies, in vivo stability, 29P(ab)
Gallium-68, PET imaging, somatostatin receptor-positive tumors, 317
Gamma camera
bremsstrahlung image restoration, hybrid neural network for, 143P(ab)
CAMAC-modular, research imaging, 178P(ab)
dual-headed, imaging of gastric motility, 171P(ab)

emission phantoms for, use of inkjet printers, 127P(ab)
Hal O. Anger, inventor, 13N(5)
imaging and quantitation, yttrium-90 Bremsstrahlung, 1381
single-crystal, first-pass ejection fraction with, 1292, 1301
three detector, ^{18}F FDG cardiac scintigraphy, 111P(ab)
Gastric emptying
antral motor activity and, gastrokinetic compound effects, radiogastrogram, 88P(ab)
diabetes patients
postprandial glucose and insulin levels in, 87P(ab)
solid and liquid, 88P(ab)
different particle sizes, comparison to solid meal, 170P(ab)
elderly, comparison with younger subjects, 169P(ab)
lag phase, clinical, mathematical and in vitro studies, 172P(ab)
lag phase of, 1023
liquids and solids, breath test for, 824
mathematical model, physiological basis, 170P(ab)
Mexican Americans and non-hispanic whites, body mass glucose and insulin levels in, 88P(ab)
noninsulin-dependent diabetics, 164P(ab)
oil and aqueous meal components, pancreatic insufficiency, 168P(ab)
oral erythromycin ethylsuccinate formulations and, 87P(ab)
Gastric motility
dual-headed gamma camera imaging, 171P(ab)
evaluation, Fourier analysis of condensed images, 87P(ab)
Gastric reflux, ^{99m}Tc MIBI, SPECT myocardial imaging, 619
Gastric surgery, gallbladder emptying, reproducibility in scintigraphy, 835
Gastroenteropancreatic endocrine tumors, Octreoscan 111 scintigraphy, 96P(ab)
Gastrointestinal hemorrhage, angiodysplasia and, scintigraphy, 870
Germ cell tumor
postchemotherapy residual, FDG uptake in, PET, 117P(ab)
^{99m}Tc anti-AFP antibody evaluation, 11P(ab)
GFR, *See* Glomerular filtration rate
Glioma
glucose metabolism and methionine uptake, interstitial irradiation effects, 235P(ab)
malignant, direct intratumor or intralesional radioimmunotherapy, 144P(ab)
MRI lesions after therapy, ^{201}Tl SPECT and ^{18}F FDG PET comparison in, 220P(ab)
^{201}T evaluation of, 43P(ab)
uptake of labeled antibody, lysosomal inhibitors and, 233P(ab)
uptake of labeled antibody in, pre-injection of unlabeled monoclonal antibody and, 87P(ab)
Gliosarcoma, intracerebral, tracer localization in, 221P(ab)
Glomerular filtration fraction, childhood, 58P(ab)
Glomerular filtration rate
comparison of single sample methods for, 100P(ab)
determination with ^{99m}Tc DTPA, renal insufficiency, 100P(ab)
normalization of, children, 438
real-time monitoring, ischemic injury, 99P(ab)
Glucoheptonic acid kit, stannous ion in, biological effect of, 264P(ab)
Glucose
loading, hyperglycemia effects on FDG uptake, brain, 1104
metabolic rate
FDG and, effects on normal liver, 818
FDG dose uptake ratio for blood radioactivity, 8P(ab)
metabolism
Alzheimer's disease, PET, 1
brain, intersubject variability, young normal males, 1457, 1466
cerebral, schizophrenia, MRI measurements, 214P(ab)
experimental inflammatory tissue, 45P(ab)
microdialysis, ^{18}F FDG use in, 252P(ab)
myocardial viability and, 8S
regional cerebral, schizophrenia, 74P(ab)
rotating positron tomography, 184P(ab)
soft tissue sarcoma, PET FDG evaluation of, 90
total lesion metabolic changes, serial tumor, FDG PET studies, 137P(ab)
Glucose transporter, FDG uptake and, 1842
Glucose transport proteins, H-3-cytochalasin B binding to, normal tissue and tumors, 225P(ab)
Glutathione, localization, ^{99m}Tc HMPAO, brain, 263P(ab)
P-Glycoprotein, recombinant human multidrug resistance, expression in insect cells, 510
GMCSF, *See* Granulocyte-macrophage colony-stimulating factor
Goiter
multinodular
^{131}I dosimetry of, 163P(ab)
radioiodine and l-thyroxine treatment, 165P(ab)
nontoxic, ^{131}I treatment, 163P(ab)
Gonadal steroids, effects on cerebral blood flow, PET, 53P(ab)
Governmental responsibilities, LLRW generators feel Barnwell's closure, 24N(10)
Government relations, health care reform, commentary, 34N(5)
Graduate medical education, health care reform and, 32N(5)
Granulation tissues, intratumoral, FDG uptake in, 104
Granulocyte-macrophage colony-stimulating factor
bone marrow response to, FDG PET imaging, 8P(ab)
changes in skeletal images induced by, breast cancer, 89P(ab)
Granulocytes, double labeling of, prosthetic hip infection, 172P(ab)
Graves' disease
euthyroid ophthalmic, scintigraphic findings, 811
^{131}I-Na therapy, antithyroid medication effects, 14P(ab)
orbitopathy after, 918
therapy dose calculations with ^{123}I dose calculation, 165P(ab)

H

Haloperidol, displacement of ^{123}I IBZM, brain SPECT, 199P(ab)
Harper, Paul V., nuclear medicine pioneer, 17N(5)
Hawaii, health care reform by, 21N(9)
Head and neck cancer, ^{99m}Tc-labeled monoclonal antibody E48, clinical imaging with, 775
Head movement, brain PET imaging, head restraint use in, 1538
Head trauma
acute closed, cerebral blood flow after, ^{99m}Tc HMPAO SPECT in, 213P(ab)
mild, early cerebral perfusion after, CT/MRI and SPECT brain comparison, 212P(ab)
minor closed, ^{99m}Tc HMPAO SPECT evaluation in, 213P(ab)
Health care, cost-effectiveness, nuclear medicine practitioners, 13N(2)
Health care reform
Hawaii, 21N(9)
nuclear medicine, viewpoint, 18N(6)
nuclear medicine and, commentary, 34N(5)
nuclear medicine workforce after, 7N(3)
postponement, 18N(11)
quality assurance, commentary, 21N(11)
restructuring, mid-winter meeting, 10N(4)
viewpoints, 32N(5), 18N(6), 15N(9), 26N(8)
visions and revisions, 23N(5)
Heart
acromegaly, impaired left ventricular diastolic filling, 165P(ab)
dynamic studies, model-based estimation method for, 185P(ab)
failure
after revascularization, myocardial viability relations, 49P(ab)
beta-blocking therapy, 81P(ab)
MIBG imaging for prediction of sudden death, 80P(ab)
resting renal cortical blood flow in, PET, 265P(ab)
flow, function, and metabolism, comparison before and after bypass surgery, 38P(ab)
^{123}I IPT cocaine analogue uptake, 129P(ab)
isolated mitochondrial model, ^{99m}Tc tetrofosmin uptake, 46P(ab)
left ventricular volume measurement, ^{99m}Tc sestamibi SPECT, 70P(ab)
neuronal enzyme function, mapping with ^{11}C PHEN, 109P(ab)
oxidative metabolism, autoradiographic measurement of, 98P(ab)
SPECT
attenuation compensation and their remedies, 115P(ab)
attenuation correction without transmission source, 82P(ab)
effect of truncation in, 4P(ab)
fast conjugate gradient reconstruction, 82P(ab)
motion during
detection and correction, 194P(ab)
effects of prone imaging, 154P(ab)
^{201}Tl distribution in, 154P(ab)
^{99m}Tc tetrofosmin extraction and washout, 47P(ab)
^{201}Tl perfusion imaging, reduction of attenuation artifacts from, 82P(ab)
transplantation, *See* Transplantation
Hemangiomatosis, intraosseous, bone scintigraphy in, 1482
Hematologic toxicity, ^{131}I MIBG therapy, 234P(ab)
Hematoma, subcutaneous, localization, ^{99m}Tc RBC scintigraphy, 1333
Hemispherectomy, versus ^{99m}Tc HMPAO SPECT, intractable childhood seizures, 207P(ab)
Hemobilia, angiodysplasia complicated by, scintigraphy, 870
Hepatic binding protein, scintigraphic quantification, double injection protocol for, 13P(ab)
Hepatic-to-cardiac activity ratio, ^{99m}Tc SPECT studies, quantitative phantom analysis of artifacts, 356

Hepatobiliary excretion, ^{99m}Tc MAG3, radiochemical purity and, 349
Hepatobiliary imaging, morphine-augmented versus conventional, acute cholecystitis, 171P(ab)
Hepatobiliary tract
assessment of liver function, ^{99m}Tc PMT, 171P(ab)
patterns of bile leak, predictive value of, 171P(ab)
Hepatocellular carcinoma
FDG PET after interventional therapy, 1965
FDG PET and CT comparison, 225P(ab)
fibrolamellar, differential diagnostic problems, 1342
inoperable, ^{131}I lipiodol use in, 1313, 1318
liver cirrhosis patients, immunoscintigraphy in, 218P(ab)
portal vein thrombosis with, intra-arterial ^{131}I iodized oil versus medical support, 1782
subtraction imaging, ^{201}Tl/^{99m}Tc-phytate, 1134
^{99m}Tc anti-AFP antibody, scintigraphy, 11P(ab)
Hepatopulmonary shunt syndrome, evaluation, nuclear medicine role in, 275P(ab)
Heptadecanoic acid, kinetics of, rest, exercise, and dipyridamole injection, 51
Heroin
abuse effect on cerebrovascular perfusion, gender differences, SPECT study of women, 1902
rCBF and, ^{99m}Tc HMPAO SPECT in, 214P(ab)
dependence, quantitative brain perfusion SPECT in, 210P(ab)
Hippocampus, blood flow
decreased after cardiovascular surgery, 64P(ab)
elderly patients with memory impairment, MRI, 214P(ab)
Hip prosthesis
loosening, radionuclide arthrography and transmission imaging for, 851
total, loosening, nuclear arthrography, 89P(ab)
total arthroplasty, ^{99m}Tc MDP uptake in, 1788
Histiocytoma, malignant, bone and gallium scan in, 232P(ab)
Histiocytosis X, thyroid involvement in, 263
Hodgkin's disease
benign transformation, ^{67}Ga uptake in mass of, 465
imaging, ^{111}In IP, 132P(ab)
staging of, FDG whole body PET in, 221P(ab)
Holmium-166, separation from ^{166}Dy, development of method for, 241P(ab)
Holmium-166 DOTMP, bone marrow ablation, multiple myeloma, 37P(ab)
Human immunodeficiency virus, *See also* Acquired immunodeficiency syndrome
focal gallium uptake, PCP, 1038
gay men infected with, cerebral SPECT abnormalities in, 118P(ab)
Human radiation experiments, governmental committee and SNM panel, 13N(7)
Huntington's disease, direct gene testing for, FDG PET in, 94P(ab)
Hürthle cell carcinoma, thyroid gland, ^{99m}Tc sestamibi whole body scan in, 219P(ab)
Hybrid neural network, gamma camera bremsstrahlung image restoration, 143P(ab)
Hydrazino nicotinamide
derivatized chemotactic peptides, co-ligand effects, 19P(ab)
polyclonal antibody modified by, Tc-glucoheptonate as transchelating agent, 105P(ab)
Hydrazinopyridine linkers, cleavable and non-cleavable, Fab' antibody fragments, 29P(ab)
Hydrocarbon spacer, ^{111}In monoclonal antibody with, decreased hepatic activity, 29P(ab)
Hydrogen-3 CYI, experimental validation of, marker for serotonin innervation in rat brain, 67P(ab)
Hydroxyapatite, total hip prosthesis coated with, ^{99m}Tc MDP uptake in, 1788
4-Hydroxybutyrate, effects on PET studies, low and high affinity dopamine D2 receptors, 140P(ab)
Hyperbilirubinemia, rotor syndrome and, cholescintigraphy in diagnosis, 1048
Hyperglycemia, FDG-PET and, brain tumor patients, 43P(ab)
Hyperparathyroidism
primary
FDG PET and double-phase sestamibi SPECT in, 68P(ab)
parathyroid scintigraphy in, 15P(ab)
^{201}Tl/^{99m}Tc MO4 subtraction scintigraphy in, 164P(ab)
Hypertension
chronic renal failure and, captopril renal scintigraphy, 251, 254
dynamic renal imaging with ^{99m}Tc sestamibi, 1959
mild to moderate, exercise renography in, 99P(ab)
portal, abdominal blood pool SPECT and MRI comparison in, 169P(ab)
pulmonary, ventilation-perfusion lung scanning, 793
renovascular
MAG3-lasix-enalaprilat scintigraphy, 266P(ab)
screening procedures for, 265P(ab)
Hyperthermia, monoclonal antibody uptake and, small cell lung cancer xenografts, 504
Hyperthyroidism
rapid diagnosis, ^{99m}Tc MIBI, 922(le)
treating with radioiodine, 1558(le)
Hyperthyroxinemia, scintigraphic spectrum, 271P(ab)
Hypometabolism
brain, PET FDG, 138P(ab)
brain images, PET FDG, 72P(ab)
Hypoxia
imaging, synthesis of fluoroetanidazole for, 6P(ab)
nitroimidazole complex, heart, 152P(ab)

I

Idiopathic rotational torticollis, dopamine receptor imaging, ^{123}I IBZM SPECT, 1921
Image analysis, radionuclide distribution, tissue sections, 1217
Image formats, medical, automated analysis and display, 178P(ab)
Image quantitation, source to background concentrations, 180P(ab)
Image registration
brain studies, 2011
SPECT and CT/MRI, clinical validation of, radiolabeled Mab studies of colorectal carcinoma, 1976
Image subtraction technique, stochastic sign change criterion, dual-isotope SPECT, 189P(ab)
Imaging agent, thrombus, platelet GPIIb/IIIa antagonists, 52P(ab)
Immunoconjugates, ^{67}Cu 2IT-BAT-Lym-1, substitution effects on immunoreactivity, 259P(ab)
Immunophenotypic study, transferrin receptor expression and, ^{67}Ga imaging of lymphoma, 231P(ab)
Immunoscintigraphy
avidin use in, improved clearance of radiolabeled biotinylated monoclonal antibody, 1677
bone marrow
clinical significance in tumor patients, 120P(ab)
^{99m}Tc antigranulocyte antibody in, 113P(ab)
breast cancer, axillary metastases and, 217P(ab)
CEA, colorectal cancer, 108P(ab)
chimeric antibody chCE7, 217P(ab)
complete versus fragmented antibodies for, 218P(ab)
evaluation of radiation effects, hematopoetic bone marrow, 111P(ab)
hepatocarcinomas, liver cirrhosis patients, 218P(ab)
^{111}I anti-CEA monoclonal antibodies, bifunctional chelating agents for, 12P(ab)
liver metastases, 55P(ab)
pitfalls in, infective foci in renal allografts, 173P(ab)
Pneumocystis carinii, AIDS patients, 1028, 1034
pre-targeted, avidin-biotin system, 55P(ab)
^{99m}Tc Anti-CEA fab, nonsmall cell lung cancer, 217P(ab)
^{99m}Tc fab fragments, colorectal cancer, 86P(ab)
Immunotherapy, anti-idiotypic antibody cascade, cellular immune response and, after OC125, 234P(ab)
IMP, *See* Iodoamphetamine
Implants, glass seeds, neutron-activatable, for brachytherapy, 242P(ab)
Indium-111
bioevaluation, labeling of monoclonal antibodies, 890
decay effects, pBR322 DNA, 162P(ab)
ethylenediamines labeled with, biological evaluation, 43P(ab)
triazacyclononane ligands for use with, 243P(ab)
Indium-111 antagonist chemotactic peptide, focal infection imaging with, 45P(ab)
Indium-111 anti-CEA
immunoscintigraphy, bifunctional chelating agents for, 12P(ab)
pre-therapy imaging trial, CEA-producing malignancies, 234P(ab)
Indium-111 anti-ICAM-1, early detection, lung allograft rejection, 239P(ab)
Indium-111 antimyosin
cardiac SPECT images, compensation for crosstalk, 190P(ab)
pericardial and myocardial localization of, acute myocarditis, 469
pulmonary uptake, after cardiac transplantation, 266
Indium-111 antisense, noninvasive imaging, c-*myc* oncogenes, mammary tumor model, 1054, 1064
Indium-111 antisense oligonucleotide, c-erbB2 oncogene, breast tumor, 65P(ab)
Indium-111 benzyl-EDTA, biological comparison, ^{111}In monoclonal antibodies and peptides, 259P(ab)
Indium-111 biotin, ^{111}In-labeled imaging, 112P(ab)
Indium-111 CDTA, monoclonal antibody conjugates, comparative studies, 258P(ab)

Indium-111 CYT-103, monoclonal antibodies, localization of colorectal carcinoma, 11P(ab)
Indium-111 CYT-356, SPECT
occult residual prostate cancer, 216P(ab)
prostate cancer, 216P(ab)
Indium-111 CYT-372
localization, colorectal carcinoma, 219P(ab)
monoclonal antibodies, localization of colorectal carcinoma, 11P(ab)
Indium-111 DTPA
breath test, monitoring of gastric emptying of liquids and solids, 824
colorectal cancer recurrence, 55P(ab)
monoclonal antibody conjugates, comparative studies, 258P(ab)
scintigraphy, specific activity and tissue distribution with, 226P(ab)
targeting of adenocarcinomas, after interferon gamma, 85P(ab)
Indium-111 DTPA-octreotide, renal tubular reuptake of, inhibition, 165P(ab)
Indium-111 8-hydroxyquinoline, labeling of human platelets, historical article, 823
Indium-111 IgG
AIDS patients, with lung infection, 240P(ab)
detection of infection, patients with diminished renal function, 175P(ab)
scintigraphy, complicated osteomyelitis and septic arthritis, 89P(ab)
^{99m}Tc labeled chemotactic peptide analogs compared with, bacterial infection, 174P(ab)
Indium-111 IP, Hodgkin's disease and non-Hodgkin's lymphoma, 132P(ab)
Indium-111 LDL, parenchymal uptake, normal and estradiol-stimulated liver, 63P(ab)
Indium-111 Mab DTPA, retention, metabolism effects, liver and blood, 1851, 1858
Indium-111 monoclonal antibodies
B3, comparative biodistribution, 63P(ab)
decreased hepatic activity of, mechanism of, 29P(ab)
receptor binding ligand, as a protein carrier of, 29P(ab)
Indium-111 octreotide, uptake levels, pituitary adenomas, 166P(ab)
Indium-111 OS, ^{18}F FDG comparison, colorectal and ovarian cancer, 274P(ab)
Indium-111 oxine, bone scans, detection of soft tissue infection and osteomyelitis, 1436
Indium-111 platelets
arterial thrombosis imaging, 1731, 1738
detection of multiple thromboembolism, congenital antithrombin III deficiency, 1811
scintigraphy, pulmonary thromboembolism, 238P(ab)
Indium-111 somatostatin analogue, brain tumor localization, 44P(ab)
Indium-111 transferrin, study of intestinal protein loss, liver cirrhosis patients, 168P(ab)
Indium-111 WBC
granulocytes, radiation dosimetry for, 159P(ab)
imaging, osteomyelitis, 88P(ab)
scintigraphy, Crohn's patients with fistulization, 245
simultaneous ^{99m}Tc MDP bone SPECT, osteomyelitis, facial bones and calvarium, 113P(ab)
Indium-113m transferrin, conversion electrons from, plasma exudation in skin, 176P(ab)
Infection
bacterial, ^{99m}Tc labeled chemotactic peptide analogs compared with ^{111}In IgG, 174P(ab)
detection
FDG PET, 173P(ab)
^{99m}Tc fab fragments compared to labeled leukocytes, 172P(ab)
^{111}In IgG detection of, patients with diminished renal function, 175P(ab)
^{111}In labeled chemotactic peptides, 45P(ab)
^{111}In polyclonal IgG detection of, 74
radiolabeled chemotactic peptides, 44P(ab)
release of ^{99m}Tc-IgG and ^{111}In from, 45P(ab)
urinary tract, ^{18}F fleroxacin pharmacokinetics with, 175P(ab)
Infectious disease, imaging, ^{99m}Tc-antigranulocyte fab fragments for, 112P(ab)
Infertility
male, subclinical varicoceles detected in scrotal scintigraphy, 265P(ab)
radioiodine therapy effects, thyroid cancer, 1418
Inflammation
^{111}In polyclonal IgG detection of, 74
vascular endothelial activation, imaging of, 276, 281
Inflammatory bowel disease, detection with ^{99m}Tc HMPAO-labeled leukocytes, pediatric patients, 451
Inflammatory tissue, experimental, glucose metabolism in, 45P(ab)
Informed consent, resolutions on, 29N(8)
In memoriam
Gary Gerson Winzelberg, 46A
Majic S. Potsaid, 41A
Marshall Brucer, 45A
William D. Kaplan, 40A
Inotropic agents, myocardial viability assessment, 49S
Instrumentation
camera systems, 20N(4)
Paul V. Harper, nuclear medicine pioneer, 17N(5)
whole-body PET scanners, performance characteristics, 1398
Interferon
augmenting tumor uptake of ^{99m}Tc, biological modifiers, 86P(ab)
radioimmunotherapy patients challenged with, red marrow dose in, 111P(ab)
Interferon gamma, treatment, targeting of adenocarcinomas after, 85P(ab)
Interfile, version 3.3, compliance with, 272P(ab)
Interleukin-2 receptor, soluble, serum levels in pancreatic cancer, 146P(ab)
INTERNET
commentary, 30N(8)
assessment of, at home, 271P(ab)
global highway, nuclear medicine and, 275P(ab)
Intestine, Crohn's patients with fistulization, ^{111}In white blood cell scintigraphy, 245
Intracarotid sodium amobarbital procedure, language dominance during, ^{99m}Tc HMPAO and MRI for, 273P(ab)
Intrapulmonary shunt
early detection in liver disease, children, 1328
right-to-left, scintigraphic sign for, 1557(le)
Intravascular tracer, accuracy of target detection, subtraction imaging in, 143P(ab)
Iodination, thiol reactive reagent for, labeling peptides, 247P(ab)
Iodine-123
combined ^{99m}Tc studies, optimal collimator choice for, 181P(ab)
probe systems and gamma cameras, thyroid uptakes performed with, 167P(ab)
radionuclide therapy, electron absorbed fractions in spheres, 152
SPECT
circumferential variations in cortex, 82P(ab)
dopamine transporter, 128P(ab)
volume and activity quantitation with, 1707
uptake measurements, therapy dose calculation, Graves' disease, 165P(ab)
Iodine-123 ANP, receptor imaging, 628
Iodine-123 BMIPP
FDG-PET, myocardial metabolism, 110P(ab)
intramyocardial metabolism of, 97P(ab)
kinetics, prior myocardial infarction patients, 1279
^{201}Tl combined with, risk stratification with recent MI, 59P(ab)
uptake, myocardial, hypertrophic cardiomyopathy, 135P(ab)
Iodine-123 β-CIT
binding, dopamine transporter, 129P(ab)
biodistribution and dosimetry, brain SPECT imaging, 764
dopamine content and, MPTP-treated monkeys, 140P(ab)
SPECT imaging
age-related decline in dopamine transporter binding, 11P(ab)
dopaminergic nerve cell loss, Parkinson's disease, 10P(ab)
Parkinson's disease, 10P(ab)
Iodine-123 E2, SPECT, detection of breast cancer, 274P(ab)
Iodine-123 free fatty acids, uptake, postischemic dysfunction
Iodine-123 IBF
binding potential of, d-amphetamine-induced dopamine release effects, 84P(ab)
binding to dopamine D2 receptors, compartmental modeling of, 743
Iodine-123 IBVM, SPECT
mapping of cholinergic neurons, brain, 405
mapping of cholinergic neurons in Alzheimer's, 68P(ab)
Iodine-123 IBZM
continuous infusion, SPECT brain imaging, 84P(ab)
cortical retention of, SPECT, 199P(ab)
equilibrium analysis with, quantitation of dopamine D2 receptors, 202P(ab)
SPECT
assessment of dopamine D2 receptor, schizophrenic patients, 74P(ab)
dopamine receptor imaging with, idiopathic rotational torticollis, 1921
Iodine-123 IgG, staphylococcal abscess, 175P(ab)
Iodine-123 IMP
brain SPECT, early and delayed, subacute strokes, 1444
mapping of regional cerebral blood flow, validation of, 191P(ab)
quantification, regional cerebral blood flow, 192P(ab)
quantitative mapping, regional cerebral blood flow, 2019
SPECT
chronic ischemic brain lesions, 205P(ab)
measurement of cerebral blood flow, one point arterial monitoring, 209P(ab)
split dose method of measurement, cerebral blood flow, 208P(ab)
split dose SPECT, cerebral blood flow change and, 1226

Iodine-123 IMT
comparison with C-11-MET, brain tumor patients, 8P(ab)
transfer from PET to SPECT, brain tumor patients, 9P(ab)
Iodine-123 iomazenil
PET-SPECT comparison, 18P(ab)
quantification of benzodiazepine receptors with, SPECT, 194P(ab)
SPECT
biodistribution and dosimetry of, 399
measurement of benzodiazepine receptors, brain, 228
Iodine-123 IPPA
after coronary revascularization, prediction of recovery, 49P(ab)
myocardial viability, 4S, 32S, 38S
biopsy and reinjection SPECT thallium comparison, 43S
serial tomographic imaging, myocardial viability, 50P(ab)
Iodine-123 IPT, cocaine analogue
brain and cardiac uptake, 129P(ab)
euphorogenic doses of, 130P(ab)
Iodine-123 IUdR
infusion into hepatic artery, colorectal cancer patients with liver metastases, 144P(ab)
management of bladder cancer, 144P(ab)
Iodine-123 methyl tyrosine, brain tumor localization, 44P(ab)
Iodine-123 MIBG
diabetic patients
autonomic neuropathy and, myocardial uptake, 154P(ab)
cardiac sympathetic nerve dysfunction, 153P(ab)
injection from cold kit, imaging of neuroendocrine tumors after, 69P(ab)
myocardial images, idiopathic dilated cardiomyopathy and tachyarrhythmia, 81P(ab)
predictor of sudden death from heart failure, 80P(ab)
scintigraphy, neuroblastoma, 238P(ab)
screening, pheochromocytoma, 1138
SPECT, versus planar imaging, neural crest tumors in children, 1753
Iodine-123 NCQ-298, studying dopamine D2 receptors, baboon and human, 122P(ab)
Iodine-123 p-MPPI, 5-HT_{1A} receptor antagonist, SPECT imaging, 93P(ab)
Iodine-123 (S)-IBZM, scintigraphic detection of melanoma metastasis, 1741
Iodine-123-Tyr-3-octreotide, uptake, pancreatic endocrine tumors, 57
Iodine-125
positional decay, DNA strand breaks after, 79P(ab)
radioiodinated YM-09151-2 derivative, SPECT studies of dopamine D2 receptors, 247P(ab)
residualizing form, antibodies labeled with, 55P(ab)
TSH-induced uptake, FRTL-5 thyroid cells, 146P(ab)
Iodine-125 antisense oligonucleotide, uptake, intestinal smooth muscle cells, 151P(ab)
Iodine-125 HPBN, detection of radicals, 246P(ab)
Iodine-125 IUdR, management of bladder cancer, 144P(ab)
Iodine-125 LDL, parenchymal uptake, normal and estradiol-stimulated liver, 63P(ab)
Iodine-125 MIBG, clearance, myocardium, cardiomyopathic hamsters, 152P(ab)
Iodine-125 OIH, ^{99m}Tc LLEC comparison, renal transplant recipients, 1951
Iodine-131
ablation of thyroid remnants, effects of scanning doses, 14P(ab)
breast milk, after therapy for thyroid carcinoma, 1797
conjugate view image quantitation, attenuation correction in, 143P(ab)
dosimetry in
CT-SPECT fusion plus conjugate views for, 1714
large, multinodular goiters, 165P(ab)
high dose, therapy for differentiated thyroid cancer, 15P(ab)
low dose-rate therapy, thyroid cancer, 165P(ab)
misadministration, quality management programs, 166P(ab)
quantitative Anger camera imaging of, 142P(ab)
radioimmunotherapy, metastatic renal cancer, 101P(ab)
radionuclide therapy
electron absorbed fractions in spheres, 152
magnetically enhanced, 157
source to background concentrations, distinguishing tumors from blood vessels and background, 180P
therapy, thyroid cancer, 2053(le)
treatment, volume reduction in nontoxic goiter after, 163P(ab)
whole body scans, metastatic differentiated thyroid carcinoma, 257
Iodine-131 anti-B1, radioimmunotherapy, non-Hodgkin's lymphoma without marrow transplant, 101P(ab)
Iodine-131 anti-ICAM-1, stroke model, brain, 106P(ab)
Iodine-131 CC49
alpha interferon and, refractory metastatic breast cancer, 101P(ab)
radioimmunotherapy with, metastatic colon cancer, 102P(ab)
Iodine-131 cholografin, measurement of pericardial fluid, IHSA heart scan, historical article, 663 myocardium, 50P(ab)
Iodine-131 HIM, radiolabeled monoclonal antibodies, synthesis and evaluation, 30P(ab)
Iodine-131 iodized oil, therapy, hepatocellular carcinoma with portal vein thrombosis, 1782
Iodine-131 iododeoxyuridine, brain tumor proliferative activity, 1407
Iodine-131 6β-iodomethylnorcholesterol, scintigraphic evaluation, clinically silent adrenal masses, 1145, 1152
Iodine-131 lipiodol, radiation therapy with, inoperable liver cancer, 1313, 1318
Iodine-131 MIBG
chemotherapy response, advanced neuroblastoma, 1429
FDA grant of approval, 13N(6)
hematologic toxicity related to, 234P(ab)
injection from cold kit, imaging of neuroendocrine tumors after, 69P(ab)
Iodine-131-Na, therapy in Graves' disease, antithyroid medication effects, 14P(ab)
Iodine-131 NCL-6, adrenocortical scintigraphy, aldosteronoma treated by absolute ethanol, 68P(ab)
Iodine-131 OIH, renal imaging, 840
Iodoamphetamine
extraction, parenchymal cells, liver, 13P(ab)
SPECT, brain, Moyamoya disease, 44
Iodobenzovesamicol, SPECT and, mapping of cholinergic neurons, brain, 405
Iodotamoxifen, imaging of estrogen receptor sites, breast tumor response, 256P(ab)
IQNP, absolute configuration of, muscarinic receptor subtype selectivity, 93P(ab)
Irradiation, lung injury, ^{99m}Tc HMPAO used as marker of, 1520
Ischemia
cerebral, showing on SPECT, 1476
myocardial, metabolic tracers labeled with positron-emitting radionuclides, 15S
Ischemic penumbra, acute stroke, ^{18}F FMISO PET, 205P(ab)
Isosorbide dinitrate, sublingual, ^{99m}Tc teboroxime perfusion defect reversibility, 1274
Isotopes, supply, NBTF hopeful for DOE grant, 12N(1)
Iterative filtered backprojection, weighted least-squares reconstruction, comparison, 28P(ab)

K

Kawasaki syndrome, without coronary artery aneurysm, scintigraphic abnormalities, school children, 237P(ab)
Kidney
cancer, FDG PET, preoperative lymphodestaging, 223P(ab)
clearance, ^{99m}Tc MAG_3 complexes, 1198
disease, ^{11}C acetate PET in, 124P(ab)
extraction, ^{99m}Tc MAG3, protein binding effects, 264P(ab)
failure
captopril renal scintigraphy in, 251, 254
reduced protein binding of ^{99m}Tc MAG3, 265P(ab)
function agents, cationic ^{99m}Tc complexes of *N*-alkyl pyridoxal, 1691
ischemic injury, real-time monitoring of GFR, 99P(ab)
obstructive renal disease, comparative study of imaging agents, 840
parenchymal retention, renal transplants, ^{99m}Tc MAG3 use in, 846
plasma flow, reproducibility of measurement, deconvolved linear response method, 266P(ab)
^{99m}Tc L,L-EC characterization in, 263P(ab)
transplant, *See* Transplantation
unilateral disease, vesicoureteral reflux and, ^{99m}Tc DMSA detection of, children, 445, 449
urinary tract obstruction patients, diuretic renography in diagnosis, 266P(ab)
Kidney cortex, defects, cone beam tomography for, infants, 58P(ab)
K1 parametric images, validation of, 77P(ab)

L

L-735,286, radioiodinated, characterization of, 52P(ab)
Lag phase, solid meal, gastric emptying, 1023
Laminin-derived peptide, thrombus-specific imaging, 106P(ab)
Landau-Kleffner syndrome, brain SPECT imaging, before and after treatment, 211P(ab)
Laparotomy, second-look, ovarian cancer, PET before, 117P(ab)
Laser spectroscopy, ^{13}C breath tests, 108P(ab)
Latex D-dimer assay, diagnosis, pulmonary embolism, 189(le)
Lead x-rays, spectral and spatial distributions of, 61P(ab)

Left bundle branch block, dobutamine-thallium imaging in, false-positive reversible perfusion defect during, 1989
Left ventricular dysfunction
evaluation by radionuclide angiography, phase and sector analysis, 1766
serial changes, after coronary bypass surgery, 136P(ab)
^{201}Tl rest imaging, dobutamine echocardiography and, 136P(ab)
viable myocardium in, 135P(ab)
Left ventricular functional reserve, nonobstructive hypertrophic cardiomyopathy, 1937
Legislation, health care reform, viewpoint, 15N(9)
Lesch-Nyhan disease, dopamine reuptake sites, measured by ^{11}C WIN, 130P(ab)
Leukemic cells, killing by ^{153}Sm labeled antisense oligodeoxynucleotide probes, 145P(ab)
Leukocytes, radiolabeled, quality control with monoclonal antibodies, 184(le)
Leukocyte scan, ^{99m}Tc HMPAO, diagnosis of prosthetic vascular graft infection, 1303
Ligand-receptor interaction studies, tissue heterogeneity in, 137P(ab)
Ligands, evaluation, yttrium labeling of monoclonal antibodies, 882
Linear accelerator, commercial isotope venture, 19N(10)
Lines from the President, 21N(1), 24N(3)
Liposomes, ^{99m}Tc-labeled, use in tumor imaging, 1491
Liver
cirrhosis
early detection of intrapulmonary shunt, children, 1328
^{201}Tl per rectum scintigraphy in, 832
glucose metabolic rates, FDG and, 818
metastases
immunoscintigraphy, 55P(ab)
perfusion patterns, ^{15}O water, 236P(ab)
transplantation, *See* Transplantation
tumor
^{18}F FDG PET, therapeutic effects, 234P(ab)
radioembolization with yttrium-90 glass microspheres, 1637, 1644
Lossy compression, dynamic studies, eigenimage methods, 715
Low-level radioactive waste, Barnwell's closure, 24N(10)
Lung
allograft rejection, ^{111}In anti-ICAM-1 in early detection of, 239P(ab)
aspiration of foreign body, ventilation/perfusion scintigraphy, 238P(ab)
cancer
antibody uptake by *N*-deglycosylation, 289
false-positive radioiodine uptake in, 2056(le)
^{18}F FDG PET in evaluation of, 223P(ab)
glucose metabolism, dose uptake ratio use in, 1308
increased ^{201}Tl uptake in collapsed lung, 1125
metabolic activity, whole-body PET, 226P(ab)
primary and regionally metastatic, ^{99m}Tc sestamibi, 232P(ab)
SPECT quantitation of ^{57}Co bleomycin for prediction, 1129
staging by PET, 76P(ab)
untreated, quantitative FDG PET scans in, 75P(ab)
cancer xenograft, radioimmunodetection of dHB4C5, 217P(ab)
carcinoma xenografts, blood-brain barrier disruption effects on monoclonal antibody localization, 1831
chemical and irradiation injury, ^{99m}Tc HMPAO used as marker of, 1520
density, hybrid attenuation correction technique, 3-D PET, 187P(ab)
endothelium, streptavidin accumulation in, 1358
end-stage disease, right to left shunt in, 133P(ab)
epithelial permeability
diabetes and, ^{99m}Tc DTPA aerosol scintigraphy in, 204, 207
system sclerosis, ^{99m}Tc DTPA clearance rate and, 1933
focal abnormalities
FDG PET data in, 228P(ab)
FDG PET for optimum time imaging, 225P(ab)
interstitial disease, alveolar integrity and inflammation, ^{99m}Tc DTPA radioaerosol in, 240P(ab)
left-to-right shunts, scintigraphic sign for, 1557(le)
malignant lesions, ^{99m}Tc SPECT evaluation of, 227P(ab)
neoplasms
FDG PET images, 1771
PET evaluation of, 220P(ab)
nonsmall cell cancer
radioimmunoscintigraphy of, 217P(ab)
sigma receptors expressed in, 248P(ab)
tumor marker sensitivity and specificity in, 147P(ab)
perfusion and ventilation, quantification using SPECT and CT, 784
perfusion scan, Monte Carlo simulation, 239P(ab)
pleural abnormalities, FDG PET studies of, 228P(ab)
quantitative perfusion scintigraphy, congenital right ventricular outflow tract lesions, 240P(ab)
radiation-induced disease, co-registration of SPECT and high resolution CT in, 276P(ab)
shunting, hepatocellular carcinoma, ^{99m}TC-MAA use in, 70
small cell lung cancer xenografts
anti-NCAM monoclonal antibodies, 296, 300
hyperthermia effects on monoclonal antibody uptake, 504
solitary nodules, FDG PET diagnosis of, 76P(ab)
squamous cell carcinoma, radioiodine uptake by, 474
^{201}Tl uptake, 271P(ab)
ventilation-perfusion scan
active and chronic pulmonary embolism, 47P(ab)
comparison in different patient populations, 25P(ab)
features, response to thrombolytic therapy and, 47P(ab)
long-term survival, 48P(ab)
low probability interpretation, 25P(ab)
modified PIOPED criteria for, 24P(ab)
original and revised PIOPED criteria for, 25P(ab)
patient position effects, 24P(ab)
revised PIOPED criteria for, 25P(ab)
single segmental mismatch, pulmonary embolism in, 1928, 1931
with and without pulmonary embolism, 239P(ab)
Lymphadenopathy, ^{18}F FDG uptake in, 1647, 1650, 1653
Lymph node, immunologic functions, 275P(ab)
Lymphoma
anti-B-cell antibody, chimeric and humanized, preclinical evaluation, 236P(ab)
benign transformation of Hodgkin's disease, ^{67}Ga uptake in mass of, 465
bone, ^{67}G citrate differentiation, post-treatment changes, 131P(ab)
Hodgkin's and non-Hodgkin's, somatostatin receptor scintigraphy, 132P(ab)
liver, ^{67}G scintigraphic appearance of, 229P(ab)
masses after chemotherapy, FDG-PET for metabolism classification of, 131P(ab)
somatostatin receptor imaging, 132P(ab)
Lymphoscintigraphy
lymphedema, pediatric, 237P(ab)
prediction of lymph edema development, breast cancer patients, 224P(ab)
Lytic metastases, multiple myeloma, treatment with ^{89}Sr, bone scintigraphy for selection of patients, 1992, 1994

M

Macrolides, velocity of mucous transport and, chronic asthma, ^{99m}Tc HSA aerosol use in, 240P(ab)
Macrophages, intratumoral, FDG uptake in, 104
Magnetic fields, radionuclide therapy, 157
Magnetic resonance imaging
brain
glucose metabolism, schizophrenia, 214P(ab)
multimodality displays with interleaved pixels with independent color scales, 1815
three-dimensional image registration, 2011
changes during visual stimulation, PET comparison, 32P(ab)
correction for PET partial volume effects, gray matter radioactivity, 197P(ab)
functional, PET combination, dementia, 20P(ab)
perfluorocarbons, tumor architecture, 216P(ab)
PET guided by, speech-induced focal metabolic activations by, 107P(ab)
three-dimensional, fully automated approach, 127P(ab)
three-dimensional brain, real-time reconstruction, 127P(ab)
validation study with, non-linear transformation for intersubject averaging, 177(ab)
Magnetic resonance spectroscopy
pH assessment with, fluorinated bifunctional macromolecular probe, 216P(ab)
SPECT comparison, Alzheimer's disease, 207P(ab)
Magnetoencephalography, brain activity, during VERB, 33P(ab)
Major depressive disorder, rCBF disorders
changes after fluoxetine treatment, 54P(ab)
PET and SPECT studies, 54P(ab)
Mammography
abnormalities, ^{99m}Tc sestamibi use in, 229P(ab)
breast cancer detection, augmented breasts, 872
positron emission, low dose, feasibility study for, 61P(ab)
Mammoplasty, augmentation, PET detection of breast cancer in, 872
Managed care, nuclear medicine practitioners, 17N(11)
Market share, patient care and, commentary, 22N(7)
Mast cell diseases, systemic, bone scan, 149P(ab)
Mastocytosis, bone scan abnormalities in, 1471
Matrix elements, direct reconstruction of SPECT images using, 28P(ab)
MBBG, *See* Bromide-76 MBBG

Mechanical function, assessment, myocardial perfusion and metabolism studies, 1005
Meckel's diverticulum, detection, pentagastrin and histamine H_2 receptor blocker combination, 1656
Mediastinitis, sternal infection and, planar and SPECT imaging, 174P(ab)
Mediastinum, disorders, ^{18}F FDG and ^{11}C methionine comparison, 227P(ab)
Medical administration, NRC's mismanagement, 17N(2)
Medical treatment project, commercial isotope venture, 19N(10)
Melanoma
cutaneous, radioguided sentinel node biopsy, 224P(ab)
malignant
FDG and ^{99m}Tc sestamibi in, 231P(ab)
whole body FDG PET for staging of, 8P(ab)
malignant metastatic
efficacy of FDG PET in staging and management, 230P(ab)
^{18}F FDG PET studies in, 38P(ab)
scintigraphic detection, ^{123}I (S)-IBZM, 1741
Memory loss
elderly patients, hippocampal blood flow and, ^{123}I IMP SPECT, 214P(ab)
temporal lobe perfusion in, ^{99m}Tc HMPAO brain SPECT, 119P(ab)
Meningiomas
differentiation, somatostatin receptor and brain scintigraphy, 220P(ab)
SPECT imaging with thallium-201, 9P(ab)
Mercaptoacetyltriglycerine, retention, renal transplants, 846
Metabolism, retention of ^{111}In Mab DTPA and, liver and blood, 1851, 1858
76-Bromine MBBG-Metabromobenzylguanidine
kinetics, Michaelis-Menten constants for, isolated heart, 57P(ab)
uptake, metoprolol effects, myocardium, 57P(ab)
Metaiodobenzylguanidine (MIBG)
distribution, thorax level, pediatric patients, 134P(ab)
interpretation of scans, children, 803
mechanistic studies of, rat heart, 57P(ab)
reduced cardiac uptake, chronic elevation of norepinephrine and, 56P(ab)
role of adrenergic receptors, cultured neuroblastoma cells, 66P(ab)
Methionine, uptake, tumor tissues, microautoradiography, 256P(ab)
Methohexital, anesthesia, human PET studies, 198P(ab)
Methoxytetrabenazine, evaluation, tracer of monoamine nerve terminal integrity, 121P(ab)
Methylphenidate
brominated and radioiodinated derivatives of, for dopamine transporter, 94P(ab)
as radioligand, presynaptic dopaminergic neuron, 129P(ab)
Methylsulfone, aromatic activating group, ^{18}F nucleophilic substitution reactions using, 251P(ab)
Metoprolol, uptake of MBBG and, myocardium, 57P(ab)
Mickey Mouse sign, Paget's disease, 924(le)
Microautoradiography
FDG uptake, methionine uptake by tumor tissues and, 256P(ab)
intratumoral dynamics, FDG uptake, 104
Microchannel plate detector, as beta and alpha camera, three-dimensional dosimetry, 179P(ab)
Microdialysis, drug pharmacokinetics and pharmacodynamics, 67P(ab)
Microdosimetry
cell nucleus dose rate, tracer localization effects, 113
tissue section autoradiographs, 1217
Micrometastases
multicellular dosimetry for, 521
radioimmunotherapy, evaluation of adjuvant treatment, 161P(ab)
radioimmunotherapy effectiveness against, prediction of, 123P(ab)
MIRD Schema, special contribution, 531
Mitochondrial electron transport chain, ^{18}F FDHR, PET, 73P(ab)
Modeling
^{11}C acetate kinetics, simultaneous fitting of coupled multiple ROIs, 1286
compartmental, ^{99m}Tc teboroxime kinetics, fast dynamic SPECT, 1265
linear-quadratic, radioimmunotherapy, 1861
molecular, structure of ^{99m}Tc complexes, accurate prediction of, 243P(ab)
parametric images, unidirectional metabolic rates, 1206
Monoamines, innervation, density, brain, 1822
Monoamine nerve terminal, integrity, methoxytetrabenazine tracer of, 121P(ab)
Monoamine oxidase
activity, quantitative mapping, brain, clorgyline derivative, 254P(ab)
heart, ^{11}C phenylephrine marker for, 7P(ab)
Monoamine oxidase B, inhibition of, treatment of Parkinson's disease, 7P(ab)
Monoclonal antibodies
accumulation enhancement of, *N*-deglycosylation, lung tumor, 289
anti-NCAM, radioimmunotherapy of SCLC xenografts with, 296, 300
bifunctional chelating agents, biological method of evaluation, 890
biotinylated, improved clearance with avidin, 1677
E48, ^{99m}Tc-labeled, head and neck cancer, 775
^{18}F-labeled, PET imaging of osteosarcoma, dogs, 1506
^{67}Ga chelator conjugates, in vivo stability, 29P(ab)
hyperthermia effects on uptake, small cell lung cancer xenografts, 504
^{125}I-labeled biotinylated, radioimmunoguided surgery using, 1970
localization, intracerebral human lung carcinoma xenografts, 1831
measurement of carcinoembryonic antigen distribution, quantitative autoradiography, 1499
protein carrier of receptor-bin. ing ligand, ^{111}In chelator, 29P(ab)
quality control with, radiolabeled leukocytes, 184(le)
radiochemical design for, 326
radiolabeled
colorectal carcinoma, 1976
synthesis and evaluation, 30P(ab)
^{99m}Tc labeled, arterial thrombosis imaging, 1731, 1738
^{99m}Tc-labeled, influence on binding sites, 876
^{99m}Tc-labeled-anti-fibrin DD-3B6/22 fag fragments, thrombus detection with, 195, 202
^{88}Y labeling of, ligand evaluation for, 882
Monte Carlo simulated data, scatter correction methods, comparison, 143
Motion
compensation for, renal scintigraphic studies, 34P(ab)
correction, myocardial SPECT, 1193
Moyamoya disease, cerebral blood flow study, IMP SPECT, 44
Multicenter trial
quantitative ^{99m}Tc sestamibi SPECT, quantitative, 609
^{201}Tl planar myocardial imaging, before and after reinjection, 601
Multidrug resistance
P-glycoprotein
cell lines and xenograft sections, monoclonal antibody, 232P(ab)
expression in insect cells, 510
^{99m}Tc EIBI is a transport substrate for, 230P(ab)
^{99m}Tc sestamibi transported by, 19P(ab)
tumor, uptake of ^{14}C colchicine for identification, 1179
Multidrug resistance factor, cultured tumor cells, ^{99m}Tc sestamibi accumulation in, 219P(ab)
Multimodality displays, brain images, interleaved pixels with independent color scales, 1815
Multiparameter quantitation, Cramer-Rao bound as model of, 60P(ab)
Multiple myeloma, treatment with ^{89}Sr, bone scintigraphy for selection of patients, 1992, 1994
Muscarinic agonists, characterizing Alzheimer's disease, 83P(ab)
Muscarinic antagonist, microimaging of, cocaine blockers, 201P(ab)
Muscarinic receptors, subtype selectivity, IQNP effects, 93P(ab)
Muscle, exercise-induced injury, ^{99m}Tc WBC accumulation in, 150P(ab)
Myelotoxicity, radioantibody-induced, cytokine intervention, 102P(ab)
Myocardium
dihydropyridine binding sites, PET study, 78P(ab)
extraction of betamethylheptadecanoic acid, 496
^{18}F FDG uptake, hyperglycemia, 152P(ab)
^{18}F PFBG uptake, dog, 255P(ab)
gated SPECT, automatic analysis of, 116P(ab)
glucose metabolism, enhancement by a nicotinic acid derivative, 989
glucose utilization, Patlak graphical analysis, coronary artery disease patients, 156P(ab)
hibernating, free fatty acid metabolism in, 136P(ab)
hypoxic
ischemic, and stunned, ^{99m}Tc nitroimidazole as tissue marker in, 46P(ab)
^{99m}Tc nitroimidazole binding kinetics in, 46P(ab)
ischemic
detection by nitroimidazole, 3P(ab)
^{62}Cu PTSM as a perfusion tracer for PET, 156P(ab)
glucose metabolism after ^{18}F FDG thrombolytic therapy, 156P(ab)
kinetics of ^{99m}Tc teboroxime, 3P(ab)
polar mapping, PET, 2031
without infarct, ^{99m}Tc PYP uptake as indicator of, 1366
left ventricular, reorientation of, cardiac SPECT, 116P(ab)

low dose dobutamine, wall motion and flow response to, 39P(ab)
metabolism
hypertrophic cardiomyopathy, FDG-PET, 110P(ab)
^{123}I BMIPP, 97P(ab)
metabolic tracers labeled with positron-emitting radionuclides, 15S
nitroimidazole complex in, 152P(ab)
normoxic, hypoxic, ischemic, and stunned, ^{99m}Tc nitroimidazole kinetics in, 1371
occlusion model, ^{18}F PFBG kinetics in, 157P(ab)
oxidative metabolism, hyperthyroidism, ^{11}C acetate PET assessment of, 155P(ab)
oxygen supply and energy conversion, ^{11}C acetate, dynamic gated PET, 110P(ab)
perfusable mass, ^{99m}Tc sestamibi gated SPECT, 26P(ab)
perfusion
^{62}Cu PTSM PET study, 78P(ab)
during dobutamine ^{99m}Tc sestamibi scintigraphy, 16P(ab)
evaluation of ^{15}O water and butanol PET, 77P(ab)
perfusion and hemodynamics, smoking effects, 3P(ab)
perfusion and viability, assessment of ^{38}P, 77P(ab)
postischemic dysfunction, free fatty acid uptake in, 50P(ab)
regional wall motion, recovery from, ^{201}Tl dynamic SPECT, 153P(ab)
reperfusion, evaluation of infarct size before and after, 1076
retention of ^{99m}Tc BMS181321, low flow effects, perfused heart, 46P(ab)
reversible ischemia, severe stress ^{99m}Tc sestamibi perfusion defects, 69P(ab)
SPECT imaging
^{99m}Tc TcN-NOET, 114P(ab)
three-dimensional reference model for, 127P(ab)
^{99m}TC sestamibi, stress perfusion/stress wall motion, 81P(ab)
^{201}Tl and PET imaging in evaluation of, 707
^{76}Br MBBG uptake, metoprolol effects, 57P(ab)
viability
after coronary thrombolysis, 1758
change in heart failure post revascularization and, 49P(ab)
clinical issue, 4S
comparison of SPECT methods, 49P(ab)
defect severity in ^{99m}Tc MIBI SPECT, 569
detection of hibernation, ^{201}Tl reinjection, 621
echocardiography use in, 49S
identification with ECG-gated ^{99m}Tc MIBI, 153P(ab)
^{123}I IPPA use in, 4S, 32S, 38S, 43S
patients with poor left ventricular function, 135P(ab)
serial tomographic ^{123}I IPPA imaging, 50P(ab)
stunned, demonstration with ^{99m}Tc sestamibi, 1805
^{99m}Tc MIBI SPECT, coronary artery disease, 115P(ab)
^{99m}Tc sestamibi scintigraphy, 921(le)
^{99m}Tc teboroxime imaging, 1274
volumes, improving quantitation of, attenuation and resolution compensation, 189P(ab)
washout imaging, clinical utility of ^{99m}Tc teboroxime, 575

Myocardial blood flow
dilated cardiomyopathy and, 23P(ab)
^{13}N-ammonia and PET measurements of, 24P(ab)
^{15}O water and dynamic PET, 183P(ab)
^{15}O water model, correction for time shifts in, 183P(ab)
^{38}P and ^{62}Cu PTSM comparison, 1116, 1122
quantification with ^{13}N ammonia, 155P(ab)
regional
autoradiographic microsphere imaging, 180P(ab)
^{15}O water and PET measurement of, 137P(ab)

Myocardial infarction
exercise and pharmacologic stress testing for prognosis, 716
experimental nonreperfused, ^{99m}TC glucarate in, 4P(ab)
functional recovery after, PET, 39P(ab)
^{123}I BMIPP and ^{201}Tl imaging, risk stratification, 59P(ab)
^{123}I BMIPP imaging, 1279
left circumflex, reperfusion therapy benefit in, 114P(ab)
nontransmural, sympathetic nerves in, 57P(ab)
perfusion estimates in, ^{15}O water and ^{13}N ammonia use, 157P(ab)
prognosis after, multivariate determinations, 39P(ab)
residual viability after, PET determination, 40P(ab)
size, evaluation before and after reperfusion, 1076
^{99m}Tc sestamibi distribution, viability determination, 152P(ab)
two-step targeting of, streptavidine-anitbody and radiolabeled biotin, 98P(ab)

Myocardial perfusion imaging
adenosine, coronary artery disease, 734
biodistribution of ^{99m}Tc NOET, 155P(ab)
class of neutral agents, 334
defects, ^{201}T washout analysis, 26P(ab)
dipyridamole
coronary artery disease, 730
pediatric patients, 135P(ab)
dobutamine, coronary artery disease, 737
dual isotope SPECT, separate or simultaneous rest ^{201}Tl/stress ^{99m}Tc sestamibi, 542
exercise, coronary artery disease, 726
exercise and pharmacologic stress testing, after myocardial infarction, 716
extended, minimizing attenuation, 625
fast Fourier transform approximation, determination of systolic wall thickening, 1185
interpretation, role of clinical data in, 740
interpretation reproducibility of, experience effects, 26P(ab)
mechanical function as an adjunct to, editorial, 1005
motion, two-dimensional fit method for correction, 181P(ab)
non-circular scan orbit, resolution deconvolution for, 190P(ab)
normal dobutamine stress thallium in, 125P(ab)
^{15}O PET, correlation with Doppler CFR, 23P(ab)
parametric positron, endothelial functions studied by, 23P(ab)
patient motion during, R-Made Patient Support System, 154P(ab)
perfusion defects, abnormal segmental contraction and, 639
PET, 689
PET rubidium-82, accuracy of, 23P(ab)
PET with, time discrepancy effects, 558, 567
radiopharmaceuticals for, 17N(4)
rest SPECT, reduced inferior attenuation on, 91P(ab)
single-photon, myocardial viability assessment, 23S
SPECT artifacts, detection of, 699
standard SPECT, left ventricular surface, 190P(ab)
^{99m}Tc MIBI
coronary artery disease, 1110
significant gastric reflux in, 619
^{99m}Tc Q3, dogs, 1698
^{99m}Tc Q12, biodistribution, dosimetry and clinical use, 1571
^{99m}Tc sestamibi
analysis of available imaging protocols, 681
applicability, 103P(ab)
dipyridamole infusion and, coronary artery disease, 1254
^{99m}Tc teboroxime, special contribution, 689
^{99m}Tc tetrofosmin
assessment of blood flow, 664
one-day and two-day protocol comparison, 1581
^{201}Tl and angiography comparison, 587
^{201}Tl
circumferential profiles, historical article, 671
historical article, 889
special contribution, 674
^{201}Tl infusion, 103P(ab)
^{201}Tl mechanism, ^{99m}Tc MIBI uptake and, in thyroid, 164P(ab)
^{201}Tl stress redistribution, coronary artery disease and perioperative risk, 703

Myocarditis, ^{111}In antimyosin localization in, pericardial and myocardial, 469
Myosin, cardiac, V1 and V3 isoforms of, 145P(ab)

N

Nasopharyngeal carcinoma, hypoxia in, ^{18}F FMISO muscle ratio in detection of, 142P(ab)
National Biomedical Tracer Facility, isotope supply, 12N(1), 10N(12)
Neoglycoalbumin, bioevaluation, labeling of monoclonal antibodies, 890
Neopterin, soluble, serum levels in pancreatic cancer, 146P(ab)
Neural cell adhesion molecule, antibody against, tumor uptake, hyperthermia effects, small cell lung cancer xenografts, 504
Neural control, saccadic eye movement, ^{15}O water and PET, 205P(ab)

Neural network
adaptive resonance theory, category detection in PET image series, 182P(ab)
Alzheimer's disease subjects, PET cameras, 7
artificial
diagnosis of pulmonary embolism, 186, 187
thallium scintigraphy, 2041, 2047
classifier, cerebral perfusion imaging, 771
estimation of scattered photons using, SPECT, 17P(ab)
subserving semantic judgments, Alzheimer's disease, 206P(ab)
Yttrium-90 attenuation measurements, maximum entropy image restoration, 161P(ab)

Neuroactivation studies, PET, objective analysis, 71P(ab)

Neuroblastoma
chemotherapy response in, ^{131}I MIBG imaging to monitor, 1429
^{123}I MIBG scintigraphy, 238P(ab)
^{123}I MIBG SPECT versus planar imaging, children, 1753
MIBG scans, redefining interpretations, children, 803
PET FDG studies of, 135P(ab)
radioimmunoscintigraphy with chimeric antibody chCE7, 217P(ab)
Neuroblastoma cells, cultured, MIBG storage, adrenergic receptors and, 66P(ab)
Neuroendocrine tumors
European multicenter clinical trial group on, 96P(ab)
imaging, after injection of ^{123}I MIBG or ^{131}I MIBG, 69P(ab)
Neuroleptics, typical and atypical, schizophrenic patients, ^{123}I IBZM SPECT for assessment, 74P(ab)
Neurological manifestations, transient, during dipyridamole stress test, 1802
Neuroradiology, interventional, cerebral perfusion mapping, ^{99m}Tc HMPAO use in, 275P(ab)
Neuroreceptors, m2mAChR subtype, selectivity, fluoroalkyl demonstration of, Alzheimer's, 200P(ab)
Neurotoxic chemicals, exposure to, cerebral blood flow and, 210P(ab)
Neurotoxicity, manganese toxicity, ^{99m}Tc HMPAO brain SPECT in, 863
Neutrophils, margination to lung, during cardiopulmonary bypass, 153P(ab)
Nicotinic acid derivative, enhancement of glucose metabolism, myocardial, 989
Nitrates, identification of viable myocardium with ^{99m}Tc MIBI, coronary artery disease, 115P(ab)
Nitrogen-13 ammonia
myocardial perfusion PET, chest pain patients, 60P(ab)
PET
myocardial blood flow measurements, 24P(ab)
reduced coronary flow reserve in diabetics, 4P(ab)
quantification of right ventricular blood flow, 155P(ab)
Nitrogen-13 nitrous oxide, no-carrier added, synthesis and properties of, 72P(ab)
Nitroimidazole
characterization and subcellular distribution, heart, 152P(ab)
hypoxic retention, rat heart, 18P(ab)
physiochemical and biological behavior of, substituent effects, 18P(ab)
Nitrous oxide
anesthesia, human PET studies, 198P(ab)
^{13}N, no-carrier added, synthesis and properties of, 72P(ab)
Nonenteric hemorrhage, localization of, ^{99m}Tc RBC scintigraphy, 1333
Non-Hodgkin's lymphoma
imaging, ^{111}In IP, 132P(ab)
radioimmunodetection of, 86P(ab)
sequential imaging, 230P(ab)
without marrow transplant, ^{131}I anti-B1 radioimmunotherapy, 101P(ab)
Norepinephrine
alterations of cardiac accumulation, progression of heart failure, 56P(ab)
circulating, reduced cardiac MIBG uptake, 56P(ab)
sympathetic innervation, ^{18}F 6F-DA PET scanning, 964
Nuclear activation, stable isotope content in biological samples, 177P(ab)
Nuclear arthrography, total hip prosthesis loosening, 89P(ab)
Nuclear cardiology, European data base, 176P(ab)
Nuclear magnetic resonance, investigation of errors, PET studies of small structures, 182P(ab)
Nuclear medicine
ACR/NEMA format images, Microsoft Windows-based viewing and processing station, 272P(ab)
assessment of INTERNET at home, 271P(ab)
cable television, 22N
cardiovascular
adenosine myocardial perfusion imaging, 734
dipyridamole myocardial perfusion imaging, 730
dobutamine myocardial perfusion imaging, 737
editorial, 672
historical article, 608
exercise and pharmacologic stress testing, 716
exercise myocardial perfusion imaging, 726
^{99m}Tc sestamibi, myocardial perfusion imaging, 681
^{99m}Tc teboroxime, myocardial perfusion imaging, 689
myocardial perfusion imaging with PET, 693
myocardial perfusion SPECT artifacts with, 699
radionuclide ventriculography in coronary artery disease, 721
^{201}Tl, myocardial perfusion imaging, 674
^{201}Tl and PET imaging in evaluation of myocardial viability, 707
^{201}Tl myocardial perfusion imaging, 703
training guidelines, 169
computer-based teaching file for Windows, 272P(ab)
computer simulation and mathematical analysis, interactive off-the-shelf tools for, 273P(ab)
evaluation of urine leak, kidney transplant patients, 267P(ab)
global INTERNET highway and, 275P(ab)
Interfile version 3.3, compliance with, 272P(ab)
LUNIS mosaic, 271P(ab)
perceptual illusion phenomena, 276P(ab)
Pneumocystis carinii pneumonia, AIDS and, 1028, 1034
procedures, resolutions on, 29N(8)
radiology, interactive digital teaching file for, 272P(ab)
role in evaluation of hepatopulmonary shunt syndrome, 275P(ab)
viewpoints, 26N(8)
Nuclear medicine physicians
components of professional competence, 1234
viewpoints on health care reform, 26N(8)
Nuclear medicine pioneer, Paul V. Harper, 17N(5)
Nuclear medicine practice, commentary, 38N(6)
Nuclear Regulatory Commission
mismanagement of medical misadministration, 17N(2)
regulation of nuclear medicine and conflicts with FDA, 11N(12)
ruling on patient release, 22N(9)

O

Obsessive-compulsive disorder
cerebral perfusion patterns in, ^{99m}Tc HMPAO SPECT, 214P(ab)
neutral auditory stimulation in, PET study of, 75P(ab)
simple phobia, behavioral challenge, ^{15}O PET study, 75P(ab)
Octreotide, hormonal inhibition by, somatostatin scan of endocrine tumors, 57
Octreotide analogs, radiolabeled, precursor to, 106P(ab)
Odontogenic infections, detection by ^{18}F FMISO, 113P(ab)
Oleic acid, lung injury, ^{99m}Tc HMPAO used as marker of, 1520
Oligodeoxynucleotides, receptor-mediated uptake, liver targeting by, 269
Opiates, analgesia, central mechanism of, elucidation by PET, 198P(ab)
Optical spectroscopy, on-line monitoring of radionuclide production, 249P(ab)
Orbitopathy, after treatment of Graves's disease, 918
Orthopedic disease, foot and ankle, three-dimensional SPECT image display in, 151P(ab)
Osseous lesions, FDG PET evaluation of, 230P(ab)
Osteomyelitis
correlative imaging in, 277P(ab)
detection
^{111}In IgG scintigraphy, 89P(ab)
^{111}In WBC and ^{99m}Tc, 89P(ab)
^{111}In WBC vs ^{99m}Tc WBC imaging, 88P(ab)
^{99m}Tc detection of, 1436
facial bones and calvarium, ^{111}In WBC/^{99m}Tc MDP bone SPECT in, 113P(ab)
osteopetrosis, scintigraphic detection, 95
vertebral, labeled leukocyte and sequential bone/gallium imaging, 173P(ab)
Osteonecrosis
after chemotherapy and short-term corticosteroid therapy, small-cell bronchogenic carcinoma, 1347
high-risk femoral head, ^{18}F PET in, 35P(ab)
Osteopetrosis, osteomyelitis in, scintigraphic detection, 95
Osteoporosis
cortical and trabecular bone in, SPECT evaluation, women, 1155, 1159
phosphate and etidronate cyclic treatment, ^{153}Gd dual photon absorptiometry, 90P(ab)
Osteosarcoma, PET imaging, ^{18}F-labeled monoclonal antibody use in, dogs, 1506
Otitis externa, necrotizing external otitis differentiation from, diabetic patients, SPECT bone scintigraphy, 411
Outcomes research, health care reform, 23N(5)
commentary, 21N(11)
Ovarian cancer
pelvic masses suspicious for, FDG PET evaluation, 231P(ab)
radiolabeled monoclonal antibody against, development of, 218P(ab)
second-look laparotomy, PET before, 117P(ab)
Oxygen-15
clinically useful amounts, tandem cascade accelerator, 249P(ab)
PET, intraoperative cortical stimulation and, 107P(ab)
Oxygen-15 carbon dioxide, PET study, simple phobia, obsessive-compulsive disorder, 75P(ab)

Oxygen-15 water
blood flow determination, distributed model for, 273P(ab)
dosimetry, physiologic approach, 158P(ab)
dynamic PET, regional myocardial blood flow, 183P(ab)
perfusion patterns, liver metastases, 236P(ab)
PET
activation study, mental representations related to, 107P(ab)
brain during memory task, 201P(ab)
cerebral blood flow changes, 138P(ab)
cerebral involvement in pain perception, 32P(ab)
evaluation of cochlear implant, 95P(ab)
language processing, rCBF and, 200P(ab)
measurement of regional myocardial blood flow, 137P(ab)
muscle perfusion assessment, 24P
neural control of saccadic eye movement, 205P(ab)
regional cerebral blood flow, 1870, 1878
visual selective attention, 32P(ab)
Oxygen-15 water and butanol, PET, evaluation of myocardial perfusion, 77P(ab)

P

Pacemakers, permanent transvenous, reversible exercise ^{201}T perfusion defects in, 26P(ab)
Paget's disease, Mickey Mouse sign in, 924(le)
Pancreas
cancer
FDG and thallium SPECT compared, 222P(ab)
FDG PET vs CT in detection of, 224P(ab)
increased uptake of FDG, GLUT-1 effects, 117P(ab)
serum levels of soluble interleukin-2 receptor and neopterin in, 146P(ab)
^{201}Tl SPECT for, 109P(ab)
imaging, ^{11}C acetate, 108P(ab)
insufficiency, gastric emptying of oil and aqueous meal components in, 168P(ab)
masses, FDG-PET evaluation of, 117P(ab)
transplantation, *See* Transplantation
Pancreatitis, infected necrosis groove in, labeled granulocyte scanning usefulness, 175P(ab)
Parathyroid
adenoma
^{99m}Tc MIBI detection of, 162P(ab)
^{201}Tl/^{99m}Tc MO4 subtraction scintigraphy in, 164P(ab)
anatomy, pathology, and imaging, 277P(ab)
scintigraphy, ^{99m}Tc sestamibi and factor analysis of dynamic structures, 1631
tumors, three imaging methods, comparison, 167P(ab)
Parathyroidectomy, preoperative ^{99m}Tc sestamibi SPECT, intraoperative PTH measurement and, 68P(ab)
Parathyroid hormones, measurement, role in parathyroidectomy, 68P(ab)
Parenchymal cells, liver, iodoamphetamine extraction by, 13P(ab)
Parietotemporal metabolism, Alzheimer's disease, PET, 1
Parkinsonism, primate model, PET imaging of ^{11}C CFT, CCT, and DCCT, 140P(ab)
Parkinson's disease
clinical disability, FDG PET prediction of, 211P(ab)
early, detection with F-18-FDG and PET, 10P(ab)
FDOPA quantitation, 955
^{123}I β-CIT SPECT imaging in, 10P(ab)
monkey model, PET imaging of dopaminergic function in, 197P(ab)
pallidotomy for, preoperative lentiform glucose metabolism and, 11P(ab)
PET studies of dopamine D1 receptors, brain, 1916
treatment, monoamine oxidase B inhibitor in, 7P(ab)
Patient care, commentary, 22N(7)
Patient motion, *See* Motion
Patient outcome, nuclear medicine practitioners, evaluation of cost-effectiveness, 13N(2)
PCP, *See Pneumocystis carinii* pneumonia
Pectus excavatum, abnormal exercise scintigraphy, 1985
Pediatric patients
cystic fibrosis and liver disease, hepatobiliary scintigraphy, 432, 436
developmental speech disorders, ^{99m}Tc HMPAO SPECT in, 134P(ab)
glomerular filtration fraction in, 58P(ab)
glomerular filtration rate, normalization of, 438
good response to furosemide, normal separate clearance and, 265P(ab)
HIV cardiomyopathy, early detection, 237P(ab)
inflammatory bowel disease, ^{99m}Tc HMPAO-labeled leukocytes, 451
liver disease, intrapulmonary shunt, early detection of, 1328
liver-transplanted, biliary stenosis in, scintigraphy, 59P(ab)
lymphedema, lymphoscintigraphy in, 237P(ab)
MIBG scans, redefining interpretations of, 803
mineral disorders, cortical and trabecular bone mineral status in, 59P(ab)
myocardial perfusion scintigraphy, dipyridamole, 135P(ab)
neuroblastoma, ^{123}I MIBG SPECT versus planar imaging, 1753
primary reflux, direct vesicoureteral scintigraphy, 1602, 1608
quantitative brain FDG studies, PET without blood sampling, 104P(ab)
refractory epilepsy, interictal brain SPECT in, 134P(ab)
scintigraphic abnormalities, Kawasaki's disease without coronary artery aneurysm, 237P(ab)
seizures, hemispherectomy versus ^{99m}Tc HMPAO SPECT, 207P(ab)
thorax, MIBG distribution in, 134P(ab)
vesicoureteral reflux, 237P(ab)
^{99m}Tc DMSA uptake, SPECT, 445, 449
^{99m}Tc DMSA SPECT in, 238P(ab)
Pentagastrin, histamine h_2 receptor blocker combination, detection of Meckel's diverticulum, 1656
Pentamidine, aerosolized prophylaxis, focal gallium uptake in PCP and, 1038
Peptides
GPIIb/IIIa receptor-binding, radiolabeled with ^{99m}Tc structure-activity relations, 257P(ab)
labeling, thiol reactive iodination reagent for, 247P(ab)
somatostatin receptor binding, radiolabeled with ^{99m}Tc structure-activity relations, 257P(ab)
Perfluorocarbons, tumor architecture using, MRI staining, 216P(ab)
Periampullary tumor, abdominal, ^{201}Tl SPECT in, 109P(ab)
Pericardial effusion, ^{111}In antimyosin localization, myocarditis, 469
Perioperative risk, coronary artery disease, ^{201}Tl myocardial perfusion imaging in, 703
Peripheral vascular disease, legs, ^{82}Rb PET determination of, 156P(ab)
Periventricular hyperintensity, decreased cerebral blood flow and, ^{15}O PET, 211P(ab)
Permeability index, transendothelial, compared with single-pass brain extraction, 1514
PET, *See* Positron emission tomography
PET Conference, Fifth International, cost-effectiveness and competitiveness, 14N(1)
pH, noninvasive assessment of, magnetic resonance spectroscopy, 216P(ab)
Phantom analysis, hepatic artifacts, ^{99m}Tc SPECT, 356
Phantom contrast detail approach, tumor detection, 221P(ab)
Phase analysis, radionuclide angiography comparison, evaluation of left ventricular asynchrony, 1766
Phenethylpiperidine derivatives, halogenated, synthesis, potent serotonin receptor ligands, 252P(ab)
Phenytoin, pneumonitis induced by, ^{67}Ga citrate detection of, 471
Pheochromocytoma
^{123}I MIBG screening test for, 1138
^{131}I MIBG, FDA approval, 13N(6)
malignant tumor sites, somatostatin receptor scintigraphy, 96P(ab)
Phosphorus-32, SPECT, attenuation-corrected activity determination, 1213
Phosphorus hydrazides, thiol functionalized, new ^{99m}Tc, 139P(ab)
Photodiode detectors, pharmaceutical biodistribution quantitation with, high-resolution PET, 1390, 1396
Photon Detection Kernel, analytical theory of, SPECT, 5P(ab)
Photon dosimetry, unified approach, 1721
Physiologic parameters, age and sex, ^{99m}Tc MAG_3 renal studies, 1612
Picture archiving systems (PACs), filmless all-digital nuclear medicine department, 28N(10)
Pituitary, adenomas, ^{111}I octreotide uptake levels in, 166P(ab)
Placenta, ^{99m}Tc HMPAO transfer in, human and animal, 245P(ab)
Planar imaging, small animal, new system for, 61P(ab)
Planar myocardial imaging, ^{201}Tl, multicenter trial, 601
Pleural effusion
bone scan features of, malignancy based on pleural fluid cytopathology, 429
clinical utility of bone scan features, 2056(le)
Plutonium, government radiobiological experiments, nuclear medicine and, 9N(3)
***Pneumocystis carinii* pneumonia**
immunoscintigraphy, AIDS patients, 1028, 1034
presenting as focal bibasilar uptake, gallium scan, 1038
Pneumonitis, phenytoin-induced, ^{67}Ga citrate detection of, 471
Pneumothorax, bronchopleural fistula, localization of, ventilation scintigraphy use in, 867
Polar maps, PET, perfusion defects in canine myocardium, 2031

Polyethylene glycol
liposomes coated with, ^{99m}Tc-labeled, as a blood pool agent, 42P(ab)
synthetic copolymer kit, blood-pool imaging, 1880
Positron emission tomography (PET)
activation paradigms, brain, 182P(ab)
adenosine stress myocardial perfusion, chest pain patients, 60P(ab)
before and after embolization, blood flow, arteriovenous malformation, 205P
after myocardial infarction, residual viability, 40P(ab)
Alzheimer's disease, 391
angiotensin II receptors, 124P(ab)
aortic regurgitation for, validation of model, 77P(ab)
assessment of β-adrenergic receptor concentration, 921(le)
assessment of receptor occupancy, 197P(ab)
attenuation correction in, singles transmission source, 41P(ab)
attenuation-correction whole-body, Bayesian reconstruction for, 34P(ab)
bandwidth selection for reconstruction, time of flight information, 188P(ab)
Bayesian formulations for, hyperparameter estimation effects, 72P(ab)
benzodiazepine receptor occupancy, unlabeled drugs, 141P(ab)
betamethylheptadecanoic acid, myocardial extraction of, 496
BGO, high resolution camera, circular phototubes, 40P(ab)
brain studies
anatomic standardization of, 1528
^{11}C MP pharmacokinetics, 85P(ab)
head holder for, 186P(ab)
head movement in, with and without head restraint, 1538
head position during, 40P(ab)
left prefrontal cortex in verbal tasks, 201P(ab)
multimodality displays with interleaved pixels with independent color scales, 1815
signal transduction images in, 121P(ab)
three-dimensional image registration, 2011
brain activity, during VERB, 33P(ab)
brain perfusion tracer for, generator produced ^{62}Cu PTSM for, 201P(ab)
^{11}C acetate
and methionine production for, 248P(ab)
myocardial oxidative metabolism, hyperthyroidism, 155(ab)
^{11}C flumazenil
hippocampal neuronal loss, 207P(ab)
kinetics, brain, 184P(ab)
^{11}C iomazenil, radiation dose estimates for, 159P(ab)
^{11}C labeled substance P, synthesis of, 254P(ab)
^{11}C MeNTI tracer kinetic analysis, brain, 67P(ab)
^{11}C methionine
^{18}F FDG study, brain hematoma, 1162
glucose metabolism, glioma patients, 235P(ab)
uterine carcinoma, 1618
^{11}C or FDG, after myocardial infarction, 39P(ab)
^{11}C S 11568, myocardial dihydropyridine binding sites, 78P(ab)
^{11}C SCH39166 and ^{11}C NNC 756, dopamine D1 receptors, brain, 1916
^{11}C thymidine, brain tumors, 974
carazolol measured with, 1665
cardiac
measurement of left ventricular function, 999 in support of, 925(le)
category detection, adaptive resonance theory neural networks, 182P(ab)
cerebral blood flow, carotid artery stenosis, 64P(ab)
changes during visual stimulation, MRI comparison, 32P(ab)
clinical, current status, 192(le)
^{55}Co, visualization of ischemic damage, brain tissue, 456
^{55}Co and ^{11}C tyrosine, brain tumors, 213P(ab)
community hospital-based center, coronary artery disease detection, 1586
constructing glucose metabolism images with, 185P(ab)
^{64}Cu-labeled monoclonal antibodies, colorectal cancer, 12P(ab)
^{62}Cu PTSM as a perfusion tracer for, 1910
^{62}Cu PTSM as perfusion tracer, myocardium, 156P(ab)
cyanoimipramine as marker of serotonin, innervation density, brain, 1822
Three-Dimensional (3D)
iterative reconstruction for volume imaging, 51P(ab)
model-based scatter correction, 51P(ab)
scatter correction techniques, 50P(ab)
delta opioid receptors, temporal lobe epilepsy, 31P(ab)
detection of breast cancer, augmented breasts, 872
detection of free radicals, 83P(ab)
detection probability matrix for reconstruction, efficient storage for, 187P
determining cerebral potentials, temporal and spatial origins of, 197P(ab)
dispensing/injection system for, 188P(ab)
dopamine D2 receptor imaging, brain, 198P(ab)
dopamine reuptake site, ^{11}C WIN for, normal human brain, 196P(ab)
dopaminergic function, Parkinson disease monkey model, 197P(ab)
drug pharmacokinetics and pharmacodynamics, 67P(ab)
emission and transmission data, misalignment, 186P(ab)
ETM scatter correction techniques, 1D deconvolution comparison, 50P(ab)
evaluation of chest masses, 220P(ab)
FDG
accumulation in breasts, aging effects, 142P(ab)
blood time activity curve in, 71P(ab)
bone lymphoma, 35P(ab)
bone marrow response to GMCSF, 8P(ab)
brain
analyzing hypometabolism from, 72P(ab)
automatic anatomical mapping, 71P(ab)
pediatric protocol, 104P(ab)
tumor evaluation, 228P(ab)
breast cancer studies, 142P(ab)
cancer or inflammation, 1653
cerebral blood flow and glucose metabolism, 209P(ab)
cerebral glucose metabolism in AIDS dementia complex, 118P(ab)
chemotherapy evaluation with, 90
chemotherapy response monitoring, 75P(ab)
chest wall accumulation, bronchogenic carcinoma, 76P(ab)
childhood brain tumors, 44P(ab)
clinical disability, Parkinson's disease, 211P(ab)
colorectal cancer, 108P(ab)
CT comparison, hepatocellular carcinoma, 225P(ab)
direct gene testing for Huntington's disease, 94P(ab)
dose uptake ratio, 1308
evaluation of pulmonary lesions, 223P(ab)
focal pulmonary abnormalities, 225P(ab), 228P(ab)
glucose metabolic rate monitored with, 37P(ab)
glycolysis-associated genes, animal tumor models, 220P(ab)
heart, spillover correction in, 105P(ab)
hepatocellular carcinoma after interventional therapy, 1965
high-risk femoral head, osteonecrosis, 35P(ab)
hyperglycemia effects, brain tumor patients, 43P(ab)
hyperglycemia effects on uptake in brain and glioma, 1104
hypometabolism, brain, 138P(ab)
inter-ictal brain perfusion SPECT compared with, epilepsy, 207P(ab)
kidney and urinary bladder neoplasm, lymphodestaging, 223P(ab)
lung cancer metabolic activity, 226P(ab)
metabolic classification of untreated prostate cancer, 230P(ab)
metastatic malignant melanoma, 230P(ab)
metastatic melanoma, 38P(ab)
MRI lesions, glioma patients after therapy, 220P(ab)
myocardial viability, 49P(ab)
neuroblastoma, 135P(ab)
oncology atlas, 273P(ab)
osseous lesions, 230P(ab)
pancreatic cancer, 224P(ab)
pancreatic masses, 117P(ab)
pelvic masses suspicious for ovarian cancer, 231P(ab)
pleural abnormalities, 228P(ab)
postinjection transmission for, cancer studies, 188P(ab)
primary degenerative and vascular dementia, 119P(ab)
probable Alzheimer's disease, 210
rapid detection of infections, 173P(ab)
rate constants of, 184P(ab)
recurrent rectal cancer, 118P(ab)
reproducibility of fluorine-18-6-fluorodopa in, 18
response to neoadjuvant therapy of sarcomas, 38P(ab)
sarcoidosis, 1647, 1650, 1653
semiquantitative and visual analysis, pulmonary abnormalities, 1771
solitary pulmonary nodules, 76P(ab)
SPECT comparison, primary hyperparathyroidism, 68P(ab)
staging of Hodgkin's disease and lymphoma, 221P(ab)
standard uptake values measured with, 185P(ab)
studies in psychiatry, editorial, 24
suspicious breast tumors, 222P(ab)
^{99m}Tc sestamibi and, malignant melanoma, 231P(ab)
temporal lobe hypometabolism, 30P(ab)
thallium comparison
pancreatic cancer, 222P(ab)
radiation necrosis in brain, 222P(ab)
therapeutic effects, experimental liver tumor, 234P(ab)
thermal injury effects, 175P(ab)

total lesion glucose metabolic changes, serial tumor, 137P(ab)
tumor metabolism after radioimmunotherapy, 38P(ab)
untreated lung cancer, 75P(ab)
uptake, postchemotherapy residual germ cell tumors, 117P(ab)
uptake in vitro, 1842
uptake of, musculoskeletal inflammation, 113P(ab)
whole-body, with attenuation correction, 104P(ab)
wrist, inflammatory arthritis, 35P(ab)
FDG and DOPA, cerebral glucose metabolism, spinocerebellar, 210P(ab)
FDG and FES, assessment of breast lesions with, 141P(ab)
FDOPA
Parkinsonism, 955
Patlak analysis of, 183P(ab)
^{18}F, liver metastases with intraarterial chemotherapy, 38P(ab)
^{18}F 6F-DA, pharmacokinetics and dosimetry, 964
^{18}F FDG uptake, myocardial, enhancement by a nicotinic acid derivative, 989
^{18}F FDOPA, clearance, protein-rich diet effects, 212P(ab)
^{18}F fleroxacin, urinary tract infections and bronchitis, 175P(ab)
^{18}F fluorocarazolol, imaging of pulmonary β-receptors, 257P(ab)
^{18}F-labeled biotin, infection localization with, 1685
^{18}F LDOPA, validation of venous input function in, 185P(ab)
^{18}F L-FDG, biodistribution, rats and monkeys, 254P(ab)
^{18}F MIBG analog, synthesis and preliminary evaluation, 248P(ab)
^{18}F Phe, amino acid transport, cerebral infarction, 63P(ab)
gated, calculation of ejection fraction, 104P(ab)
glucose consumption, spasmodic torticolis, 95P(ab)
glucose metabolism, brain, intersubject variability, young normal males, 1457, 1466
gonadal steroid effects, cerebral blood flow, 53P(ab)
hemodynamic and metabolic data, carotid artery disease, 202P(ab)
high-resolution, pharmaceutical distribution in a small animal, 1390, 1396
hypoxic radiosensitizer for, ^{18}F FMISO, 73P(ab)
^{131}I iododeoxyuridine, brain tumor proliferative activity, 1407
involuntary movements, methohexital and nitrous oxide anesthesia, 198P(ab)
kinetic modeling, ^{11}C acetate, 1286
metabolic and receptor images, right-left asymmetry profiles for, 31P(ab)
metabolic imaging, myocardial viability, 8S, 43S
mitochondrial electron transport chain for, ^{18}F FDHR, 73P(ab)
MRI and, evaluation of dementia, 20P(ab)
MRI-guided, speech-induced focal metabolic activations by, 107P(ab)
multicenter sequential, middle cerebral artery occlusion, 197P(ab)
myocardial imaging, potassium-38 and copper-62-PTSM comparison, 1116, 1122
myocardial perfusion estimates, ^{15}O water and ^{13}N ammonia use, 157P
myocardial perfusion imaging, 689
comparison, 23P(ab)
coronary disease, 23P(ab)
neuroactivation studies, objective analysis, 71P(ab)
^{15}O
intraoperative cortical stimulation and, 107P(ab)
mood induction effects on rCBF, 54P(ab)
periventricular hyperintensity, 211P(ab)
^{15}O carbon dioxide, Wernicke's aphasia, 120
^{15}O water
activation study, mental representations, 107P(ab)
blood flow model, correction for time shifts, 183P(ab)
brain, 181P(ab)
cerebral involvement in pain perception, 32P(ab)
evaluation of cochlear implant, 95P(ab)
muscle perfusion assessment, 24P(ab)
regional cerebral blood flow, 1870, 1878
statistical power analysis, 182P(ab)
visual selective attention, 32P(ab)
opioid analgesia, central mechanism of, 198P(ab)
organ uptake of ^{18}F FDG and ^{11}C MET, oncologic patients, 220(ab)
ovarian cancer, before second-look laparotomy, 117P(ab)
parametric images
unidirectional metabolic rates, 1206
unidirectional rate constants and blood space, 184P(ab)
partial volume effects, gray matter radioactivity, MRI correction, 197P(ab)
point spread function correction in, algorithm for, 187P(ab)
polar mapping, perfusion defects in canine myocardium, 2031
quantifying perfusion and ventilation, lung, 784
quantitation of small structures, investigation of errors in, 182P(ab)
radioligands, improved synthesis of, 250P(ab)
radionuclide generator for, Ce-134/La-134 pair, 42P(ab)
radionuclide uptake, cell stress and, 120
^{82}Rb, occlusive arterial disease in legs, 156P(ab)
rCBF disorders, major depressive disorders, 54P(ab)
regional cerebral blood flow, diurnal variation of, 32P(ab)
regional myocardial perfusion with, time discrepancy effects, 558, 567
scanner, gamma camera and, ^{18}F FDG cardiac scintigraphy, 111P(ab)
scanning sequences for, automated experimental design of, 71P(ab)
septa-less scanners, normalization measurement, 41P(ab)
serotonin-dopamine interactions measured with, 85P(ab)
serotonin receptor ligands for, 252P(ab)
severe heart failure, resting renal cortical blood flow in, 265P(ab)
sickle cell anemia patients, cerebral ischemia and stroke, 134P(ab)
single-injection, measurement of receptor concentration, 66P(ab)
single-photon perfusion imaging, myocardial viability, 23S
small animal
new system for, 61P(ab)
resolution and sensitivity, 40P(ab)
SPECT co-registration, brain tumor patients, 7P(ab)
staging, lung cancer, 76P(ab)
stereotactic, atlas of human brain, 949
study of auditory stimulations, obsessive-compulsive disorder, 75P(ab)
^{94}Tc application in, 253P(ab)
thoracic, emission-transmission registration in, 1777, 1781
thorax imaging, attenuation correction with emission data for, 51P(ab)
three-dimensional
EM algorithm for, 187P(ab)
fully automated approach, 127P(ab)
lung density, attenuation correction technique, 187P(ab)
time-activity curve, statistical correction in, 183P(ab)
^{201}Tl and, evaluation of myocardial viability, 707
tracer, measurement of galactokinase activity, 255P(ab)
transient, randomly occurring neuropsychological events, brain, 185P(ab)
triple-head FDG, oncology, 7P(ab)
vesamicol receptor for, 94P(ab)
vs SPECT, discordance between cerebellar metabolism and perfusion, 209P(ab)
whole-body
compression for remote viewing, 51P(ab)
scanner, performance characteristics, 1398
staging of malignant melanoma, 8P(ab)
Potassium-38
kinetics, myocardial perfusion and viability, 77P(ab)
myocardial kinetics, copper-62-PTSM comparison, 1116, 1122
Practice guidelines
nuclear medicine and health care, 18N(6)
SPECT cerebral perfusion imaging, 2003
Pregnancy, fetal skeleton, ^{99m}Tc MDP uptake in, 1338
Premenstrual syndrome, ^{99m}Tc HMPAO SPECT imaging, 215P(ab)
Prostaglandins, DTPA-stimulated release, neutrophils, 133P(ab)
Prostate
cancer
bone metastases from, whole body bone scintigraphy for, 149P(ab)
disseminated intravascular coagulation, ^{89}Sr therapy, 1662
^{18}F FDG metabolic pathways in, 256P(ab)
^{111}In CYT-356 detection of occult residual, 216P(ab)
metastatic, ^{186}Re HEDP dose escalation study, 36P(ab)
metastatic, treatment with radiolabeled antibody CC49, 1017
primary and recurrent, radioimmunodetection of, 218P(ab)
SPECT imaging, ^{111}In CYT-356, 216P(ab)
untreated
bone scans and prostate specific antigen in, 120P(ab)
metabolic classification by FDG PET, 230P(ab)
without bone metastases, prostate specific antigen levels in, 225P(ab)
carcinoma, bone scintigraphy in, serum PSA and osteocalcin levels compared with, 146P(ab)
fluorine-18 labeled androgen receptor ligand imaging, baboon, 53P(ab)
model, use in internal dosimetry, 516
Prostate specific antigen

bone scans and, newly diagnosed untreated prostate cancer, 120P(ab)
levels, prostate cancer without bone metastases, 225P(ab)
Protein
binding
renal extraction of ^{99m}Tc MAG3 and, 264P(ab)
^{99m}Tc MAG3, renal failure, 265P(ab)
^{18}F labeling of, PET, 73P(ab)
intestinal loss, liver cirrhosis, ^{111}I transferrin study, 168P(ab)
labeling, one-step synthesis of ^{18}F, 249P(ab)
metabolism, cardiac, PET, validation of model, 77P(ab)
^{99m}Tc labeled, premortem biodistribution, blood and tissue, 243P(ab)
Pulmonary embolism
acute experimental, ^{99m}Tc DTPA deposition and clearance with, 1351
detection with ^{99m}Tc-anti-D-dimer Fab,' 195, 202
diagnosis, artificial neural networks in, 186, 187
^{111}In platelet scintigraphy, 238P(ab)
latex-D-dimer assays for diagnosis, 189(le)
resolution rates, inhaled ^{15}O-labeled carbon dioxide, historical article, 796
single segmental mismatch, lung scanning, 1928, 1931
ventilation imaging, ^{99m}Tc pertechnetate comparison with ^{133}X, 48P(ab)
ventilation-perfusion lung scanning, 793, 47P(ab), 239P(ab)
comparison in different patient populations, 25P(ab)
expert system for, 797
in aortic dissection, 1044
low probability interpretation, 25P(ab)
modified PIOPED criteria for, 24P(ab)
original and revised PIOPED criteria for, 25P(ab)
patient position effects, 24P(ab)
revised PIOPED criteria in, 25P(ab)
Pulmonary vascular granulocytes, kinetics, alveolocapillary barrier damage and, inflammation, 132P(ab)

Q

Qualifying boards, commentary, 38N(6)
Quality assurance, health care reform, commentary, 21N(11)
Quality management programs
cast and foil collimators, 180P(ab)
misadministration of ^{131}I, 166P(ab)
3-Quinuclidinyl benzilate (QNB), derivatives of, analysis, 53P(ab)

R

Radiation
detection, fiber-optically coupled positron-sensitive surgical probe, 909
environmental, radon update, 368
selective internal, ^{131}I lipiodol, inoperable liver cancer, 1313, 1318
Radiation mucositis, diagnosis, ^{99m}Tc DTPA, newly developed agent, 170P(ab)
Radiation protection, dispensing/injection system, PET, 188P(ab)
Radiation synovectomy, knee, ^{153}Sm hydroxyapatite particles in, 37P(ab)
Radiation therapy
^{211}At, small volumes, 180P(ab)
brain tumors, regional glucose metabolism before and after, 213P(ab)
cellular doses, labeled neutrophils and platelets, historical article, 450
dose, walls of hollow organs, 78P(ab)
dose estimates
^{11}C iomazenil, 159P(ab)
marrow and bone by skeletal regions, 112P(ab)
injury, lung, ^{99m}Tc DTPA aerosol clearance in assessment of, 234P(ab)
magnetic reduction of positron range, 162P(ab)
necrosis, brain
FDG and ^{201}Tl comparison, 222P(ab)
recurrent tumor, FDG and ^{201}Tl comparison, 223P(ab)
pharmacokinetics and, ^{90}Y citrate and EDTMP, 233P(ab)
production of rhenium, aluminum perrhenate targets for, 242P(ab)
response to cancer to, thymidine uptake as a monitor of, 66P(ab)
unsealed source, electron paramagnetic resonance dosimetry for, 111P(ab)
Radicals, detection, ^{125}I HPBN ligand for, 246P(ab)
Radioaerosols
deposition and clearance, acute experimental pulmonary arterial occlusion effects, 1351
purity, ^{99m}Tc HMPAO prepared by ultrasound and jet nebulizer, 244P(ab)
Radiobiological experiments, government, nuclear medicine and, 9N(3)
Radiochemical purity, reconstitution factors affecting, hepatobiliary excretion of ^{99m}Tc MAG3, 349
Radiochemistry, Al_2O_3/KF in, 82P(ab)
Radiochemotherapy, lung cancer, ^{18}F FDG PET monitoring of tumor response, 37P(ab)
Radioembolic therapy, hepatic, yttrium-90 glass microspheres, 1637, 1644
Radioembolization, pretherapeutic, CNS tumors, 145P(ab)
Radiofrequency catheter ablation, W-P-W syndrome, supraventricular tachycardia and, ventriculography, 90P(ab)
Radiogastrogram, gastric emptying and antral motor activity, gastrokinetic compound effects, 88P(ab)
Radioimmunoassay
quantification of cardiac myosin, V1 and V3 isoforms of, 145P(ab)
serum cytokeratin 19 concentration, gastrointestinal and gynecological malignancies, 146P(ab)
Radioimmunoconjugates, antibody/tumor model system, biodistribution and, 30P(ab)
Radioimmunodetection
dHB4C5, lung cancer xenograft, 217P(ab)
non-Hodgkin's lymphoma, 86P(ab)
primary and recurrent prostate cancer, 218P(ab)
^{99m}Tc for, anti-CEA antibody fragments labeled with, 258P(ab)
Radioimmunodiagnosis, lymph node in, 275P(ab)
Radioimmunoguided surgery
^{125}I-labeled biotinylated monoclonal antibodies, cold avidin and, 1970
lymph node in, 275P(ab)
Radioimmunoscintigraphy
^{18}F-labeled monoclonal antibody, imaging of osteosarcoma, dogs, 1506
^{99m}Tc-labeled monoclonal antibody E48, head and neck cancer, 775
Radioimmunotherapy
antibodies and their radiolabels, bound to surface tumor cells, 899
antibodies to assess feasibility, 100P(ab)
avidin-biotin pretargeting, 219P(ab)
based on projected whole body dose, dose escalation in, 233P(ab)
CT-SPECT fusion, ^{131}I dosimetry, 1714
^{64}Cu and ^{67}Cu comparison, tumor-bearing hamsters, 161P(ab)
direct intratumor or intralesional, control of malignant gliomas, 144P(ab)
^{131}I, breast cancer, 235P(ab)
^{131}I G250, metastatic renal cancer, 101P(ab)
internal dosimetry for, SPECT-based 3-D methodology for, 123P(ab)
linear-quadratic model, 1861
application of, 123P(ab)
microdosimetry in tumors for, 233P(ab)
micrometastases, adjuvant treatment, 161P(ab)
multicellular dosimetry, micrometastases, 521
prediction of effectiveness, micrometastases, 123P(ab)
prostate cancer, CC49 use in, 1017
quantitative SPECT image for, three-dimensional dose calculation, 160P(ab)
small cell lung carcinoma xenografts, anti-NCAM monoclonal antibodies, 296, 300
therapeutic efficacy, taxol effects, 102P(ab)
time-dose-fractionation effect in, modeling of tumor uptake, 1561(le)
tumor, ^{67}Cu production for, 259P(ab)
tumor metabolism after, FDG PET monitoring of, 38P(ab)
Radioiodination
7'iodonaltrindole, cerebral delta opioid receptors, 245P(ab)
nonpeptide angiotensin II receptors, 246P(ab)
Radioiodine therapy
differentiated thyroid carcinoma, testicular function and, 1418
thyroid cancer, accurate dosimetry for, 112P(ab)
treatment, hyperthyroidism, 1558(le)
uptake, false-positive, lung cancer, 2056(le)
well-differentiated thyroid cancer, 1944
Radioisotope conjugates, catabolism of, bound to surface tumor cells, 899
Radioisotopes
commercial venture, 19N(10)
medical, proposed national resource for production, 245P(ab)
separation methods for isolation, 241P(ab)
therapy, absorbed dose by quantitative SPECT, thyroid cancer, 14P(ab)
Radioligands, dopamine D2 receptor, comparison of three, 257P(ab)
Radionuclide fistulogram, arteriovenous fistula malfunction, chronic hemodialysis patients, 124P(ab)
Radionuclides
crosstalk components, lesion detectability and, 61P(ab)
electron-emitting, spheres of various sizes, 152
intracellular metabolism of, 1559(le)
magnetically enhanced therapy, 157
membrane-transport and intracellular hybridization, c-myc probe, leukemic cells, 42P(ab)
multicellular dosimetry, micrometastases, 521
positron-emitting, metabolic tracers labeled with, myocardial viability, 15S
production, on-line monitoring of, optical spectroscopy, 249P(ab)
radioactive imaging, Crohn's patients with fistulization, 245
therapy

bone pain from skeletal metastases, 63
extravasation, 158P(ab)
versus medical support, hepatocellular carcinoma with portal vein thrombosis, 1782
treatment planning system, absorbed dose distribution in, SPECT, 123P(ab)
Radionuclide studies
atypical renal artery stenosis, renal transplant, 1051
myocardial viability, 8S
Radionuclide-synoviorthesis, therapeutic effects, rheumatoid arthritis, 36P(ab)
Radiopharmaceutical kits
cyclodextrin-stabilized TECHNESCAN Q_{12}, novel chemistry used in, 139P(ab)
quality control of, 138P(ab)
Radiopharmaceuticals, *See also* specific substance
antisense, noninvasive imaging of *c-myc* oncogene with, 1054, 1064
^{11}C acetate and methionine, production for PET, 248P(ab)
cell nucleus dose rate, tracer localization effects, 113
clorgyline derivative, quantitative mapping, brain, 254P(ab)
myocardial perfusion imaging, 17N(4)
quantification of stannous ion, perrhenate reduction, 243P(ab)
stannous chloride concentration effects, Neurolite radiochemical purity, 260P(ab)
Radioscintigraphy, breath test, monitoring of gastric emptying of liquids and solids, 824
Radiosurgery, cerebral hemodynamic changes after, ^{99m}Tc HMPAO SPECT, 204P(ab)
Radon
risk, drinking water, EPA, 9N(1)
update, environmental facts, 368
rCBF, *See* Blood flow, cerebral, regional
Reactors, advanced neutron source, medical radioisotope production, 245P(ab)
Receptor imaging, atrial natriuretic peptide, 628
Reconstruction variance, cone-beam data sufficiency and, evaluation, 5P(ab)
Rectal cancer, recurrent, ^{18}F FDG PET in, 118P(ab)
Reflex sympathetic dystrophy, bone scintigraphy, pattern recognition in, 150P(ab)
Registration, emission transmission, evaluation of, thoracic PET, 1777, 1781
Renal artery, atypical stenosis, renal transplant, radionuclide studies, 1051
Renal artery stenosis, MAG3-lasix-enalaprilat scintigraphy, 266P(ab)
Renal studies, ^{99m}Tc MAG_3, physiologic parameters as function of age and sex, 1612
Renography
captopril, hypertension and chronic renal failure, 251, 254
comparative study of imaging agents, obstructive renal disease, 840
deconvolved linear response method, measurement of renal plasma flow, 266P(ab)
diuresis, duplex Doppler sonography as alternative to, 124P(ab)
diuretic, urinary tract obstruction, 266P(ab)
exercise, mild to moderate hypertension, 99P(ab)
^{99m}Tc sestamibi, hypertension, potential for renovascular disorders, 1959
scleroderma patients, 264P(ab)
^{99m}Tc MA_2G_2-β as potential agent for, 263P(ab)
Re-N,S chelates, synthesis and evaluation, post-formed labeling of biomolecules, 139P(ab)
Reperfusion therapy, benefits of, left circumflex infarction, 114P(ab)
Research funding, health care reform, commentary, 34N(5)
Reserpine, dopamine uptake sites and, binding of ^{3}H WIN-35,428, 199P(ab)
Residencies, health care reform, nuclear medicine workforce after, 7N(3)
Restructuring, health care reform, mid-winter meeting, 10N(4)
Rhenium-186
labeling of CC49 monoclonal antibody, bifunctional chelating agents, 258P(ab)
production, aluminum perrhenate targets for, 242P(ab)
radionuclide therapy, magnetically enhanced, 157
Rhenium complex, synthesis and characterization of, 244P(ab)
Rhenium-186 HEDP
dose escalation study, metastasized prostate cancer, 36P(ab)
individual dosage recommendations, thrombocytopenia in painful bone metastases, 1423
Rhenium-186 (Sn)HEDP, nonenriched targets, painful skeletal metastases, 244P(ab)
Rhenium-188, direct labeling of antibodies, 260P(ab)
Rhenium-188 MT-S, streptavidin labeled with, 242P(ab)
Rhodium-105, amine oxime ligand, biodistribution, bifunctional chelates, 241P(ab)
Rhodium-105 tetrathiamacrocyle, formulation of bifunctional chelates, 41P(ab)
Rim sign, acute cholecystitis, 14P(ab)
RMP-7, blood-brain barrier permeability and, 95P(ab)
Ro 19 6327, treatment of Parkinson's disease, 7P(ab)
ROC analysis
cerebellar blood flow deficits, thresholds for, 1547
cold lesions, lesion detectability evaluation, 135
Rotating positron tomography (PRT), physical and clinical performance, 41P(ab)
Rotenone, marker, mitochondrial complex I activity, 256P(ab)
Rotor syndrome, cholescintigraphy in, 1048
Rubidium-82, PET, coronary artery disease detection, community hospital-based center, 1586
Rubidium-86, distribution, dog heart, historical article, 875

S

Salivary gland, ^{99m}Tc pertechnetate imaging, Warthin's tumor, 179
Samarium-153
antisense oligodeoxynucleotide probes labeled by, leukemic cell killing, 145P(ab)
hydroxyapatite particles, chronic knee synovitis, 37P(ab)
Samarium-153 EDTMP
dosimetry, 191(le)
palliative agent, bone metastases, 235P(ab)
toxicity, bone pain due to skeletal metastases, 63
Sarcoidosis
^{18}F FDG uptake in, 1647, 1650, 1653
ventilation-perfusion imaging in, 476
Sarcoma
soft tissue
limb perfusion in, PET FDG evaluation of, 90
musculoskeletal and, neoadjuvant therapy, PET monitoring of, 38P(ab)
Scaphoid, suspected fracture, bone scintigraphy in, 151P(ab)
Scatter correction techniques
comparison, Monte Carlo simulated source distributions, 143
Compton free imaging method, 143P(ab)
correction for, 143P(ab)
1D deconvolution comparison, PET, 50P(ab)
3D PET, 50P(ab)
model-based, 51P(ab)
general-purpose, energy spectrum fitting, 34P(ab)
geometrical mean and channel ratio, organ radioactivity quantification, 179P(ab)
may randoms evolve into?, 1568(le)
quantitative SPECT, Alzheimer's disease, 116P(ab)
SPECT cardiac imaging, 189P(ab)
^{201}Tl cardiac imaging, 192P(ab)
transmission-dependent, SPECT, 360
triple-camera system, cardiac SPECT, 81P(ab)
Scattered photons
estimation using neural network, SPECT, 17P(ab)
incomplete data method of treatment, SPECT, 17P(ab)
use of information content of, SPECT, 17P(ab)
Schizophrenia
cerebral glucose metabolism in, MRI measurement, 214P(ab)
dopamine receptors in
antipsychotic drug therapy, 74P(ab)
^{123}I IBZM SPECT in, 74P(ab)
hypoperfusion, left temporal lobe, ^{99m}Tc HMPAO SPECT in, 215P(ab)
prefrontal and temporal blood flow in, resting and activation ^{99m}Tc HMPAO SPECT patterns in, 935
regional cerebral glucose metabolism, verbal memory performance and, 74P(ab)
Schwannoma, extremities, comparison of MRI and ^{99m}Tc DMSA and ^{67}Ga citrate scintigraphy, 1174
Scintigraphy
abnormalities in children, Kawasaki's disease without coronary artery aneurysm, 237P(ab)
acquired congenital heterotopic bone formation, 276P(ab)
adrenal
deactivation of aldosterone by absolute ethanol, 68P(ab)
detection of preclinical Cushing's adenomas, 69P(ab)
antisense probes, 65P(ab)
artifacts, systematic approach to, 274P(ab)
biliary stenosis, liver-transplanted children, 59P(ab)
bone
bisphosphonate effects, metastatic breast cancer, 119P(ab)
differentiation of otitis externa, diabetic patients, 411
fetal skeleton, ^{99m}Tc MDP uptake in, 1338
flare after Taxol chemotherapy for breast cancer, 1748
intraosseous hemangiomatosis, 1482
marrow metastasis from breast cancer, 1485
pleural effusion, malignancy based on pleural fluid cytopathology, 429

reflex sympathetic dystrophy, 150P(ab)
selection of multiple myeloma patients for treatment with ^{89}Sr, 1992, 1994
stress fractures in young athletes, 120P(ab)
suspected prostate carcinoma, 146P(ab)
suspected scaphoid fracture, 151P(ab)
bone marrow, reconstruction of irradiation fields, 236P(ab)
deglutition testing, quantifying aspiration in, 1007, 1013
dipyridamole thallium, vascular patients, left ventricular size, 125P(ab)
dual renal and myocardial, ^{99m}Tc sestamibi uptake, 125P(ab)
dynamic radionuclide, cerebral brain death, 275P(ab)
esophageal transit, differentiation of esophageal motility disorders, 169P(ab)
evaluation of urine leak, kidney transplant patients, 267P(ab)
^{18}F FDG, cardiac, gamma camera and PET scanner for, 111P(ab)
^{67}Ga, uptake, benign transformation of Hodgkin's disease, 465
gallbladder emptying, reproducibility in, 835
hemobilia complicating angiodysplasias, 870
hepatobiliary
after liver transplantation, 1321
common bile duct obstruction, 13P(ab)
cystic fibrosis and liver disease, children, 432, 436
liver disease with cystic fibrosis, 58P(ab)
hyperthyroxinemia, 271P(ab)
leukocyte, osteomyelitis in osteopetrosis, 95
lung, sign for left-to-right shunt, 1557(le)
MAG3-lasix-enalaprilat, renovascular hypertension, 266P(ab)
^{99m}Tc DTPA aerosol, detection of impaired lung epithelial permeability in diabetes, 204, 207
myocardial, planar ^{201}Tl dipyridamole stress-redistribution, automated interpretation, 2041, 2047
nonischemic SPECT stress myocardial perfusion, females, 60P(ab)
Octreoscan 111, gastroenteropancreatic endocrine tumors, 96P(ab)
octreotide 111
detection of somatostatin receptors, 96P(ab)
malignant pheochromocytoma tumor sites, 96P(ab)
parathyroid, primary hyperparathyroidism, 15P(ab)
pinhole, sign of chondromalacia patellae, older patients, 855
post ablative ^{131}I therapy, differentiated thyroid cancer, 15P(ab)
quantitative lung perfusion, congenital right ventricular outflow tract lesions, 240P(ab)
radioiodine, uptake in squamous cell carcinoma, 474
renal
captopril, hypertension and renal failure, 251, 254
patient motion compensation for, 34P(ab)
scrotal
detection of subclinical varicoceles, male infertility, 265P(ab)
detection of varicoceles, magnetic resonance angiography combination, 267P(ab)
testicular torsion, 58P(ab)
ultrasound comparison, testicular torsion, 125P(ab)
somatostatin receptor, primary breast cancer, 21P(ab)
stereotaxic localization technique guided by, breast tumor location, 62P(ab)
stress myocardial perfusion, coronary angiography rates after, 16P(ab)
thyroid, euthyroid ophthalmic Graves' disease, 811
^{201}Tl, malignant bone and soft tissue tumors, 225P(ab)
^{201}Tl per rectum, prognostic value in alcoholic cirrhosis, 832
urine activity, quantifying sources of error in, 157P(ab)
ventilation, localization of bronchopleural fistula, 867
ventilation/perfusion, aspiration of foreign body, 238P(ab)
vesicoureteral, children with primary reflux, 1602, 1608
whole body bone, detection of metastases from prostatic cancer, 149P(ab)
Scintillating optical fibers, plastic, imaging folate receptors, ^{125}I, 222P(ab)
Scintillation camera
biplane first pass radionuclide angiocardiography, 70P(ab)
first-pass radionuclide angiocardiography, ventricular function, 1593
Scintimammography, breast lesions, 22P(ab)
Scleroderma, renographic findings in, 264P(ab)
Sector analysis, radionuclide angiography comparison, evaluation of left ventricular asynchrony, 1766
Seizures
preoperative monitoring, ^{99m}Tc HMPAO SPECT, 207P(ab)
temporal lobe, cerebral blood flow, ^{99m}Tc HMPAO SPECT, 208P(ab)
E-Selectin, endothelial cell adhesion molecule, imaging vascular endothelial activation, 276, 281
Seminoma, extragonadal and gonadal, ^{67}Ga citrate imaging of, 1624
Sentinel node, radioguided biopsy, cutaneous melanoma, 224P(ab)
Serotonin
biosynthesis, ^{18}F and, 251P(ab)
innervation density in rat brain, cyanoimipramine as a marker for, 67P(ab)
transporter sites, without ^{11}C McN5652, brain, 85P(ab)
Serotonin-dopamine interactions, measurement, PET and ^{11}C raclopride, 85P(ab)
Serotonin receptors
synthesis of, PET studies, 252P(ab)
synthesis of halogenated phenethylpiperidine derivatives as, 252P(ab)
Sialoglycoprotein, receptor-mediated uptake, liver targeting by, 269
Sickle cell disease
bone imaging in, 36P(ab)
cerebral ischemia and stroke in, detection with PET, 134P(ab)
Sickle-cell thalassemia disease, sternal abnormalities, scintigraphic manifestations of, 1167
Sigma receptors
expression, nonsmall cell lung carcinoma, 248P(ab)
imaging of tumors, breast cancer, 246P(ab)
mapping, 93P(ab)
Silicone implants, breast, PET detection of breast cancer, 872
Single-pass extraction, brain, compared with transendothelial permeability, blood-brain barrier, 1514
Single photon emission computed tomography (SPECT)
abdominal blood pool, MRI comparison, hypertension, 169P(ab)
acetazolamide-enhanced
carotid endarterectomy, 64P(ab)
cerebral AVM, 65P(ab)
atrophy-corrected, Alzheimer's disease, 20P(ab)
balloon occlusion test, changes induced by, 204P(ab)
benzodiazepine receptors, diazepam-sensitive, 247P(ab)
bone
3-dimensional, orthopedic disease patients, 151P(ab)
suspected mechanical spine pain, 149P(ab)
vertebral hemangioma, 150P(ab)
vertebral lesions, 150P(ab)
volume three-dimensional displays and, 149P(ab)
brain
abnormalities in HIV-1-infected gay men, 118P(ab)
Alzheimer's disease, 206P(ab)
automated co-registration of, 191P(ab)
central nervous system lupus, 95P(ab)
early and delayed, subacute strokes, 1444
evaluation of papaverine, 64P(ab)
HMPAO, significance of abnormalities in, 239
ictal and interictal, epilepsy, 1896
^{123}I IBZM infusion during, 84P(ab)
impact on clinical management, 95P(ab)
nonuniform attenuation in, 188P(ab)
recent clinical reports in the *Journal of Nuclear Medicine,* 1891
three-dimensional image registration, 2011
thresholds for detection of cerebellar blood flow deficits, 1547
white matter ischemia showing on, 1476
brain perfusion, PET-measured rCBF comparison, 200P(ab)
brain perfusion imaging, with exametazine, consensus development, 2003
cardiac
abnormal segmental contraction cause perfusion defects, 639
attenuation compensation and remedies, 115P(ab)
attenuation compensation in, 91P(ab)
attenuation correction, 82P(ab), 91P(ab)
compensation for crosstalk, 190P(ab)
correction of motion, 194P(ab)
extended, minimizing attenuation, 625
fast conjugate gradient reconstruction, 82P(ab)
kinetic modeling of teboroxime with, 484
measured defect contrast with, 196P(ab)
nonhomogenous attenuation correction of, 91P(ab)
reconstruction algorithm for, 195P(ab)
reorient left ventricular myocardium, 116P(ab)
triple-camera system, scatter in, 81P(ab)
cardiac motion analysis, flow constraint, 176P(ab)
cerebral perfusion in cocaine abuse, gender differences, 1902
cervical occlusion, 1556(le)
clinical brain system, 190P(ab)
cocaine receptor probe, 200P(ab)
compton scatter, incomplete data method, 17P(ab)

cone-beam
  clinical, editorial, 141
  distal extremities, 914
  fanbeam, parallel beam collimation, lesion detectability with, 135
  shift-variant filtered-backprojection, 5(ab)
converging-beam
  detector response in, 191P(ab)
  ML-EM vs. FBP in, 190P(ab)
co-registration of, radiation-induced lung disease, 276P(ab)
CT fusion, ^{131}I dosimetry, 1714
cyanoimipramine as marker of serotonin, innervation density, brain, 1822
direct reconstruction of images, matrix elements and, 28(ab)
dobutamine stress sestamibi, coronary artery disease, 16(ab)
dopamine D2 receptor, potent radioligand for, 199P(ab)
dopamine receptor ligand for, 246P(ab)
dopamine uptake sites, radioligands for, 247P(ab)
double-phase sestamibi, primary hyperparathyroidism, 68P(ab)
dual-isotope
  monitoring brain activation, 194P(ab)
  stochastic sign change criterion applied, 189P
dual-isotope myocardial perfusion
  separate or simultaneous rest ^{201}Tl/stress ^{99m}Tc sestamibi, 542
  ^{201}Tl and ^{99m}Tc sestamibi, 549
dynamic, ^{123}I BMIPP and, prior myocardial infarction patients, 1279
dynamic cardiac, estimation of, 17P(ab)
emission-transmission system, configuration of, 195P(ab)
exercise, thallium imaging comparison, 16P(ab)
exercise gated blood pool, wall motion studies, 90P(ab)
fan-beam cardiac, effect of truncation in, 4P(ab)
fast dynamic, compartmental analysis of ^{99m}Tc teboroxime kinetics, 1265
FASTSPECT
  four-dimensional brain imager, 93P(ab)
  physical evaluation of, 28P(ab)
  simulation, accurate reconstruction and, 28P(ab)
^{18}F FDG, wall motion abnormalities, 136P(ab)
flow reserve, carotid artery occlusion, ocular signs, 203P
gated myocardial, automatic analysis of, 116P(ab)
gated sestamibi, perfusion defect size, 155P(ab)
high-resolution 4-head pinhole, animal studies, 196P(ab)
HMPAO, appearance of central nervous system toxoplasmosis, 1041
^{123}I
  circumferential variations in cortex, 82P(ab)
  localization, validation study, 755
  quantitative mapping of regional cerebral blood flow, 2019
  volume and activity quantitation with, 1707
^{123}I β-CIT, biodistribution and dosimetry, 764
^{123}I IBC, binding to dopamine D2 receptors, 743
^{123}I IBVM, cholinergic neurons, Alzheimer's, 68P(ab)
^{123}I IBZM, dopamine receptor imaging with, idiopathic rotational torticollis, 1921
^{123}I IBZM cortical retention, haloperidol and, 199(ab)
^{123}I IMP
  chronic ischemic brain lesions, 205P(ab)
  hippocampal blood flow, elderly, 214P(ab)
  split dose, cerebral blood flow change, 1226
^{123}I MIBG versus planar imaging, neuroblastoma in children, 1753
^{123}I p-MPPI, 5-HT$_{1A}$ receptor antagonist, 93P(ab)
^{123}I probes for, non-human primate brain, 201P(ab)
^{131}I iododeoxyuridine, brain tumor proliferative activity, 1407
IBVM, mapping of cholinergic neurons, brain, 405
^{111}In CYT-356, prostate cancer, 216P(ab)
interictal brain
  perfusion, FDG PET and, epilepsy, 207P(ab)
  refractory epilepsy, children, 134P(ab)
iterative, two-dimensional distance-dependent blur, 192P(ab)
lumbar spinal fusion, painful late effects of, 416, 422
magnetic resonance comparison, Alzheimer's disease, 207P(ab)
MAP-EM reconstruction, edge preserving in, 193P(ab)
measurement of benzodiazepine receptors, brain, 228
meta analysis, brain imaging in epilepsy, 31P(ab)
MIBI, coronary artery disease, 126P(ab)
motion, two-dimensional fit method for correction, 181P(ab)
MRI and, chronic fatigue syndrome, 215P(ab)
myocardial
  motion artifacts, temporal image fractionation, 1193
  three-dimensional reference model for, 127P(ab)
myocardial perfusion
  left ventricular surface, 190P(ab)
  non-circular scan orbit, 190P(ab)
myocardial perfusion artifact detection, 699
myocardial volumes, improving quantitation of, 189P(ab)
nonischemic stress, females, 60P(ab)
parallel-plus collimator for, 33P(ab)
parametric images, unidirectional metabolic rates, 1206
patient motion during
  effects of prone imaging, 154P(ab)
  R-Made Patient Support System, 154P
PET co-registration, brain tumor patients, 7P(ab)
Photon Detection Kernel for, analytical theory of, 5P(ab)
pinhole, small laboratory animals, 342
quantifying perfusion and ventilation, lung, 784
quantitative Bremsstrahlung, attenuation-correction, 1213
quantitative image for radioimmunotherapy, 160P(ab)
quantitative measurements, small organs, monkey, 179P(ab)
rCBF disorders, major depressive disorders, 54P(ab)
regional analysis, diagnosis of dementia, 206P(ab)
scanning sequences, automated experimental design, 71P(ab)
scatter correction, transmission-dependent method, 360
scatter correction techniques, comparison, 143
scattered photons in, use of information content of, 17P(ab)
selective agent for, dopamine reuptake sites, 121P(ab)
semi-automated boundary detection, scatter image, 196P(ab)
semiquantitative data, mild Alzheimer's disease, 1450, 1455
^{99m}Tc sestamibi, gender effects on value of, 60P(ab)
simultaneous transmission CT
  brain, 193P(ab)
  description, 193P(ab)
  high count rate, 192P(ab)
skull planar and bone scintigraphy, differentiation of otitis externa, diabetic patients, 411
small animal, new system for, 61P(ab)
small field-of-view, 27P(ab)
^{99m}Tc DMSA uptake, unilateral kidney disease, children, 445, 449
^{99m}Tc ECD, brain perfusion imaging, 211P(ab)
^{99m}Tc ethyl cysteinate dimer, cerebrovascular disease, 27
^{99m}Tc GSA, regional liver function, 169P(ab)
^{99m}Tc HMPAO
  acute closed head trauma, 213P(ab)
  brain
    circulation response to carbon dioxide, 32
    evaluation of neurotoxicity, 863
    FDG PET comparison, Alzheimer's disease patients, 210
    in dementia, 206P(ab)
    electroconvulsive therapy, 53P(ab)
    paralimbic hypoperfusion in unipolar depression, 929
    partial status epilepticus, 1087, 1094
    prediction of cerebral infarction, 1097
    traumatic injury, 217, 227, 942, 947
  brain perfusion, substance abusers, 214P
  caudate nuclei rCBF in fibromyalgia, 215P
  cerebral perfusion changes, trauma, 212P
  cocaine and heroin dependence, 210P(ab)
  extra-temporal lobe epilepsy, 31(ab), 112
  Landau-Kleffner syndrome patients, 211P
  mediastinitis, 174P(ab)
  minor closed head trauma, 213P(ab)
  MRI comparison, epilepsy patients, 208P
  obsessive-compulsive disorders, 214P(ab)
  partial status epilepticus, 208P(ab)
  premenstrual syndrome, 215P(ab)
  preoperative seizure monitoring, 207P(ab)
  rCBF, heroin and polydrug abuse, 214P(ab)
  reversible encephalopathy, 210P(ab)
  seizures, cerebral blood flow in, 208(ab)
  temporal lobe, schizophrenia, 215P(ab)
  visual abnormalities, 209P(ab)
  ^{133}Xe and, rCBF, 212P(ab)
^{99m}Tc HMPAO diamox, carotid artery stenosis, 202P(ab)
^{99m}Tc MDP
  cortical and trabecular bone, women with osteoporosis, 1155, 1159
  spine, differentiation of lesions, 35P(ab)
^{99m}Tc MIBI
  myocardial imaging, significant gastric reflux in, 619
  myocardial viability assessment, 569
^{99m}Tc myocardial perfusion studies
  hepatic artifacts in, 356
  scattered photons, 17P(ab)
^{99m}Tc sestamibi
  multicenter trial, 609
  myocardial perfusion, 59P(ab)
^{99m}Tc tetrofosmin, coronary artery disease, 594
thallium
  angioplasty compared to bypass surgery, 27P(ab)

exercise, women with coronary artery disease, 27P
^{201}Tl
dipyridamole, aortic stenosis patients, 983
distribution in, myocardial, 154P(ab)
exercise studies, reproducibility of, 1237
increased uptake, collapsed lung, 1125
meningioma, 9P(ab)
residual tumor viability in thymic carcinoma, 1659
transmission scans for attenuation correction, 652
^{201}Tl and FDG comparison, myocardial viability, 49P(ab)
^{201}Tl/^{99m}Tc-phytate, hepatocellular carcinoma, 1134
^{201}Tl or ^{99m}Tc sestamibi, ventricular, 126P(ab)
transmission and emission
attenuator and source, 92P(ab)
fan-beam collimation, 92P(ab)
transmission imaging with, 92P(ab)
triple-headed
collimators for, 195P(ab)
FDG, oncology, 7P(ab)
vesamicol receptor for, 94P(ab)
visual activation studies, ^{99m}Tc ECD in, 202P(ab)
volume calculations, maximum likelihood reconstruction, 193P
Single photon transaxial emission computed tomography, heart, historical article, 854
Skeletal metastases, bone pain due to, ^{153}Sm-EDTMP toxicity, 63
Sleep apnea, ^{99m}Tc HMPAO brain SPECT for, 239P(ab)
Small cell lung cancer, xenografts, radioimmunotherapy with anti-NCAM monoclonal antibodies, 296, 300
^{153}Sm-EDTMP, *See* Samarium-153-EDTMP
Smoking, myocardial perfusion and hemodynamics in, 3P(ab)
Sneddon syndrome, cerebral blood flow in, ^{99m}Tc HMPAO SPECT studies, 461
Sn-117m(4+)DTPA
bone pain palliation agent, mechanistic studies of, 52P(ab)
palliation of bone pain, 37P(ab)
Society of Nuclear Medicine
mid-winter meeting, restructuring, health care reform, 10N(4)
position, managed care, 17N(11)
relocation to Reston, VA 13N(12)
Soft tissue, infection, detection, ^{99m}Tc detection of, 1436
Somatostatin
^{111}In DTPA scintigraphy, specific activity and tissue distribution with, 226P(ab)
scintigraphy, nonmedullary thyroid cancer, 163P(ab)
tissue distribution, dose and specific activity effects, 162P(ab)
Somatostatin analogue
brain scintigraphy and, meningioma differentiation, 220P(ab)
^{99m}Tc, tumor specific peptide, 259P(ab)
Somatostatin receptors
imaging, lymphoma, 132P(ab)
new diseases expressing, octreotide 111, 96P(ab)
PET imaging of, ^{64}Cu TETA-D-Phe octreotide in, 106P(ab)
scintigraphy, lymphomas, 132P(ab)
tumors positive for, ^{67}Ga/^{68}Ga-[DFO]-octreotide PET imaging, 317
Southeast compact, LLRW generators feel Barnwell's closure, 24N(10)
Spasmodic torticolis, glucose consumption in, 95P(ab)
Specialty definition, commentary, 38N(6)
SPECT, *See* Single photon emission computed tomography
Spine
cervical, occlusion, SPECT evaluation, 1556(le)
lumbar, fusion, painful late effects, SPECT assessment, 416, 422
mechanical pain, bone SPECT utility in, 149P(ab)
Spinocerebellar degeneration, brain glucose metabolism, ^{18}F FDG and DOPA PET in, 210P(ab)
Spleen, PAF receptors, ^{11}C PAF analog imaging of, 249P(ab)
Squamous cell carcinoma
head and neck, ^{99m}Tc-labeled monoclonal antibody E48 imaging of, 775
laryngeal, ^{99m}Tc MDP uptake in thyroid cartilage, 1170
SR 46349B, PET and microdialysis studies, 67P(ab)
Stannous ion, biological effects, glucoheptonic acid kit, 264P(ab)
Status epilepticus
partial, subcortical perfusion, ^{99m}Tc HMPAO SPECT, 208P(ab)
^{99m}Tc HMPAO SPECT in, 1087, 1094
Stereotaxy, PET atlas of brain, 949
Sternal cupping, scintigraphic manifestations of, 1167
Steroids, ^{99m}Tc-labeled, synthesis and stability of, 139P(ab)
Stomach, gastric emptying, lag phase of, 172P(ab), 1023
Streptavidin
accumulation, pulmonary endothelium, 1358
localization in tumor xenografts, pretreatment with biotinylated monoclonal antibody, 12P(ab)
metallothionein-conjugated, labeled with ^{188}Re, 242P(ab)
Streptavidine-antibody, radiolabeled biotin and, experimental myocardial infarction, 98P(ab)
Stress, six different regimens, whole-body imaging of ^{201}Tl after, 425
Stress testing
pharmacologic, dobutamine myocardial perfusion imaging, 737
pharmacologic and exercise, after acute myocardial infarction, 716
Stroke
clinical prognosis, cerebral perfusion reserve in carotid stenosis, 203P(ab)
ischemic damage to brain tissue, ^{55}Co PET visualization of, 456
ischemic penumbra in, ^{18}F FMISO PET, 205P(ab)
subacute, early and delayed brain SPECT in, 1444
Strontium-85, photoscanning, metastatic bone cancer, historical article, 810
Strontium-89
adjunct, cost analysis, 235P(ab)
assay and imaging of, 127P(ab)
bone palliation with, breast cancer with bone metastases and pain, 236P(ab)
osseous metastases, 36P(ab)
palliation, bone pain due to metastatic disease, 2054(le)
therapy, metastatic prostate cancer, dissemination intravascular coagulation in, 1662
treatment for multiple myeloma, bone scintigraphy use for selection of patients, 1992, 1994
Subtraction imaging, accuracy of target detection and, use of intravascular tracer, 143P(ab)
Superficial fluids, carbon dioxide, radiotracer synthesis and purification, 42P(ab)
Surgical probe, fiber-optically coupled positron-sensitive, radiation detection, 909
Swallowing studies, radionuclide, aspiration risks, neurologic patients, 109P(ab)
Sympathetic nerves, acute and chronic responses, ischemic and reperfused myocardium, 57P(ab)
Synovectomy, ^{153}Sm particulates, radiation dosimetry for, 160P(ab)
Systemic lupus erythematosis, central nervous system, SPECT brain images, 95P(ab)
Systemic sclerosis, radionuclide imaging, ^{99m}Tc DTPA clearance rate, 1933
Systolic wall, thickening, determination with fast Fourier transform approximation, 1185

T

Tachyarrhythmia, cardiomyopathy and, ^{123}I MIBG myocardial images, 81P(ab)
Tandem Cascade Accelerator, production of ^{15}O radiopharmaceutical with, clinically useful amounts, 249P(ab)
Target selection, new radiochemical design for antibodies, 326
Taxol
bone scintigraphy following, metastatic breast cancer, 1748
effects, radioimmunotherapy, 102P(ab)
Teboroxime, kinetic modeling, dynamic SPECT imaging, 484
Technetion-99m, direct labeling of antibodies, ascorbate use in, 127
Technetium ligands, *ab initio* computational study of, 262P(ab)
Technetium-94m, positron emitting, application of, 253P(ab)
Technetium-99m
anti-CEA antibody fragments radiolabeled with, for radioimmunodetection, 258P(ab)
anti-CEA fab fragments, immunoscintigraphy of colorectal cancer, 86P(ab)
antigranulocyte fab fragments, imaging of infectious disease, 112P(ab)
binding sites, ^{99m}Tc-labeled monoclonal antibodies and, 876
cationic complexes, renal function agents, 1691
combined ^{123}I studies, optimal collimator choice for, 181P(ab)
complexes, prediction of structure of, 243P(ab)
existence, Te-123m for determination of attenuation map with, 195P(ab)
fab fragments, comparison to labeled leukocytes for detection of infection, 172P(ab)
GPIIb/IIIa receptor-binding peptides radiolabeled with, structure-activity relations, 257P(ab)
imaging based on, 17N(4)
labeling of divalent antibody fragments, radioimmunodetection, 259P(ab)
labeling proteins with, ascorbate role in, 1566(le)

liposomes, use in tumor imaging, 1491
microspheres labeled with, dosimetry of lungs at cellular level, 79P(ab)
monoclonal antifibrin antibodies labeled with, arterial thrombosis imaging, 1731, 1738
myocardial perfusion studies
determination of systolic wall thickening, 1185
three-dimensional photon scatter effects, 17P(ab)
nitroimidazole complex, based on bis(amine-phenol)ligand, 260P(ab)
polyethylene glycol coated liposomes, blood pool agent, 42P(ab)
somatostatin receptor binding peptides labeled with, structure-activity relations, 257P(ab)
SPECT, brain, attenuation compensation in, 193P(ab)
synthetic peptides
atherosclerotic plaques, 80P(ab)
detection of deep venous thrombosis, 80P(ab)
thiol functionalized phosphorus hydrazides, evaluation of, 139P(ab)
transchelation of, tumors from antibodies to cysteine, 105P(ab)
tumor uptake, augmenting with biological response modifiers, 86P(ab)

Technetium-99m albumin, breath test, monitoring of gastric emptying of liquids and solids, 824

Technetium-99m albumin macroaggregates, detection of intrapulmonary shunts, liver disease, children, 1328

Technetium-99m annexin, uptake, left atrial and coronary thrombi, 254P(ab)

Technetium-99m anti-AFP-antibody, scintigraphy
germ cell tumors, 11P(ab)
hepatocellular carcinoma, 11P(ab)

Technetium-99m antigranulocyte antibody, bone marrow immunoscintigraphy, hematologic diseases, 113P(ab)

Technetium-99m antigranulocyte Fab' fragment, detection of soft tissue infections, osteomyelitis and, 1436

Technetium-99m antisense probes, hybridization with c-myc oncogene mRNA, P388 leukemic cells, 263P(ab)

Technetium-99m bis(dithiocarbamato) nitrido compounds, neutral myocardial imaging agent, 334

Technetium-99m BMS181321, myocardial retention, low flow effects, perfused heart, 46P(ab)

Technetium-99m boroarginine thrombin inhibitors, design and synthesis, thrombus imaging agents, 241P(ab)

Technetium-99m 88BV59, detection of colorectal carcinoma, 86P(ab)

Technetium-99m chelators, peptidic, linked to chemotactic peptide, imaging inflammation with, 44P(ab)

Technetium-99m DD-3B6/22, detection of deep venous thrombi and pulmonary embolus, 195, 202

Technetium-99m dextran, extemporaneous compounding of, simple, rapid method for, 242P(ab)

Technetium-99m diaminedithiolate, derivatives of chemotactic peptides, imaging of inflammation, 19P(ab)

Technetium-99m DISIDA, hepatobiliary scintigraphy, cystic fibrosis and liver disease, children, 432, 436

Technetium-99m DMSA
kit preparation of, imaging medullary thyroid carcinoma, 263P(ab)
pentavalent, MRI comparison, schwannoma of the extremities, 1174
SPECT, vesicoureteral reflux, children, 238P(ab)
uptake
^{99m}Tc MDP comparison, bone tumors, 232P(ab)
SPECT, vesicoureteral reflux, children, 445, 449

Technetium-99m DTPA
aerosol clearance, assessment of radiation injury to the lung, 234P(ab)
asialoglycoprotein receptor among, determination in liver, 172P(ab)
assessment of bowel permeability, allogenic rat small bowel transplantation, 168P(ab)
clearance rate, early pulmonary involvement in systemic sclerosis assessed by, 1933
deconvolution analysis, transplanted kidney, 84
deposition and clearance, acute experimental pulmonary arterial occlusion effects, 1351
determination of GFR, renal insufficiency, 100P(ab)
diagnosis of radiation mucositis, 170P(ab)
evaluation of maxillary sinus drainage, after functional endoscopic sinus surgery, 150P(ab)
intestinal absorption of, small bowel transplant rejection, 12P(ab)
intraperitoneal leakage, after renal transplantation, 93
lung epithelial permeability, detection in diabetes, 204, 207
pinhole SPECT, 342
radioaerosol inhalation, alveolar integrity and inflammation with lung disease, 240P(ab)
radiochemical purity, radiopharmaceutical kits, 138P(ab)
renal functional imaging, ^{99m}Tc EC comparison, 266P(ab)

Technetium-99m EC
renal functional imaging, ^{99m}Tc DTPA comparison, 266P(ab)
renal imaging, 840

Technetium-99m ECD
brain SPECT
early and delayed, subacute strokes, 1444
ictal and interictal, epilepsy, 1896
cortical activation studies with, regional cerebral blood flow, 199P(ab)
as a leukocyte labeling agent, 245P(ab)
SPECT, brain perfusion imaging, 211P(ab)
stannous chloride concentration effects, Neurolite radiochemical purity, 260P(ab)
visual activation studies with, 202P(ab)

Technetium-99m EIBI, transport substrate, multidrug resistant P-glycoprotein, 230P(ab)

Technetium-99m-ethyl cysteinate dimer, SPECT images, cerebrovascular diseases, 27

Technetium-99m furifosmin, cyclodextrin-stabilized TECHNESCAN Q_{12} kit, novel chemistry used in, 139P(ab)

Technetium-99m glucarate, acute visualization, experimental nonreperfused myocardial infarction, 4P(ab)

Technetium-99m GSA, assessment of regional liver function, 169P(ab)

Technetium-99m HIDA
cholescintigraphy, diagnosis of rotor syndrome, 1048
diagnostic problems, hepatic carcinoma, 1342

Technetium-99m HMPAO
aerosol clearance, cigarette smoke effects on alveolar membrane, 133P(ab)
basal ganglia blood flow, pre- and post-ECT, 54P(ab)
bone scans, detection of soft tissue infection and osteomyelitis, 1436
brain SPECT, neurotoxicity, 863
cerebral blood flow
regional stability of, 108P(ab)
Sneddon syndrome, 461
cerebral distribution, age-related changes, 107P(ab)
cerebral kinetics of, linear alkylation effects, 260P(ab)
cerebral perfusion mapping, during interventional neuroradiology, 275P(ab)
co-registered, MRI and, intracarotid sodium amobarbital procedure, 273P(ab)
detection of post-transplant graft dysfunction, pancreatic transplantation, 1488
imaging, glutathione localization with, brain, 263P(ab)
isolation of, determination of isomeric purity and, 262P(ab)
leukocytes
detection of inflammatory bowel disease in children, 451
diagnosis of prosthetic vascular graft infection, 1303
localization, validation study, 755
marker of lung injury, 1520
paralimbic hypoperfusion, unipolar depression, 929
pinhole SPECT, 342
prefrontal and temporal blood flow, schizophrenia, 935
prospective evaluation, moderate traumatic brain injury, 942, 947
radiochemical purity, ultrasound and jet nebulizer, 244P(ab)
radionuclide angiography
brain perfusion, 203P(ab)
cerebral collateral circulation, 204P(ab)
SPECT
Alzheimer's disease patients, 210
appearance of central nervous system toxoplasmosis, 1041
brain
carbon dioxide reactivity, circulation, 32
in dementia, 206P(ab)
significance of abnormalities in, 239
sleep apnea, 239P(ab)
brain perfusion, substance abusers, 214P(ab)
brain uptake, quantification of, 212P(ab)
cerebral hemodynamic changes after radiosurgery, 204P(ab)
CT and MRI with, traumatic brain injury, 217, 227
developmental speech disorders, children, 134P(ab)
diagnosis of Alzheimer's disease, 20P(ab)
epileptic seizure patients, 116P(ab)
fibromyalgia syndrome, caudate nuclei rCBF in, 215P(ab)
hemispherectomy and, childhood seizures, 207P(ab)
localization of extra-temporal lobe epilepsy, 31P(ab), 112
MR comparison, epilepsy, 208P(ab)
obsessive-compulsive disorders, 214P(ab)
partial status epilepticus, 208P(ab), 1087, 1094
prediction of cerebral infarction, 1097
premenstrual syndrome, 215P(ab)
preoperative seizure monitoring, 207P(ab)

primary degenerative and vascular dementia, 119P(ab)
rCBF, heroin and polydrug abuse effects, 214P(ab)
regional cerebral hyperfixation, 204P(ab)
temporal lobe hypoperfusion, schizophrenia, 215P(ab)
visual abnormalities, 209P(ab)
white matter ischemia showing on, 1476
^{133}Xe relative to, cerebral blood flow, 212P(ab)
transfer, placental, human and animal, 245P(ab)
white matter lesions, cortical diaschisis effects, dementia, 21P(ab)
Technetium-99m HSA, mucous transport, chronic asthma, effect of macrolines on, 240P(ab)
Technetium-99m hydroxamamides, evaluation by HPLC analysis, mice biodistribution studies, 19P(ab)
Technetium-99m hydroxymethylene, intraosseous hemangiomatosis, 1482
Technetium-99m IgG
hydrazino nicotinamide modified, precursor for labeling, 105P(ab)
release, infectious foci, 45P(ab)
Technetium-99m LDL, parenchymal uptake, normal and estradiol-stimulated liver, 63P(ab)
Technetium-99m L,L-EC
D,L-ethylene-dicysteine isomer comparison, 262P(ab)
evaluation in renal transplant recipients, 1951
synthesis and characterization, renal imaging, 263P(ab)
Technetium-99m-MAA, measuring lung shunting, hepatocellular carcinoma, 70
Technetium-99m MA_2G_2-β, biological and pharmacokinetic evaluation, renal agent, 263P(ab)
Technetium-99m MAG_3
clearance, rate of renal uptake-plasma volume product, 99P(ab)
complexes, renal tubular transport, 1198
hepatobiliary excretion, radiochemical purity and, 349
^{99m}Tc LLEC comparison, renal transplant recipients, 1951
renal extraction of, protein binding effects, 264P(ab)
renal failure, reduced protein binding in, 265P(ab)
renal imaging, 840
renal studies, physiologic parameters as function of age and sex, 1612
retention, renal transplants, 846
simple flow index with, renal transplantation, 99P(ab)
Technetium-99m MDP
abnormal soft tissue uptake, incidence, 120P(ab)
bone SPECT, simultaneous ^{111}In WBC, osteomyelitis, facial bones and calvarium, 113P(ab)
scintigraphy, primary breast cancer, 22P(ab)
simultaneous ^{201}Tl SPECT, skull base involvement, 224P(ab)
SPECT, spine, differentiation of lesions, 35P(ab)
uptake
fetal skeleton at 30 weeks, 1338
thyroid cartilage, squamous-cell laryngeal carcinoma, 1170
unilateral hydroxyapatite-coated total hip prosthesis patients, 1788
Technetium-99m mebrofenin, allergic reactions to, 1569(le)
Technetium-99m MH1, detection, thrombi, 80P(ab)
Technetium-99m MIBI
detection, parathyroidal adenomas, 162P(ab)
ECG-gated, identification of viable myocardium with, 153P(ab)
efficacy on seeking metastatic lesions, thyroid cancer, 226P(ab)
hyperthyroidism, rapid diagnosis, 922(le)
initial evaluation and post-surgical scan, thyroid cancer, 166P(ab)
myocardial imaging
significant gastric reflux of, 619
viable myocardium in coronary artery disease, 621
myocardial tomography, coronary artery disease, 1110
redistribution, chronic coronary artery disease patients, 114P(ab)
sensitivity of, primary breast cancer, 22P(ab)
SPECT
identification of viable myocardium, nitrates in, 115P(ab)
malignant pulmonary lesions, 227P(ab)
myocardial viability assessment, 569
suspicious breast lesions on mammography, 933
uptake
carcinoid tumor, 1560(le)
cell stress and, 120
Technetium-99m nitroimidazole
binding kinetics, hypoxic myocardium, 46P(ab)
detection, myocardial ischemia, 3P(ab)
hypoxic retention, substituent effects, 18P(ab)
kinetics, myocardial, 1371
physiochemical and biological behavior of, substituent effects, 18P(ab)
putative hypoxic tissue marker, hypoxic, ischemic, and stunned myocardium, 46(ab)
Technetium-99m NOET, biodistribution, myocardial perfusion imaging, 155P(ab)
Technetium-99m P-280, synthetic peptide, brain tumor localization, 97P(ab)
Technetium-99m peptides, thrombus imaging, 282
Technetium-99m pertechnegas, comparison with ^{133}X, ventilation imaging in pulmonary emboli, 48P(ab)
Technetium-99m pertechnetate
brain scanning, historical article, 478
salivary gland imaging, Warthin's tumor, 179
scintigraphy, extra-abdominal desmoid tumor, 226P(ab)
whole blood marker, brain perfusion studies, 479
Technetium-99m P-gas, chemical characteristics of, 240P(ab)
Technetium-99m phytate, ^{201}Tl subtraction imaging, hepatocellular carcinoma, 1134
Technetium-99m PMT, assessment of liver function, three-compartment analysis, 171P(ab)
Technetium-99m PnAO
efficient synthesis of, T261P
new functionalized, 261P(ab)
Technetium-99m PYP, uptake, myocardial injury without infarct and, 1366
Technetium-99m Q3
myocardial uptake and kinetics, dogs, 1698
^{201}Tl comparison, detection of coronary artery disease, 581
Technetium-99m Q12, biodistribution, dosimetry and clinical use, myocardial imaging, 1571
Technetium-99m radiolabeled proteins, premortem biodistribution, blood and tissue, 243P(ab)
Technetium-99m RBC, localization of nonenteric hemorrhage, 1333
Technetium-99m RC-160, somatostatin analogue, 259P(ab)
Technetium-99m sestamibi
accumulation, tumor cells, multidrug resistance factor and, 219P(ab)
applicability, myocardial perfusion SPECT, 103P(ab)
biodistribution, whole-body autoradiography, 159P(ab)
breast cancer, 2055(le)
cardiac SPECT, attenuation correction, ^{153}Gd for, 91P(ab)
Cardiolite, chemistry of, 138P(ab)
c-neu OncoMouse, retention in breast tumor imaging, 21P(ab)
compared with MRI, dense breast, imaging of, 223P(ab)
demonstration of myocardial viability with, 1805
distribution, viability determination myocardial infarction, 152P(ab)
dobutamine scintigraphy, myocardial perfusion and, 16P(ab)
dual isotope myocardial perfusion SPECT
separate or simultaneous rest ^{201}Tl/stress, 542
sequential, 549
dynamic renal imaging, hypertension, 1959
enhanced detection, breast cancer, 274P(ab)
evaluation of coronary artery disease, dipyridamole infusion and, 1254
factor analysis of dynamic structures and, identifying abnormal parathyroid glands, 1631
first-pass radionuclide angiocardiography, ventricular function, 1593
gated tomographic
left ventricular ejection fractions, 154P(ab)
perfusion defect size and severity, 155P(ab)
multidrug resistance P-glycoprotein transport, 19P(ab)
myocardial free fatty acid uptake, after coronary thrombolysis, 1758
myocardial imaging, abnormal segmental contraction cause perfusion defects, 639
myocardial perfusion imaging, analysis of available imaging protocols, 681
myocardial SPECT, stress perfusion/stress wall motion, 81P(ab)
myocardial viability, 921(le)
normal cardiac imaging, prognostic value, 554
pancreatic transplant perfusion, 163P(ab)
prediction of recovery, post-revascularization, 49P(ab)
quality control of, 264P(ab)
recombinant human multidrug resistance P-glycoprotein, expression in insect cells, 510
scintigraphy
pancreatic transplant, 170P(ab)
pancreatic transplantation, 166P(ab)
primary breast cancer, 22P(ab)
severe stress perfusion defects, reversible ischemia in, 69P(ab)
SPECT
assessment of perfusion defect, 103P(ab)
brain tumors, comparison with ^{201}T, 43P(ab)
breast carcinoma, 229P(ab)
cavity-to-myocardial count ratio with, left ventricular function, 70P(ab)
emergency room patients with chest pain, 275
gender effects on value of, 60P(ab)
mammographic abnormalities, 229P(ab)
myocardial perfusion, patients with prior MI, 59P(ab)

perfusable myocardial mass with, 26P(ab)
perfusion defects, first-pass radionuclide angiography, 70P(ab)
primary and regionally metastatic lung cancer, 232P(ab)
role in parathyroidectomy, 68P(ab)
ventricular aneurysm, 126P(ab)
ventricular volume measurement, 70P(ab)
^{201}Tl comparison
breast tumor imaging, 222P(ab)
suspected breast cancer, 231P(ab)
uptake, dual renal and myocardial scintigraphy, 125P(ab)
whole-body scan, Hurthle cell carcinoma, 219P(ab)
Technetium-99m steroid complex, synthesis, labelling and stability of, 139P(ab)
Technetium-99m TBI, uptake, carcinoid tumor, 1560(le)
Technetium-99m TcN
with cyclodextrins, interaction, 261P(ab)
with lateral ester groups, cerebral perfusion direct labeling, 261P(ab)
Technetium-99m TcN-NOET, SPECT, myocardial imaging with, 114P(ab)
Technetium-99m teboroxime
comparison with cardiac cath and ^{201}Tl, coronary artery disease, 114P(ab)
dosimetry of, 923(le)
fast dynamic SPECT and compartmental analysis, coronary flow reserve, 115P(ab)
kinetics, compartmental analysis with fast dynamic SPECT, rest and stress, 1265
myocardial kinetics, ischemic reperfusion flow effects, 3P(ab)
myocardial perfusion imaging, special contribution, 689
myocardial washout imaging, 575
perfusion defect reversibility, sublingual isosorbide dinitrate for improvement, 1274
recall, 1569(le)
SPECT, kinetic modeling of teboroxime with, 484
washout imaging with dipyridamole, coronary artery disease, 115P(ab)
Technetium-99m tetrofosmin
extraction and washout, isolated rat heart, 47P(ab)
myocardial imaging
coronary artery disease, 594
^{201}Tl angiography comparison, 587
one-day and two-day protocol comparison, myocardial imaging, 1581
uptake
isolated mitochondria, 46P(ab)
low flow with profound systolic dysfunction, 47P(ab)
uptake and clearance, assessment of myocardial blood flow, 664
Technetium-99m (V)DMSA, intraosseous hemangiomatosis, 1482
Technetium-99m WBC
accumulation, exercise-induced muscle injury, 150P(ab)
imaging, osteomyelitis, 88P(ab)
Technetium-99m YIGSR, thrombus-specific imaging, 106P(ab)
Television, nuclear medicine update, 22N
Te-123m, attenuation map, ^{99m}Tc existence, 195P(ab)
Temporal lobe
hypometabolism, effects on PET-FDG, 30P(ab)
perfusion, patients with memory loss, 119P(ab)
Testicular torsion, scrotal scintigraphic findings in, 58P(ab)
Testis, function, radioiodine therapy effects, thyroid cancer, 1418
Testosterone, radioiodine therapy effects, thyroid cancer, 1418
Tetrabenazine, alkylated derivatives, structure-activity study, 84P(ab)
Thallium
exercise imaging with, comparison with exercise SPECT, 16P(ab)
perfusion imaging, false-positive reversible perfusion defect during, left bundle branch block, 1989
scintigraphy, detection of coronary disease and ischemia, 16P(ab)
SPECT
angioplasty compared to bypass surgery, 27P(ab)
lung uptake, coronary artery disease, 126P(ab)
stress redistribution, myocardial viability, 23S
uptake, myocardial, hypertrophic cardiomyopathy, 135P(ab)
Thallium-201
angiography, coronary, tetrofosmin imaging versus, 587, 594
biokinetics, normal subjects, 535
cardiac cath and, ^{99m}Tc teboroxime compared with, coronary artery disease, 114P(ab)
cardiac imaging
perfusion, reduction of attenuation artifacts from, 82P(ab)
scatter correction for, 192P(ab)
SPECT, compensation for crosstalk, 190P(ab)
SPECT, nonhomogenous attenuation correction of, 91P(ab)
diffuse uptake, lung, 271P(ab)
dual isotope myocardial perfusion SPECT, sequential, 549
exercise, reversible perfusion defects, patients with pacemakers, 26P(ab)
exercise imaging, prior myocardial infarction patients, 1279
^{123}I BMIPP combined, risk stratification with recent MI, 59P(ab)
increased uptake, lung cancer, 1125
infusion, rest myocardial SPECT imaging after, 103P(ab)
myocardial imaging, historical article, 889
myocardial perfusion imaging, special contribution, 674
myocardial viability, 4S
normal cardiac imaging, prognostic value, 554
PET imaging and, evaluation of myocardial viability, 707
with pharmacologic vasodilation, 15P(ab)
planar myocardial imaging, multicenter trial, 601
poorer contrast resolution, viability properties versus, 103P(ab)
prognostic value, breast cancer, 228P(ab)
recovery from regional wall motion abnormality, after exercise, ischemic heart disease, 153P(ab)
rest imaging, dobutamine and, severe left ventricular dysfunction, 136P(ab)
reversible perfusion defect, coronary arteriovenous fistula as cause for, 1808
R-Made Patient Support System, preventing patient motion during SPECT, 154P(ab)
scintigraphy
follow-up of differentiated thyroid cancer, 167P(ab)
malignant bone and soft tissue tumors, 225P(ab)
sequential imaging, non-Hodgkin's lymphoma, 230P(ab)
simultaneous ^{99m}Tc MDP SPECT, skull base involvement, 224P(ab)
SPECT
abdominal, periampullary tumor, 109P(ab)
assessment of perfusion defect, 103P(ab)
brain tumors, comparison with ^{99m}Tc sestamibi, 43P(ab)
dipyridamole, aortic stenosis patients, 983
evaluation of childhood brain tumors, 43P(ab)
evaluation of gliomas, 43P(ab)
exercise studies, reproducibility of, 1237
meningiomas, 9P(ab)
MRI lesions, glioma patients after therapy, 220P(ab)
pancreatic cancer, 109P(ab)
thymic carcinoma, residual tumor viability in, 1659
ventricular aneurysm, 126P(ab)
SPECT and CT comparison, brain tumors after therapy, 9P(ab)
stress ^{99m}Tc sestamibi dual-isotope myocardial perfusion SPECT, separate or simultaneous, 542
stress redistribution myocardial perfusion imaging, evaluation of coronary artery disease, 703
^{99m}Tc phytate subtraction imaging, hepatocellular carcinoma, 1134
^{99m}Tc Q3 comparison, detection of coronary artery disease, 581
^{99m}Tc sestamibi comparison, breast tumor imaging, 222P(ab)
uptake
cell stress and, 120
low flow with profound systolic dysfunction, 47P(ab)
washout analysis, myocardial perfusion imaging defects, 26P(ab)
whole-body imaging, after six different stress regimens, 425
Thallium-201 chloride, pinhole SPECT, 342
Thallium-201 dipyridamole
high-dose, detection of coronary artery disease, 1245
stress-redistribution scintigrams, automated interpretation, 2041, 2047
Thallium-201 per rectum, prognostic value, alcoholic cirrhosis, 832
Thermal injury, effects on uptake of ^{18}F FDG, PET, 175P(ab)
Thoracic tumors, intermodality studies, 104P(ab)
Thorax, PET imaging, attenuation correction with emission data for, 51P(ab)
Thrombi
detection, ^{99m}Tc MH1 fab fragments, 80P(ab)
imaging specific to, ^{99m}TC YIGSR for, 106P(ab)
Thrombocytopenia, painful bone metastases, ^{186}Re HEDP dosage recommendations and, 1423
Thromboembolism, multiple, detection in congenital antithrombin III deficiency, ^{111}In-platelet scintigraphy, 1811
Thrombolysis, coronary, myocardial infarction after, abnormal free fatty acid uptake in, 1758
Thrombolytic therapy, response to, features of perfusion lung scan and duration of symptoms, 47P(ab)
Thrombosis
arterial, ^{99m}Tc monoclonal antifibrin antibodies and ^{111}In platelets, comparison, 1731, 1738
deep venous

detection by ^{99m}Tc P-280, 80P(ab)
detection with ^{99m}Tc-anti-D-dimer Fab,' 195, 202
portal vein, hepatocellular carcinoma with, intra-arterial ^{131}I iodized oil versus medical support, 1782

Thrombus
imaging, ^{99m}Tc peptides, 282
imaging agents, design and synthesis of, 241P(ab)
potential imaging agents, radiolabeled GP IIb/IIIa receptor antagonist, 245P(ab)

Thymic carcinoma, residual tumor viability in, assessment with ^{201}Tl SPECT, 1659

Thymidine
2-^{11}C-labeled, PET, brain tumor imaging, 974
titrated, FDG uptake mechanism in cancer cells, 1067
uptake
response of cancer to radiation therapy and, 66P(ab)
tumor cell spheroids, 65P(ab)

Thyroglobulin, serum, ^{131}I whole body scans and, metastatic thyroid cancer, 257

Thyroid
cancer
abnormal cells in bone marrow, antithyroglobulin uptake, 218P(ab)
differentiated
high dose ^{131}I therapy, radiation effects after, 15P(ab)
post ablative ^{131}I therapy in, 15P(ab)
endogenous thyrotropin stimulation in, 227P(ab)
^{123}I on probe systems and gamma cameras, 167P(ab)
^{131}I in breast milk after therapy, 1797
^{131}I low dose rate therapy, 165P(ab)
^{131}I therapy of, 2053(le)
metastatic, ^{131}I whole body scans, 257
radioiodine therapy, testicular function and, 1418
radioisotope therapy, clinical course and, 14P(ab)
squamous cell carcinoma and, lung, radioiodine uptake, 474
^{99m}Tc MIBI scan in initial evaluation and after surgery, 166P(ab)
^{99m}Tc MIBI SPECT efficacy, 226P(ab)
^{201}Tl scintigraphy in follow-up, 167P(ab)
well-differentiated, radioiodine therapy for, 1944
FRTL-5 cells, TSH-induced uptake of ^{125}I, 146P(ab)
function, fetal, assessment in maternal serum, 164P(ab)
involvement, histiocytosis X, 263
medullary carcinoma
screening for adrenal medullary disease, 69P(ab)
^{99m}Tc DMSA imaging of, 263P(ab)
nonmedullary cancer, somatostatin scintigraphy in, 163P(ab)
scintigraphy, euthyroid ophthalmic Graves' disease, 811
^{201}Tl and ^{99m}Tc MIBI uptake, 164P(ab)

Thyroid cartilage, ^{99m}Tc MDP uptake in, squamous-cell laryngeal carcinoma, 1170

Thyroid remnants, ablation with I-131, effects of scanning doses, 14P(ab)

Thyrotropin, endogenous stimulation, varying levels, thyroid cancer, 227P(ab)

Time-dose-fractionation, modeling of tumor uptake, radioimmunotherapy, 1561(le)

Tissue attenuation, quantifying scintigraphic aspiration and, 1007, 1013

Tourette syndrome, dopamine transporter reuptake sites, measured by ^{11}C WIN, 130P(ab)

Toxoplasmosis, central nervous system, hyperperfusion and early ^{99m}Tc HMPAO SPECT appearance, 1041

Tracer kinetics, predictions of intracompartmental concentrations, total tissue activity, 176P(ab)

Transchelation, direct labeling of antibodies, ^{188}Re, 260P(ab)

Transcranial Doppler, evaluation of papaverine, cerebral vasospasm, 64P(ab)

Transendothelial permeability, radiopharmaceutical, compared with single-pass brain extraction, 1514

Transmission computed tomography (TCT)
^{241}Am and ^{99m}Tc, heart, 652
radionuclide arthrography and, hip prosthesis loosening, 851

Transplantation
bone marrow, ^{166}Ho DOTMP for bone marrow ablation, 37P(ab)
heart
^{76}MBBG kinetics in, 110P(ab)
pulmonary uptake in ^{111}In-antimyosin after, 266
heterotransplanted human cancer, nude mice, ^{18}-FDG detection of, 97
kidney
atypical renal artery stenosis in, radionuclide studies, 1051
evaluation of ^{99m}Tc LLEC in, 1951
infective foci in, immunoscintigraphy, 173P(ab)
intraperitoneal leakage of ^{99m}Tc DTPA after, 93
MAG3 retention in, 846
^{99m}Tc DTPA deconvolution study of, 84
posttransplant complications, deconvolution analysis of blood flow, 1792
urine leak in, nuclear medicine evaluation of, 267P(ab)
liver
biliary stenosis in children with, 59P(ab)
biopsy and quantitative hepatobiliary scintigraphy after, 1321
early detection of intrapulmonary shunt, children, 1328
rejection, single tracer method of evaluation, 167P(ab)
pancreas
post-transplant graft dysfunction, ^{99m}Tc HMPAO scintigraphy in detection of, 1488
^{99m}Tc sestamibi monitoring of perfusion, 163P(ab)
^{99m}Tc sestamibi scintigraphic evaluation, 166P(ab)
^{99m}Tc sestamibi scintigraphy in, 170P(ab)
simple flow index with MAG3, 99P(ab)
small bowel
allogenic rat, ^{99m}Tc DTPA assessment of bowel permeability, 168P(ab)
rejection, ^{99m}Tc-DTPA in, 12P(ab)

Transverse slat collimation, asymmetric fan transmission CT, 27P(ab)

Triple energy window method, crosstalk correction, dual isotope acquisition, 194P(ab)

Tumor cells, retention, antibodies labeled with residualizing form of ^{125}I, 55P(ab)

Tumor detection, optimization of, phantom contrast detail approach, 221P(ab)

Tumor imaging
measurement of carcinoembryonic antigen distribution, quantitative autoradiography, 1499
^{99m}Tc-labeled liposomes in, 1491

Tumor markers, sensitivity and specificity, nonsmall cell lung carcinoma, 147P(ab)

Tumor-seeking agents
^{67}Ga DMS, preparation and evaluation, 242P(ab)
histiocytosis X, thyroid involvement in, 263

Tumor targeting, liver metastases, colorectal cancer, 56P(ab)

U

Ultrasound
calcaneal stiffness, dexa measurements at lumbar spine and femur, 120P(ab)
duplex Doppler, before and after frusemide, diuresis renography and, 124P(ab)
scrotal, scintigraphy comparison, testicular torsion, 125P(ab)

Urinary tract, obstruction, diuretic renography in diagnosis of, 266P(ab)

Urine, activity, sources of error in scintigraphic measurements, 157P(ab)

Uterine cancer, imaging with ^{11}C methionine PET, 1618

Uterus, cancer, ^{11}C methionine imaging in, 117P(ab)

V

Varicoceles
scrotal scintigraphy, magnetic resonance angiography and, 267P(ab)
subclinical, scrotal scintigraphy in, 265P(ab)

Vascular endothelium, activation, imaging of, 276, 281

Vascular graft, infection, diagnosis by ^{99m}Tc HMPAO-labeled leukocytes, 1303

Vascular surgery, perioperative events, ejection fraction and incremental prognostic value, 90P(ab)

Vasoactive intestinal peptide receptors, adenocarcinomas and endocrine tumors, intestinal, 97P(ab)

Vasodilation, pharmacologic, ^{201}Tl imaging with, 15P(ab)

Venography, contrast, deep venous thrombi and pulmonary embolus, ^{99m}Tc DD-3B6/22, 195, 202

Ventilation, scintigraphy, localization of bronchopleural fistula, 867

Ventilation-perfusion scanning, *See also* Lung
aortic dissection, 1044
evaluation of pulmonary hypertension, 793
pulmonary embolism, using an expert system, 797
sarcoidosis, 476

Ventricular function
first-pass radionuclide angiocardiography, 1593
global and regional, measurement by cardiac PET, 999
left
myocardial viability, 4S
^{201}Tl and PET imaging in evaluation of, 707
^{99m}Tc sestamibi myocardial perfusion imaging, analysis of available imaging protocols, 681

Ventricular volume, count-based radionuclide method, 644

Ventriculography
first-pass radionuclide, ejection fraction obtained from, 1292, 1301

radionuclide
new motion-correction algorithm for, 179P(ab)
pectus excavatum, 1985
prognosis of coronary artery disease, 721
W-P-W syndrome and supraventricular tachycardia, 90P(ab)
Vertebral hemangioma, bone SPECT imaging in, correlation with MRI, 150P(ab)
Vesamicol receptor, selective ligands, SPECT and PET, 94P(ab)
Vesicoureteral reflux, children
direct vesicoureteral scintigraphy, 1602, 1608
quantification of, 237P(ab)
^{99m}Tc DMSA SPECT in, 238P(ab)
^{99m}Tc DMSA uptake in kidney, quanitative SPECT, 445, 449
Visual cortex, ^{99m}Tc HMPAO SPECT, localization, validation study, 755
Volume imaging scanner, FDG PET cancer studies, postinjection transmission for, 188P(ab)
Volume quantitation, ^{123}I SPECT, 1707

W

Wall dose, estimates, 190(le)
Washout imaging, myocardial, ^{99m}Tc teboroxime utility in, 575
Weighted least-squares reconstruction, iterative filtered backprojection, comparison, 28P(ab)
Wernicke's aphasia, functional recovery from, ^{15}O carbon dioxide PET technique, 120
White matter, ischemia, brain SPECT, 1476
Wisconsin Card Sort Test, prefrontal and temporal regional cerebral blood flow, ^{99m}Tc HMPAO SPECT evaluation of, 935
Workforce, nuclear medicine, health care reform and, 7N(3)

X

Xenon-133
comparison with ^{99m}Tc pertechnegas, ventilation imaging in pulmonary emboli, 48P(ab)
lower limbs, noninsulin-dependent diabetics, 163P(ab)
SPECT
regional cerebral blood flow calculation, 189P(ab)
^{99m}Tc HMPAO relative to, cerebral blood flow, 212P(ab)
ventilation imaging, detection of bronchopleural fistulae, 133P(ab)
washout, ventilation abnormalities, historical article, 509

Y

Yttrium-88
B3, comparative biodistribution, 63P(ab)
labeling of monoclonal antibodies, ligand evaluation for, 882
Yttrium-90
attenuation measurements, before and after maximum entropy image restoration, 161P(ab)
Bremsstrahlung
planar gamma camera imaging and quantitation of, 1381
radiation dose, therapy applications, 1377
Wiener filter and, 177P(ab)
glass microspheres, hepatic radioembolization with, 1637, 1644
Lipiodol labeling with, column method for, 241P(ab)
pharmacokinetics of delivery, multivalent fab fragments, 63P(ab)
radionuclide therapy
electron absorbed fractions in spheres, 152
magnetically enhanced, 157
Yttrium-90 citrate and EDTMP, pharmacokinetics, radiation dose and, 233P(ab)
Yttrium-90 DOTA peptide chimeric L6, toxicity and therapeutic potential, breast cancer, 122P(ab)